---
document_datetime: 2023-09-21 19:45:35
document_pages: 161
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/stelara-h-c-958-ii-0071-epar-assessment-report-variation_en.pdf
document_name: stelara-h-c-958-ii-0071-epar-assessment-report-variation_en.pdf
version: success
processing_time: 226.7416526
conversion_datetime: 2025-12-25 02:05:19.978865
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

25 July 2019 EMA/450688/2019 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Stelara

International non-proprietary name: ustekinumab

Procedure No. EMEA/H/C/000958/II/0071

## Note

Variation assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure                                                                                  | ..............................................7                                                           |
|-----------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|
| 1.1. Type II variation ..................................................................................................7  |                                                                                                           |
| 1.2. Steps taken for the assessment of the product.........................................................7                |                                                                                                           |
| 2. Scientific discussion                                                                                                    | ................................................................................8                         |
| 2.1. Introduction.........................................................................................................8 |                                                                                                           |
| 2.2. Non-clinical aspects                                                                                                   | ............................................................................................10            |
| 2.3. Clinical aspects                                                                                                       | ..................................................................................................10      |
| 2.3.1. Introduction....................................................................................................10   |                                                                                                           |
| 2.3.2. Pharmacokinetics.............................................................................................13      |                                                                                                           |
| 2.3.3. Pharmacodynamics..........................................................................................31         |                                                                                                           |
| 2.3.4. PK/PD modelling..............................................................................................31      |                                                                                                           |
| 2.3.5. Discussion on clinical pharmacology...................................................................34             |                                                                                                           |
| 2.3.6. Conclusions on clinical pharmacology.................................................................35              |                                                                                                           |
| 2.4. Clinical efficacy                                                                                                      | ..................................................................................................35      |
| 2.4.1. Dose response study(ies)                                                                                             | .................................................................................35                       |
| 2.4.2. Main study(ies)                                                                                                      | ...............................................................................................37         |
| 2.4.3. Discussion on clinical efficacy..........................................................................            | 100                                                                                                       |
| 2.4.4. Conclusions on the clinical efficacy...................................................................              | 105                                                                                                       |
| 2.5. Clinical safety                                                                                                        | .................................................................................................. 105    |
| 2.5.1. Discussion on clinical safety ............................................................................           | 146                                                                                                       |
| 2.5.2. Conclusions on clinical safety ..........................................................................            | 149                                                                                                       |
| 2.5.3. PSUR cycle                                                                                                           | ................................................................................................... 149   |
| 2.6. Risk management plan......................................................................................             | 149                                                                                                       |
| 2.7. Update of the Product information ......................................................................               | 154                                                                                                       |
| 2.7.1. User consultation...........................................................................................         | 154                                                                                                       |
| 3. Benefit-risk balance                                                                                                     | ............................................................................155                           |
| 3.1. Therapeutic Context .........................................................................................          | 155                                                                                                       |
| 3.1.1. Disease or condition.......................................................................................          | 155                                                                                                       |
| 3.1.2. Available therapies and unmet medical need.....................................................                      | 155                                                                                                       |
| 3.1.3. Main clinical studies .......................................................................................        | 155                                                                                                       |
| 3.2. Favourable effects                                                                                                     | ............................................................................................ 156          |
| 3.3. Uncertainties and limitations about favourable effects...........................................                      | 156                                                                                                       |
| 3.4. Unfavourable effects.........................................................................................          | 157                                                                                                       |
| 3.5. Uncertainties and limitations about unfavourable effects                                                               | ....................................... 157                                                               |
| 3.6. Effects Table....................................................................................................      | 158                                                                                                       |
| 3.7. Benefit-risk assessment and discussion...............................................................                  | 160                                                                                                       |
| 3.7.1. Importance of favourable and unfavourable effects............................................                        | 160                                                                                                       |
| 3.7.2. Balance of benefits and risks...........................................................................             | 160                                                                                                       |
| 3.8. Conclusions                                                                                                            | ..................................................................................................... 160 |

<div style=\"page-break-after: always\"></div>

## 4. Recommendations ...............................................................................  160 5. EPAR changes  ......................................................................................  161

<div style=\"page-break-after: always\"></div>

## List of abbreviations

5-ASA

5-aminosalicylate

6-MP

6-mercaptopurine

ADA

anti-drug antibody

ADR

adverse drug reaction

AE

adverse event

ATC

Anatomical Therapeutic Chemical

AZA

azathioprine

CD

Crohn's Disease

CDAI

Crohn's Disease Activity Index

CHMP

Committee for Medicinal Products for Human Use

CL

clearance

CMH

Cochran-Mantel-Haenszel

CRP

C-reactive protein

CSR

clinical study report

ECLIA

electrochemiluminescent immunoassay

EMA

European Medicines Agency

EPAR

European Public Assessment Report

EQ-5D

EuroQoL-5D Health Questionnaire

E-R

Exposure-response

EU

European Union

GCP

Good Clinical Practice

IBD

inflammatory bowel disease

IBDQ

Inflammatory Bowel Disease Questionnaire

ICH

International Conference for Harmonisation

IFN

interferon

IgG1κ

immunoglobulin G1 kappa

IL

interleukin

ISS

Integrated Summary of Safety

IV

intravenous

LTE

long-term extension

mAb

monoclonal antibody

<div style=\"page-break-after: always\"></div>

| MACE      | major adverse cardiovascular event                                       |
|-----------|--------------------------------------------------------------------------|
| MCS       | mental component summary                                                 |
| MedDRA    | Medical Dictionary for Regulatory Activities                             |
| MHRA      | Medicines Healthcare Products Regulatory Agency                          |
| MPA       | Medicinal Products Agency                                                |
| MSD       | Meso Scale Discovery                                                     |
| MTX       | methotrexate                                                             |
| NCI-CTCAE | National Cancer Institute Common Terminology Criteria for Adverse Events |
| NMCS      | nonmelanoma skin cancer                                                  |
| PCS       | physical component summary                                               |
| PD        | pharmacodynamic(s)                                                       |
| PFS       | prefilled syringe                                                        |
| PGA       | physician's global assessment                                            |
| PK        | pharmacokinetic(s)                                                       |
| PRO       | patient-reported outcome(s)                                              |
| PsA       | psoriatic arthritis                                                      |
| PSUR      | Period Safety Update Report                                              |
| PT        | preferred term                                                           |
| q12w      | every 12 weeks                                                           |
| q8w       | every 8 weeks                                                            |
| RMP       | risk management plan                                                     |
| RPLS      | reversible posterior leukoencephalopathy                                 |
| SAE       | serious adverse event                                                    |
| SAP       | Statistical Analysis Plan                                                |
| SC        | subcutaneous                                                             |
| SCE       | Summary of Clinical Efficacy                                             |
| SCP       | Summary of Clinical Pharmacology                                         |
| SCS       | Summary of Clinical Safety                                               |
| SEER      | Surveillance, Epidemiology, and End Results                              |
| SF-36     | 36-item Short Form Health Survey                                         |
| SIR       | standardized incidence ratio                                             |
| SmPC      | Summary of Product Characteristics                                       |
| SOC       | System-organ class                                                       |

<div style=\"page-break-after: always\"></div>

TB tuberculosis TNFα tumor necrosis factor (alpha) UC ulcerative colitis VAS visual analog scale WPAI-GH Work Productivity and Activity Impairment Questionnaire-General Health

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Type II variation

Pursuant to Article 16 of Commission Regulation (EC) No 1234/2008, Janssen-Cilag International NV submitted to the European Medicines Agency on 31 December 2018 an application for a variation.

The following variation was requested:

| Variation requested   | Variation requested                                                                                                            | Type    | Annexes affected   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a               | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIA         |

Extension of Indication for Stelara to include treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic or have medical contraindications to such therapies. As a consequence, the SmPC, Package Leaflet and RMP have been updated.

The requested variation proposed amendments to the Summary of Product Characteristics and Labelling and to the Risk Management Plan (RMP).

## Information on paediatric requirements

Pursuant to Article 8 of Regulation (EC) No 1901/2006, the application included an EMA Decision P/0190/2018 on the agreement of a paediatric investigation plan (PIP).

At the time of submission of the application, the PIP was not yet completed as some measures were deferred.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the applicant did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

## Scientific advice

The applicant did not seek Scientific Advice at the CHMP.

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur:

Jayne Crowe

Co-Rapporteur:

Mark Ainsworth

<div style=\"page-break-after: always\"></div>

| Timetable                                            | Actual dates     |
|------------------------------------------------------|------------------|
| Submission date                                      | 31 December 2018 |
| Start of procedure:                                  | 27 January 2019  |
| CHMP Rapporteur Assessment Report                    | 27 March 2019    |
| CHMP Co-Rapporteur Assessment Report                 | 25 March 2019    |
| PRAC Rapporteur Assessment Report                    | 27 March 2019    |
| PRAC members comments                                | 3 April 2019     |
| Updated PRAC Rapporteur Assessment Report            | 4 April 2019     |
| PRAC Outcome                                         | 11 April 2019    |
| CHMP members comments                                | 15 April 2019    |
| Updated CHMP Rapporteur(s) (Joint) Assessment Report | 16 April 2019    |
| Request for supplementary information (RSI)          | 26 April 2019    |
| PRAC Rapporteur Assessment Report                    | 31 May 2019      |
| Updated PRAC Rapporteur Assessment Report            | 6 June 2019      |
| CHMP Rapporteur Assessment Report                    | 11 June 2019     |
| PRAC Outcome                                         | 13 June 2019     |
| CHMP members comments                                | 17 June 2019     |
| Updated CHMP Rapporteur Assessment Report            | 20 June 2019     |
| 2 nd Request for supplementary information           | 27 June 2019     |
| Procedure re-start                                   | 03 July 2019     |
| CHMP Rapporteur assessment report                    | 09 July 2019     |
| PRAC Rapporteur assessment report                    | 09 July 2019     |
| PRAC members comments                                | 15 July 2019     |
| CHMP members comments                                | 15 July 2019     |
| Updated PRAC assessment report                       | 17 July 2019     |
| Updated CHMP assessment report                       | 17 July 2019     |
| Opinion                                              | 25 July 2019     |

## 2. Scientific discussion

## 2.1. Introduction

The European Commission granted the first marketing authorisation (MA) for Stelara in 2009 for the treatment of moderate to severe plaque psoriasis in adults who have failed to respond to, or who have a contraindication to, or who are intolerant to other systemic therapies including cyclosporine, methotrexate and psoralen plus ultra-violet A light [PUVA]).  Subsequently, indications were added for the treatment of plaque psoriasis in both adult and paediatric populations.  Most recently (2016) Stelara was approved the for the treatment of adult patients with moderately to severely active Crohn's disease

<div style=\"page-break-after: always\"></div>

who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a TNFα antagonist or have medical contraindications to such therapies. The new indication applied for proposes to extend the indication for Stelara to include treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic or have medical contraindications to such therapies. UC is a chronic, relapsing, inflammatory disease of the colon characterised by alternating episodes of remission and spontaneous relapse. The prevalence has been estimated to range from 38 to 249 cases per 100,000 persons in North America and 5 to 505 cases per 100,000 persons in Europe. It is most commonly diagnosed in late adolescence and early adulthood, with the peak incidence occurring between 20 to 39 years of age. The precise pathogenesis of UC is presently unknown; however, the prevailing paradigm is dysregulation of the enteric immune response in genetically susceptible individuals.  This leads to upregulation of macrophages and type-2 T helper (Th2) lymphocytes in UC, as a result of inability to appropriately downregulate both innate and adaptive immune responses to endogenous luminal antigens. This produces an excess of cytokines, interleukins (ILs) and chemokines, all of which can lead to enhanced inflammation and tissue damage. Evidence has shown that upregulation of some of the common gamma chain cytokines may play a role in the pathogenesis of inflammatory bowel disease (IBD), of which the 2 main forms are UC and Crohn's disease. Unlike CD, only the colon and rectum are affected in UC and not the entire GI tract. It can be classified into extensive, left-sided colitis and proctitis. There are pathophysiological similarities between UC and CD colitis and UC and Crohn's disease patients and about 20% have indeterminate colitis at the time of diagnosis. The hallmark clinical presentations for UC include diarrhoea, rectal bleeding, passage of mucus, tenesmus, urgency, and abdominal pain. Patients may also experience fatigue, fevers, weight loss, and dehydration, particularly in more severe cases. Mortality is not increased in UC in general, but UC causes significant morbidity and the disease may present as life-threatening fulminant colitis. Most patients follow a chronic intermittent course with periods of increased disease activity separated by periods of disease remission. After the initial diagnosis, approximately half of patients will have active disease at any single point in time and approximately 90% will have a disease course characterized by intermittent flares. Although the incidence is decreasing, patients with UC have an increased risk of developing colorectal cancer due to the development of dysplasia in the setting of chronic mucosal inflammation. The surgical option for refractory UC is a proctocolectomy. Intestinal continuity can be restored with am ileal pouch-anal anastamosis but this procedure is associated with considerable morbidity. order to provide an improved quality of life, reduction in the need for long-term corticosteroids, reduction in the need for colectomy and minimization of cancer risk. Conventional therapies for the treatment of UC include mesalamine, glucocorticoids, and thiopurines.  Approved systemic therapies for the treatment of inadequate response or were intolerant to conventional therapy. Vedolizumab and tofacitinib are the only approved products of that group that do not target TNFα and the only products that have demonstrated efficacy in patients who have had an inadequate response to (ie, primary non-response or secondary loss

The goal of UC medical treatment in general is the induction and maintenance of disease remission in UC include anti-tumor necrosis factor alpha (TNFα) agents such as golimumab, infliximab, and adalimumab, the α4β7 integrin antagonist vedolizumab, and most recently the Janus kinase inhibitor tofacitinib. These agents are currently available for the treatment of patients with UC who have had of response) or are intolerant of anti-TNFs. Systemic treatments are administered either intravenously (IV; infliximab and vedolizumab), subcutaneously (SC; golimumab and adalimumab), or orally (tofacitinib). Despite the availability of these approved therapies, not all patients respond to induction

<div style=\"page-break-after: always\"></div>

therapy (ie, primary non-response). In addition, many patients who initially respond to the approved therapies may lose response over time (secondary loss of response).

At present, no current pharmacological therapy is able to provide a cure for UC. While it appears to be decreasing, the long term colectomy rate is 15-20%. The primary treatment goal is to induce remission and then to maintain this state.

Ustekinumab is classified according to the Anatomical Therapeutic Chemical (ATC) Classification System as an Interleukin Inhibitor (ATC code: L04AC05). Ustekinumab is a human IgG1κ monoclonal antibody (mAb) that binds with high affinity and specificity to the p40 subunit common to both human interleukin (IL)-12 and human IL-23.

Ustekinumab prevents IL-12 and IL-23 bioactivity by preventing their interaction with their cell surface IL-12Rβ1 receptor protein. Through this mechanism of action, ustekinumab effectively neutralizes IL-12 (Th1)- and IL-23 (Th17)-mediated cellular responses. Abnormal regulation of IL-12 and IL-23 has been associated with multiple immune-mediated diseases, including inflammatory bowel disease [IBD; e.g., ulcerative colitis (UC) and Crohn's disease (CD)].

Ustekinumab represents a new mechanism of action for the treatment of UC and has been approved in the related indication of CD.

Based on pathophysiologic similarities between UC and CD, the commonality of medications used to treat UC and CD and the positive clinical results for ustekinumab in the treatment of Crohn's disease, a direct-to-phase 3 program was developed for the study of ustekinumab in the treatment of UC using the same induction and maintenance dose regimens as those used in the CD Phase 3 clinical program.

The UC and CD programs also employed a similar design strategy of placebo-controlled induction and randomised-withdrawal maintenance Phase 3 studies and had similar target populations (ie, biologic and conventional therapy failure subjects). The proposed ustekinumab treatment regimen is the same as is authorised for CD; an initial single IV induction dose followed by SC administration every 8 or 12 weeks during maintenance.

## 2.2. Non-clinical aspects

No new clinical data have been submitted in this application, which was considered acceptable by the CHMP.

## 2.3. Clinical aspects

## 2.3.1. Introduction

## GCP

The Clinical trials were performed in accordance with GCP as claimed by the applicant.

The applicant has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

- Tabular overview of clinical studies

<div style=\"page-break-after: always\"></div>

Tabular Overview of Phase 3 Studies in the Ulcerative Colitis Development Program for Ustekinumab

| Study Number                                                                                                                                                                                                                                                                                              | StudyPopulation                                                                                                                                                                                                                                       | Treatment Groups (n)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Duration CNTO1275UCO3001 Induction Study · 8 weeks for subjects in clinical response at Week 8 who entered maintenance ● 16 weeks for subjects in clinical response at Week 16 who entered maintenance · 20 weeks after the last administration of study agent for subjects who did not enter maintenance | Adult subjects with moderately to severely active UC who had an inadequate response to or failed to tolerate biologic (ie, TNF antagonists and/or vedolizumab) or conventional (ie, corticosteroids and/or the immunomodulators 6-MP or AZA) therapy. | Totalpopulation(n=96l): Single IV induction dose at Week 0: ●Ustekinumab 130 mg IV (n=320) ·Jatekinumab~6 mg/kg IV (n=322) ●Placebo IV (n=319) Subjects who were not in clinical response at Week 8 (n=417) received additional study agent as follows: Placebo nonresponders received ustekinumab IV ~6 mg/kg (n=184) Ustekinumab nonresponders received ustekinumab 90 mg SC (n=233)                                                                                                                                                                                                                           |
| CNTO1275UC03001 Maintenance Study ●Data through Week 44 (maintenance portion of study) included in this SCE ● Subsequent study extension continues up to Week 220                                                                                                                                         | Subjects who were in clinical response at Week 8orWeek 16of the induction study                                                                                                                                                                       | Totalpopulation(n=783) Primary population: Randomized subjects (responders to ustekinumab IV induction; n=523): ·Placebo SC (n=175) ·Jatekinumab.90 mg SC q12w (n=172) ·Ustekinumab90 mg SCq8w (n=176) Nonrandomized subjects (n=260): ● Placebo-treated only: Subjects in clinical response to placebo IV induction (n=103); these subjects received SC placebo in this study ·Delayed responders: Subjects who did not respond to ustekinumab IV induction,received ustekinumab 90 mg SC at induction Week 8, and responded at Week 16 (n=157); these subjects received ustekinumab 90 mg SC q8w in this study |

6-MP=6-mercaptopurine; AZA=azathioprine; IV=intravenous; q8w=every 8 weeks; q12w=every 12 weeks; SC=subcutaneous; SCE=Summary of Clinical Efficacy; TNF=tumor necrosis factor; UC=ulcerative colitis.

AdaptedfromMod5.3.5.1/CNTO1275UCO3001/Induction/AtfTSIDEM01, AttTSIDS01

The pivotal development program consists of two Phase 3 studies, an IV induction study and an SC maintenance study, which were conducted under a single protocol (UCO3001) but were designed and analysed as two separate studies with separate endpoints and Type I error control. The induction study randomized adult subjects with moderately to severely active UC who had demonstrated an inadequate response to or failure to tolerate conventional or biologic therapy. The maintenance study was a randomized-withdrawal study targeting subjects with moderately to severely active UC who had demonstrated a clinical response to induction treatment with IV ustekinumab.

The MAH have submitted PK data for serum concentration, exposure-response analysis and Population PK based on the pivotal phase 3 induction and maintenance study UCO3001. A list of the studies included in the ustekinumab development program in UC and supporting studies for Crohn's disease is presented below. As mentioned in the introduction, based on pathophysiologic similarities between UC and CD, CD studies are considered to provide supportive information.

<div style=\"page-break-after: always\"></div>

## Listing of Ustekinumab Clinical Studies as Summarized in the Summary of Clinical Pharmacology

| Study ID/Phase                          | Subject Populati on                                                                        | Dose Regimen                                                                                       | Route of Administ ration   | Number of Subjects Treated   |                    |
|-----------------------------------------|--------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------|----------------------------|------------------------------|--------------------|
| Ulcerative Colitis                      | Ulcerative Colitis                                                                         | Ulcerative Colitis                                                                                 | Ulcerative Colitis         | Ulcerative Colitis           | Ulcerative Colitis |
| CNTO1275UCO3001 / Phase 3 (Induction)   | Moderatel y to severely active UC                                                          | IV: Placebo, 130 mg or ~6 mg/kg UST at Week 0 Placebo at Week 0 followed by UST ~6 mg/kg at Week 8 | IV                         | 960                          |                    |
|                                         |                                                                                            | IV and SC: 130 mg or ~6 mg/kg at Week 0 followed by 90 mg SC at Week 8.                            | IV, SC                     |                              |                    |
| CNTO1275UCO3001 / Phase 3 (Maintenance) | Moderatel y to severely active UC and were responder s to induction in the induction study | SC: Placebo, 90 mg UST q12w or q8w                                                                 | SC                         | 783                          |                    |
| Crohn's Disease                         | Crohn's Disease                                                                            | Crohn's Disease                                                                                    | Crohn's Disease            | Crohn's Disease              | Crohn's Disease    |
| CNTO1275CRD3001 / Phase 3 (Induction)   | Moderatel y to severely active Crohn's disease who failed                                  | IV: Placebo, 130 mg, or ~6 mg/kg UST at Week 0                                                     | IV                         | 740                          |                    |

<div style=\"page-break-after: always\"></div>

|                                         | or were intolerant to TNF antagonis t therapy                                               |                                                             |          |       |
|-----------------------------------------|---------------------------------------------------------------------------------------------|-------------------------------------------------------------|----------|-------|
| CNTO1275CRD3002 / Phase 3 (Induction)   | Moderatel y to severely active Crohn's disease who were refractory to conventio nal therapy | IV: Placebo, 130 mg, or ~6 mg/kg UST at Week 0              | IV       | 627   |
| CNTO1275CRD3003 / Phase 3 (Maintenance) | Moderatel y to severely active Crohn's disease                                              | SC: Placebo, 90 mg UST q12w or q8w IV: 130 mg UST at Week 0 | IV or SC | 1,280 |

Abbreviations: ~6 mg/kg=weight-range-based doses approximating 6 mg/kg; CSR=clinical study report; eCTD=electronic Common Technical Document; Mod=module; q8w=every 8 weeks; q12w=every 12 weeks; TNF=tumor necrosis factor; UC=ulcerative colitis; UST=ustekinumab.

## 2.3.2. Pharmacokinetics

The pharmacology of Ustekinumab was described in the original application in 2009. Relevant to the formulation and dosing in this extension variation into UC, the pharmacokinetics (PK) and immunogenicity of ustekinumab following intravenous (IV) and/or subcutaneous (SC) administration were evaluated in 2 Phase II (C0379T07, C0743T26) and 3 Phase III (CNTO1275CRD3001 [CRD3001], CNTO1275CRD3002 [CRD3002], CNTO1275CRD3003 [CRD3003]) clinical studies in subjects with moderately to severely active Crohn's disease.

A population PK analysis and exposure-response analysis with respect to efficacy and safety, using combined data from C0743T26, CRD3001, CRD3002 and CRD3003 has been performed.

The company have submitted PK data for serum concentration, exposure-response analysis and Population PK based on the pivotal phase 3 induction and maintenance study UCO3001.

Validated bioanalytical methods were used. Validation reports were provided. They were considered acceptable by CHMP.

<div style=\"page-break-after: always\"></div>

## Serum Ustekinumab concentrations over time

## Induction

Following a single IV administration of the 130 mg ustekinumab fixed dose (which approximates 2 mg/kg dose) or ~6 mg/kg ustekinumab at induction Week 0, median serum ustekinumab concentrations were approximately dose proportional and were detectable at all sampling time points through induction Week 8. Median peak serum ustekinumab concentrations 1 hour after the induction Week 0 infusion were 43.16 μg/mL (mean±SD: 43.8±9.2 μg/mL) and 127.0 μg/mL (mean±SD: 129.1±27.6 μg/mL) for the 130 mg and ~6 mg/kg groups, respectively. At induction Week 8, median serum ustekinumab concentrations were 2.51 μg/mL and 8.59 μg/mL for the 130 mg and ~6 mg/kg groups, respectively

## Maintenance

Subjects randomized to ustekinumab 90 mg q8w or 90 mg q12w had sustained ustekinumab serum concentrations through maintenance Week 44, while in those subjects randomized to placebo, median ustekinumab serum concentrations were below the lowest quantifiable concentration by maintenance Week 16

Median Serum Ustekinumab Concentrations (µg/mL) Through Week 44 of the CNTO1275UCO3001 Maintenance Study; Randomized Subjects

<!-- image -->

SC=subcutaneous;q12w=every12weeks;q8w=every8weeks

■= Ustekinumab dosing in the 90 mg SC q12w group; ^ = Ustekinumab dosing in the 90 mg SC q8w group

<div style=\"page-break-after: always\"></div>

<!-- image -->

.O.Placebo SC

Ustekinumab90mg q12wUstekinumab90mgq8w

Steady-state trough ustekinumab concentrations in subjects who received ustekinumab 90 mg q8w were approximately 3-fold the concentrations in subjects who received ustekinumab 90 mg q12w. For example, at maintenance Week 24, the only concurrent preadministration time point during maintenance for both ustekinumab randomized maintenance treatment groups, the median trough serum ustekinumab concentration was 2.74 μg/mL in the ustekinumab 90 mg q8w group and 0.92 μg/mL in the ustekinumab 90 mg q12w group

The impact of the different IV induction doses on the serum ustekinumab concentrations during maintenance continued to diminish over time. In subjects randomized to placebo maintenance, median serum ustekinumab concentration declined below the lowest quantifiable concentration at maintenance

<div style=\"page-break-after: always\"></div>

Week 12 in subjects who had received ustekinumab 130 mg IV induction, or at maintenance Week 20 in subjects who had received ustekinumab ~6 mg/kg IV induction.

## Serum Ustekinumab concentrations and body-weight categories

In general, following the fixed 90 mg SC ustekinumab administration, median serum trough ustekinumab concentrations tended to be lower in subjects with higher body weight. For example, at Week 24 in the ustekinumab 90 mg q8w group, median serum ustekinumab concentration in the upper 2 quartile subgroups were 2.39 µg/mL and 2.11 µg/mL respectively, compared with 3.45 µg/mL and 3.49 µg/mL in the lower 2 quartile subgroups (Table 2).

Similarly, at Week 24 in the ustekinumab 90 mg q12w group, median serum ustekinumab concentrations in the upper 2 quartile subgroups were 0.78 µg/mL and 0.85 µg/mL respectively, compared with 1.18 µg/mL and 1.46 µg/mL in the lower 2 quartile subgroups, respectively (Table 2).

Despite these trends, there was no notable impact of body weight on efficacy

| Table 1: Summary of Median Trough Serum Ustekinumab Concentrations (µg/mL) During Maintenance Through Week 44 by Baseline Body-weight Quartile Subgroups; Treated Subjects Who Were Randomized to Ustekinumab   | Table 1: Summary of Median Trough Serum Ustekinumab Concentrations (µg/mL) During Maintenance Through Week 44 by Baseline Body-weight Quartile Subgroups; Treated Subjects Who Were Randomized to Ustekinumab   | Table 1: Summary of Median Trough Serum Ustekinumab Concentrations (µg/mL) During Maintenance Through Week 44 by Baseline Body-weight Quartile Subgroups; Treated Subjects Who Were Randomized to Ustekinumab   | Table 1: Summary of Median Trough Serum Ustekinumab Concentrations (µg/mL) During Maintenance Through Week 44 by Baseline Body-weight Quartile Subgroups; Treated Subjects Who Were Randomized to Ustekinumab   | Table 1: Summary of Median Trough Serum Ustekinumab Concentrations (µg/mL) During Maintenance Through Week 44 by Baseline Body-weight Quartile Subgroups; Treated Subjects Who Were Randomized to Ustekinumab   | Table 1: Summary of Median Trough Serum Ustekinumab Concentrations (µg/mL) During Maintenance Through Week 44 by Baseline Body-weight Quartile Subgroups; Treated Subjects Who Were Randomized to Ustekinumab   | Table 1: Summary of Median Trough Serum Ustekinumab Concentrations (µg/mL) During Maintenance Through Week 44 by Baseline Body-weight Quartile Subgroups; Treated Subjects Who Were Randomized to Ustekinumab   | Table 1: Summary of Median Trough Serum Ustekinumab Concentrations (µg/mL) During Maintenance Through Week 44 by Baseline Body-weight Quartile Subgroups; Treated Subjects Who Were Randomized to Ustekinumab   | Table 1: Summary of Median Trough Serum Ustekinumab Concentrations (µg/mL) During Maintenance Through Week 44 by Baseline Body-weight Quartile Subgroups; Treated Subjects Who Were Randomized to Ustekinumab   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                                                 | Ustekinumab                                                                                                                                                                                                     | Ustekinumab                                                                                                                                                                                                     | Ustekinumab                                                                                                                                                                                                     | Ustekinumab                                                                                                                                                                                                     | Ustekinumab                                                                                                                                                                                                     | Ustekinumab                                                                                                                                                                                                     | Ustekinumab                                                                                                                                                                                                     | Ustekinumab                                                                                                                                                                                                     |
|                                                                                                                                                                                                                 | 90 mg SC q12w                                                                                                                                                                                                   | 90 mg SC q12w                                                                                                                                                                                                   | 90 mg SC q12w                                                                                                                                                                                                   | 90 mg SC q12w                                                                                                                                                                                                   | 90 mg SC q8w                                                                                                                                                                                                    | 90 mg SC q8w                                                                                                                                                                                                    | 90 mg SC q8w                                                                                                                                                                                                    | 90 mg SC q8w                                                                                                                                                                                                    |
|                                                                                                                                                                                                                 | ≤1st quartile a                                                                                                                                                                                                 | >1st and ≤2nd quartile a                                                                                                                                                                                        | >2nd and ≤3rd quartile a                                                                                                                                                                                        | >3rd quartile a                                                                                                                                                                                                 | ≤1st quartile a                                                                                                                                                                                                 | >1st and ≤2nd quartile a                                                                                                                                                                                        | >2nd and ≤3rd quartile a                                                                                                                                                                                        | >3rd quartile a                                                                                                                                                                                                 |
| Randomized PK Analysis Set; N                                                                                                                                                                                   | 43                                                                                                                                                                                                              | 44                                                                                                                                                                                                              | 42                                                                                                                                                                                                              | 43                                                                                                                                                                                                              | 43                                                                                                                                                                                                              | 47                                                                                                                                                                                                              | 41                                                                                                                                                                                                              | 44                                                                                                                                                                                                              |
| Week 8                                                                                                                                                                                                          | -                                                                                                                                                                                                               | -                                                                                                                                                                                                               | -                                                                                                                                                                                                               | -                                                                                                                                                                                                               | 3.54                                                                                                                                                                                                            | 4.00                                                                                                                                                                                                            | 1.95                                                                                                                                                                                                            | 2.02                                                                                                                                                                                                            |
| Week 12                                                                                                                                                                                                         | 1.24                                                                                                                                                                                                            | 1.39                                                                                                                                                                                                            | 1.12                                                                                                                                                                                                            | 1.09                                                                                                                                                                                                            | -                                                                                                                                                                                                               | -                                                                                                                                                                                                               | -                                                                                                                                                                                                               | -                                                                                                                                                                                                               |
| Week 16                                                                                                                                                                                                         | -                                                                                                                                                                                                               | -                                                                                                                                                                                                               | -                                                                                                                                                                                                               | -                                                                                                                                                                                                               | 2.91                                                                                                                                                                                                            | 3.68                                                                                                                                                                                                            | 2.07                                                                                                                                                                                                            | 2.18                                                                                                                                                                                                            |
| Week 24 b                                                                                                                                                                                                       | 1.18                                                                                                                                                                                                            | 1.46                                                                                                                                                                                                            | 0.78                                                                                                                                                                                                            | 0.85                                                                                                                                                                                                            | 3.45                                                                                                                                                                                                            | 3.49                                                                                                                                                                                                            | 2.39                                                                                                                                                                                                            | 2.11                                                                                                                                                                                                            |
| Week 32                                                                                                                                                                                                         | -                                                                                                                                                                                                               | -                                                                                                                                                                                                               | -                                                                                                                                                                                                               | -                                                                                                                                                                                                               | 3.74                                                                                                                                                                                                            | 3.40                                                                                                                                                                                                            | 2.27                                                                                                                                                                                                            | 2.13                                                                                                                                                                                                            |
| Week 36                                                                                                                                                                                                         | 1.18                                                                                                                                                                                                            | 1.28                                                                                                                                                                                                            | 0.75                                                                                                                                                                                                            | 0.87                                                                                                                                                                                                            | -                                                                                                                                                                                                               | -                                                                                                                                                                                                               | -                                                                                                                                                                                                               | -                                                                                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

Table 1: Summary of Median Trough Serum Ustekinumab Concentrations (µg/mL) During Maintenance Through Week 44 by Baseline Body-weight Quartile Subgroups; Treated Subjects Who Were Randomized to Ustekinumab

|         | Ustekinumab     | Ustekinumab              | Ustekinumab              | Ustekinumab     | Ustekinumab     | Ustekinumab              | Ustekinumab              | Ustekinumab     |
|---------|-----------------|--------------------------|--------------------------|-----------------|-----------------|--------------------------|--------------------------|-----------------|
|         | 90 mg SC q12w   | 90 mg SC q12w            | 90 mg SC q12w            | 90 mg SC q12w   | 90 mg SC q8w    | 90 mg SC q8w             | 90 mg SC q8w             | 90 mg SC q8w    |
|         | ≤1st quartile a | >1st and ≤2nd quartile a | >2nd and ≤3rd quartile a | >3rd quartile a | ≤1st quartile a | >1st and ≤2nd quartile a | >2nd and ≤3rd quartile a | >3rd quartile a |
| Week 40 | -               | -                        | -                        | -               | 4.01            | 3.25                     | 2.39                     | 2.16            |

Abbreviations: q8w=every 8 weeks; q12w=every 12 weeks a Quartiles are based on subjects in each treatment group as follows: 90 mg SC q12w: 1st quartile=59.70 kg, 2nd quartile=70.00 kg, 3rd quartile=83.50 kg. 90 mg SC q8w: 1st quartile=58.15 kg, 2nd quartile=70.00 kg, 3rd quartile=82.95 kg.

b Week 24 represents the only trough time point where data are available for both q8w and q12w regimens.

Adapted From: [TPKCONC03.RTF]

[CNTO1275\\UCO3001\\DBR\\_CSRWEEK44\\RE\\_CSRWEEK44\\PROD\\TPKCONC03.SAS] 23OCT2018, 17:56

## Effect of Immunomodulator use and biological failure status on serum Ustekinumab concentrations

There was no discernible impact of immunomodulators on serum ustekinumab concentrations. In the UCO3001 induction and maintenance studies, median serum ustekinumab concentrations in their respective treatment groups were similar between subjects who were receiving immunomodulators compared with those who were not receiving immunomodulators.

Serum ustekinumab concentrations in subjects with UC were evaluated by biologic failure status in the UCO3001 maintenance study. By their respective SC maintenance doses, median serum concentrations over time were generally comparable between subjects who had previously failed biologics and those who had not failed biologics

## Comparison of ustekinumb concentrations in UC and Crohn's studies

Following the same IV induction dose, ustekinumab peak concentrations were similar between subjects with UC (UCO3001 induction) and Crohn's disease (pooled CRD3001 and CRD3002 studies). At 1-hour postinfusion Week 0, median serum ustekinumab concentration in subjects with UC were 43.16 μg/mL and 127.0 μg/mL following a single IV infusion of ustekinumab 130 mg or ~6 mg/kg, respectively. In comparison, the corresponding data in subjects with Crohn's disease were 41.9 μg/mL and 126.1 μg/mL, respectively. At induction Week 8, the time of the primary efficacy endpoint in the UC and Crohn's disease studies, median serum ustekinumab concentration in subjects with UC were 2.51 μg/mL and 8.59 μg/mL following a single IV infusion of ustekinumab 130 mg or ~6 mg/kg, respectively. In comparison, the corresponding concentration data in subjects with Crohn's disease were slightly lower at 2.09 μg/mL and 6.36 μg/mL

<div style=\"page-break-after: always\"></div>

Following the same SC maintenance dose regimens, ustekinumab concentrations appeared slightly higher in subjects with UC compared with Crohn's disease. For example, at Week 24, median serum ustekinumab concentrations were 0.92 µg/mL and 2.74 µg/mL in subjects with UC in the SC ustekinumab 90 mg q12w and 90 mg q8w groups, respectively. The corresponding concentrations among subjects with Crohn's disease were 0.62 µg/mL and 2.11 µg/mL, respectively.

No notable difference in demographic characteristics or known covariates of ustekinumab PK between subjects with UC and Crohn's disease could account for this apparent difference in trough ustekinumab concentrations; however, the magnitude of the difference is not unusual considering the PK variability involved in cross-study comparisons for biological products.

## Neutralising antibodies

In the UCO3001 induction study, of the 4 treated subjects with UC who were positive for antibodies to ustekinumab through induction Week 8 in the UCO3001 induction study, 2 subjects were positive for Nabs

In the UCO3001 maintenance study, of the 39 treated subjects with UC who were positive for antibodies to ustekinumab through maintenance Week 44 of treatment with ustekinumab, 11 (28.2%) were positive for NAbs equating an overall incidence of 1.6% for Nabs

Of the 635 ustekinumab-treated subjects with appropriate samples through Week 8 in the UCO3001 induction study, 4 subjects (0.6%) were positive for antibodies to ustekinumab from Week 0 through Week 8.

Among 523 randomized subjects with appropriate samples in the UCO3001 maintenance study, the incidence of antibodies to ustekinumab was similar in subjects on 90 mg q12w (3.5%) and 90 mg q8w (3.4%) but higher among those receiving placebo after a single ustekinumab IV induction (9.1%).

Because of the limited number of subjects (N=28) who were positive for antibodies to ustekinumab at any time during maintenance through Week 44 in the randomized population, these results should be interpreted with caution.

## Population PK analysis

## Objectives

- To develop a population PK model to characterize the PK of ustekinumab in adult subject with UC following intravenous (IV) and subcutaneous (SC) administration of ustekinumab.
- To identify and quantify the effect of covariates which significantly influence ustekinumab PK in adult subjects with UC.
- To evaluate the necessity of covariate-based dose adjustment of ustekinumab in adult subjects with UC.
- To provide ustekinumab exposure metrics to facilitate further modeling analysis such as exposure-response analysis of ustekinumab in adult subjects with UC.

## Data

The population PK analysis was performed using data from subjects enrolled in the clinical development program for ustekinumab in UC which consisted of 1 induction study and 1 maintenance study, conducted under a single protocol (CNTO1275UCO3001). Both studies were Phase 3, randomized, double-blind, placebo-controlled, parallel-group, multicenter studies of ustekinumab in subjects with moderately to severely active UC.

<div style=\"page-break-after: always\"></div>

## Data handling

Fifty-five (55) serum ustekinumab concentration records from 27 subjects were removed from the analysis due to incorrect/incomplete sampling/dosing time, as pre-specified in the Analysis Plan.

All concentration records prior to the first ustekinumab dose were excluded from the analysis. These included 48 samples above the limit of quantification, and 1502 samples below the limit of quantification (BLQ).

Of the remaining 10,399 post-dose serum ustekinumab concentrations, 1364 samples (13.1%) were BLQ. These samples were excluded from the population PK analysis. Of note, approximately 80% (1162 out of 1364) of these samples came from subjects who received ustekinumab IV induction but were randomized to the placebo maintenance treatment. Therefore, the serum concentration values from these subjects are expected to be BLQ for a substantial portion of the maintenance study. Nevertheless, to avoid bias in the model parameter estimates as a result of excluding the censored BLQ data, a sensitivity analysis was conducted using the M3 approach1 in NONMEM for the final PK model, per the Analysis Plan.

21 post-dose ustekinumab concentration records from 12 subjects were excluded as outliers.

The final dataset included a total of 9,014 serum ustekinumab concentrations from 823 subjects with UC.

## Methods

The population PK analysis was performed using NONMEM (version 7.4.1). The first-order conditional estimation with interaction (FOCE-I) method was employed for all model runs.

The population PK analysis involved the development of a base model and a covariate model. The effects of body weight were included a priori on the clearance and volumes of distribution parameters in the base model. The covariate model development used a full-model approach with backward elimination (nominal p &lt;0.001). Covariates assessed in the popPK analysis are provided in Table 4. The final model was obtained by removing covariates with effect sizes less than 10% of the typical values of the respective PK parameter from the full covariate model. This reduced model was regarded as the final population PK model which was subsequently used for PK simulations and exposure-response modelling.

<div style=\"page-break-after: always\"></div>

| Table 4:                         | Covariates Assessed in the Population Pharmacokinetic Analysis                                                                                                                                                               | Covariates Assessed in the Population Pharmacokinetic Analysis   |
|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------|
| Category                         | Covariate                                                                                                                                                                                                                    | Type                                                             |
| Demographic Characteristics      | Weight (BWT), Age (AGE)                                                                                                                                                                                                      | Continuous                                                       |
| Demographic Characteristics      | Sex (SEX), Race (RACE)                                                                                                                                                                                                       | Discrete                                                         |
| Renal Function                   | Estimated creatinine clearance (CRCL)                                                                                                                                                                                        | Continuous                                                       |
| Laboratory Characteristics       | Baseline alkaline phosphatase (ALP), Baseline albumin (BALB), Baseline platelet (IPLT)                                                                                                                                       | Continuous                                                       |
| Baseline Disease Characteristics | Baseline Mayo score (BMAY), Disease duration (IDDUR), Baseline C-reactive protein (IBCRP)/over time (ICRPT), Baseline fecal calprotectin (ICALP)/over time (ICALPT)*, Baseline fecal lactoferrin (IFELA)/over time (IFELAT)a | Continuous                                                       |
| Baseline Disease Characteristics | Biologic failure status (FBIO), Extent of disease at baseline (IEXT), Baseline endoscopic subscore (ENDO)                                                                                                                    | Discrete                                                         |
| Concomitant Medication           | Immunomodulator use (ie, azathioprine/6-mercaptopurine/methotrexate) at baseline (BIMM) and over time (IMMT)a, Baseline corticosteroid use (CORT)/corticosteroid use over time (CSTT)a                                       | Discrete                                                         |
| Immunogenicity                   | Subject-level (IRP) and dynamic-level antibodies (IRPD/IRPT) to ustekinumab status (Positive/Negative)b                                                                                                                      | Discrete                                                         |
| Life Style                       | Current smoking status (SMOK)                                                                                                                                                                                                | Discrete                                                         |

UC PopPK Analysis Report

## Results

## Base model

A 2-compartment linear model with first-order absorption and first-order elimination was selected with IIV on CL, V2, V3, first-order absorption rate constant (Ka), and SC bioavailability (F1). Additionally, correlation terms were included between CL, V2 and V3 (Ω block), and between Ka and F1, respectively. The residual error was best described by a combined additive and proportional error model. The effects of body weight on V2, CL, Q, and V3 were included in the 2-compartment structural model, in line with the Analysis Plan.

## Covariate model

The impact of the covariates on the respective PK parameters in the full covariate model is illustrated in Figure 1.

<div style=\"page-break-after: always\"></div>

Figure 1. Effects of Covariates on the Population Pharmacokinetic Parameters of Ustekinumab in the Full Covariate Model (Run 78)

<!-- image -->

Effects of covariates assessed with the full covariate model. For discrete covariates, the covariate effects were the parameter estimates for status of 'Yes' relative to the reference of ^No'. For continuous covariates, the covariate effect was estimated as the ratio of E75/E25, where E25 and E75 represent PK parameter values corresponding to the covariate values at 25th percentile and 75th percentile of the population respectively.

Filled circles represent model predictions and solid line segments are the corresponding 90% confidence intervals. The associated values are shown on the right column. The gray vertical lines are the 80% to 125% bioequivalence intervals and the 90% to 110% significance interval.

Key: CL=clearance of the central compartment; Q=inter-compartmental clearance; V2=volume of distribution of the central compartment; V3=volume of distribution of the peripheral compartment.

## Final population PK model

The final population PK parameter estimates along with estimates of the included covariate effects are summarized in Table 5. All parameters were reasonably well described with relative standard errors (RSEs) less than 20% for all the structural PK and covariate effect parameter estimates with the exception of the effect of body weight on Q, which had a RSE of 41.2%. ETA shrinkages of the structural PK parameters were low to moderate (4.03% for CL, 17.2% and 18.1% for V2 and V3, respectively, and 33.5% and 31.6% for Ka and F1, respectively).

The typical population PK parameter estimates of ustekinumab for CL, Q, V2 and V3 in a UC subject weighing 71.2 kg was 0.186 L/day, 0.157 L/day, 3.01 L and 1.43 L, respectively. The typical Ka was approximately 0.142 day-1 and the typical subcutaneous F1 was approximately 87.2%. The estimate of the terminal elimination half-life (T1/2) derived from the typical population PK parameters was 19.2 days.

<div style=\"page-break-after: always\"></div>

The covariates in the final PK model included the effects of body weight on V2, V3, Q, CL, and the effects of BALB, SEX, and immune response status over time on CL. The potential impact of these factors on ustekinumab PK was further assessed by evaluating the PK parameter across a representative range of covariate values and compared with the typical population value of the parameter.

About 5.5% of subjects had antibodies to ustekinumab at any time; however, these subjects were not positive for antibodies at every evaluation time point. A total of 119 concentration records (out of 9014, 1.3%) were associated with positive antibodies to ustekinumab. Using the antibodies to ustekinumab over time status to model the effect of antibodies to ustekinumab on CL, a 14% higher CL was predicted for subjects with positive antibodies status compared to those with negative antibodies status.

Table 5. Parameter Estimates in the Final PopulationPharmacokinetic Model for Ustekinumabin Subjects with Ulcerative Colitis (Run 79)

| Parametersa                       | Estimateb            | 95% CI\"             | Magnitude of Changeh   |
|-----------------------------------|----------------------|---------------------|------------------------|
| CL (L/day)                        | 0.186 (1.68)         | (0.179, 0.192)      |                        |
| BWT on CL                         | 0.641 (7.52)         | (0.553, 0.737)      | -10.0% t0 +10.8%       |
| BALB on CL                        | -1.64 (7.78)         | (-1.91, -1.39)      | +8.5% t0 -10.9%        |
| SEX on CL                         | 1.08 (2.12)          | (1.04, 1.13)        | +8.0%                  |
| IRPD on CL                        | 1.14 (3.31)          | (1.08, 1.21)        | +14 %                  |
| Q (L/day)d                        | 0.157 (10.2)         | (0.121, 0.188)      |                        |
| BWT on Q                          | 0.631 (41.2)         | (0.154, 1.19)       | -9.9% to +10.6%        |
| V2 (L) e                          | 3.01 (0.815)         | (2.96, 3.07)        |                        |
| BWT on V2                         | 0.592 (4.74)         | (0.537, 0.651)      | -9.3% to +9.9%         |
| V3 (L)f                           | 1.43 (3.39)          | (1.31, 1.51)        |                        |
| BWT on V3                         | 0.667 (16.4)         | (0.473, 0.896)      | -10.4% to +11.3%       |
| Ka (1/day)                        | 0.142 (3.88)         | (0.127, 0.155)      |                        |
| F1                                | 0.872 (1.46)         | (0.845, 0.899)      |                        |
| IIV of V2 (CV%)                   | 5.45% (40.3) [17.2]b | (4.17%, 8.67%)      |                        |
| Covar (V2, CL)                    | 0.0112 (21.2)        | (0.00646, 0.0166)   |                        |
| IIV of CL (CV%)                   | 27.5% (6.13) [4.03]b | (25.8%, 29.3%)      |                        |
| Covar (V3, V2)                    | 0.0114 (38.1)        | (0.00216, 0.0261)   |                        |
| Covar (V3, CL)                    | -0.0186 (39.6)       | (-0.0346, -0.00445) |                        |
| IIV of V3 (CV%)                   | 41.2% (20.0) [18.1]b | (33.5%, 50.1%)      |                        |
| IIV of Ka (CV%)                   | 52.2% (12.3) [33.5]b | (45.6%, 58.4%)      |                        |
| Covar (F1, Ka)                    | -0.419 (13.9)        | (-0.588, -0.279)    |                        |
| IIV of F1 (CV%)                   | 130% (12.5) [31.6]b  | (114%, 144%)        |                        |
| Proportional residual error (CV%) | 19.2% (2.62)         | (18.2%, 20.0%)      |                        |
| Additive residual error (μg/mL)   | 0.0925 (21.3)        | (0.0532, 0.138)     |                        |

<!-- formula-not-decoded -->

h The magnitude of change in the parameter estimate caused by a continuous covariate was expressed as a range, ie, % change from the median value when the covariate factor varied from 25th percentile to 75th percentile of the population.

8 95% CI was obtained from 1000 bootstrap runs implemented in PsN.

<div style=\"page-break-after: always\"></div>

Overall, ustekinumab demonstrated similar PK characteristics in subjects with UC and Crohn's disease. The typical PK parameter estimates, including CL, V2, V3, Ka and F1, were reasonably consistent between these 2 disease populations (within 3-25%), with the exception of Q, which was ~ 45% lower in subjects with UC compared to those with Crohn's disease (0.157 versus 0.287 L/day). Model-derived typical half-lives were also comparable between subjects with UC and Crohn's disease (approximately 19 days). With respect to factors associated with ustekinumab PK, similar covariates such as body weight, BALB level, sex, and antibodies to ustekinumab were found to influence the PK of ustekinumab in both UC and Crohn's disease.

Figure 2 shows the basic goodness-of-fit plots for the final PK model. Overall, there was no apparent bias in these goodness-of-fit plots, suggesting that the final model predictions are in good agreement with the observed data.

Figure 2. Basic Goodness-of-fit Plots for Final Population Pharmacokinetic Model (Run 79)

<!-- image -->

The black solid line is the line of identity or the zero line, and the red solid line is the trend line. The blue circles are the observations.

Units: Observations or predictions=μg/ml; Time=day.

Key: liWRES|=absolute individual weighted residuals.

<div style=\"page-break-after: always\"></div>

The results of the sensitivity analysis implementing the M3 approach in NONMEM showed that the major PK parameters were similar (within 5% for CL, Q, V2, V3, Ka, and F1) to those in the final PK model; however, the condition number was much larger (7.82E+14) for the model with M3 implementation indicating an unstable model. These results suggest that there was no appreciable bias in the model parameter estimates as a result of excluding the censored BLQ data.

## Model Evaluation/Qualification

The performance of the final population PK model was evaluated using pcVPC (Figure 3) and VPC with stratifications by treatment group (Figure 4) and race (with respect to Japanese population) (data not shown). The final PK model adequately captured the median concentration-time profile of ustekinumab as well as the associated variabilities, across the treatment groups and race (with respect to Japanese population).

Figure 3. Predicted Corrected Visual Prediction Check for Final Population Pharmacokinetic Model

<!-- image -->

Red solid and dashed lines are the 50th and 5th/95th percentile of the observations. Black solid and dashed lines are the 50th and 5th/95th percentile of the model predictions. Green areas are the 90% confidence interval (CI) of the simulated median trend. Gray areas are the 90% CI of the simulated trends at 5th and 95th percentiles.

Key: TSLD=time since last dose

<div style=\"page-break-after: always\"></div>

Figure 4. Observed versus Simulated Serum Ustekinumab Concentration-Time Profiles Stratified by Treatment Groups for Final Population Pharmacokinetic Model

130mg IV →Placebo SC

6 mg/kg IV → Placebo SC

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

Red solid and dashed lines are the 50th and 5th/95th percentile of the observations. Black solid and dashed lines are the 50th and 5th/95th percentile of the model predictions. Green areas are the 90% CI of the simulated median trend. Gray areas are the 90% CI of the simulated trends at 5th and 95th percentiles.

Key: CI=confidence interval; IV=intravenous; q8w=every 8 weeks; q12w=every 12 weeks; SC=subcutaneous; TSLD=time since last dose; UC=ulcerative colitis.

<div style=\"page-break-after: always\"></div>

## Pharmacokinetic Simulations

The final population PK model was used to simulate 5000 ustekinumab concentration-time profiles following the dose regimens evaluated in the induction and maintenance UC studies and to compute the systemic exposure metrics during the induction and maintenance therapy, respectively. Subject level immune response IIRP was used in the simulation to capture the effects of antibodies to ustekinumab on ustekinumab PK.

Figure 5 shows the simulated median ustekinumab serum concentration-time profile following IV ustekinumab induction treatment at Week 0 and SC ustekinumab maintenance treatment from Week 8 and beyond. Figure 6 and Figure 7 show the predicted ustekinumab PK metrics during the induction and maintenance studies, respectively.

As shown in Figure 5, steady-state of serum ustekinumab concentrations for the maintenance study would be achieved by the start of the second maintenance dose following ustekinumab induction and maintenance treatment. With respect to maintenance, subjects with lower body weights tended to have higher serum steady-state ustekinumab exposures (Css,trough and Css,ave) (Figure 7). Simulations also suggest that the steady-state exposures would be similar among subjects who received different induction doses but had the same maintenance dose regimen.

<div style=\"page-break-after: always\"></div>

Figure 5. Predicted Median Concentration-Time Profiles for Induction and Maintenance Treatment of Ustekinumab by Regimen

By 130mgIV and ~6 mg/kg IVInduction Dose Regimen

By 130mgIV and 260/390/520mgIVInductionDoseRegimen

<!-- image -->

130 mg IV W0

390 mg IV WO

260 mg IV W0

520 mg IV w0

<!-- image -->

Simulations were conducted using the final population pharmacokinetic model (n=5,0oo).

Key: IV=intravenous; q8w=every 8 weeks; q12w=every 12 weeks; SC=subcutaneous.

<div style=\"page-break-after: always\"></div>

Figure 6. Simulated Ustekinumab Pharmacokinetic Exposures Over Induction Study Week8TroughConcentration

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

Simulations were conducted using the final population pharmacokinetic model (n= 5,ooo).

Key: IV=intravenous; q8w=every 8 weeks; q12w=every 12 weeks; SC=subcutaneous.

Predicted effects of dose adjustment on steady-state trough concentrations for subjects who experience loss of clinical response

Figure 8 shows the predicted ustekinumab steady-state trough concentrations for subjects who received the 90 mg SC q12w maintenance regimen and had a loss of clinical response during the maintenance study.

Among subjects who received 90 mg SC q12w, those who experienced loss of response tended to have a lower median steady-state serum trough concentration compared to those with a sustained clinical response (0.67 μg/mL versus 1.05 μg/mL, respectively; a difference of approximately 36%). If the dose regimen for the subjects who experienced loss of response on 90 mg q12w was adjusted to 90 mg SC q8w, their model predicted serum trough concentrations would increase about 3-fold from 0.67 μg/mL to 2.1 μg/mL, which is close to the median ustekinumab concentration observed in those receiving 90 mg q8w initially (2.74 μg/mL).

<div style=\"page-break-after: always\"></div>

Figure 8. Effects of Increased Maintenance Dose Regimen on Steady-State Trough Concentrations of Ustekinumab for Subjects Who Experienced Loss of Clinical Response

<!-- image -->

Key: q8w=every 8 weeks; q12w=every 12 weeks.

## 2.3.3. Pharmacodynamics

## Mechanism of action

Ustekinumab is a fully human IgG1κ monoclonal antibody that binds with specificity to the shared p40 protein subunit of human cytokines interleukin (IL) 12 and IL 23. Ustekinumab inhibits the bioactivity of human IL 12 and IL 23 by preventing p40 from binding to the IL 12Rβ1 receptor protein expressed on the surface of immune cells.

## 2.3.4. PK/PD modelling

## Exposure-response Analysis

The modeling evaluation of E-R with respect to efficacy was performed using a model-based approach with exposure metrics obtained from the population PK analysis of ustekinumab in UC.

## Induction

The results demonstrate a positive E-R, which implies that subjects who attain higher ustekinumab concentrations are more likely to be associated with clinical response at Week 8 than those with lower concentrations. Of note, in comparison with the 130 mg group, a greater proportion of subjects in the ~6 mg/kg group tend to achieve concentrations in the upper portion of the E-R curve associated with the highest clinical response rates at induction Week 8.

<div style=\"page-break-after: always\"></div>

Figure 1: Goodness-of-fit Plot for the Induction Exposure-response Model for Clinical Response at Week 8

<!-- image -->

The solid line curve represents the model-predicted probabilities of achieving clinical response by ustekinumab concentration at Week 8. The dark circle symbols represent observed clinical response rate in the placebo group (corresponding to zero concentration) and in each ustekinumab concentration quartile bin plotted at the median ustekinumab concentration for each bin. The vertical bars on each diamond symbol represent the 95% confidence intervals of the observed rates of clinical response based on the binomial distribution. The solid line segments at the bottom of the chart show the 5 th and 95 th percentiles of predicted concentrations at Week 8 with the open circles on the line segments plotted at the median values, for the 130 mg IV and the ~6 mg/kg doses, respectively.

## Maintenance

From the maintenance E-R model for clinical remission, remission status at randomization was an influential covariate on the intercept parameter. The model implies that subjects who were in clinical remission at randomization had a higher probability of being in clinical remission at Week 44 compared with those who were not in remission at randomization.

To assess the goodness-of-fit of the maintenance E-R model, the predicted serum ustekinumab concentrations were binned into quartiles and the predicted remission rates were computed for each concentration bin. The observed remission rates at maintenance Week 44 were also determined according to these bins. The goodness-of-fit plot by remission at randomization status for the maintenance E-R model is shown in Figure 13 below, while a comparison between the observed and predicted remission rates during maintenance is presented in Table 9 below. The distribution of the trough ustekinumab concentrations on the E-R curve suggests that, while the 90 mg q8w regimen may more effectively cover the upper portion of E-R curve associated with the highest clinical remission rates at maintenance Week 44, the 90 mg q12w regimen may also be effective for certain subjects, especially those already in remission following induction treatment.

<div style=\"page-break-after: always\"></div>

Figure 13: Goodness-of-fit Plot for the Maintenance Exposure-response Model

<!-- image -->

<div style=\"page-break-after: always\"></div>

| Table 2: Assessment of the Goodness-of-fit of the Maintenance Exposure-response   | Model                          | Model             | Model                | Model             |
|-----------------------------------------------------------------------------------|--------------------------------|-------------------|----------------------|-------------------|
|                                                                                   | Ustekinumab Concentration Bins | N                 | %Observed (95% CI) a | %Predicted b      |
| Global Definition                                                                 | Global Definition              | Global Definition | Global Definition    | Global Definition |
| Not in remission at randomization                                                 | Placebo (0.0 µg/mL)            | 125               | 16.8 (10.2,          | 15.8              |
|                                                                                   | 0.0164 to <0.801 µg/mL         | 66                | 18.2 (8.88,          | 24.9              |
|                                                                                   | 0.801 to <1.7 µg/mL            | 64                | 28.1 (17.1,          | 32.4              |
|                                                                                   | 1.7 to <3.04 µg/mL             | 66                | 40.9 (29.0,          | 37.9              |
|                                                                                   | ≥3.04 µg/mL                    | 51                | 49.0 (35.3,          | 42.9              |
| In remission at randomization                                                     | Placebo (0.0 µg/mL)            | 50                | 42.0 (28.3,          | 38.2              |
| In remission at randomization                                                     | 0.0164 to <0.801 µg/mL         | 20                | 45.0 (23.2,          | 53.8              |
| In remission at randomization                                                     | 0.801 to <1.7 µg/mL            | 23                | 78.3 (61.4,          | 61.3              |
| In remission at randomization                                                     | 1.7 to <3.04 µg/mL             | 20                | 60.0 (38.5,          | 66.3              |
| In remission at randomization                                                     | ≥3.04 µg/mL                    | 36                | 61.1 (45.2,          | 70.7              |
| US Definition                                                                     | US Definition                  | US Definition     | US Definition        | US Definition     |
| Not in remission at randomization                                                 | Placebo (0.0 µg/mL)            | 125               | 16.8 (10.2,          | 16.4              |
| Not in remission at randomization                                                 | 0.0164 to <0.801 µg/mL         | 66                | 22.7 (12.6,          | 26.6              |
| Not in remission at randomization                                                 | 0.801 to <1.7 µg/mL            | 64                | 31.2 (19.9,          | 32.9              |
| Not in remission at randomization                                                 | 1.7 to <3.04 µg/mL             | 66                | 36.4 (24.8,          | 36.7              |
| Not in remission at randomization                                                 | ≥3.04 µg/mL                    | 51                | 45.1 (31.4,          | 39.7              |
| In remission at randomization                                                     | Placebo (0.0 µg/mL)            | 50                | 44.0 (30.2,          | 39.7              |
|                                                                                   | 0.0164 to <0.801 µg/mL         | 20                | 45.0 (23.2,          | 56.3              |
|                                                                                   | 0.801 to <1.7 µg/mL            | 23                | 78.3 (61.4,          | 62.3              |
|                                                                                   | 1.7 to <3.04 µg/mL             | 20                | 60.0 (38.5,          | 65.7              |
|                                                                                   | ≥3.04 µg/mL                    | 36                | 61.1 (45.2,          | 68.5              |

Abbreviations: CI=confidence interval.

a  95% CI around the observed data was computed based on the normal approximation for proportions.

b  Calculated using median ustekinumab concentration of each bin.

## 2.3.5. Discussion on clinical pharmacology

Overall, the popPK analyses were conducted adequately. The goodness-of-fit plots did not suggest any model misspecifications. There were no apparent trends in the residual plots. The predictive performance of the model was demonstrated in the VPCs.

Body weight was the primary covariate contributing to the observed PK variability of ustekinumab where CL, Q, V2 and V3 increased non-linearly with body weight. In addition, subjects with higher baseline serum albumin levels had lower CL. Male subjects tended to have 8% higher CL compared to females, and the development of antibodies to ustekinumab was associated with a 14% increase in CL. Nevertheless, the impacts of these covariates on the respective PK parameters were all within the 0.8 to 1.25 range when evaluated across the 25th to 75th percentile of covariate values or categories in the analysis dataset. Therefore, none of these covariates were deemed to be clinically significant.

Ustekinumab demonstrated similar PK characteristics in subjects with UC and Crohn's disease. With respect to factors associated with ustekinumab PK, similar covariates such as body weight, BALB level,

UC Exposure-response Analysis Report

<div style=\"page-break-after: always\"></div>

sex, and antibodies to ustekinumab were found to influence the PK of ustekinumab in both UC and Crohn's disease. Additionally in Crohn's disease, clearance was affected by C-reactive protein, TNF antagonist failure status and race (Asian versus non-Asian) (5.2 of the SmPC).The PopPK and the serum concentration results are generally consistent with the Crohn's data except for the slightly higher concentrations in UC.

The body weight effect on clearance appears small (~10%) but statistically significant. It is notable that bodyweight had no effect on efficacy. However among all the covariates that influence the PK of ustekinumab, body weight was the most significant covariate for ustekinumab PK and was adopted in the Phase 3 IV induction studies in Crohn's disease and UC to account for the impact of body weight on ustekinumab exposure. It is also noted that selection of the ~6 mg/kg dose was based on the efficacy and safety of the ~6 mg/kg dose at Week 8, as well as on results through maintenance in subjects who received this dose. Clinical response and the proportion of subjects with a rectal bleeding subscore of 0 was greater at week 8 for the 6mg/kg and this considered clinically important. The company has also demonstrated that subjects who were originally randomized to ~6 mg/kg perform better in maintenance than those originally randomized to 130 mg across a range of endpoints with both higher absolute efficacy rates and larger differences versus placebo. Therefore the proposed induction dose is agreed.

Based on currently available data, the development of antibodies to ustekinumab did not have a notable impact on clinical efficacy as measured by multiple endpoints such as clinical remission at Week 44, clinical response at Week 44, and endoscopic healing at Week 44. Because of the limited number of subjects (N=28) who were positive for antibodies to ustekinumab at any time during maintenance through Week 44 in the randomized population, these results should however be interpreted with caution.

In other indications such as Crohn's disease, where impact on efficacy was assessed through 2 years of treatment similar efficacy was observed in subjects who were positive for antibodies to ustekinumab and those who were not. In psoriasis through 5 years of treatment there was some reduced efficacy in subjects who were positive for antibodies to ustekinumab; however, antibody positivity did not preclude a clinical response. With these data, the CHMP does not consider that there are specific reasons for concern regarding the impact of immunogenicity on loss of efficacy for ustekinumab. Also it is noted that the applicant will continue evaluating the effect of antibodies to ustekinumab on efficacy during the CNTO1275UCO3001 long-term extension (which is included in the EU RMP as a category 3 Post-authorisation Safety Study [PASS]) which is acceptable.

## 2.3.6. Conclusions on clinical pharmacology

No formal dose-ranging was studied for ustekinumab in UC and the dose regimens selected were those studied in the Phase 3 program for ustekinumab in subjects with CD.The company submitted PK data for serum concentration, exposure-response analysis and PopPK based on the pivotal phase 3 induction and maintenance study UCO3001 which is considered acceptable. Pharmacokinetics (PK), exposure-response (E-R) relationships, immunogenicity, pharmacodynamics, and biomarker data have been thoroughly investigated in the clinical studies (induction + maintenance) to support the UC indication. The PK characteristics in subjects with ulcerative colitis were overall comparable to what has previously been observed in subjects with Crohn's disease with no unexpected findings.

## 2.4. Clinical efficacy

## 2.4.1. Dose response study(ies)

<div style=\"page-break-after: always\"></div>

## Induction Dose Rationale

Although no formal dose ranging was studied for ustekinumab in UC, dose ranging was performed in a Phase 2 study of ustekinumab in Crohn's disease. The rationale that follows justified the 2 induction regimens studied in UC.

Intravenous administration was chosen for the induction studies in the ustekinumab Crohn's disease program, and subsequently in the UC program, because the evaluation of biomarker changes in response to ustekinumab treatment in the Phase 2a ustekinumab study in Crohn's disease (C0379T07) suggested a very rapid onset of action after IV administration that was not observed after SC administration.

The specific IV doses selected for the Phase 3 induction studies were based on the results of the Phase 2b ustekinumab study in Crohn's disease (C0743T26).  Greater proportions of subjects in the ustekinumab 1 mg/kg, 3 mg/kg, and 6 mg/kg treatment groups were in clinical response at Week 6 (36.6%, 34.1%, and 39.7%, respectively) and at Week 8 (32.1%, 31.8%, and 43.5%, respectively) compared with placebo (23.5% and 17.4% at Weeks 6 and 8, respectively). However, in the 1 mg/kg group, serum ustekinumab concentrations through Week 8 appeared lower in nonresponders at Week 6, a difference that was not apparent in the other treatment groups. Subjects in the 1 mg/kg group also appeared to lose response earlier than in the 3 mg/kg or 6 mg/kg treatment groups, suggesting that the 1 mg/kg group may not provide sufficient drug exposure to achieve or maintain clinical response through 8 weeks. Accordingly, it was determined that a single 6 mg/kg IV dose (which was well tolerated and was the most effective induction dose in C0743T26), along with a lower dose (that was higher than 1 mg/kg), would be evaluated in the Phase 3 Crohn's disease studies. In addition, an approach was adopted that allowed the use of complete vials, resulting in simpler drug administration. Based on these considerations, a ustekinumab 130 mg IV fixed dose (approximately 2 mg/kg on a milligram per kilogram basis) was chosen for the low-dose group and weight-range-based doses approximating 6 mg/kg IV ( ≤ 55 kg: 260 mg ustekinumab; &gt;55-85 kg: 390 mg ustekinumab; &gt;85 kg: 520 mg ustekinumab) were chosen as the high-dose group in the Phase 3 Crohn's disease studies. Given the similarity in the underlying inflammatory mechanism of UC and Crohn's disease and the similar response to available treatments, these same doses (ustekinumab 130 mg IV and weight-range-based doses approximating 6 mg/kg IV) were chosen for the ustekinumab induction study in UC.

## Maintenance Dose Rationale

The 2 SC ustekinumab regimens used in the UC maintenance study were also the same as those in the Phase 3 maintenance study in the ustekinumab Crohn's disease program, ustekinumab 90 mg every 12 weeks (q12w) and 90 mg every 8 weeks (q8w). The ustekinumab 90 mg SC q8w regimen was selected because it was considered safe and effective in achieving remission among subjects randomized as responders to ustekinumab induction in the Phase 2b Crohn's disease study. To explore a lower dose regimen, the ustekinumab 90 mg SC q12w regimen was included because it was the next lower dose SC regimen that had been studied extensively in psoriasis and was considered likely to succeed in maintaining clinical efficacy over time in patients with Crohn's disease. These maintenance doses provided systemic exposures that were likely to meet the safety and efficacy objectives for the development of ustekinumab in Crohn's disease and subsequently in UC.

<div style=\"page-break-after: always\"></div>

## 2.4.2. Main study(ies)

A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis

## Study Design for CNTO1275UCO3001

<!-- image -->

## - Induction Study -

## Methods

## Study participants

A total of 961 subjects from 244 sites were randomized according to the following regions:

- •
- Asia: 13.8%
- Eastern Europe: 38.2%
- Rest of World: 48.0% (including North America, Western Europe, Israel, Australia, and New Zealand)

<div style=\"page-break-after: always\"></div>

## Inclusion Criteria

- Eligible subjects were men or women 18 years of age or older with moderately to severely active UC, as defined by a Mayo score of 6 to 12, inclusive, at Week 0 of the study, including an endoscopy subscore ≥2 as assessed during central review of the video of the endoscopy.
- Subjects may have been biologic failures, ie, have received treatment with 1 or more TNF antagonists or vedolizumab (an integrin receptor antagonist) at a dose approved for the treatment of UC, and either did not respond initially, responded initially but then lost response, or were intolerant of the medication. A minimum of 40% and a maximum of 50% of the total subject population in the induction study were to be biologic failures.

## OR

- Subjects may have been biologic-naïve or may have been exposed to biologic therapy but did not demonstrate an inadequate response or intolerance to treatment with a biologic agent (ie, a TNF antagonist, or vedolizumab). These subjects must have demonstrated an inadequate response to, or have failed to tolerate, at least 1 of the following conventional UC therapies: oral or IV corticosteroids or the immunomodulators azathioprine (AZA) or6-mercaptopurine (6-MP). Subjects who demonstrated corticosteroid dependence (ie, an inability to successfully taper corticosteroids without a return of the symptoms of UC) were also eligible for entry into the study.

All UC-specific medical therapies were to be maintained at stable doses throughout the induction study, and could only be discontinued or reduced in dose if in the investigator's judgment this was required because of toxicity or medical necessity.

## Exclusion Criteria

Subjects who met any of the following criteria were ineligible for entry into the study:

- Severe extensive colitis as evidenced by:
- o Hospitalization for the treatment of UC
- o Investigator judgment that the subject was likely to require a colectomy within 12 weeks of baseline
- o Symptom complex at screening or baseline visits that included at least 4 of the following:
-  Diarrhoea with ≥6 bowel movements/day with macroscopic blood in stool
-  Focal severe or rebound abdominal tenderness
-  Persistent fever (≥37.5°C)
-  Tachycardia (&gt;90 beats/minute)
-  Anaemia (hemoglobin &lt;8.5 g/dL)
- Subjects with UC limited to the rectum only or &lt;20 cm of the colon.
- Presence of a stoma, a fistula, a bowel obstruction, or adenomatous colonic polyps that were not removed.
- Diagnosis of indeterminate colitis, microscopic colitis, ischemic colitis, or Crohn's disease, or clinical findings suggestive of Crohn's disease.
- A stool culture or other examination that was positive for an enteric pathogen, including

<div style=\"page-break-after: always\"></div>

Clostridium difficile toxin, in the previous 4 months, unless a repeat examination was negative and there were no signs of ongoing infection with that pathogen.

## Treatments

The ustekinumab dose regimens selected for the UCO3001 induction and maintenance studies in subjects with UC were the same as those that were being studied in the Phase 3 program for ustekinumab in subjects with Crohn's disease.

The dose regimens studied in the Phase 3 Crohn's disease program were based on the dose-finding data and the efficacy and safety results from the Phase 2 studies of ustekinumab in Crohn's disease

The subsequent results from the Phase 3 Crohn's disease program confirmed that these were appropriate doses and are reflected in the approved posology for use in Crohn's disease.

All subjects were randomized in a 1:1:1 ratio (using permuted block randomization stratified by biologic failure status [yes or no] and region [Eastern Europe, Asia, or rest of world]) to receive a single IV administration of placebo or one of two induction doses of ustekinumab at Week 0 as follows:

## Placebo IV

Ustekinumab 130 mg IV (130 mg group)

Weight-range-based dose approximating ustekinumab 6 mg/kg IV (~6 mg/kg group):

Ustekinumab 260 mg (body weight ≤55 kg)

Ustekinumab 390 mg (body weight &gt;55 kg but ≤85 kg)

Ustekinumab 520 mg (body weight &gt;85 kg)

Subjects who did not achieve a clinical response at Week 8, including subjects who received placebo at Week 0, received an additional dose of study agent in a blinded manner at Week 8. Subjects who were in clinical response at Week 8 or Week 16 were eligible to enter the maintenance study. Subjects who did not enter the maintenance study were to have a safety follow-up visit approximately 20 weeks after the last administration of study agent.

<div style=\"page-break-after: always\"></div>

## Schema for CNTO1275UCO3001 Induction Study

<!-- image -->

Subjects who were in clinical response at Week 8 (based on local endoscopy) were eligible to enter the maintenance study. Subjects who were not in clinical response at Week 8 received ustekinumab at Week 8,as shown in Figure 3. Those who subsequently responded at Week 16 were eligible to enter the maintenance study; those who were not in clinical response at Week 16 were discontinued from study agent.

## Treatment of Subjects who were not in Clinical Response at Week 8 in the CNTO1275UCO3001 Induction Study

<!-- image -->

Subjects were permitted to receive concomitant UC medications (ie, oral 5-aminosalicylates [5-ASAs], oral corticosteroids, and immunomodulators [6-MP, AZA, and methotrexate (MTX)]); the dosage was to remain stable (including corticosteroids) without initiation or increase throughout the induction study. Subjects who initiated or increased the dose of a UC- specific medication (or any restricted/prohibited medication) during the induction study were prohibited from entering the maintenance study.

An interim analysis (IA) was conducted in the induction study to assess futility. This analysis occurred when the first 30% of randomized subjects had either completed the induction Week 8 visit or terminated

<div style=\"page-break-after: always\"></div>

study participation before Week 8. Based on the criteria defined in the Interim Analysis Plan (IAP), the induction study was continued as planned. The IA was conducted by the Data Monitoring Committee (DMC), and the Applicant remained blinded to treatment assignment.

## Objectives

## Primary Objectives

The primary objectives of the induction study were:

- To evaluate the efficacy of IV ustekinumab in inducing clinical remission in subjects with moderately to severely active UC.
- To evaluate the safety of IV ustekinumab in subjects with moderately to severely active UC.

## Secondary Objectives

- The secondary objectives of this study were:
- To evaluate the efficacy of IV ustekinumab in inducing endoscopic healing (ie, improvement in the endoscopic appearance of the mucosa) in subjects with moderately to severely active UC.
- To evaluate the efficacy of IV ustekinumab in inducing clinical response in subjects with moderately to severely active UC.
- To evaluate the impact of IV ustekinumab on disease-specific health-related quality of life.
- To evaluate the efficacy of ustekinumab treatment on mucosal healing (a combination of endoscopic healing and histologic healing).
- To evaluate the efficacy of induction therapy with IV ustekinumab by biologic failure status.

## Exploratory Objectives

The exploratory objectives were:

- To evaluate response using the Mayo score without the physician's global assessment (PGA) subscore.
- To evaluate the performance of the Bristol Stool Form Scale (BSFS) score.

Terminology of some endpoints used in the UC dossier is different than the terminology proposed to be used in the EU Product Information. The proposed terminology for the EU Product Information is in line with the terminology used in the EU label of other approved products and/or the UC guideline (CHMP/EWP/18463/2006 Rev 1). An overview of the different terminologies is included in Table 10.

| 10: Endpoint Terminology for Product Information   | 10: Endpoint Terminology for Product Information   |
|----------------------------------------------------|----------------------------------------------------|
| Global Dossier                                     | Product information                                |
| Endoscopic healing #                               | Mucosal healing                                    |
| Mucosal healing ¥                                  | Histo-endoscopic mucosal healing                   |
| Durable Partial Mayo Remission §                   | Durable Remission                                  |

<div style=\"page-break-after: always\"></div>

## Outcomes/endpoints

## Primary Endpoint

- Clinical remission at Week 8. Clinical remission was defined as a Mayo score ≤2 points, with no individual subscore &gt;1.

Major Secondary Endpoints (presented in the order in which they were tested)

- Endoscopic healing at Week 8. Endoscopic healing (ie, improvement in the endoscopic appearance of the mucosa) was defined as an endoscopy subscore of the Mayo score of 0 or 1.
- Clinical response at Week 8. Clinical response was defined as a decrease from baseline in the Mayo score by ≥30% and ≥3 points, with either a decrease from baseline in the rectal bleeding subscore ≥1 or a rectal bleeding subscore of 0 or 1.
- The change from induction baseline in the total score of the IBDQ at Week 8.

## Other Multiplicity-Controlled Endpoint:

· Mucosal healing at Week 8. Mucosal healing was defined as a combination of histologic healing and endoscopic healing. Histologic healing, based on features of the Geboes score, was defined as neutrophil infiltration in &lt;5% of crypts, no crypt destruction, and no erosions, ulcerations, or granulation tissue.

Efficacy results presented for CNTO1275UCO3001 induction and maintenance studies were based on central review of endoscopies.

## Sample size

Induction study analyses were based on the 961 subjects who were randomized 1:1:1 to receive placebo IV, ustekinumab 130 mg IV, or ustekinumab ~6 mg/kg IV.

Efficacy results for the 157 subjects who were ustekinumab induction delayed responders and received 90 mg q8w in maintenance were not included the primary population or key efficacy analyses

The sample size in the induction study was based on statistical power considerations and the objective of providing the primary population for the maintenance study.

Sample size/power calculations were based on the chi-square test to detect a significant difference for the primary endpoint of clinical remission at Week 8 between the induction ustekinumab treatment groups and placebo.

It was assumed that the clinical remission rate based on the global definition is 19% for each induction ustekinumab treatment group and 7% for the placebo group. These remission rates were similar to those from other recently approved therapies in active UC.  The treatment effect was assumed to be the same for the 2 induction ustekinumab treatment groups because the data from the Phase 2b study of ustekinumab in Crohn's disease showed similar levels of response across the range of doses studied.

Assuming a 7% clinical remission (global definition) rate in the placebo group and 19% in each ustekinumab group, 135 subjects per treatment group (405 subjects in total) will provide an overall power of 90% using a step-up Hochberg procedure at the 0.05 (2-sided) level.

<div style=\"page-break-after: always\"></div>

To provide a sufficient number of subjects for the primary population in the maintenance study, however, it was estimated that a target of 951 subjects (317 subjects per treatment group) should be enrolled in the induction study. Therefore, enrolment in the induction study was to continue until at least 951 subjects have been enrolled. The table below show the power for detecting a treatment difference between the ustekinumab induction treatment groups and the placebo group based on different proportions of subjects in clinical remission at Week 8 for the global definition with a fixed sample size of 951.

| Table 1:                                                  | Power for detecting a treatment effect based on different proportions of subjects in clinical remissionatWWeek8(global definition)withafixedsamplesizeof 951subjects(317per treatment group)   | Power for detecting a treatment effect based on different proportions of subjects in clinical remissionatWWeek8(global definition)withafixedsamplesizeof 951subjects(317per treatment group)   | Power for detecting a treatment effect based on different proportions of subjects in clinical remissionatWWeek8(global definition)withafixedsamplesizeof 951subjects(317per treatment group)   |
|-----------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Proportion of Subjectsin Clinical Remission at Week 8 (%) | Proportion of Subjectsin Clinical Remission at Week 8 (%)                                                                                                                                      | Proportion of Subjectsin Clinical Remission at Week 8 (%)                                                                                                                                      | Powera (%)                                                                                                                                                                                     |
| Placebo                                                   | OneUstekinumab TreatmentGroup                                                                                                                                                                  | OtherUstekinunab TreatmentGroup                                                                                                                                                                | Powera (%)                                                                                                                                                                                     |
| 7                                                         | 19                                                                                                                                                                                             | 19                                                                                                                                                                                             | 99                                                                                                                                                                                             |
|                                                           | 15                                                                                                                                                                                             | 19                                                                                                                                                                                             | 99                                                                                                                                                                                             |
|                                                           | 13                                                                                                                                                                                             | 15                                                                                                                                                                                             | 90                                                                                                                                                                                             |
|                                                           | 14                                                                                                                                                                                             | 14                                                                                                                                                                                             | 89                                                                                                                                                                                             |
|                                                           | 7                                                                                                                                                                                              | 16                                                                                                                                                                                             | 92                                                                                                                                                                                             |
|                                                           | 7                                                                                                                                                                                              | 15                                                                                                                                                                                             | 85                                                                                                                                                                                             |
|                                                           | 7                                                                                                                                                                                              | 14                                                                                                                                                                                             | 75                                                                                                                                                                                             |

The applicant argued that a sample size of 951 subjects (317 per treatment group) also provides sufficient power for the major secondary endpoints of endoscopic healing at Week 8 and clinical response at Week 8. The applicant argued that the given sample size will provide 99% power to detect a 15% difference (40% vs 25% for each ustekinumab dose group vs placebo) in endoscopic healing at Week 8 and to detect a 20% difference (50% vs 30% for each ustekinumab dose group vs placebo) in clinical response at Week 8 based on the Hochberg testing procedure at the 0.05 (2-sided) level. The Applicant stated that the assumptions noted above are based on the relevant clinical difference observed for other biologics in this indication.

## Randomisation

Randomisation was used to minimize bias in the assignment of subjects to groups, to increase the likelihood that known and unknown subject attributes (e.g. demographic and baseline characteristics) were evenly balanced across all treatment groups, and to enhance the validity of statistical comparisons across all treatment groups. Blinded treatment was used to reduce potential bias during data collection and evaluation of clinical endpoints.

Central randomisation for treatment allocation was implemented in the induction study. A computer-generated randomization schedule was prepared for this study under the supervision of the sponsor or delegate. At each call to the interactive web response system (IWRS) for a treatment assignment, the IWRS assigned a treatment code that dictated the treatment assignment and matching study agent kit for each subject.

Subjects were randomised to 1 of 3 groups (placebo IV, ustekinumab 130 mg IV, or ustekinumab ~6 mg/kg IV) at Week 0, using permuted block randomization with biologic failure status (yes/no) and region (Eastern Europe, Asia, or rest of world) as stratification variables.

<div style=\"page-break-after: always\"></div>

## Blinding (masking)

To maintain the study blind, the study agent container had a label containing the study name, medication number, and reference number. A tear-off label was designed to be torn off, separated from the study agent container, and attached to the subject's source documents. The label did not identify the study agent in the container. The medication number was entered in the electronic case report form (eCRF) when the drug was dispensed. The study agents were identical in appearance and packaging.

The investigator was not provided with randomization codes. The codes were maintained within the IWRS, which has the functionality to allow the investigator to break the blind for an individual subject.

Data that may have potentially unblinded the treatment assignment (ie, study agent serum concentrations, antibodies to study agent) were handled with special care to ensure that the integrity of the blind was maintained and the potential for bias was minimized. The post baseline results of CRP, faecal lactoferrin, and faecal calprotectin tests performed by the central laboratory were blinded to the investigative sites.

Treatment assignment blinding is to be maintained for investigative sites, site monitors, and subjects participating in this study until the Week 44 analyses for the maintenance study are completed.

## Statistical methods

## Analysis Populations

The Primary Efficacy Analysis Set consisted of all subjects randomized in the induction study. Following the Intention-to-Treat (ITT) principle, all subjects were to be analysed according to the treatment to which they were assigned regardless of the treatment they actually received.

Some pre-specified efficacy analyses will also be conducted for the Week 8 Treated Analysis Set , which consists of subjects who are not in clinical response at Week 8 as determined by the IWRS and receive ustekinumab at Week 8.

## Analysis Methods - Primary endpoint

The global definition of clinical remission is: A Mayo score ≤2 points, with no individual subscore &gt;1. In addition to the clinical remission status based on the Mayo score, treatment failure rules will be applied to determine the final clinical remission status for a subject. Subjects who have a protocol-defined treatment failure prior to Week 8 will be considered not to be in clinical remission at Week 8, regardless of the actual computation of clinical remission based on the Mayo score. Subjects who have all 4 Mayo subscores missing at Week 8 will be considered not to be in clinical remission. If 1 or more of the 4 Mayo subscores is missing at a specific visit, but not all 4 subscores are missing, the last available value for each missing subscore will be carried forward to compute a full Mayo score (where the full mayo score is scheduled to be collected).

The proportions of subjects in clinical remission were to be compared between each ustekinumab treatment group and the placebo group using a Cochran-Mantel-Haenszel (CMH) chi-square test stratified by biologic failure status (yes or no) and region (Eastern Europe, Asia, or Rest of World).

Summaries of the proportion of subjects in clinical remission by treatment group, the adjusted treatment difference (with Cochran-Mantel-Haenszel weight) between each ustekinumab treatment group and the placebo group, as well as the associated 95% confidence interval were to be provided.

<div style=\"page-break-after: always\"></div>

## Sensitivity Analyses - Primary endpoint

The following sensitivity analyses were to be performed to examine the robustness of the primary endpoint analysis for the global definition of the primary endpoint:

Sensitivity Analysis 1 ( ' modified ITT ' analysis): excludes subjects who are randomized but not treated.

Sensitivity Analysis 2 (Observed case): excludes subjects who have missing data at Week 8 and have not had an event of treatment failure prior to Week 8.

For the global definition, subjects with missing data are those who are missing all four Mayo subscores.

Sensitivity Analysis 3 (LOCF for missing data): For subjects with missing data at Week 8 (as defined in Sensitivity Analysis 2), the last available value for each subscore will be carried forward to impute missing data.

Sensitivity Analysis 4 (nonresponder if any missing subscore ): subjects with missing data for any of the Mayo components pertaining to the primary endpoint (ie, the four Mayo subscores for the global definition and the absolute stool number, Mayo rectal bleeding

subscore, and Mayo endoscopy subscore for the US-specific definition) at Week 8 are considered not to be in clinical remission.

Sensitivity Analysis 5 (per-protocol ' analysis): excludes subjects with at least 1 of the following deviations that might affect efficacy:

- a. subject is found to have Crohn's disease instead of UC
- b. subject is randomized, but does not receive study agent
- c. subject receives the incorrect study agent or dose at Week 0, or
- d. subject does not meet major inclusion criteria or does meet major exclusion criteria, or has other deviations that will be identified and documented prior to unblinding.

Sensitivity Analysis 6 (logistic regression): For the global definition, the primary endpoint will be analyzed based on a logistic regression with treatment group, baseline Mayo score, biologic failure status, and region as covariates.

Sensitivity Analysis 7 (multiple imputation): This analysis will be based on the multiple imputation method which involves the following distinct steps:

- 1) The missing Mayo components pertaining to the primary endpoint (see Sensitivity Analysis number 4) at Week 8 will be imputed 5 times to generate 5 complete data sets using the Markov Chain Monte Carlo method, assuming missing at random (MAR) and a multivariate normal distribution (since the amount of missing data will be minimal based on the past UC induction studies). The following variables will be included in the imputation model: Mayo components at Week 0, treatment group, biologic failure status, and region.
- 2) Before the multiple imputation method is applied, the Mayo data after treatment failure will be set to missing. For each multiple-imputed data set, each subject ' s clinical remission status at Week 8 will be calculated.

<div style=\"page-break-after: always\"></div>

- 3) Each of the 5 resulting data sets will be analyzed using a logistic regression model with treatment group, baseline Mayo score (for global definition) or baseline modified Mayo score (for US-specific definition), biologic failure status, and region as covariates.
- 4) The results from the 5 data sets will be combined to produce inferential results.

Sensitivity Analysis 8 (clinical remission based on local endoscopy subscores): the primary analysis will be repeated with clinical remission derived based on local endoscopy subscores, instead of the final reported endoscopic subscores.

Sensitivity Analysis 9 (Worst case): subjects receiving placebo who have missing data at

Week 8 and have not had an event of treatment failure prior to Week 8 will be considered to be in clinical remission, and subjects receiving ustekinumab who have missing data at Week 8 will be considered not to be in clinical remission.

For Sensitivity Analyses 1, 5, 6 and 8 the same missing data rules as are used in the primary analysis were also to be applied. Note that treatment failure rules were to override the missing data rules. Subjects who had a treatment failure prior to Week 8 were considered not to be in clinical remission at Week 8, regardless of the observed or missing data.

## Analysis Methods - Major secondary endpoints

The major secondary endpoint analyses were to be based on the Primary Efficacy Analysis Set.

The proportions of subjects with endoscopic healing at Week 8 and the proportions of subjects in clinical response at Week 8 were to be compared between each ustekinumab treatment group and the placebo group using a 2-sided CMH chi-square test stratified by biologic failure status and region. Summaries of the proportion of subjects with endoscopic healing by treatment group and summaries of the proportion of subjects in clinical response by treatment group, the adjusted treatment difference (with Cochran-Mantel-Haenszel weight) between each ustekinumab treatment group and the placebo group for each of these two endpoints, as well as the associated

95% confidence interval (97.5% confidence interval for the US-specific testing procedure), were to be provided.

For the major secondary endpoint of change from baseline in the IBDQ score at Week 8, the treatment groups were to be compared using ANCOVA on the van der Waerden normal scores

## Type I error control - multiple testing procedure

A Hochberg step-up multiple testing procedure will be employed to control the overall Type 1 error rate at the 0.05 level (2-sided) for the primary endpoint (see figure below). For this step-up procedure, if p-values for both comparisons (ustekinumab 130 mg treatment group versus placebo group and ustekinumab ~6 mg/kg treatment group versus placebo group) are &lt;0.05, then it will be concluded that both ustekinumab treatment groups are effective compared with placebo. Otherwise, the smaller of the 2 p-values will be compared with 0.025; if the smaller p-value is &lt;0.025, then it will be concluded that the ustekinumab treatment group associated with the smaller of the 2 p-values is effective compared with placebo.

A positive study is defined as a statistically significant test for at least 1 ustekinumab treatment group

<div style=\"page-break-after: always\"></div>

## Hochberg Testing procedure

<!-- image -->

If the primary endpoint of clinical remission (global definition) was not significant for a dose, then all the major secondary endpoints for that dose were to be considered not to be significant. Otherwise, a hierarchical testing procedure as shown the figure below was to be employed to control the overall Type 1 error rate over the 3 major secondary endpoints at the 2-sided 0.05 significance level within a dose group. A major secondary endpoint for a dose group was to be considered significant only if both the previous endpoints in the hierarchy and current endpoint test positive at the 2-sided 0.05 level of significance. If an endpoint was not significant, all subsequent tests in the hierarchy were to be considered not to be significant. Nominal p-values were to be reported for all analyses.

Furthermore, mucosal healing at Week 8 will be adjusted for multiplicity. The endpoint of mucosal healing at Week 8 will be considered significant only if both the previous endpoints in the hierarchy and this mucosal healing endpoint test positive.

<div style=\"page-break-after: always\"></div>

<!-- image -->

## Subgroup analyses

The consistency of treatment effect for the primary endpoint was to be evaluated for subgroups based on demographics and baseline UC disease characteristics, baseline UC-related concomitant medication usage, and UC-related Medication History (when the number of subjects within each level of the subgroup permits).

For each of these subgroups, the odds ratio of each ustekinumab dose group vs placebo and the associated confidence interval (95% for the global definition and 97.5% for the US-specific definition) were to be provided. The odds ratios and confidence intervals were to be provided based on the logistic regression model that includes factors for treatment group, biologic failure status and region (for the subgroup analyses based on biologic failure status or region, the corresponding factor will not be included in the model).

## Demographics

- Gender (male, female)
- Race (Caucasian, non-Caucasian)
- Age ( ≤ median age, &gt; median age)
- Weight ( ≤ 1st quartile, &gt;1st quartile and ≤ 2nd quartile, &gt;2nd quartile and ≤ 3rd quartile,
- &gt;3rd quartile)

<div style=\"page-break-after: always\"></div>

- Smoking status (nonsmoker, prior smoker, current smoker)
- Region
- -Asia : Japan, South Korea
- -Eastern Europe : Belarus, Bulgaria, Czech Republic, Hungary, Poland, Romania,
- -Russia, Serbia, Slovakia, Ukraine
- -Rest of World : Australia, Austria, Belgium, Canada, Denmark, France, Germany, Israel,
- -Italy, Netherlands, New Zealand, United Kingdom, United States

## Baseline UC Clinical Disease Characteristics

- UC disease duration ( ≤ 5 years, &gt; 5 years to ≤ 15 years, &gt; 15 years)
- Extent of disease (limited, extensive)
- Severity of UC disease (moderate: 6 ≤ Mayo score ≤ 10, severe: Mayo score &gt;10)
- Extraintestinal manifestations (absent, present)
- CRP (≤3 mg/L, &gt;3 mg/L)
- CRP (≤ median, &gt; median)
- CRP (≤10 mg/L, &gt;10 mg/L)
- Fecal calprotectin (≤250 mg/kg, &gt; 250 mg/kg)
- Fecal lactoferrin (≤7.24 μg/g, &gt;7.24 μg/g)

## Baseline UC-related Concomitant Medication Usage

- Oral 5-ASA compounds (receiving, not receiving)
- Oral corticosteroids including budesonide and beclomethasone dipropionate (receiving, not
- receiving)
- 6-MP/AZA/MTX (receiving, not receiving)
- Oral corticosteroids and (6-MP/AZA/MTX) (receiving, not receiving)
- Oral corticosteroids or (6-MP/AZA/MTX) (receiving, not receiving)

## UC-related Medication History

- Refractory or intolerant to 6-MP/AZA (yes, no)
- Refractory, dependent or intolerant to oral or IV corticosteroids (yes, no)
- Refractory, dependent, or intolerant to oral or IV corticosteroids, but not refractory or intolerant to 6-MP/AZA (yes, no)
- Refractory, dependent or intolerant to oral or IV corticosteroids, and refractory or intolerant to 6-MP/AZA (yes, no)
- Biologic failure status (yes, no)
- Subjects with biologic failure

<div style=\"page-break-after: always\"></div>

- -Primary nonresponse, secondary nonresponse, or intolerance to
-  At least one anti-TNF (yes, no)
-  Anti-TNF only (yes, no)
-  Vedolizumab (yes, no)
-  Vedolizumab and at least one anti-TNF (yes, no)
- -For subjects with biologic failure to anti-TNF only
-  primary nonresponse (yes, no)
-  secondary nonresponse (yes, no)
-  intolerance (yes, no)
- Subjects without biologic failure (naïve, bio-experienced [but not documented failure])

## Interim Analysis

A futility analysis based on the primary endpoint of clinical remission at Week 8 was to be conducted when 30% of randomized subjects had either completed the I-8 visit or have terminated study participation before Week 8. The study (including both induction and maintenance) may have been stopped for futility when the conditional power on both ustekinumab doses is less than 20%.

The applicant argued that this futility analysis would result in minimal loss in power (≤2% when the treatment effect is in the expected range of 10% to 12%) and would not affect the overall Type I error rate (α=0.05, 2-sided) for the primary endpoint analysis; therefore, no alpha was to be allocated for this interim analysis for global submission (submission outside the United States).

The details of the interim analysis were provided in the Interim Analysis Plan (IAP).

## Results

## Participant flow

Subject Disposition - Randomized Subjects (CNTO1275UCO3001)

<div style=\"page-break-after: always\"></div>

1-8=Induction.Week8I-16=Induction.Week16IV=Intravenous SFU=Safetvfollow-un

<!-- image -->

Among 961 randomized subjects, 912  (94.9%)  subjects  completed  study participation: 783 (81.5%) subjects entered maintenance and 129 (13.4%) subjects who did not enter maintenance completed the final safety visit.

Forty-nine subjects (5.1%) terminated study participation during the study. A total of 20 subjects (2.1%) terminated study participation prior to Week 8. The most common reason for termination before Week 8 was withdrawal of consent which was reported for 14 subjects (1.5%; no subjects in the ~6 mg/kg group, 5 subjects [1.6%] in the 130 mg group, and 9 subjects [2.8%] in the placebo group). Of the remaining 29 subjects who terminated study participation, 4 subjects terminated at Week 8 and 25 subjects terminated after Week 8.

Three subjects were unblinded during the study (2 subjects in the ~6 mg/kg group and 1 subject in the placebo group). None of these subjects completed the Week 8 visit, however, all 3 subjects completed the final safety visit.

## Recruitment

19 August 2015 (Date first subject signed informed consent) to 11 December 2017 (Date of last observation for last subject recorded as part of the database)

## Conduct of the study

This study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and that are consistent with Good Clinical Practices and applicable regulatory requirements.

There were 2 amendments to the protocol, both of which were substantial. The first amendment (14 July 2015) was implemented before study initiation and incorporated health authority feedback. The second amendment (20 April 2016) addressed health authority requests for additional data collection and

<div style=\"page-break-after: always\"></div>

included other clarifications. The table below presents the changes that affected study conduct or data analyses of the induction study only.

Protocol Amendment Changes Affecting the Induction Study

| Amendment Numbel Date   | Protocol Amendment Changes                                                                                                                                                                                                                                                                                                                                                         |
|-------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1 14 Jul 2015           | Sample collection for anti-ustekinumab antibodies was changed fromWeek 2 to Week 4 during induction and another sample collection was added during maintenance.                                                                                                                                                                                                                    |
| 1 14 Jul 2015           | The Cochran-Mantel-Haenszel test (rather than the logistic regression model) was study.                                                                                                                                                                                                                                                                                            |
| 1 14 Jul 2015           | Details were clarified regarding the futility analysis and theroles of theDMC and the sponsor.                                                                                                                                                                                                                                                                                     |
| 1 14 Jul 2015           | The definition of failure to respond to corticosteroids was clarified                                                                                                                                                                                                                                                                                                              |
| 2 20 Apr 2016           | Clarified that the US definition of clinical remission will be used to support the US submission only, and added that each defimition (global and US definition) will be applied to all subjectsin the analysispopulation.                                                                                                                                                         |
| 2 20 Apr 2016           | Per health authority request, collection of stool consistency data using the BSFS was added as an exploratory analysis.                                                                                                                                                                                                                                                            |
| 2 20 Apr 2016           | Clarified that if tuberculin was unavailable for the tuberculosis （TB) skin test, this method of testing was not tobe considered required for Ukrainian study centers. QuantiFERON-TB Gold and chest radiograph were doneif tuberculosis（TB)was suspected, along with referral to a TB specialist if possible Clarifiedprocedures to determine clinical flare and loss ofresponse. |
| 2 20 Apr 2016           | Beclomethasone dipropionate was added to the inclusion criteria because this extended-release formulation is approved for the treatment of UC in some regions where the study was being conducted.                                                                                                                                                                                 |
| 2 20 Apr 2016           | The recommendation for tapering budesonide was revised and tapering for beclomethasone dipropionate was incorporated.                                                                                                                                                                                                                                                              |
| 2 20 Apr 2016           | The corticosteroid text was updated to include approved extended-release corticosteroids such asbudesonide and beclomethasone dipropionate for the treatment of UC, and to clarify the definition of corticosteroid dependence.                                                                                                                                                    |
| 2 20 Apr 2016           | Exclusion criterion 17 was updated to reflect the availability ofhighly effective antiviral therapy with HCV clearance (as measured by HCV RNA).                                                                                                                                                                                                                                   |
| 2 20 Apr 2016           | Text was added to clarify unblinding related to the futility analysis and the third database lock duringinduction                                                                                                                                                                                                                                                                  |
| 2 20 Apr 2016           | Guidance was added about what to do if a subject's screening procedures could not be completed within the specified 8-week window.                                                                                                                                                                                                                                                 |
| 2 20 Apr 2016           | Clarification of which endoscopy score was used to determine subject eligibility at baseline and for the primary and major secondary endpoints involving endoscopy subscores.                                                                                                                                                                                                      |
| 2 20 Apr 2016           | Approved biosimilars\"were added as TNF antagonist therapies to which definitions ofinadequateinitialresponse,loss ofresponse,orintolerance couldbe applied to identify a subject as a biologic failure.                                                                                                                                                                            |
| 2 20 Apr 2016           | Adverse event definitions were updated per-protocol template requirements,and anticipated safety events were added.                                                                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

## Baseline data

For the induction study, 60.6% of trial subjects were male, 76.0% were white, the median age was 41.0 years, and the median weight was 71.2 kg. The median duration of disease was approximately 6 years and the median Mayo score was 9.0 (84.4% of subjects had moderate UC [ie, Mayo score ≥6 and ≤10] and 15.3% had severe disease [Mayo score &gt;10]), 45.7% of subjects had extensive diseaseAmong the 961 randomized subjects, 51.1% had a documented history of biologic failure (50.5% had failed at least one anti-TNF agent and 16.6% had failed both an anti-TNF agent and vedolizumab) and 48.9% did not have a history of biologic failure (46.1% were biologic naïve and 2.8% were biologic experienced but were not documented biologic failures).  Infliximab, golimumab and adalimumab were the TNF inhibitors that subjects were previously exposed to and exposure was similar across the three groups.  Vedolizumab was the other biologic that patients may have been exposed to.

Biologic failures to vedolizumab (regardless of anti-TNF) were 17.3% (Note: 6 subjects were biologic failures to only vedolizumab).

<div style=\"page-break-after: always\"></div>

## Demographic Baseline Data

|                                                    | Induction Study   | Maintenance Studya   |
|----------------------------------------------------|-------------------|----------------------|
| Primary efficacy analysis set                      | 961               | 523                  |
| Demographic characteristics                        |                   |                      |
| Sex, % male                                        | 582 (60.6%)       | 297 (56.8%)          |
| Race, % white                                      | 730 (76.0%)       | 387 (74.0%)          |
| Median age (years)                                 | 41.0              | 40.0                 |
| Median weight (kg)                                 | 71.20             | 70.00                |
| UC disease characteristies                         |                   |                      |
| Median UC disease duration (years)                 | 5.97              | 6.05                 |
| Median Mayo score                                  | 9.0               | 9.0                  |
| Extent of disease = extensive                      | 436 (45.7%)       | 246 (47.1%)          |
| Median CRP (mg/L)                                  | 4.7               | 3.58                 |
| Median fecal Jactoferrin (ug/g)                    | 186.7             | 182.5                |
| Median fecal calprotectin (mg/kg)                  | 1392.0            | 1437.0               |
| Endoscopy score = 3 (severe disease)               | 668 (69.5%)       | 350 (66.9%)          |
| UC-related concomitant medication                  |                   |                      |
| Any UC medication                                  | 867 (90.2%)       | 469 (89.7%)          |
| Corticosteroid use                                 | 498 (51.8%)       | 273 (52.2%)          |
| Immunomodulators (6-MP/AZA, MTX)                   | 271 (28.2%)       | 139 (26.6%)          |
| Aminosalicylates                                   | 660 (68.7%)       | 370 (70.7%)          |
| UC-related medication history                      |                   |                      |
| Subjects with inadequate response, intolerance, or |                   |                      |
| dependence to corticosteroids and/or 6-MP/AZA      | 903 (94.0%)       | 489 (93.5%)          |
| Corticosteroids                                    | 776 (80.7%)       | 405 (77.4%)          |
| 6-MP/AZA                                           | 530 (55.2%)       | 284 (54.3%)          |
| Subjects without a history of biologic failure     | 470 (48.9%)       | 274 (52.4%)          |
| Biologic-naive                                     | 443 (46.1%)       | 258 (49.3%)          |
| Biologic-experienced, but not documented failure   | 27 (2.8%)         | 16 (3.1%)            |
| Subjects with a history of biologic failure        | 491 (51.1%)       | 249 (47.6%)          |
| Only anti-TNF (not to yedolizumab)                 | 325 (33.8%)       | 177 (33.8%)          |
| At least one anti-TNF (regardless of vedolizumab)  | 485 (50.5%)       | 247 (47.2%)          |
| -Primary nonresponseb                              | 235 (48.5%)       | 114 (46.2%)          |
| Any anti-TNF and vedolizumab                       | 160 (16.6%)       | 70 (13.4%)           |
| Vedolizumab (regardless of anti-TNF)               | 166 (17.3%)       | 72 (13.8%)           |

More specifically in terms of disease characteristics the results at baseline show that they were generally similar across all treatment groups.  At baseline:

- The median duration of disease was 5.97 years
- 45.7% of subjects had extensive disease
- The median Mayo score was 9.0
- 84.4% of subjects had moderate UC (ie, a Mayo score ≥6 and ≤10), and 15.3% had severe disease (Mayo score &gt;10)

Baseline median fecal lactoferrin and fecal calprotectin concentrations were higher for subjects in both ustekinumab groups (226.9 µg/g and 1506.5 mg/kg, respectively, in the ~6 mg/kg group, and 190.1 µg/g and 1382.0 mg/kg, respectively, in the 130 mg group) compared with subjects in the placebo group (152.0 µg/g and 1224.0 mg/kg, respectively), with the highest concentrations in the ~6 mg/kg group. Consistent with this finding, a greater proportion of subjects in the ~6 mg/kg group (74.8%) had an

<div style=\"page-break-after: always\"></div>

endoscopy subscore of 3 (indicating severe disease) compared with the 130 mg (65.9%) and placebo (67.7%) groups.

The proportions of subjects who had abnormal levels of inflammatory markers at baseline were similar across all treatment groups. The total proportions of subjects who had abnormal levels of inflammatory markers among subjects with baseline measurements were as follows:

- CRP (&gt;3 mg/L): 59.8%
- Faecal lactoferrin (&gt;7.24 μg/g): 95.9%
- Faecal calprotectin (&gt;250 mg/kg): 89.0%

## Summary of UC Disease Characteristics at Baseline: Primary Efficacy Analysis Set

|                               |               | UstekinumabIV   | UstekinumabIV   | UstekinumabIV   |               |
|-------------------------------|---------------|-----------------|-----------------|-----------------|---------------|
|                               | Placebo IV    | 130mg           | 6mg/kga         | Combined        | Total         |
| PrimaryEfficacyAnalysisSet    | 319           | 320             | 322             | 642             | 961           |
| UC disease duration (yrs)     |               |                 |                 |                 |               |
| N                             | 319           | 320             | 322             | 642             | 961           |
| Mean (SD)                     | 8.01 (7.190)  | 8.13 (7.179)    | 8.17 (7.822)    | 8.15 (7.502)    | 8.10 (7.397)  |
| Median                        | 5.97          | 5.90            | 6.03            | 5.97            | 5.97          |
| IQ range                      | (2.71; 11.30) | (2.84; 11.41)   | (2.68; 11.07)   | (2.80; 11.16)   | (2.78; 11.20) |
| Range                         | (0.3; 36.1)   | (0.3; 34.0)     | (0.3; 54.1)     | (0.3; 54.1)     | (0.3; 54.1)   |
| Extent of disease             |               |                 |                 |                 |               |
| N                             | 316           | 318             | 320             | 638             | 954           |
| Limited to left side of colon | 167 (52.8%)   | 183 (57.5%)     | 168 (52.5%)     | 351 (55.0%)     | 518 (54.3%)   |
| Extensive                     | 149 (47.2%)   | 135 (42.5%)     | 152 (47.5%)     | 287 (45.0%)     | 436 (45.7%)   |
| Mayo score (0-12)             |               |                 |                 |                 |               |
| N                             | 319           | 320             | 321             | 641             | 960           |
| Mean (SD)                     | 8.9 (1.62)    | 8.9 (1.57)      | 8.9 (1.51)      | 8.9 (1.54)      | 8.9 (1.57)    |
| Median                        | 9.0           | 9.0             | 9.0             | 9.0             | 9.0           |
| IQ range                      | (8.0; 10.0)   | (8.0; 10.0)     | (8.0; 10.0)     | (8.0; 10.0)     | (8.0; 10.0)   |
| Range                         | (5; 12)       | (5; 12)         | (6; 12)         | (5; 12)         | (5; 12)       |
| Severity of UC disease        |               |                 |                 |                 |               |
| N                             | 319           | 320             | 321             | 641             | 960           |
| Moderate (6≤ Mayo score ≤ 10) | 263 (82.4%)   | 271 (84.7%)     | 276 (86.0%)     | 547 (85.3%)     | 810 (84.4%)   |
| Severe (Mayo score >10)       | 54 (16.9%)    | 48 (15.0%)      | 45 (14.0%)      | 93 (14.5%)      | 147 (15.3%)   |
| Extraintestinalmanifestations |               |                 |                 |                 |               |
| N                             | 319           | 320             | 322             | 642             | 961           |
| Present                       | 84 (26.3%)    | 90 (28.1%)      | 97 (30.1%)      | 187 (29.1%)     | 271 (28.2%)   |
| Absent                        | 235 (73.7%)   | 230 (71.9%)     | 225 (69.9%)     | 455 (70.9%)     | 690 (71.8%)   |
| Biologicfailure status        |               |                 |                 |                 |               |
| N                             | 319           | 320             | 322             | 642             | 961           |
| Yes                           | 161 (50.5%)   | 164 (51.3%)     | 166 (51.6%)     | 330 (51.4%)     | 491 (51.1%)   |
| No                            | 158 (49.5%)   | 156 (48.8%)     | 156 (48.4%)     | 312 (48.6%)     | 470 (48.9%)   |
| CRP (mg/L)                    |               |                 |                 |                 |               |
| N                             | 316           | 315             | 320             | 635             | 951           |

<div style=\"page-break-after: always\"></div>

|                                          |                  | UstekinumabIV    | UstekinumabIV    | UstekinumabIV    |                  |
|------------------------------------------|------------------|------------------|------------------|------------------|------------------|
|                                          | PlaceboIV        | 130mg            | 6mg/kg           | Combined         | Total            |
| Mean (SD)                                | 9.8 (16.65)      | 9.6 (17.07)      | 12.1 (19.34)     | 10.9 (18.28)     | 10.5 (17.75)     |
| Median                                   | 4.7              | 4.5              | 4.8              | 4.7              | 4.7              |
| IQ range                                 | (1.4; 10.0)      | (1.6; 9.9)       | (1.8; 13.7)      | (1.6; 12.4)      | (1.5; 11.6)      |
| Range                                    | (0; 139)         | (0; 148)         | (0; 183)         | (0; 183)         | (0; 183)         |
| Abnommal CRP (>3 mg/L)                   | 185 (58.5%)      | 185 (58.7%)      | 199 (62.2%)      | 384 (60.5%)      | 569 (59.8%)      |
| Fecal Lactofemrin (μg/g)                 |                  |                  |                  |                  |                  |
| N                                        | 294              | 302              | 306              | 608              | 902              |
| Mean (SD)                                | 267.5 (293.41)   | 279.3 (281.88)   | 327.8 (308.60)   | 303.7 (296.38)   | 291.9 (295.74)   |
| Median                                   | 152.0            | 190.1            | 226.9            | 202.8            | 186.7            |
| IQ range                                 | (49.8; 373.1)    | (67.0; 418.3)    | (88.1; 462.0)    | (73.8; 442.0)    | (64.1; 423.2)    |
| Range                                    | (0;1000)         | (0;1000)         | (0;1000)         | (0;1000)         | (0;1000)         |
| Abnormal fecal lactoferrin (>7.24 μg/g)  | 280 (95.2%)      | 291 (96.4%)      | 294 (96.1%)      | 585 (96.2%)      | 865 (95.9%)      |
| Fecal Calprotectin (mg/kg)               |                  |                  |                  |                  |                  |
| N                                        | 289              | 296              | 300              | 596              | 885              |
| Mean (SD)                                | 2412.3 (4296.60) | 2676.1 (4061.17) | 2936.5 (4573.74) | 2807.2 (4325.10) | 2678.2 (4317.36) |
| Median                                   | 1224.0           | 1382.0           | 1506.5           | 1480.5           | 1392.0           |
| IQ range                                 | (496.0; 2224.0)  | (564.5; 2681.0)  | (621.5; 3192.5)  | (601.5; 2905.5)  | (567.0; 2713.0)  |
| Range                                    | (31;36000)       | (15; 25249)      | (15;36000)       | (15;36000)       | (15;36000)       |
| Abnormal fecal calprotectin(> 250 mg/kg) | 250 (86.5%)      | 264 (89.2%)      | 274 (91.3%)      | 538 (90.3%)      | 788 (89.0%)      |

a Weight-range based ustekinumab doses approximating 6 mg/kg: 260 mg (weight ≤ 55 kg), 390 mg (weight &gt; 55 kg and ≤ 85 kg), 520 mg (weight &gt; 85 kg). [TSIDEM02.RTF][/SAS/2709/CNTO1275UCO3001/FILES/RE/CSRINDUCTIONFINAL/PR0GRAMS/TSIDEM02.SAS]06FEB2018,05:02

## Summary of Concomitant Medications for UC at baseline: Primary Efficacy Analysis Set

At baseline, 90.2% of subjects were receiving a concomitant UC medication, with similar proportions of subjects across all treatment groups.

More than half (51.8%) of subjects were using corticosteroids at baseline and 28.2% were using immunomodulatory drugs (AZA, 6-MP, or MTX).  The proportion of subjects using aminosalicylates was 68.7%.

## Numbers analysed

## Missing Data

For subjects with missing data the last observation was carried forward for continuous endpoints.  An exception to this was with the Mayo and partial Mayo scores, where the last available Mayo subscores were carried forward.

For dichotomous endpoints, subjects with missing data were considered not to have achieved the respective endpoints.

Treatment failure rules overrode missing data rules. This meant that if a subject had an event of treatment failure, baseline values were assigned from the point of treatment failure onward for continuous endpoints, and subjects were not considered to have achieved the respective endpoints for dichotomous endpoints, regardless of whether the data were observed or missing.

## Protocol Deviations

Through Week 8, 138 subjects (14.4%) had the following major protocol deviations:

- Ninety-two subjects (9.6%) were reported to have entered the study but did not meet entry criteria; 1 additional subject did not complete the optional genetic informed-consent form but was not reported as having a major protocol deviation.
- Four subjects (0.4%) were reported to have received the wrong treatment or incorrect dose of study agent at Week 0.
- One subject (0.1%) was reported to have received a disallowed concomitant medication.
- Fifty-one subjects (5.3%) were reported to have had protocol deviations for other reasons.

<div style=\"page-break-after: always\"></div>

Through the final safety visit, 146 subjects (15.2%; including protocol deviations that occurred through Week 8) were reported to have at least 1 major protocol deviation. At or after Week 8, 1 subject (0.1%) developed withdrawal criteria but did not withdraw; 3 subjects received the wrong treatment or incorrect dose of study agent at

Week 8; and 9 subjects were reported to have protocol deviations for other reasons.

Subjects may have been counted in more than 1 category or may have had more than 1 deviation within a category.

## Outcomes and estimation

## Primary and Major Secondary Results for the Induction Study

## Clinical Remission at Week 8 - Global Definition

The primary endpoint for the induction phase of the study was the induction of clinical remission.  Clinical remission was defined as a Mayo score ≤2 points, with no individual subscore &gt;1.

The results demonstrate that at Week 8, significantly greater proportions of subjects in the ~6 mg/kg and 130 mg groups achieved clinical remission (15.5% and 15.6%, respectively) compared with subjects in the placebo group (5.3%; p&lt;0.001 for both comparisons).

## Number of Subjects in Clinical Remission (Global Definition) at Week 8: Primary Efficacy Analysis Set

|                                          |            | UstekinumabIV    | UstekinumabIV   | UstekinumabIV    |
|------------------------------------------|------------|------------------|-----------------|------------------|
|                                          | Placebo IV | 130 mg           | 6mg/kg          | Combined         |
| Primary Efficacy Analysis Set            | 319        | 320              | 322             | 642              |
| Week 8                                   |            |                  |                 |                  |
| N                                        | 319        | 320              | 322             | 642              |
| Subjects in clinical remission cd        | 17 (5.3%)  | 50 (15.6%)       | 50 (15.5%)      | 100 (15.6%)      |
| Adjusted treatment difference (95% CI) * |            | 10.3 (5.7, 14.9) | 10.2 (5.6,14.8) | 10.2 (6.6, 13.9) |
| p-value                                  |            | <0.001           | <0.001          | <0.001           |

[TEFCREM01\\_G.RTF]

[/SAS/2709/CNT01275UC03001/FILES/RE/CSRINDUCTIONFINAL/PROGRAMS/TEFCREM01\\_04\\_05\\_06\\_10\\_UG.SAS]06FEB2018.

05:51

## Clinical Remission at Week 8 - US Definition

The primary endpoint of clinical remission at Week 8, US definition, was defined as an absolute stool number ≤3, a Mayo rectal bleeding subscore of 0, and a Mayo endoscopy subscore of 0 or 1.

At Week 8, significantly greater proportions of subjects in the ~6 mg/kg and 130 mg groups achieved clinical remission (18.9% and 16.6%, respectively) compared with subjects in the placebo group (6.3%; p&lt;0.001 for both comparisons).

<div style=\"page-break-after: always\"></div>

## Number of Subjects in Clinical Remission (US Definition) at Week 8: Primary Efficacy Analysis Set

An absolute stool number ≤3, a Mayo rectal bleeding subscore of O, and a Mayo endoscopy subscore of O or 1.

|                                   |            | Ustekinumab IV   | Ustekinumab IV   | Ustekinumab IV   |
|-----------------------------------|------------|------------------|------------------|------------------|
|                                   | Placebo IV | 130 mg           | 6 mg/kg          | Combined         |
| Primary Efficacy Analysis Set     | 319        | 320              | 322              | 642              |
| Week 8                            |            |                  |                  |                  |
| N                                 | 319        | 320              | 322              | 642              |
| Subjects in clinical remission .d | 20 (6.3%)  | 53 (16.6%)       | 61 (18.9%)       | 114 (17.8%)      |
| Adjusted treatment difference     |            |                  |                  |                  |
| (97.5% CI) *                      |            | 10.3 (4.8, 15.8) | 12.7 (7.0, 18.4) | 11.5 (7.0, 16.0) |
| p-value F                         |            | <0.001           | <0.001           | <0.001           |

- The confidence intervals were based on the Wald statistic with Mantel-Haenszel weight.

<!-- formula-not-decoded -->

## Major Secondary Analyses - Endoscopic Healing, Clinical Response, and IBDQ Score at Week 8 Endoscopic Healing at Week 8

Endoscopic healing (ie, improvement in the endoscopic appearance of the mucosa) was defined as Mayo endoscopy subscore of 0 or 1.

At Week 8, significantly greater proportions of subjects in the ~6 mg/kg and 130 mg groups achieved endoscopic healing (27.0% and 26.3%, respectively) compared with subjects in the placebo group (13.8%; p&lt;0.001 for both comparisons).

## Number of Subjects with Endoscopic Healing at Week 8: Primary Efficacy Analysis Set

|                                      |            | Ustekinumab IV   | Ustekinumab IV   | Ustekinumab IV   |
|--------------------------------------|------------|------------------|------------------|------------------|
|                                      | Placebo IV | 130mg            | 6mg/kga          | Combined         |
| Primary Efficacy Analysis Set        | 319        | 320              | 322              | 642              |
| Week 8                               |            |                  |                  |                  |
| N                                    | 319        | 320              | 322              | 642              |
| Subjects with endoscopic healing b.c | 44 (13.8%) | 84 (26.3%)       | 87 (27.0%)       | 171 (26.6%)      |
| Adjusted treatment                   |            |                  |                  |                  |
| difference                           |            | 12.4             | 13.3             | 12.8             |
| (95% CI) d                           |            | (6.5.18.4)       | (7.3.19.3)       | (7.9, 17.8)      |
| (97.5% CI)                           |            | (5.6, 19.2)      | (6.4, 20.1)      | (7.2, 18.5)      |
| p-value                              |            | ≤0.001           | ≤0.001           | ≤0.001           |

[TEFEND001.RTF] [/SAS/2709/CNTO1275UC03001/FILES/RE/CSRINDUCTIONFINAL/PR0GRAMS/TEFEND001.SAS] 06FEB2018, 05:51

<div style=\"page-break-after: always\"></div>

## Clinical Response at Week 8

Clinical response (second major secondary endpoint) was defined as a decrease from baseline in the Mayo score by ≥30% and≥3 points, with either a decrease from baseline in the rectal bleeding subscore ≥1 or a rectal bleeding subscore of 0 or 1.

Significantly greater proportions of subjects in the ~6 mg/kg and 130 mg groups achieved clinical response (61.8% and 51.3%, respectively) at Week 8 than in the placebo group (31.3%; p&lt;0.001 for both ustekinumab groups; Table 9 below). The proportion of subjects in clinical response at Week 8 in the ~6 mg/kg group was approximately 10 percentage points higher than in the 130 mg group.

## Number of Subjects in Clinical Response at Week 8: Primary Efficacy Analysis Set

|                                   |             | Ustekinumab IV   | Ustekinumab IV   | Ustekinumab IV   |
|-----------------------------------|-------------|------------------|------------------|------------------|
|                                   | Placebo IV  | 130 mg           | 6 mg/kg          | Combined         |
| Primary Efficacy Analysis Set     | 319         | 320              | 322              | 642              |
| Week 8                            |             |                  |                  |                  |
| N                                 | 319         | 320              | 322              | 642              |
| Subjects in clinical response b,e | 100 (31.3%) | 164 (51.3%)      | 199 (61.8%)      | 363 (56.5%)      |
| Adjusted treatment                |             |                  |                  |                  |
| difference                        |             | 19.9             | 30.5             | 25.2             |
| (95% C1) d                        |             | (12.5, 27.3)     | (23.2,37.8)      | (18.9, 31.5)     |
| (97.5%CI)                         |             | (11.4, 28.3)     | (22.2, 38.8)     | (18.0, 32.4)     |
| p-value                           |             | ≤0.001           | <0.001           | <0.001           |

## Change from Baseline in Total IBDQ Score at Week 8

The IBDQ is a disease-specific instrument composed of 32 Likert-scaled items. The total score ranges from 32 to 224 using the 7-point response options, with higher scores indicating better health-related quality of life; an increase of ≥16 points has been observed to be consistent with clinically relevant improvement.

The IBDQ scale contains 4 component dimensions: bowel symptoms, systemic symptoms, emotional function, and social function. Each dimension can be computed with total scores ranging from 10 to 70, 5 to 35, 12 to 84, and 5 to 35, respectively.

At baseline, median IBDQ scores were similar across all treatment groups. At Week 8, the median improvements from baseline in the IBDQ scores were significantly greater in the ~6 mg/kg and 130 mg groups (31.0 and 31.5, respectively) compared with the placebo group (10.0; p&lt;0.001 for both comparisons).

05:51

<div style=\"page-break-after: always\"></div>

## Summary of Change from Baseline in the Total IBDQ Score at Week 8: Primary Efficacy Analysis Set

|                               |                | UstekinumabIV   | UstekinumabIV   | UstekinumabIV   |
|-------------------------------|----------------|-----------------|-----------------|-----------------|
| Primary Efficacy Analysis Set | Placebo IV 319 | 130 mg 320      | 6 mg/kg a 322   | Combined 642    |
| Baseline                      |                |                 |                 |                 |
| N                             | 317            | 316             | 321             | 637             |
| Mean (SD)                     | 127.4 (34.45)  | 126.0 (33.14)   | 127.0 (33.27)   | 126.5 (33.19)   |
| Median                        | 126.0          | 129.0           | 126.0           | 128.0           |
| IQ range                      | (100.0;155.0)  | (100.5; 149.0)  | (104.0; 152.0)  | (103.0; 150.0)  |
| Range                         | (51; 211)      | (41; 209)       | (34; 209)       | (34; 209)       |
| Week 8 b.c                    |                |                 |                 |                 |
| N                             | 319            | 319             | 322             | 641             |
| Mean (SD)                     | 143.5 (39.96)  | 159.2 (37.16)   | 161.9 (35.64)   | 160.6 (36.40)   |
| Median                        | 147.0          | 164.0           | 166.0           | 165.0           |
| IQ range                      | (114.0; 177.0) | (132.0; 190.0)  | (137.0; 190.0)  | (136.0; 190.0)  |
| Range                         | (48; 214)      | (47; 220)       | (34; 224)       | (34; 224)       |
| Changefrombaseline            |                |                 |                 |                 |
| Week 8 bc                     |                |                 |                 |                 |
| N                             | 317            | 316             | 321             | 637             |
| Mean (SD)                     | 16.1 (31.39)   | 33.4 (32.53)    | 35.0 (31.86)    | 34.2 (32.18)    |
| Median                        | 10.0           | 31.5            | 31.0            | 31.0            |
| IQ range                      | (-2.0;34.0)    | (7.5; 53.5)     | (11.0; 56.0)    | (9.0; 55.0)     |
| Range                         | (-58; 120)     | (-45; 134)      | (-36; 130)      | (-45; 134)      |
| p-value                       |                | 0.001           | 0.001           | 0.001           |

[TEFIBDQ01.RTF] [/SAS/2709/CNIO1275UC03001/FILES/RE/CSRINDUCTI0NFINAL/PROGRAMS/TEFIBDQ01.SAS] 06FEB2018,

## Mucosal Healing (additional multiplicity-controlled endpoint)

Mucosal healing was defined as a combination of both endoscopic healing (ie, a Mayo endoscopy subscore of 0 or 1) and histologic healing (defined as neutrophil infiltration in &lt;5% of crypts, no crypt destruction, and no erosions, ulcerations, or granulation tissue). At Week 8, significantly greater proportions of subjects in the ~6 mg/kg and 130 mg groups achieved mucosal healing (18.4% and 20.3%, respectively) compared with subjects in the placebo group (8.9%; p&lt;0.001 for both comparisons).

05:51

<div style=\"page-break-after: always\"></div>

## Number of Subjects with Mucosal Healing at Week 8: Primary Efficacy Analysis Set

|                                    |            | Ustekinumab IV   | Ustekinumab IV   | Ustekinumab IV   |
|------------------------------------|------------|------------------|------------------|------------------|
|                                    | Placebo IV | 130 mg           | 6 mg/kg          | Combined         |
| Primary Efficacy Analysis Set      | 319        | 320              | 322              | 642              |
| Week 8 Nb                          | 316        | 316              | 315              | 631              |
| Subjects with mucosal healing C.de | 28 (8.9%)  | 64 (20.3%)       | 58 (18.4%)       | 122 (19.3%)      |
| Adjusted treatment difference      |            | 11.3             | 9.7              | 10.5             |
| (95% CI) t                         |            | (6.0.16.6)       | (4.5, 14.9)      | (6.2. 14.8)      |
| (97.5% CI)                         |            | (5.2, 17.4)      | (3.7, 15.7)      | (5.6, 15.4)      |
| p-value                            |            | <0.001           | 0.001            | <0.001           |

## Ancillary analyses

## Other Secondary Efficacy Endpoints

## Clinical Remission at Week 8

When remission was assessed as clinical remission (global definition) with a rectal bleeding subscore of 0 at Week 8, the proportions of subjects who achieved this endpoint were in line with those observed based on the primary efficacy analysis (global definition). Significantly greater proportions of subjects in the ~6 mg/kg and 130 mg groups achieved this endpoint (15.2% and 15.3%, respectively) compared with subjects in the placebo group (5.3%; p&lt;0.001 for both comparisons).

## Number of Subjects in Clinical Remission (Global Definition) with a Rectal Bleeding Score of 0 at Week 8: Primary Efficacy Analysis Set

| PrimaryEfficacyAnalysisSet      | Placebo IV 319   | 130 mg 320   | UstekimumabIV 6 mg/kg 322   | Combined 642   |
|---------------------------------|------------------|--------------|-----------------------------|----------------|
| Week 8                          |                  |              |                             |                |
| N                               | 319              | 320          | 322                         | 642            |
| Subjects inclinical remission . | 17 (5.3%)        | 49 (15.3%)   | 49 (15.2%)                  | 98 (15.3%)     |
| p-value                         |                  | 0.001        | <0.001                      | ≤0.001         |

[TEFCREM16RTF][/SAS/2709/CNTO1275UC03001/FILES/RE/CSRINDUCTIONFINAL/PROGRAMS/TEFCREM16.SAS]06FEB2018,05:51

## Symptomatic Remission at Week 8

Symptomatic remission was defined as a Mayo stool frequency subscore of 0 or 1 and a rectal bleeding subscore of 0.

<div style=\"page-break-after: always\"></div>

At Week 8, significantly greater proportions of subjects in the ~6 mg/kg and 130 mg groups achieved symptomatic remission (44.7% and 41.3%, respectively) compared with subjects in the placebo group (22.6%; p&lt;0.001 for both comparisons).

## Number of Subjects in Symptomatic Remission at Week 8: Primary Efficacy Analysis Set

|                                        |            | UstekinumabIV   | UstekinumabIV   | UstekinumabIV   |
|----------------------------------------|------------|-----------------|-----------------|-----------------|
|                                        | PlaceboIV  | 130 mg          | 6mg/kg\"         | Combined        |
| PrimaryEfficacyAnalysisSet             | 319        | 320             | 322             | 642             |
| Week 8                                 |            |                 |                 |                 |
| N                                      | 319        | 320             | 322             | 642             |
| Subjects in symptomatic remission be.d | 72 (22.6%) | 132 (41.3%)     | 144 (44.7%)     | 276 (43.0%)     |
| p-value                                |            | 0.001           | ≤0.001          | 0.001           |

- Subjects who had a prohibited change in concomitant UC medication or an ostomy or colectomy prior to the Week Svisit were considered not to be insymptomatic remission

## Normal or Inactive Mucosal Disease at Week 8

Normal or inactive mucosal disease was defined as a Mayo endoscopy subscore of 0. At Week 8, significantly greater proportions of subjects in the ~6 mg/kg and 130 mg groups achieved normal or inactive mucosal disease (7.8% and 10.3%, respectively) compared with subjects in the placebo group (3.8%; p=0.028 and p=0.001, respectively).

Number of Subjects with Normal or Inactive Mucosal Disease at Week 8: Primary Efficacy Analysis Set

|                                                     |           | UstekinumabIV   | UstekinumabIV   | UstekinumabIV   |
|-----------------------------------------------------|-----------|-----------------|-----------------|-----------------|
|                                                     | PlaceboIV | 130 mg          | 6mg/kg          | Combined        |
| PrimiryEfmicacyAnalysisSet                          | 319       | 320             | 322             | 719             |
| Week 8                                              |           |                 |                 |                 |
| N                                                   | 319       | 320             | 322             | 642             |
| Subjectswithnormal or inactivemucosal disease b.c.d | 12 (3.8%) | 33 (10.3%)      | 25 (7.8%)       | 58 (9.0%)       |
| p-value                                             |           | 0.001           | 0.028           | 0.003           |

## Histologic Healing at Week 8

Histologic healing was neutrophil infiltration in &lt;5% of crypts, no crypt destruction, and no erosions, ulcerations, or granulation tissue.

At Week 8, significantly greater proportions of subjects in the ~6 mg/kg and 130 mg groups achieved histologic healing (35.6% and 37.9%, respectively) compared with subjects in the placebo group (21.9%; p&lt;0.001 for both comparisons).  For this analysis subjects with an unevaluable biopsy at Week 8 were excluded.  A post-hoc sensitivity analysis was conducted by considering subjects with an unevaluable biopsy (ie, a biopsy that was collected, but could not be assessed due to sample preparation or technical errors) at Week 8 as not having histologic healing and the results were consistent with those presented below.

<div style=\"page-break-after: always\"></div>

## Number of Subjects with Histologic Healing at Week 8: Primary Efficacy Analysis Set

|                                      |            | UstekinumabIV   | UstekinumabIV   | UstekinumabIV   |
|--------------------------------------|------------|-----------------|-----------------|-----------------|
|                                      | Placebo IV | 130 mg          | 6mg/kg          | Combined        |
| Primary Efficacy Analysis Set        | 319        | 320             | 322             | 642             |
| Week 8                               |            |                 |                 |                 |
| Nb                                   | 297        | 298             | 295             | 593             |
| Subjects with histologic healing dde | 65 (21.9%) | 113 (37.9%)     | 105 (35.6%)     | 218 (36.8%)     |
| p-value                              |            | 0.001           | 0.001           | 0.001           |

[TEFHIST01.RTF] [/SAS/2709/CNTO1275UC03001/FILES/RE/CSRINDUCTIONFINAL/PR0GRAMS/TEFHIST01.SAS] 06FFR201R 06-07

## Markers of Inflammation

Ustekinumab reduced both a serum-based marker of inflammation (CRP) and fecal-based markers of inflammation (fecal calprotectin and fecal lactoferrin).

Significant reductions in, and normalization of, these biomarkers were observed for both dose groups as early as Week 2 (the first postbaseline visit) for CRP and Week 4 for the fecal markers

For both fecal markers of inflammation, the ~6 mg/kg group had greater reductions from baseline than the 130 mg group at all visits through Week 8.

Summary of Change from Baseline in Inflammatory Markers at Week 8: Primary Efficacy Analysis Set

<div style=\"page-break-after: always\"></div>

|                                     |                   | Ustekinunab IV     | Ustekinunab IV   |
|-------------------------------------|-------------------|--------------------|------------------|
|                                     | Placebo IV        | 130 mg             | ~6 mg/kg a       |
| Primary efficacy analysis set       | 319               | 320                | 322              |
| Baseline                            |                   |                    |                  |
| Median CRP (mg/L) b                 | 4.66              | 4.51               | 4.80             |
| Median fecal lactoferrin (μg/g) c   | 152.04            | 190.14             | 226.91           |
| Median fecal calprotectin (mg/kg) d | 1224.00           | 1382.00            | 1506.50          |
| Change from baseline at Week 8      |                   |                    |                  |
| Median CRP (mg/L) b                 | 0.00              | -1.30*             | -1.43*           |
| IQ range                            | (-2.47; 2.61)     | (-5.04; 0.30)      | (-7.63; 0.00)    |
| Median fecal lactoferrin (μg/g) c   | -4.71             | -43.41**           | -101.46*         |
| IQ range                            | (-149.28; 92.90)  | (-220.99; 29.10)   | (-301.23; 0.00)  |
| Median fecal calprotectin (mg/kg) d | -59.00            | -431.50*           | -715.50*         |
| IQ range                            | (-996.00; 751.00) | (-1635.50; 175.00) | (-1913.50; 0.00) |

CRP=C-reactive protein; IQ=interquartile range; IV=intravenous.

* p&lt;0.001.

** p=0.025.

- ≤85kg), 520 mg (weight &gt; 85kg).

b: For CRP, n=316 (placebo IV), n=315 (ustekinumab IV 130 mg), n=320 (ustekinumab IV ~6 mg/kg).

- d: For fecal calprotectin, n=289 (placebo IV), n=296 (ustekinumab IV 130 mg), n=300 (ustekinumab IV ~6 mg/kg).

AdaptedfromMod5.3.5.1/CNTO1275UCO3001/Induction/AttTEFCRP01,AttTEFFLAC01,AttTEFFCAL01

## Mayo Score Endpoints

The MAH has also presented results based on Mayo score and partial mayo score over time.

The Mayo score is calculated as the sum of the four subscores of stool frequency, rectal bleeding, findings of endoscopy, and PGA; values range from 0 to 12.  The partial Mayo score excludes endoscopy findings and the modified Mayo score excludes the PGA subscore; values for each range from 0 to 9. At baseline, the mean Mayo scores were the same across all treatment groups (8.9 for all groups). At Week 8, the mean decreases from baseline in Mayo scores were significantly greater in the ~6 mg/kg and 130 mg groups (3.5 and 3.2, respectively) compared with the placebo group (1.8; p&lt;0.001 for both comparisons).

At baseline, the mean partial Mayo scores were the same across all treatment groups (6.2 for all groups). As early as Week 2 and continuing for visits through Week 8, the mean decreases in the partial Mayo score were significantly greater in the ~6 mg/kg and 130 mg groups compared with the placebo group.

At Week 2, the mean decreases from baseline in the partial Mayo scores were 1.6 and 1.5, in the ~6 mg/kg and 130 mg, respectively, compared with 1.0 in the placebo group (p&lt;0.001 for both comparisons).

At Week 8, the mean decreases from baseline in the partial Mayo scores were 2.9 and 2.6, in the ~6 mg/kg and 130 mg, respectively, compared with 1.5 in the placebo group (p&lt;0.001 for both comparisons).

At baseline the mean modified Mayo score was also the same across all treatment groups (6.6 for all groups).  At Week 8, the mean decreases from baseline in the modified Mayo score were significantly greater in the ~6 mg/kg (2.6) and 130 mg (2.3) groups than in the placebo group (1.3; p&lt;0.001 for both comparisons).

<div style=\"page-break-after: always\"></div>

## Health-Related Quality of Life

The SF-36 evaluates 8 individual subscales (physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health) and the physical component summary (PCS; calculated from the subscales physical functioning, role-physical, bodily pain, and general health) and the mental component summary (MCS; calculated from the subscales vitality, social functioning, role-emotional and mental health) scores.  Each of the SF-36 subscales and 2 summary scores were derived and were scaled to scores with a mean of 50 and standard deviations of 10. Higher scores indicate better general health status.

At Week 8, significantly greater median increases in the PCS, MCS, and all 8 scale scores of the SF-36 were observed in both ustekinumab groups compared with the placebo group. In addition, greater proportions of subjects in both ustekinumab groups achieved a clinically meaningful improvement (≥5-point) from baseline in both PCS and MCS scores, indicating greater improvement in general health-related quality of life.

At Week 8, median changes from baseline in the EQ-5D index and the health state VAS were significantly greater in both ustekinumab groups compared with the placebo group.

## Summary of Health-Related Quality of Life Measurement sat Week 8: Primary Efficacy Analysis Set

|                                        |                | Ustekinumab IV   | Ustekinumab IV   |
|----------------------------------------|----------------|------------------|------------------|
|                                        | Placebo IV     | 130 mg           | ~6 mg/kga        |
| Primary efficacy analysis set          | 319            | 320              | 322              |
| IBDQ score                             |                |                  |                  |
| Median change from baseline            | 10.0           | 31.5 *           | 31.0 *           |
| IQ range                               | (-2.0; 34.0)   | (7.5; 53.5)      | (11.0; 56.0)     |
| Subjects with≥16-point improvement     | 141 (44.2%)    | 213 (66.6%)*     | 221 (68.6%)*     |
| IBDQ remission (total IBDQ score ≥170) | 101 (31.7%)    | 141 (44.2%)*     | 150 (46.6%)*     |
| SF-36                                  |                |                  |                  |
| PCS                                    |                |                  |                  |
| Median change from baseline            | 1.6            | 4.4 *            | 4.1 *            |
| IQ range                               | (-1.4; 5.4)    | (0.2; 8.9)       | (1.0; 8.9)       |
| Subjects with ≥5-point improvement     | 83 (26.0%)     | 154 (48.3%)*     | 146 (45.3%)*     |
| MCS                                    |                |                  |                  |
| Median change from baseline            | 1.0            | 3.8 *            | 3.6 *            |
| IQ range                               | (-4.0; 7.2)    | (-0.9; 10.9)     | (-1.0; 10.4)     |
| Subjects with ≥5-point improvement     | 100 (31.3%)    | 140 (43.9%)*     | 143 (44.4%)*     |
| EQ-5D health state VAS                 |                |                  |                  |
| Median change from baseline            | 5.00           | 10.00*           | 10.00*           |
| IQ range                               | (-5.00; 20.00) | (0.00; 25.00)    | (0.00; 25.00)    |
| EQ-5D index                            |                |                  |                  |
| Median change from baseline            | 0.01           | 0.06 *           | 0.06 *           |
| IQ range                               | (-0.02; 0.13)  | (0.00; 0.19)     | (0.00; 0.21)     |

*p≤0.001.

component summary; PCS=physical component summary; SF-36=Short Form Mental Health Survey; VAS=visual analog scale.

≤85 kg), 520 mg (weight &gt;85 kg).

Adapted from UC/Mod2.7.3/Tab7

<div style=\"page-break-after: always\"></div>

## Clinical Endpoints by Biologic Failure Status

For subjects with, and subjects without a history of biologic failure, the proportions of subjects who achieved clinical remission (global and US definitions), endoscopic healing, and clinical response were significantly greater in the ~6 mg/kg and 130 mg groups compared with subjects in the placebo group (p&lt;0.025 for both comparisons).

Though the treatment differences were generally similar between subjects who had a history of biologic failure and those who did not, the proportions of subjects who achieved each endpoint were consistently lower across all treatment groups for subjects who had a history of biologic failure compared with those who did not have a history of biologic failure.

## Clinical remission by biologic failure status - Global Definition

Of the subjects who had a history of biologic failure, significantly greater proportions of subjects in the ~6 mg/kg and 130 mg groups (12.7% and 11.6%, respectively), achieved clinical remission at Week 8 (global definition) compared with subjects in the placebo group (1.2%; p&lt;0.001 for both comparisons).

Of the subjects who did not have a history of biologic failure, significantly greater proportions of subjects in the ~6 mg/kg and 130 mg groups (18.6% and 19.9% respectively), achieved clinical remission at Week 8 (global definition), compared with subjects in the placebo group (9.5%; p=0.022 and p=0.009, respectively).

## Number of Subjects in Clinical Remission (Global Definition) at Week 8 by Biologic Failure Status: Primary Efficacy Analysis Set

| PrimaryEfficacyAnalysisSet                    | Placebo IV 319   | 130 mg 320                             | UstekinumabIV 6 mg/kgb 322             | Combined 642                           |
|-----------------------------------------------|------------------|----------------------------------------|----------------------------------------|----------------------------------------|
| Week8                                         |                  |                                        |                                        |                                        |
| Subjectswhoarebiologicfailure                 |                  |                                        |                                        |                                        |
| N                                             | 161 2 (1.2%)     | 164 19 (11.6%) 10.4 (5.2, 15.5) ≤0.001 | 166 21 (12.7%) 11.4 (6.1, 16.7) ≤0.001 | 330 40 (12.1%) 10.9 (7.0, 14.8) ≤0.001 |
| Subjects in clinical remission c.d            |                  |                                        |                                        |                                        |
| Adjusted treatment difference (95% C1)        |                  |                                        |                                        |                                        |
| p-valuef                                      |                  |                                        |                                        |                                        |
| Subjects who are not biologic failure         |                  |                                        |                                        |                                        |
| N                                             | 158              | 156                                    | 156                                    | 312                                    |
| Subjects in clinical remission .d             | 15 (9.5%)        | 31 (19.9%)                             | 29 (18.6%)                             | 60 (19.2%)                             |
| Adjusted treatmentdifference(9s%Cl)* p-value! |                  | 10.4 (2.7,18.1) 0.009                  | 9.0 (1.4,16.5) 0.022                   | 9.7 (3.4,16.0) 0.007                   |

The p-values Were based on the Cochran-Mantel-Haenszel (CMH) test.

The confidence intervalswerebasedontheWald statisticwithMantel-Haenszelweight.

[TEFCREM12\\_GRTF][/SAS/2709/CNTO1275UCO3001/FILES/RE/CSRINDUCTIONFINAL/PR0GRAMS/TEFCREM12\\_UG.SAS]06FEB2018.05:51

Of the subjects with a history of biologic failure, significantly greater proportions of subjects in the ~6 mg/kg and 130 mg groups (13.3% and 11.6%, respectively), achieved clinical remission at Week 8 (US definition) compared with subjects in the placebo group (2.5%; p&lt;0.001 and p=0.001,).

Of the subjects who did not have a history of biologic failure, significantly greater proportions of subjects in the ~6 mg/kg and 130 mg groups (25.0% and 21.8%, respectively) achieved clinical remission (US definition) at Week 8 compared with subjects in the placebo group (10.1%; p&lt;0.001, p=0.005, respectively).

<div style=\"page-break-after: always\"></div>

## Number of Subjects in Clinical Remission (US Definition) at Week 8 by Biologic Failure Status: Primary Efficacy Analysis Set

| Primary EfficacyAnalysisSet                                                         | Placebo IV 319   | 130 mg 320                           | UstekinumabIV 6mg/kg 322               | Combined 642                          |
|-------------------------------------------------------------------------------------|------------------|--------------------------------------|----------------------------------------|---------------------------------------|
| Week8                                                                               |                  |                                      |                                        |                                       |
| Subjectswhoarebiologicfailure                                                       |                  |                                      |                                        |                                       |
| N Subjects in clinical remission d Adjusted treatment difference (97.5%C1) p-value? | 161 4 (2.5%)     | 164 19 (11.6%) 9.1 (2.8, 15.3) 0.001 | 166 22 (13.3%) 10.8 (4.3,17.3) <0.001  | 330 41 (12.4%) 9.9 (5.0, 14.8) <0.001 |
| Subjectswho are not biologicfailure                                                 |                  |                                      |                                        |                                       |
| N Subjects in clinical remission .d Adjustedtreatmentdifference(97.5%C1) p-value!   | 158 16 (10.1%)   | 156 34 (21.8%) 11.7 (2.6,20.8) 0.005 | 156 39 (25.0%) 14.7 (5.4, 24.1) <0.001 | 312 73 (23.4%) 13.2 (5.7,20.8) <0.001 |

[TEFCREM12\\_URTF][/SAS/2709/CNTO1275UCO3001/FILES/RE/CSRINDUCTIONFINAL/PROGRAMS/TEFCREM12\\_UGSAS]06FEB2018,05:51

## Endoscopic healing at Week 8 by biologic failure status

Of the subjects with a history of biologic failure, significantly greater proportions of subjects in the ~6 mg/kg and 130 mg groups (21.1% and 18.3%, respectively) achieved endoscopic healing at Week 8 compared with subjects in the placebo group (6.8%; p&lt;0.001, p=0.002, respectively).

Of the subjects who did not have a history of biologic failure, significantly greater proportions of subjects in the ~6 mg/kg and 130 mg groups (33.3% and 34.6%, respectively) achieved endoscopic healing at Week 8 compared with subjects in the placebo group (20.9%; p=0.014 and p=0.006, respectively).

## Number of Subjects with Endoscopic Healing at Week 8 by Biologic Failure Status: Primary Efficacy Analysis Set

|                                            |            | UstekinumabIV    | UstekinumabIV    | UstekinumabIV     |
|--------------------------------------------|------------|------------------|------------------|-------------------|
|                                            | PlaceboIV  | 130 mg           | 6mg/kg           | Combined          |
| PrimaryEfficacyAnalysisSet                 | 319        | 320              | 322              | 642               |
| Week 8                                     |            |                  |                  |                   |
| Subjectswhoarebiologicfailure              |            |                  |                  |                   |
| N                                          | 161        | 164              | 166              | 330               |
| Subjects with endoscopic healing           | 11 (6.8%)  | 30 (18.3%)       | 35 (21.1%)       | 65 (19.7%)        |
| p-value                                    |            | 0.002            | <0.001           | <0.001            |
| Subjects who are not biologic failure      |            |                  |                  |                   |
| N                                          | 158        | 156              | 156              | 312               |
| Subjects with endoscopic healing * p-value | 33 (20.9%) | 54 (34.6%) 0.006 | 52 (33.3%) 0.014 | 106 (34.0%) 0.003 |

[TEFENDO05.RTF][/SAS/2709/CNTO1275UCO3001/FILES/RE/CSRINDUCTIONFINAL/PROGRAMS/TEFEND005.SAS]06FEB201S,05:51

Subjects who had a missing endoscopy score at Week8were considered not to have endoscopic healing.

## Clinical response at Week 8 by biologic failure status

Of the subjects with a history of biologic failure, significantly greater proportions of subjects in the ~6 mg/kg and 130 mg groups (57.2% and 45.1%, respectively) achieved clinical response at Week 8, compared with subjects in the placebo group (27.3%; p&lt;0.001 for both comparisons).

Of the subjects who did not have a history of biologic failure, significantly greater proportions of subjects in the ~6 mg/kg and 130 mg groups (66.7% and 57.7%, respectively) achieved clinical response at Week 8 compared with subjects in the placebo group (35.4%; p&lt;0.001 for both comparisons).

<div style=\"page-break-after: always\"></div>

Consistent with the rates of clinical response in the primary analysis population, the proportion of subjects achieving clinical response at Week 8 was higher in the ~6 mg/kg group than in the 130 mg group regardless of biologic failure history.

Number of Subjects in Clinical Response at Week 8 by Biologic Failure Status: Primary Efficacy Analysis Set

<!-- image -->

|                                          |            | UstekinumabIV     | UstekinumabIV      | UstekinumabIV      |
|------------------------------------------|------------|-------------------|--------------------|--------------------|
|                                          | PlaceboIV  | 130mg             | 6mg/kg             | Combined           |
| PrimaryEfficacyAnalysisSet               | 319        | 320               | 322                | 642                |
| Week 8                                   |            |                   |                    |                    |
| Subjectswhoarebiologicfailure            |            |                   |                    |                    |
| N                                        | 161        | 164               | 166                | 330                |
| Subjects in clinical response b.e        | 44 (27.3%) | 74 (45.1%) <0.001 | 95 (57.2%)         | 169 (51.2%)        |
| p-value                                  |            |                   | <0.001             | <0.001             |
| Subjectswhoarenotbiologicfailure         |            |                   |                    |                    |
| N                                        | 158        | 156               | 156                | 312                |
| Subjects in clinical response .e p-value | 56 (35.4%) | 90 (57.7%) <0.001 | 104 (66.7%) <0.001 | 194 (62.2%) <0.001 |

Subjectswhohada prohibited changeinconcomitantUCmedicationoranostomyorcolectomypriorto theWeek8visitwereconsiderednottobeinclinicalresponse.

[TEFCRES03.RTF][/SAS/2709/CNTO1275UCO3001/FILES/RE/CSRINDUCTIONFINAL/PROGRAMS/TEFCRES03.SAS]06FEB2018,05:51

Subjects who had all 4 Mayo subscores missing at Week 8were considered not to be in clinical response.

## Clinical Endpoints Based on Selected Biologic Failure Profiles

Post-hoc analyses were conducted to evaluate the efficacy of the clinical endpoints of clinical remission (global and US definitions), endoscopic healing, clinical response, and mucosal healing based on the following biologic failure profiles: subjects who were biologic-naïve, subjects who were biologic failures to at least 1 anti-TNF (regardless of vedolizumab), and subjects who were biologic failures to both anti-TNF and vedolizumab. These subpopulations were identified as they represent the general treatment pathway for patients with UC and indicate progressively more refractory disease.

Subjects who were biologic-naïve comprised 94.3% of subjects (443 of 470 subjects) who did not have a history of biologic failure. In this subpopulation, the proportions of subjects who achieved each of the clinical endpoints of clinical remission (global and US definitions), endoscopic healing clinical response, and mucosal healing were significantly greater in the ~6 mg/kg and 130 mg groups compared with subjects in the placebo group (p&lt;0.05 for both comparisons)

<div style=\"page-break-after: always\"></div>

## Summary of UC-Related Biologic Medication History: Primary Analysis Set

|                                                               | UstekinumabIV   | UstekinumabIV   | UstekinumabIV   | UstekinumabIV   | UstekinumabIV   |
|---------------------------------------------------------------|-----------------|-----------------|-----------------|-----------------|-----------------|
|                                                               | PlaceboIV       | 130mg           | 6 mg/kg a       | Combined        | Total           |
| PrimaryEfficacyAnalysisset                                    | 319             | 320             | 322             | 642             | 961             |
| Subjects without a history of biological failure              | 158 (49.5%)     | 156 (48.8%)     | 156 (48.4%)     | 312 (48.6%)     | 470 (48.9%)     |
| Biologic-naive                                                | 151 (47.3%)     | 145 (45.3%)     | 147 (45.7%)     | 292 (45.5%)     | 443 (46.1%)     |
| Biologic-experienced, but not documented failure              | 7 (2.2%)        | 11 (3.4%)       | 9 (2.8%)        | 20 (3.1%)       | 27 (2.8%)       |
| Subjects with a history of biological failure                 | 161 (50.5%)     | 164 (51.3%)     | 166 (51.6%)     | 330 (51.4%)     | 491 (51.1%)     |
| Primary nonresponse, secondary nonresponse, or intolerance to |                 |                 |                 |                 |                 |
| Only anti-TNF (NOT to vedolizumab)                            | 112 (35.1%)     | 107 (33.4%)     | 106 (32.9%)     | 213 (33.2%)     | 325 (33.8%)     |
| Primary nonresponse b                                         | 52 (46.4%)      | 41 (38.3%)      | 50 (47.2%)      | 91 (42.7%)      | 143 (44.0%)     |
| Secondary nonresponse b                                       | 68 (60.7%)      | 70 (65.4%)      | 68 (64.2%)      | 138 (64.8%)     | 206 (63.4%)     |
| Intolerance b                                                 | 15 (13.4%)      | 18 (16.8%)      | 12 (11.3%)      | 30 (14.1%)      | 45 (13.8%)      |
| Atleastoneanti-TNF(regardlessof vedolizumab)                  | 159 (49.8%)     | 162 (50.6%)     | 164 (50.9%)     | 326 (50.8%)     | 485 (50.5%)     |
| Primary nonresponse                                           | 77 (48.4%)      | 78 (48.1%)      | 80 (48.8%)      | 158 (48.5%)     | 235 (48.5%)     |
| Secondary nonresponse                                         | 97 (61.0%)      | 98 (60.5%)      | 108 (65.9%)     | 206 (63.2%)     | 303 (62.5%)     |
| Intolerance                                                   | 24 (15.1%)      | 33 (20.4%)      | 18 (11.0%)      | 51 (15.6%)      | 75 (15.5%)      |
| Any anti-TNF andvedolizumab                                   | 47 (14.7%)      | 55 (17.2%)      | 58 (18.0%)      | 113 (17.6%)     | 160 (16.6%)     |
| Primary nonresponse d                                         | 31 (66.0%)      | 42 (76.4%)      | 36 (62.1%)      | 78 (69.0%)      | 109 (68.1%)     |
| Secondary nonresponse d                                       | 38 (80.9%)      | 40 (72.7%)      | 46 (79.3%)      | 86 (76.1%)      | 124 (77.5%)     |
| Intolerance                                                   | 11 (23.4%)      | 17 (30.9%)      | 7 (12.1%)       | 24 (21.2%)      | 35 (21.9%)      |
| Vedolizumab (regardless of anti-TNF)                          | 49 (15.4%)      | 57 (17.8%)      | 60 (18.6%)      | 117 (18.2%)     | 166 (17.3%)     |
| Primary nonresponse ?                                         | 17 (34.7%)      | 23 (40.4%)      | 23 (38.3%)      | 46 (39.3%)      | 63 (38.0%)      |
| Secondary nonresponse e                                       | 30 (61.2%)      | 32 (56.1%)      | 36 (60.0%)      | 68 (58.1%)      | 98 (59.0%)      |
| Intolerance °                                                 | 3 (6.1%)        | 2 (3.5%)        | 1 (1.7%)        | 3 (2.6%)        | 6 (3.6%)        |

(  &lt;am)  o (x ss &gt;e  s &lt;m)  0ae ( s ram)  pg y 9 e ssp qn sq s-m e

To at least one anti-TNF. Denominator is subjects who are primary nonresponse, secondary nonresponse, or intolerance to at least one anti-TNF (regardless of yedolizumab).

To vedolizumab. Denominator is subjects who are primary nonresponse, secondary nonresponse, or intolerance to vedolizumab (regardless of anti-TNF).

d To at least one anti-TNF or vedolizumab. Denominator is subjects who are primary nonresponse, secondary nonresponse, or intolerance to any anti-TNF and vedolizumab.

Subjects who were biologic failures to at least 1 anti-TNF (regardless of vedolizumab) comprised 98.8% of subjects (485 of 491 subjects) who had a history of biologic failure. In this subpopulation, the proportions of subjects who achieved each of the clinical endpoints of clinical remission (global and US definitions), endoscopic healing, clinical response, and mucosal healing were significantly greater in the ~6 mg/kg and 130 mg groups compared with subjects in the placebo group (p≤0.002 for all comparisons).

<div style=\"page-break-after: always\"></div>

## Summary of Key Efficacy Endpoints at Week 8: Subjects in Primary Efficacy Analysis Set who Failed at Least 1 Anti-TNF (regardless of Vedolizumab)

|                                                                                    | PlaceboIV    | 130mg             | UstekinumabIV 6 mg/kg a   | Combined          |
|------------------------------------------------------------------------------------|--------------|-------------------|---------------------------|-------------------|
| SubjectsinPrimaryEfficacyAnalysisSetwhofailed atleast1TNF(regardlessofvedolizumab) |              |                   |                           |                   |
| N                                                                                  | 159          | 162               | 164                       | 326               |
| Subjects in clinical remission (global definition) b at                            |              |                   |                           |                   |
| Week 8 e,f p-value                                                                 | 2 (1.3%)     | 18 (11.1%) <0.001 | 21 (12.8%) <0.001         | 39 (12.0%) <0.001 |
| Subjects in clinical remission(US definition)°at                                   |              |                   |                           |                   |
| Week 8 e,f                                                                         | 4 (2.5%)     | 18 (11.1%)        | 22 (13.4%)                | 40 (12.3%)        |
| p-value                                                                            |              | 0.002             | <0.001                    | <0.001            |
| Subjects with endoscopic healing at Week 8 def                                     | 11 (6.9%)    | 29 (17.9%)        | 35 (21.3%)                | 64 (19.6%)        |
| p-value                                                                            |              | 0.003             | <0.001                    | <0.001            |
| Subjects in clinical response at Week 8 e,f                                        | 43 (27.0%)   | 73 (45.1%)        | 94 (57.3%)                | 167 (51.2%)       |
| p-value                                                                            |              | <0.001            | <0.001                    | <0.001            |
| Subjects with mucosal healing at Week 8 d.efe                                      | 3.8% (6/159) | 13.2% (21/159)    | 13.4% (22/164)            | 13.3% (43/323)    |
| p-value                                                                            |              | 0.002             | 0.002                     | 0.001             |

² Weight-range based ustekinumab doses approximating 6 mg/kg: 260 mg (weight≤ 55 kg), 390 mg (weight &gt; 55 kg and ≤ 85 kg), 520 mg (weight &gt; 85 kg).

Clinical remission (US definition): An absolute stool number ≤ 3, a Mayo rectal bleeding subscore of 0, and a Mayo endoscopy subscore of 0 or 1.

b Clinical remission (global definition): A Mayo score ≤ 2 points, with no individual subscore &gt; 1.

d Mucosal healing is defined as having both endoscopic healing and histologic healing. Endoscopic healing is defined as an endoscopy subscore of O or 1. Histologic healing is defined as 0-&lt;5% neutrophils in epithelium, no crypt destruction, and no erosions or ulcerations or granulations.

f Subjects who had all 4 Mayo subscores missing at Week 8 were considered not to be in clinical remission (global definition) or clinical response; subjects who were missing all 3ofthe Mayo components pertaining toUS definition of clinical remission(absolute stool number,rectalbleeding subscore, and Mayo endoscopy subscore) at Week 8 visit were considered not to be in clinical remission (US definition); subjects who had a missing endoscopy score at Week 8 were considered not to have endoscopic healing; subjects who had a missing endoscopy score or were missing any of the components pertaining to histologic healing endpoint (i.e., assessment of neutrophils in epithelium, crypt destruction, or erosions or ulcerations or granulations) at Week8were considered not tohave mucosal healing.

eSubjectswhohad aprohibited changein concomitant UCmedication or anostomy orcolectomy prior to theWeek8visit wereconsidered not tobe in clinicalremission(for both global andUSdefinitions)or clinicalresponse and not tohave endoscopic healing or mucosal healing.

Excludessubjectswhose mucosal healing status could not be determined atWeek8dueto anunevaluable biopsy(ie,abiopsy that was collected,but could not be assessed duetosamplepreparationortechnicalerrors).Notethatsubjectswhohadanunevaluablebiopsy atWeek8butwhodidnotachieveendoscopichealingwereconsiderednot to havemucosal healing.

Subjects who are biologic failures to both anti-TNF and vedolizumab comprised 16.6% of subjects randomized in this study (160 of 961 subjects) and 32.6% of subjects (160 of 491 subjects) who had a history of biologic failure. In this subpopulation, the proportions of subjects who achieved clinical remission (global definition) were significantly greater in the ~6 mg/kg and 130 mg groups compared with subjects in the placebo group (p=0.033, p=0.019, respectively).

For the other clinical endpoints (clinical remission [US definition], endoscopic healing, clinical response, and mucosal healing) statistical significance was not reached however the proportions of subjects who achieved each endpoint were numerically greater in the ~6 mg/kg and 130 mg groups compared with subjects in the placebo group.  The exception is the result for the clinical response endpoint for the ~6 mg/kg group, where statistical significance was achieved (p=0.036).

<div style=\"page-break-after: always\"></div>

## Summary of Key Efficacy Endpoints at Week 8: Subjects in Primary Efficacy Analysis Set who are Biologic Failure to both anti-TNF and Vedolizumab

|                                                      | Placebo IV   | 130 mg       | UstekinumabIV 6 mg/kg a   | Combined       |
|------------------------------------------------------|--------------|--------------|---------------------------|----------------|
| SubjectsinPrimaryEfficacyAnalysisSetwhoare           |              |              |                           |                |
| biologicfailuretoboth anti-TNFandvedolizumab N       | 47           | 55           | 58                        | 113            |
| Subjects in clinical remission (global definition)at |              |              |                           |                |
| Week 8 e,f                                           | 0            | 6 (10.9%)    | 6 (10.3%)                 | 12 (10.6%)     |
| p-value                                              |              | 0.019        | 0.033                     | 0.024          |
| Subjects in clinical remission(US definition)°at     |              |              |                           |                |
| Week 8 ef                                            | 1 (2.1%)     | 5 (9.1%)     | 6 (10.3%)                 | 11 (9.7%)      |
| p-value                                              |              | 0.133        | 0.133                     | 0.114          |
| Subjects with endoscopic healing at Week 8 de.f      | 5 (10.6%)    | 8 (14.5%)    | 12 (20.7%)                | 20 (17.7%)     |
| p-value                                              |              | 0.537        | 0.271                     | 0.336          |
| Subjects in clinical response at Week 8 e,f          | 13 (27.7%)   | 22 (40.0%)   | 30 (51.7%)                | 52 (46.0%)     |
| p-value                                              |              | 0.171        | 0.036                     | 0.050          |
| Subjects with mucosal healing at Week 8 def.:        | 6.4% (3/47)  | 11.1% (6/54) | 10.3% (6/58)              | 10.7% (12/112) |
| p-value                                              |              | 0.393        | 0.598                     | 0.442          |

Excludes subjects whose mucosal healing status could not be determined at Week 8 due to an unevaluable biopsy (ie, a biopsy that was collected, but could not be assessed due tosample preparation or technical errors).Note that subjectswhohad an unevaluablebiopsy at Week 8but whodid not achieve endoscopichealingwere considerednot tohave mucosalhealing.

f Subjects who had all 4 Mayo subscores missing at Week 8 were considered not to be in clinical remission (global definition) or clinical response; subjects who were missing all 3 ofthe Mayo components pertaining to US definition of clinical remission (absolute stool number, rectal bleeding subscore, andMayo endoscopy subscore)at Week 8 visit were considered not to be in clinical remission (US definition); subjects who had a missing endoscopy score at Week 8 were considered not to have endoscopic healing; subjects who had a missing endoscopy score or were missing any of the components pertaining to histologic healing endpoint (i.e., assessment of neutrophils in epithelium, crypt destruction, or erosions or ulcerations or granulations) at Week 8 were considered not to have mucosal healing.

[TEFKEY01.RTF][/SAS/2709/CNTO1275UCO3001/FILES/RE/CSRINDUCTIONFINAL/PROGRAMS/TEFKEY01.SAS]14MAY2018,14:13

## Summary of main studies

The following tables summarise the efficacy results from the main studies supporting the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

<div style=\"page-break-after: always\"></div>

## Summary of efficacy for trial CNTO1275UCO3001-Induction (UNIFI-I)

| Title: A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinwmah Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis   | Title: A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinwmah Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis   | Title: A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinwmah Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis   | Title: A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinwmah Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis   | Title: A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinwmah Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis   | Title: A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinwmah Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                                           | UCO3001-Induction(UNIFI-I)                                                                                                                                                                                                                                 | UCO3001-Induction(UNIFI-I)                                                                                                                                                                                                                                 | UCO3001-Induction(UNIFI-I)                                                                                                                                                                                                                                 | UCO3001-Induction(UNIFI-I)                                                                                                                                                                                                                                 | UCO3001-Induction(UNIFI-I)                                                                                                                                                                                                                                 |
| Design                                                                                                                                                                                                                                                     | Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study                                                                                                                                                                            | Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study                                                                                                                                                                            | Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study                                                                                                                                                                            | Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study                                                                                                                                                                            | Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study                                                                                                                                                                            |
| Design                                                                                                                                                                                                                                                     | Duration of main phase: Duration of Run-in phase: Duration of Extension phase:                                                                                                                                                                             | Duration of main phase: Duration of Run-in phase: Duration of Extension phase:                                                                                                                                                                             | 8 Weeks Not Applicable Not Applicable                                                                                                                                                                                                                      | 8 Weeks Not Applicable Not Applicable                                                                                                                                                                                                                      | 8 Weeks Not Applicable Not Applicable                                                                                                                                                                                                                      |
| Hypothesis                                                                                                                                                                                                                                                 | Superiority                                                                                                                                                                                                                                                | Superiority                                                                                                                                                                                                                                                | Superiority                                                                                                                                                                                                                                                | Superiority                                                                                                                                                                                                                                                | Superiority                                                                                                                                                                                                                                                |
| Treatments groups                                                                                                                                                                                                                                          | Ustekinumab. 130 mg                                                                                                                                                                                                                                        | Ustekinumab. 130 mg                                                                                                                                                                                                                                        | SingleIV administration ofustekinumah; randomized n=320                                                                                                                                                                                                    | SingleIV administration ofustekinumah; randomized n=320                                                                                                                                                                                                    | SingleIV administration ofustekinumah; randomized n=320                                                                                                                                                                                                    |
| Treatments groups                                                                                                                                                                                                                                          | Ustekinumab, 6 mg/kg                                                                                                                                                                                                                                       | Ustekinumab, 6 mg/kg                                                                                                                                                                                                                                       | Single IV administration of ustekinumah; randomized n=322                                                                                                                                                                                                  | Single IV administration of ustekinumah; randomized n=322                                                                                                                                                                                                  | Single IV administration of ustekinumah; randomized n=322                                                                                                                                                                                                  |
| Treatments groups                                                                                                                                                                                                                                          | Placebo                                                                                                                                                                                                                                                    | Placebo                                                                                                                                                                                                                                                    | Single IV administration of placebo; randomized n=319                                                                                                                                                                                                      | Single IV administration of placebo; randomized n=319                                                                                                                                                                                                      | Single IV administration of placebo; randomized n=319                                                                                                                                                                                                      |
| Endpoints and definitions                                                                                                                                                                                                                                  | Primary endpoint                                                                                                                                                                                                                                           | Clinical Remission at Week 8                                                                                                                                                                                                                               | Mayo score ≤2 points, with no individual suhscore >1                                                                                                                                                                                                       | Mayo score ≤2 points, with no individual suhscore >1                                                                                                                                                                                                       | Mayo score ≤2 points, with no individual suhscore >1                                                                                                                                                                                                       |
| Endpoints and definitions                                                                                                                                                                                                                                  | Major Secondary endpoint                                                                                                                                                                                                                                   | Endoscopic healing at Week 8                                                                                                                                                                                                                               | Endoscopy suhsoone of 0 or 1                                                                                                                                                                                                                               | Endoscopy suhsoone of 0 or 1                                                                                                                                                                                                                               | Endoscopy suhsoone of 0 or 1                                                                                                                                                                                                                               |
| Endpoints and definitions                                                                                                                                                                                                                                  | Major Secondary endpoint                                                                                                                                                                                                                                   | Clinical response at Week 8                                                                                                                                                                                                                                | Decrease from baseline in the Mayo score by ≥30% and ≥3 points, with either a decrease from baseline in the rectal bleeding suhscore ≥1 or a rectal bleeding subscore of 0 or 1                                                                            | Decrease from baseline in the Mayo score by ≥30% and ≥3 points, with either a decrease from baseline in the rectal bleeding suhscore ≥1 or a rectal bleeding subscore of 0 or 1                                                                            | Decrease from baseline in the Mayo score by ≥30% and ≥3 points, with either a decrease from baseline in the rectal bleeding suhscore ≥1 or a rectal bleeding subscore of 0 or 1                                                                            |
| Endpoints and definitions                                                                                                                                                                                                                                  | Major Secondary endpoint                                                                                                                                                                                                                                   | Change from baseline in IBDQ score at Week 8                                                                                                                                                                                                               | Median change from baseline in the total IBDQ score                                                                                                                                                                                                        | Median change from baseline in the total IBDQ score                                                                                                                                                                                                        | Median change from baseline in the total IBDQ score                                                                                                                                                                                                        |
| Database lock                                                                                                                                                                                                                                              | 14 Aug 2017                                                                                                                                                                                                                                                | 14 Aug 2017                                                                                                                                                                                                                                                | 14 Aug 2017                                                                                                                                                                                                                                                | 14 Aug 2017                                                                                                                                                                                                                                                | 14 Aug 2017                                                                                                                                                                                                                                                |
| Results and Analysis                                                                                                                                                                                                                                       | Results and Analysis                                                                                                                                                                                                                                       | Results and Analysis                                                                                                                                                                                                                                       | Results and Analysis                                                                                                                                                                                                                                       | Results and Analysis                                                                                                                                                                                                                                       | Results and Analysis                                                                                                                                                                                                                                       |
| Analysis description                                                                                                                                                                                                                                       | Primary Analysis                                                                                                                                                                                                                                           | Primary Analysis                                                                                                                                                                                                                                           | Primary Analysis                                                                                                                                                                                                                                           | Primary Analysis                                                                                                                                                                                                                                           | Primary Analysis                                                                                                                                                                                                                                           |
| Analysis population and time point description                                                                                                                                                                                                             | Intent to treat-Week 8                                                                                                                                                                                                                                     | Intent to treat-Week 8                                                                                                                                                                                                                                     | Intent to treat-Week 8                                                                                                                                                                                                                                     | Intent to treat-Week 8                                                                                                                                                                                                                                     | Intent to treat-Week 8                                                                                                                                                                                                                                     |
| Descriptive statistics and estimate variability                                                                                                                                                                                                            | Treatment group                                                                                                                                                                                                                                            | Treatment group                                                                                                                                                                                                                                            | Ustekinumah 6 mg/kg                                                                                                                                                                                                                                        | Ustekinumah. 130 mg                                                                                                                                                                                                                                        | Placebo                                                                                                                                                                                                                                                    |
| Descriptive statistics and estimate variability                                                                                                                                                                                                            | Number of subject                                                                                                                                                                                                                                          | Number of subject                                                                                                                                                                                                                                          | 322                                                                                                                                                                                                                                                        | 320                                                                                                                                                                                                                                                        | 319                                                                                                                                                                                                                                                        |
| Descriptive statistics and estimate variability                                                                                                                                                                                                            | Primary endpoint- Clinical Remission at Week 8                                                                                                                                                                                                             | Primary endpoint- Clinical Remission at Week 8                                                                                                                                                                                                             | 50 (15.5%)                                                                                                                                                                                                                                                 | 50 (15.6%)                                                                                                                                                                                                                                                 | 17 (5.3%)                                                                                                                                                                                                                                                  |
| Descriptive statistics and estimate variability                                                                                                                                                                                                            | Adjusted treatment difference (95% CI)                                                                                                                                                                                                                     | Adjusted treatment difference (95% CI)                                                                                                                                                                                                                     | 10.2 (5.6, 14.8)                                                                                                                                                                                                                                           | 10.3 (5.7, 14.9)                                                                                                                                                                                                                                           | N.A.                                                                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

| Effect estimate per comparison                  |                                                         | Comparison groups        | Comparison groups        | Ustekinumah130 mg vs Placebo     | Ustekinumah130 mg vs Placebo     |
|-------------------------------------------------|---------------------------------------------------------|--------------------------|--------------------------|----------------------------------|----------------------------------|
| Effect estimate per comparison                  |                                                         | P-value                  | P-value                  | < 0.001                          | < 0.001                          |
| Effect estimate per comparison                  |                                                         | Comparison groups        | Comparison groups        | Ustekinumah. ~6 mg/kg vs Placebo | Ustekinumah. ~6 mg/kg vs Placebo |
| Effect estimate per comparison                  |                                                         | P-value                  | P-value                  | < 0.001                          | < 0.001                          |
| Analysis description                            | Major Secondary Analysis                                | Major Secondary Analysis | Major Secondary Analysis | Major Secondary Analysis         | Major Secondary Analysis         |
| Analysis population and time point description  | Intent to treat -Week 8                                 | Intent to treat -Week 8  | Intent to treat -Week 8  | Intent to treat -Week 8          | Intent to treat -Week 8          |
| Descriptive statistics and estimate variability | Treatment group                                         | Ustekinumah. 6 mg/kg     | Ustekinumah. 130 mg      | Ustekinumah. 130 mg              | Placebo                          |
| Descriptive statistics and estimate variability | Number of subject                                       | 322                      | 320                      | 320                              | 319                              |
| Descriptive statistics and estimate variability | Major Secondary endpoint - Endoscopic healing at Week 8 | 87 (27.0%)               | 84 (26.3%)               | 84 (26.3%)                       | 44 (13.8%)                       |
| Descriptive statistics and estimate variability | Adjusted treatment difference (95% CI)                  | 13.3 (7.3, 19.3)         | 12.4 (6.5, 18.4)         | 12.4 (6.5, 18.4)                 | N.A.                             |
| Descriptive statistics and estimate variability |                                                         | Comparison groups        | Comparison groups        | Ustekinumab130 mg vs Placebo     | Ustekinumab130 mg vs Placebo     |
| Descriptive statistics and estimate variability |                                                         | P-value                  | P-value                  | <0.001                           | <0.001                           |
| Descriptive statistics and estimate variability |                                                         | Comparison groups        | Comparison groups        | Ustekinumah. ~6 mg/kg vs Placebo | Ustekinumah. ~6 mg/kg vs Placebo |
| Descriptive statistics and estimate variability |                                                         | P-value                  | P-value                  | < 0.001                          | < 0.001                          |
| Analysis description                            | Major Secondary Analysis                                | Major Secondary Analysis | Major Secondary Analysis | Major Secondary Analysis         | Major Secondary Analysis         |
| Analysis population and time point description  | Intent to treat -Week 8                                 | Intent to treat -Week 8  | Intent to treat -Week 8  | Intent to treat -Week 8          | Intent to treat -Week 8          |
| Descriptive statistics and estimate variability | Treatment group                                         | Ustekinumah. 6 mg/kg     | Ustekinumab. 130 mg      | Ustekinumab. 130 mg              | Placebo                          |
| Descriptive statistics and estimate variability | Number of subject                                       | 322                      | 320                      | 320                              | 319                              |
| Descriptive statistics and estimate variability | Major Secondary endpoint - Clinical response at Week 8  | 199 (61.8%)              | 164 (51.3%)              | 164 (51.3%)                      | 100 (31.3%)                      |
| Descriptive statistics and estimate variability | Adjusted treatment difference (95% CI)                  | 30.5 (23.2) 37.8)        | 19.9 (12.5, 27.3)        | 19.9 (12.5, 27.3)                | N.A.                             |
| Descriptive statistics and estimate variability |                                                         | Comparison groups        | Comparison groups        | Ustekinumab 130 mg vs            | Ustekinumab 130 mg vs            |
| Descriptive statistics and estimate variability |                                                         | P-value                  | P-value                  | Placebo < 0.001                  | Placebo < 0.001                  |
| Descriptive statistics and estimate variability |                                                         | Comparison groups        | Comparison groups        | Ustekinumab 6 mg/kg vs           | Ustekinumab 6 mg/kg vs           |
| Descriptive statistics and estimate variability |                                                         | P-value                  | P-value                  | Placebo < 0.001                  | Placebo < 0.001                  |
| Analysis description                            | Major Secondary Analysis                                | Major Secondary Analysis | Major Secondary Analysis | Major Secondary Analysis         | Major Secondary Analysis         |
| Analysis population and time point description  | Intent to treat -Week 8                                 | Intent to treat -Week 8  | Intent to treat -Week 8  | Intent to treat -Week 8          | Intent to treat -Week 8          |

<div style=\"page-break-after: always\"></div>

A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis

## - Maintenance Study -

## Methods

## Study participants

The maintenance study was a Phase 3, multicenter, placebo-controlled, parallel-group, double-blind, randomized-withdrawal study that was designed to evaluate the efficacy and safety of SC regimens of ustekinumab maintenance therapy in the primary population of subjects with moderately to severely active UC who were induced into clinical response with IV ustekinumab.

Although all subjects who were responders to study agent in the induction study were eligible to be enrolled in the maintenance study, only subjects who were in clinical response to IV ustekinumab during induction comprised the primary population in the maintenance study (Figure 4). The following subjects from the induction study were included in the primary population of the maintenance study:

- Subjects who were randomized to receive IV ustekinumab at Week 0 of the induction study and were in clinical response at Week 8 of the induction study.
- Subjects who were randomized to receive IV placebo at Week 0 of the induction study and were not in clinical response at Week 8 but were in clinical response at Week 16 of the induction study after receiving an induction dose of IV ustekinumab (~6 mg/kg) at Week 8.

Figure 4: Schema for the CNTO1275UCO3001 maintenance study

<!-- image -->

## Treatments

The 2 SC ustekinumab regimens are the same as those used in the Phase 3 maintenance study in the

<div style=\"page-break-after: always\"></div>

ustekinumab Crohn's disease program, which were chosen based on data from the Phase 2b study in Crohn's disease. The ustekinumab 90 mg SC q8w dose regimen was selected because it was considered safe and effective in achieving remission among subjects randomized as responders to ustekinumab induction in the Phase 2b study.26 To explore a lower dose regimen in the Phase 3 study in Crohn's disease, the ustekinumab 90 mg SC q12w dose regimen was included because it was the next lower dose regimen that had been studied extensively in psoriasis and was considered likely to succeed in maintaining clinical efficacy over time in patients with Crohn's disease. These maintenance doses provided systemic exposures that were likely to meet the safety and efficacy objectives for the development of ustekinumab in Crohn's disease and subsequently in UC.

## Steroid tapering

For subjects who were receiving oral corticosteroids on entry into the maintenance study, the investigator was to begin tapering the daily dose of corticosteroids beginning at Week 0 of the maintenance study.

The recommended tapering schedule for oral prednisone-equivalent (P.Eq) corticosteroids was as follows:

- Subjects receiving &gt;20 mg/day P.Eq: taper daily dose by 5 mg/week until 0 mg/day.
- Subjects receiving ≤20 mg/day P.Eq: taper daily dose by 2.5 mg/week until 0 mg/day.

Tapering of budesonide or beclomethasone dipropionate followed local clinical practice. Subjects were permitted to transiently (ie, for ≤4 weeks) use increased doses of corticosteroids for reasons other than loss of response (eg, stress doses of corticosteroids for surgery, asthma flare, adrenocortical insufficiency).

## Objectives

The primary objectives of the maintenance study were:

- To evaluate clinical remission for SC maintenance regimens of ustekinumab in subjects with moderately to severely active UC induced into clinical response with ustekinumab.
- To  evaluate  the  safety  of  SC  maintenance  regimens  of  ustekinumab  in  subjects  with moderately to severely active UC induced into clinical response with ustekinumab.

The secondary objectives of the maintenance study were:

- To evaluate the efficacy of ustekinumab in maintaining clinical response in subjects induced into clinical response with ustekinumab.
- To  evaluate  endoscopic  healing  (ie,  improvement  in  the  endoscopic  appearance  of  the mucosa) in subjects induced into clinical response with ustekinumab.
- To evaluate the efficacy of ustekinumab in achieving corticosteroid-free clinical remission in subjects induced into clinical response with ustekinumab.
- To  evaluate  the  efficacy  of  ustekinumab  in  maintaining  clinical  remission  in  subjects induced into clinical remission with ustekinumab.
- To evaluate the efficacy of ustekinumab treatment on mucosal healing (ie, a combination of endoscopic healing and histologic healing).
- To  evaluate the impact  of SC ustekinumab on disease-specific patient-reported health-related quality of life.

<div style=\"page-break-after: always\"></div>

- To evaluate the efficacy of maintenance therapy with SC ustekinumab by biologic failure status.
- To evaluate the pharmacokinetics (PK) and immunogenicity of ustekinumab, as well as changes in levels of C-reactive protein (CRP), fecal calprotectin, fecal lactoferrin, and other pharmacodynamic (PD) biomarkers.

The exploratory objective of the maintenance study was to evaluate response using the Mayo score without the physician's global assessment (PGA) subscore.

## Outcomes/endpoints

## Primary Endpoint

- Clinical remission at Week 44. Clinical remission was defined as a Mayo score ≤2 points, with no individual subscore &gt;1.

Major Secondary Endpoints (presented in the order in which they were tested)

- Maintenance of clinical response through Week 44. Clinical response was defined as a decrease from induction baseline in the Mayo score by ≥30% and ≥3 points, with either a decrease from induction baseline in the rectal bleeding subscore ≥1 or a rectal bleeding subscore of 0 or 1. Clinical response was calculated at Week 44 and at other time points during maintenance when endoscopy subscores were collected (eg, at the time of clinical flare to assess loss of clinical response or at the time of discontinuation of study agent or termination of study participation); subjects who were not in clinical response at any of these times were considered not to be in clinical response through Week 44.
- Endoscopic healing at Week 44. Endoscopic healing (ie, improvement in the endoscopic appearance of the mucosa) was defined as endoscopy subscore of the Mayo score = 0 or 1.
- Clinical remission and not receiving concomitant corticosteroids (ie, corticosteroid-free clinical remission) at Week 44.
- Maintenance of clinical remission through Week 44 among the subjects who had achieved clinical remission at maintenance baseline. Clinical remission was calculated at Week 44 and at other time points during maintenance when endoscopy subscores were collected (eg, at the time of clinical flare to assess loss of clinical response or at the time of discontinuation of study agent or termination of study participation); subjects who were not in clinical remission at any of these times were considered not to be in clinical remission through Week 44.

Efficacy results presented for CNTO1275UCO3001 induction and maintenance studies were based on central review of endoscopies.

Terminology of some endpoints used in the UC dossier is different than the terminology proposed to be used in the EU Product Information. An overview of the different terminologies is included in Table 10.

## Sample size

For both global and US-specific testing procedures, a fixed-sequence testing procedure, starting with the high dose group (q8w), will be used to control the overall Type I error rate at the0.05 level (2-sided). Therefore, sample size/power calculations were based on the chi-square test to detect a significant difference between subjects receiving SC ustekinumab 90 mg q8w and those receiving placebo.

The treatment effect for the global definition of the primary endpoint of clinical remission at Week 44 in the maintenance study, was based on maintenance data from similarly designed studies of the anti-TNFα

<div style=\"page-break-after: always\"></div>

golimumab and of vedolizumab. In the golimumab UC maintenance study, the proportions of subjects in clinical remission (based on the global definition) at Week 54 (among subjects in clinical response to golimumab induction) were 34% and 22% in the 100 mg group and the placebo group, respectively. In the vedolizumab UC study, the proportions of subjects in clinical remission (based on the global definition) at Week 52 (among subjects in clinical response at Week 6) were 42% and 16% in the vedolizumab q8w group and the placebo group, respectively. For the CNTO1275UCO3001 maintenance study, it was assumed that clinical remission rates (based on the global definition) at Week 44 were 40% and 20%, respectively, for the ustekinumab 90 mg SC q8w and placebo groups.

Assuming a 20% clinical remission rate (for both global and US definitions) in the placebo group and 40% in the SC ustekinumab 90 mg q8w group, the applicant argued that 109 subjects in each treatment group (327 subjects in total) would provide statistical power of 90% at a significance level of 0.05 (2-sided). The table below shows the power for detecting a treatment difference between the SC ustekinumab 90 mg q8w and the placebo group based on different proportions of subjects in clinical remission (for both the global and US definitions) at Week 44 with a fixed sample size of 327.

<!-- image -->

| Table l:                                            | Powerfordetectingatreatmenteffectbasedondifferentproportionsofsubjectsinclinical remission(bothglobalandUSdefinitions)atWeek44withafixedsamplesizeof327subjects (109ineachtreatmentgroup)   | Powerfordetectingatreatmenteffectbasedondifferentproportionsofsubjectsinclinical remission(bothglobalandUSdefinitions)atWeek44withafixedsamplesizeof327subjects (109ineachtreatmentgroup)   |
|-----------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Proportionof SubjectsinClinicalRemissionatWeek44(%) | Proportionof SubjectsinClinicalRemissionatWeek44(%)                                                                                                                                         |                                                                                                                                                                                             |
| Placebo                                             | Ustekinumab                                                                                                                                                                                 | Powerd(%)                                                                                                                                                                                   |
| 20                                                  | 45                                                                                                                                                                                          | 98                                                                                                                                                                                          |
| 20                                                  | 42                                                                                                                                                                                          | 94                                                                                                                                                                                          |
| 20                                                  | 40                                                                                                                                                                                          | 90                                                                                                                                                                                          |
| 20                                                  | 37                                                                                                                                                                                          | 80                                                                                                                                                                                          |
| 20                                                  | 35                                                                                                                                                                                          | 70                                                                                                                                                                                          |

The table below shows the power for detecting a treatment difference between the ustekinumab 90 mg SC q8w and the placebo group for each of the major secondary endpoints with 327 subjects in the primary population. The assumptions about the proportion of subjects achieving each major secondary endpoint were based on data from the golimumab and vedolizumab maintenance studies in subjects with moderately to severely active UC.

<!-- image -->

| Table 2: Powerfordetectingatreatmenteffectforeachofthemajorsecondaryendpointswith327 subjects in the primary population (1o9 in each treatment group)   | Table 2: Powerfordetectingatreatmenteffectforeachofthemajorsecondaryendpointswith327 subjects in the primary population (1o9 in each treatment group)   | Table 2: Powerfordetectingatreatmenteffectforeachofthemajorsecondaryendpointswith327 subjects in the primary population (1o9 in each treatment group)   | Table 2: Powerfordetectingatreatmenteffectforeachofthemajorsecondaryendpointswith327 subjects in the primary population (1o9 in each treatment group)   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------|
| Majorsecondaryendpoints                                                                                                                                 | Proportionofsubjectsachieving the endpoint                                                                                                              | Proportionofsubjectsachieving the endpoint                                                                                                              |                                                                                                                                                         |
|                                                                                                                                                         | Placebo                                                                                                                                                 | Ustekinumab                                                                                                                                             | Power*(%)                                                                                                                                               |
| Maintenance of clinicalresponse throughWeek 44                                                                                                          | 25                                                                                                                                                      | 50                                                                                                                                                      | 97                                                                                                                                                      |
| Endoscopic healing at Week 44                                                                                                                           | 25                                                                                                                                                      | 45                                                                                                                                                      | 88                                                                                                                                                      |
| Clinical remission and not receiving concomitant corticosteroids atWeek 44                                                                              | 15                                                                                                                                                      | 30                                                                                                                                                      | 76                                                                                                                                                      |
| Maintenance of clinical remission through Week 44 among thesubjectswhohadachievedclinicalremission at maintenancebaseline(bothglobal andUSdefinitions)  | 25                                                                                                                                                      | 50                                                                                                                                                      | 65                                                                                                                                                      |
| a: Based on testing the SC ustekinumab 90 mg q8w group versus placebo at α=0.05 (2-sided). remission at Week O of maintenance.                          | a: Based on testing the SC ustekinumab 90 mg q8w group versus placebo at α=0.05 (2-sided). remission at Week O of maintenance.                          | a: Based on testing the SC ustekinumab 90 mg q8w group versus placebo at α=0.05 (2-sided). remission at Week O of maintenance.                          | a: Based on testing the SC ustekinumab 90 mg q8w group versus placebo at α=0.05 (2-sided). remission at Week O of maintenance.                          |

The number of subjects in the primary analysis population of the maintenance study will depend on the number of subjects from the following 2 groups of the induction study:

- 1) subjects in clinical response to IV ustekinumab induction at Week 8 of the induction study (Group A), and

<div style=\"page-break-after: always\"></div>

- 2) subjects who were not in clinical response to IV placebo induction at Week 8 of the induction study but were in clinical response at induction Week 16 after receiving an induction dose of IV ustekinumab at Week 8 (Group B).

If the average clinical response rate to IV ustekinumab induction is 45%, 317 subjects in each induction treatment group (for a total of 951 subjects) will result in about 328 subjects in the primary population of the maintenance study, assuming 15% attrition from the induction study to the maintenance study. However, the average clinical response rate to IV ustekinumab induction could range from 40% to 50% and attrition from the induction study to the maintenance study could range from 10% to 15%. With 317 subjects in each induction treatment group, the number of subjects in the primary population of the maintenance study could range from 290 to 385

| Table 3:                                         | Projected number of subjects in the primary population of the maintenance study with a sample sizeof95lsubjects(317pertreatmentgroup)intheinductionstudy   | Projected number of subjects in the primary population of the maintenance study with a sample sizeof95lsubjects(317pertreatmentgroup)intheinductionstudy   | Projected number of subjects in the primary population of the maintenance study with a sample sizeof95lsubjects(317pertreatmentgroup)intheinductionstudy   | Projected number of subjects in the primary population of the maintenance study with a sample sizeof95lsubjects(317pertreatmentgroup)intheinductionstudy   |
|--------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Attrition From InductionStudyto MaintenanceStudy | Clinical Response Rate to IV Ustekinumab Induction                                                                                                         | SubjectsinGroup A EnteringMaintenance                                                                                                                      | Subjects in Group B Entering Maintenance                                                                                                                   | Numberof Subjects in Primary Population of Maintenance                                                                                                     |
| 15%                                              | 40%                                                                                                                                                        | 216                                                                                                                                                        | 75                                                                                                                                                         | 291                                                                                                                                                        |
|                                                  | 45%                                                                                                                                                        | 243                                                                                                                                                        | 85                                                                                                                                                         | 328                                                                                                                                                        |
|                                                  | 50%                                                                                                                                                        | 269                                                                                                                                                        | 94                                                                                                                                                         | 363                                                                                                                                                        |
| 10%                                              | 40%                                                                                                                                                        | 228                                                                                                                                                        | 80                                                                                                                                                         | 308                                                                                                                                                        |
|                                                  | 45%                                                                                                                                                        | 257                                                                                                                                                        | 90                                                                                                                                                         | 347                                                                                                                                                        |
|                                                  | 50%                                                                                                                                                        | 285                                                                                                                                                        | 100                                                                                                                                                        | 385                                                                                                                                                        |

GroupA=Subjectsinclinicalresponse toIVustekinumabinduction atinductionWeek8;GroupB=Subjectsnotinclinical response to IV placebo induction at induction Week 8 but in clinical response at induction Week 16 after receiving an induction doseofIVustekinumabatWeek8.

a: The proportion of subjects not in clinical response to intravenous placebo induction at Week 8 of the induction study is assumed to be 70%.

## Randomisation

Subjects who were in clinical response to IV ustekinumab induction were randomized in a 1:1:1 ratio to one of the following three treatment groups at the maintenance Week 0/baseline visit of the maintenance study:

- Placebo SC
- Ustekinumab 90 mg SC every 12 weeks (q12w)
- Ustekinumab 90 mg SC every 8 weeks (q8w)

Eligible subjects were allocated to a treatment group using a permuted block randomization with clinical remission status at maintenance baseline (yes/no, with remission defined as Mayo score ≤2 points, with no individual subscore &gt;1), oral corticosteroid use at maintenance baseline (yes/no), and induction treatment as stratification variables.

The stratification levels for induction treatment were defined as follows: subjects who received ustekinumab ~6 mg/kg IV (Week 0); subjects who received ustekinumab 130 mg IV (Week 0); subjects who received placebo IV at induction Week 0, did not respond, and received ustekinumab ~6 mg/kg IV at induction Week 8 [this group is hereafter referred to as the placebo IV (Week 0) → ~6 mg/kg IV (Week 8) group].

Because subjects in this study were assigned to different dosing frequencies, all subjects received study agent (ie, ustekinumab or placebo) at all scheduled study agent administration visits to maintain the blind.

<div style=\"page-break-after: always\"></div>

There were no interim analyses and the first database lock (DBL) for the maintenance study occurred when all subjects in the maintenance study completed the Week 44 visit or terminated study participation before Week 44.

## Blinding (masking)

The sponsor was blinded to treatment assignment in the maintenance study until after the Week 44 DBL occurred. To minimize bias and protect the integrity of the clinical program, treatment assignment blinding was maintained (for both the induction and maintenance studies) for investigative sites, site monitors, and subjects participating in this protocol until the Week 44 analyses were completed.

## Statistical methods

## Analysis Populations

The Primary Efficacy Analysis Set consists of all subjects randomized at Week 0 of this maintenance study, that is, subjects in clinical response to IV ustekinumab induction as determined by the IWRS (i.e., subjects who are in clinical response to IV ustekinumab induction at I-8, or subjects who are not in clinical response to IV placebo induction at I-8 but are in clinical response at I-16 after receiving an induction dose of IV ustekinumab at I-8).

Some prespecified efficacy analyses will also be conducted in the Non-randomized Analysis Set , which includes:

- -Subjects in clinical response to placebo IV induction dosing at I-8.
- -Subjects who are delayed responders to ustekinumab induction.

## Analysis Methods - Primary endpoint

The global definition of clinical remission is: A Mayo score ≤2 points, with no individual subscore &gt;1. In addition to the clinical remission status based on the Mayo score, treatment failure rules will be applied to determine the final clinical remission status for a subject. Subjects who have a protocol-defined treatment failure prior to Week 44 will be considered not to be in clinical remission at Week 44, regardless of the actual computation of clinical remission based on the Mayo score. Subjects who have all 4 Mayo subscores missing at Week 44 will be considered not to be in clinical remission. If 1 or more of the 4 Mayo subscores is missing at a specific visit, but not all 4 subscores are missing, the last available value for each missing subscore will be carried forward to compute a full Mayo score (where the full mayo score is scheduled to be collected).

The proportions of subjects in clinical remission were to be compared between each ustekinumab treatment group and the placebo group using a Cochran-Mantel-Haenszel (CMH) chi-square test stratified by clinical remission status at baseline (yes/no as determined by the IWRS) and induction treatment (placebo IV [I-0] → ustekinumab ~6 mg/kg IV [I-8], ustekinumab 130 mg IV [I-0], or ustekinumab ~6 mg/kg IV [I-0]).

Summaries of the proportion of subjects in clinical remission by treatment group, the adjusted treatment difference (with Cochran-Mantel-Haenszel weight) between each ustekinumab treatment group and the placebo group, as well as the associated 95% confidence interval were to be provided.

## Sensitivity Analyses - Primary endpoint

The following sensitivity analyses were to be performed to examine the robustness of the primary endpoint analysis for the global definition of the primary endpoint:

<div style=\"page-break-after: always\"></div>

Sensitivity Analysis 1 (Observed case): exclude subjects who have missing data at Week 44 and have not had an event of treatment failure prior to Week 44.

For the global definition, subjects with missing data are those who are missing all four Mayo subscores.

Sensitivity Analysis 2 (nonresponder if any missing subscore ): subjects with missing data for any of the Mayo components pertaining to the primary endpoint (ie, the four Mayo subscores for the global definition and the absolute stool number, Mayo rectal bleeding subscore, and Mayo endoscopy subscore for the US-specific definition) at Week 44 are considered not to be in clinical remission.

Sensitivity Analysis 3 (multiple imputation): This analysis was to be based on the multiple imputation method which involves the following distinct steps:

- 1) Any missing Mayo components pertaining to the primary endpoint (see Sensitivity Analysis number 4) at Week 44 will be imputed 5 times to generate 5 complete data sets using the Markov Chain Monte Carlo method, assuming missing at random (MAR) and a multivariate normal distribution (since the amount of missing data will be minimal based on the past UC induction studies). The following variables will be included in the imputation model: Mayo components at Week 0 of induction study and at week 0 and week 44 of the maintenance study, induction dose factor and maintenance treatment group
- 2) Before the multiple imputation method is applied, the Mayo data after treatment failure will be set to missing. For each multiple-imputed data set, each subject's clinical remission status at Week 44 will be calculated.
- 3) Each of the 5 resulting data sets will be analyzed using a logistic regression model with treatment group, baseline Mayo score (for global definition) and induction treatment as covariates.
- 4) The results from the 5 data sets will be combined to produce inferential results.

Sensitivity Analysis 4 (Worst case): subjects receiving placebo who have missing data at Week 44 and have not had an event of treatment failure prior to Week 44 will be considered to be in clinical remission, and subjects receiving ustekinumab who have missing data at Week 44 will be considered not to be in clinical remission.

Sensitivity Analysis 5 ('modified ITT' analysis): excludes subjects who are randomized but not treated.

S ensitivity Analysis 6 (per-protocol' analysis): excludes subjects with at least 1 of the following deviations that might affect efficacy:

- 1) subjects who are found to have Crohn's disease instead of UC,
- 2) subjects who are randomized, but do not receive study agent,
- 3) subjects who are a treatment failure in the induction study,
- 4) subjects who are excluded in the Per-Protocol analysis in the induction study,
- 5) subjects who are randomized to the placebo group at Week 0 but receive a ustekinumab injection at any administration visit through Week 44 or subjects who are randomized to one of the ustekinumab groups at Week 0 but receive only placebo through Week 44 ,
- 6) subjects who are not in clinical response on entry into the maintenance study based on the final reported endoscopy score and the eCRF Mayo score data, or have other deviations that will be identified and documented prior to unblinding.

Sensitivity Analysis 7 (logistic regression): For the global definition, the primary endpoint will be analyzed based on a logistic regression with maintenance baseline Mayo score, induction treatment, and maintenance treatment group as covariates

<div style=\"page-break-after: always\"></div>

Sensitivity Analysis 8 (clinical remission based on local endoscopy subscores): the primary analysis will be repeated with clinical remission derived based on local endoscopy subscores, instead of the final reported endoscopic subscores.

The same treatment failure rules as were used in the primary analysis were to be applied. For Sensitivity Analyses 5 through 8, the same missing data rules as are used in the primary analysis were also to be applied. Note that treatment failure rules were to override the missing data rules. Subjects who have a treatment failure prior to Week 44 were considered not to be in clinical remission at Week 44, regardless of the observed or missing data.

## Analysis Methods - Major secondary endpoints

The major secondary endpoint analyses were to be based on the Primary Efficacy Analysis Set. Except for the fourth major secondary endpoint of maintenance of clinical remission, analyses of major secondary endpoints were to be conducted using a CMH chi-square test stratified by clinical remission status at maintenance baseline (yes/no as determined by the IWRS) and induction treatment. For the fourth major secondary endpoint, a CMH chi-square test stratified by induction treatment will be used.

Summaries of the proportion of subjects by treatment group, the adjusted treatment difference (with Cochran-Mantel-Haenszel weight) between each ustekinumab treatment group and the placebo group, as well as the associated 95% confidence interval, were to be provided for all the major secondary endpoints.

## Type I error control - multiple testing procedure

A fixed-sequence testing procedure was to be used to control the overall Type I error rate at the .05 level for the primary endpoint. Specifically, the high maintenance dose group

(i.e., ustekinumab 90 mg SC q8w) will be considered significant if its p-value is &lt; 0.05. The low maintenance dose group (ustekinumab 90 mg SC q12w) will be significant if the p-value for both high and low maintenance dose groups are &lt; 0.05.

The study was to be considered positive if the test involving the high maintenance dose group (ustekinumab 90 mg SC q8w) shows a statistically significant difference versus placebo for the primary endpoint of clinical remission at Week 44, regardless of the result of the test for the low maintenance dose (ustekinumab 90 mg SC q12w).

A hierarchical testing procedure as shown below was to be employed to control the overall Type 1 error rate over the 4 major secondary efficacy analyses at the (2-sided) 0.05 significance level within a dose group. A major secondary endpoint for a dose group will be considered significant only if both the previous endpoints in the hierarchy and current endpoint test positive at the 2-sided 0.05 level of significance. If an endpoint is not significant, all subsequent tests in the hierarchy will be considered not to be significant. Nominal p-values will be reported for all analyses.

<div style=\"page-break-after: always\"></div>

<!-- image -->

## Subgroup analyses

The consistency of treatment effect for the primary endpoint was to be evaluated for subgroups based on demographics and baseline UC disease characteristics, UC-related concomitant medication usage, and UC-related Medication History, all at Week 0 of the induction study, as well as maintenance stratification factors and UC clinical disease characteristics at Week 0 of the maintenance study, when the number of subjects within each level of the subgroup permits

For each of these subgroups, the odds ratio of each ustekinumab dose group vs placebo and the associated confidence interval (95% for the global definition and 97.5% for the US-specific definition) were to be provided. The odds ratios and confidence intervals were to be provided based on the logistic regression model that includes factors for treatment group, biologic failure status and region (for the subgroup analyses based on biologic failure status or region, the corresponding factor will not be included in the model).

<div style=\"page-break-after: always\"></div>

## Demographics at week 0 of the induction study

- Gender (male, female)
- Race (Caucasian, non-Caucasian)
- Age (≤ median age, &gt; median age)
- Weight (≤ 1st quartile, &gt;1st quartile and ≤ 2nd quartile, &gt;2nd quartile and ≤ 3rd quartile,
- &gt;3rd quartile)
- Smoking status (nonsmoker, prior smoker, current smoker)
- Region
- -Asia : Japan, South Korea
- -Eastern Europe : Belarus, Bulgaria, Czech Republic, Hungary, Poland, Romania, Russia, Serbia, Slovakia, Ukraine
- -Rest of World : Australia, Austria, Belgium, Canada, Denmark, France, Germany, Israel, Italy, Netherlands, New Zealand, United Kingdom, United States

## Baseline UC Clinical Disease Characteristics at week 0 of the induction study

- UC disease duration (≤ 5 years, &gt; 5 years to ≤ 15 years, &gt; 15 years)
- Extent of disease (limited, extensive)
- Severity of UC disease (moderate: 6≤ Mayo score ≤ 10, severe: Mayo score &gt;10)
- Extraintestinal manifestations (absent, present)
- CRP (≤3 mg/L, &gt;3 mg/L)
- CRP (≤ median, &gt; median)
- CRP (≤10 mg/L, &gt;10 mg/L)
- Fecal calprotectin (≤250 mg/kg, &gt; 250 mg/kg)
- Fecal lactoferrin (≤7.24 μg/g, &gt;7.24 μg/g)

## UC-related Concomitant Medication Usage at week 0 of the induction study

- Oral 5-ASA compounds (receiving, not receiving)
- Oral corticosteroids including budesonide and beclomethasone dipropionate (receiving, not
- receiving)
- 6-MP/AZA/MTX (receiving, not receiving)
- Oral corticosteroids and (6-MP/AZA/MTX) (receiving, not receiving)
- Oral corticosteroids or (6-MP/AZA/MTX) (receiving, not receiving)

## UC-related Medication History at week 0 of the induction study

- Refractory or intolerant to 6-MP/AZA (yes, no)
- Refractory, dependent or intolerant to oral or IV corticosteroids (yes, no)

<div style=\"page-break-after: always\"></div>

- Refractory, dependent, or intolerant to oral or IV corticosteroids, but not refractory or intolerant to 6-MP/AZA (yes, no)
- Refractory, dependent or intolerant to oral or IV corticosteroids, and refractory or intolerant to 6-MP/AZA (yes, no)
- Biologic failure status (yes, no)
- Subjects with biologic failure
- -Primary nonresponse, secondary nonresponse, or intolerance to
-  At least one anti-TNF (yes, no)
-  Anti-TNF only (yes, no)
-  Vedolizumab (yes, no)
-  Vedolizumab and at least one anti-TNF (yes, no)
-  For subjects with biologic failure to anti-TNF only
-  primary nonresponse (yes, no)
-  secondary nonresponse (yes, no)
-  intolerance (yes, no)
- Subjects without biologic failure (naïve, bio-experienced [but not documented failure])

## Stratification variables for the maintenance study

- Clinical remission status at maintenance baseline as determined by the IWRS (yes, no)
- Induction treatment (placebo IV [I-0] → ustekinumab ~6 mg/kg IV [I-8], ustekinumab 130 mg IV [I-0], ustekinumab ~6 mg/kg IV [I-0])
- Oral corticosteroid use at maintenance baseline as recorded in the IWRS (yes, no)

## UC clinical disease characteristics at Week 0 of the maintenance study

- Endoscopic healing status (yes, no)
- CRP (≤3 mg/L, &gt;3 mg/L)
- CRP (≤ median, &gt; median)
- CRP (≤10 mg/L, &gt;10 mg/L)
- Fecal calprotectin (≤250 mg/kg, &gt;250 mg/kg)
- Fecal lactoferrin (≤7.24 μg/g, &gt;7.24 μg/g)

In addition, the consistency of treatment effect for the major secondary endpoints will be evaluated for the following subgroups, when the number of subjects within each level of the subgroup permits.

## CRP and Fecal Biomarkers (calprotecin and lactoferrin), both at Week 0 of the induction study and at Week 0 of the maintenance study

- CRP (≤3 mg/L, &gt;3 mg/L)
- CRP (≤ median, &gt; median)

<div style=\"page-break-after: always\"></div>

- CRP (≤10 mg/L, &gt;10 mg/L)
- Fecal calprotectin (≤250 mg/kg, &gt;250 mg/kg)
- Fecal lactoferrin (≤7.24 μg/g, &gt;7.24 μg/g)

Induction baseline Weight (≤ 1st quartile, &gt;1st quartile and ≤ 2nd quartile, &gt;2nd quartile and ≤ 3rd quartile, &gt;3rd quartile)

## Treatment failure criteria

Subjects who had any of the following events were considered to be a treatment failure from the time of event onward:

An ostomy or colectomy (partial or total).

Discontinued study agent due to lack of therapeutic effect or due to an AE of worsening of UC.

Used a rescue medication after clinical flare: Any initiation or increase in the dose of 6-MP/AZA/MTX, oral budesonide &gt;3 mg/day, oral beclomethasone dipropionate &gt;5 mg/day, or oral corticosteroids (excluding budesonide and beclomethasone dipropionate) &gt;5 mg/day (prednisone equivalent) above the dose received at maintenance baselinefollowing a clinical flare was considered a rescue medication.

A prohibited change in UC medication:

Initiation of restricted or prohibited medication

## Missing data

For subjects with missing data, unless otherwise specified, the last observation was carried forward for continuous endpoints, with the exception of the Mayo and partial Mayo scores where the last available Mayo subscores were carried forward. For dichotomous endpoints, subjects with missing data were considered not to have achieved the respective endpoints.

Treatment failure rules overrode missing data rules. This meant that if a subject had an event of treatment failure, induction baseline values were assigned from the point of treatment failure onward for continuous endpoints, and subjects were not considered to have achieved the respective endpoints for dichotomous endpoints, regardless of whether the data were observed or missing.

## Interim Analysis

No interim analysis was planned for the maintenance study.

## Results

## Participant flow

<div style=\"page-break-after: always\"></div>

## Subject disposition in CNTO1275UCO3001 Maintenance Study; Randomized Subjects

<!-- image -->

*Provided in separate disposition figure.

q8w=every8weeks q12w=every12weeks

A total of 783 subjects who completed the induction study and were in clinical response to induction study agent were enrolled in this maintenance. Of these, 523 subjects were in the targeted primary population for the maintenance study and were randomized (i.e., were in clinical response to IV ustekinumab induction; randomized subjects) and 260 subjects were not part of the primary population for the maintenance study and were not randomized (i.e., placebo induction responders and ustekinumab induction delayed responders; nonrandomized subjects).

Subject Disposition in CNTO1275UCO3001 Maintenance Study; Nonrandomized Subjects

<div style=\"page-break-after: always\"></div>

<!-- image -->

q8w=every8weeks

## Data sources: Table 2, Attachment TSIDS01, Attachment LSIDS04

<!-- image -->

| Table 2:                                                                 | Number ofSubjectsWhoDiscontinuedStudyAgentPriortoWeek40byReasonforDiscontinuation;EnrolledSubjects (CNT01275UC03001)   | Number ofSubjectsWhoDiscontinuedStudyAgentPriortoWeek40byReasonforDiscontinuation;EnrolledSubjects (CNT01275UC03001)   | Number ofSubjectsWhoDiscontinuedStudyAgentPriortoWeek40byReasonforDiscontinuation;EnrolledSubjects (CNT01275UC03001)   | Number ofSubjectsWhoDiscontinuedStudyAgentPriortoWeek40byReasonforDiscontinuation;EnrolledSubjects (CNT01275UC03001)   | Number ofSubjectsWhoDiscontinuedStudyAgentPriortoWeek40byReasonforDiscontinuation;EnrolledSubjects (CNT01275UC03001)   | Number ofSubjectsWhoDiscontinuedStudyAgentPriortoWeek40byReasonforDiscontinuation;EnrolledSubjects (CNT01275UC03001)   | Number ofSubjectsWhoDiscontinuedStudyAgentPriortoWeek40byReasonforDiscontinuation;EnrolledSubjects (CNT01275UC03001)   | Number ofSubjectsWhoDiscontinuedStudyAgentPriortoWeek40byReasonforDiscontinuation;EnrolledSubjects (CNT01275UC03001)   |
|--------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------|
|                                                                          | Randomized subiects                                                                                                    | Randomized subiects                                                                                                    | Randomized subiects                                                                                                    | Randomized subiects                                                                                                    | Randomized subiects                                                                                                    |                                                                                                                        |                                                                                                                        |                                                                                                                        |
|                                                                          |                                                                                                                        | Responders to ustekinumabIV induction                                                                                  | Responders to ustekinumabIV induction                                                                                  | Responders to ustekinumabIV induction                                                                                  | Responders to ustekinumabIV induction                                                                                  | Non-randomized subjects                                                                                                | Non-randomized subjects                                                                                                |                                                                                                                        |
|                                                                          |                                                                                                                        |                                                                                                                        | Ustekinumab                                                                                                            |                                                                                                                        |                                                                                                                        | Responders to placebo IV induction                                                                                     | Delayed responders * Ustekinumab                                                                                       |                                                                                                                        |
|                                                                          |                                                                                                                        | 90 mg SC q12w                                                                                                          | 90 mg SC                                                                                                               | Combined 348                                                                                                           | Total                                                                                                                  | Placebo SC b                                                                                                           | 90 mg SC                                                                                                               | Overalltotal                                                                                                           |
| Enrolled subjects                                                        | Placebo SC * 175                                                                                                       | 172                                                                                                                    | q8w 176                                                                                                                |                                                                                                                        | 523                                                                                                                    | 103                                                                                                                    | q8w 157                                                                                                                | 783                                                                                                                    |
| Subjects who discontinued study agent                                    | 43 (24.6%)                                                                                                             | 24 (14.0%)                                                                                                             | 18 (10.2%)                                                                                                             | 42 (12.1%)                                                                                                             | 85 (16.3%)                                                                                                             | 27 (26.2%)                                                                                                             | 29 (18.5%)                                                                                                             | 141 (18.0%)                                                                                                            |
| Reasonfor discontinuation                                                |                                                                                                                        |                                                                                                                        |                                                                                                                        |                                                                                                                        |                                                                                                                        |                                                                                                                        |                                                                                                                        |                                                                                                                        |
| Adverse event                                                            | 19 (10.9%)                                                                                                             | 8 (4.7%)                                                                                                               | 4 (2.3%)                                                                                                               | 12 (3.4%)                                                                                                              | 31 (5.9%)                                                                                                              | 11 (10.7%)                                                                                                             | 10 (6.4%)                                                                                                              | 52 (6.6%)                                                                                                              |
| Worsening of UC                                                          | 16 (9.1%)                                                                                                              | 4 (2.3%)                                                                                                               | 0                                                                                                                      | 4 (1.1%)                                                                                                               | 20 (3.8%)                                                                                                              | 8 (7.8%)                                                                                                               | 8 (5.1%)                                                                                                               | 36 (4.6%)                                                                                                              |
| Other than worsening of UC                                               | 3 (1.7%)                                                                                                               | 4 (2.3%)                                                                                                               | 4 (2.3%)                                                                                                               | 8 (2.3%)                                                                                                               | 11 (2.1%)                                                                                                              | 3 (2.9%)                                                                                                               | 2 (1.3%)                                                                                                               | 16 (2.0%)                                                                                                              |
| Lack ofefficacy                                                          | 15 (8.6%)                                                                                                              | 7 (4.1%)                                                                                                               | 6 (3.4%)                                                                                                               | 13 (3.7%)                                                                                                              | 28 (5.4%)                                                                                                              | 9 (8.7%)                                                                                                               | 10 (6.4%)                                                                                                              | 47 (6.0%)                                                                                                              |
| Lost to follow up                                                        | 0                                                                                                                      | 0                                                                                                                      | 0                                                                                                                      | 0                                                                                                                      | 0                                                                                                                      | 0                                                                                                                      | 0                                                                                                                      | 0                                                                                                                      |
| Not in partial Mayo response 16 weeks following initiation ofrescue meds | 4 (2.3%)                                                                                                               | 2 (1.2%)                                                                                                               | 0                                                                                                                      | 2 (0.6%)                                                                                                               | 6 (1.1%)                                                                                                               | 3 (2.9%)                                                                                                               | 2 (1.3%)                                                                                                               | 11 (1.4%)                                                                                                              |
| Death                                                                    | 0                                                                                                                      | 0                                                                                                                      | 0                                                                                                                      | 0                                                                                                                      | 0                                                                                                                      | 0                                                                                                                      | 1 (0.6%)                                                                                                               | 1 (0.1%)                                                                                                               |
| Other                                                                    | 5 (2.9%)                                                                                                               | 7 (4.1%)                                                                                                               | 8 (4.5%)                                                                                                               | 15 (4.3%)                                                                                                              | 20 (3.8%)                                                                                                              | 4 (3.9%)                                                                                                               | 6 (3.8%)                                                                                                               | 30 (3.8%)                                                                                                              |

b Subjects who were in clinical response to placebo IV induction dosing and received placebo SC on enty into this maintenance study.

[TSIDS02.RTF][CNTO1275\\UCO3001IDBR\\_CSRWEEK44RE\\_CSRWEEK44PRODITSIDS02.SAS]13AUG201S,22:49

<div style=\"page-break-after: always\"></div>

## Recruitment

19 August 2015 (Date first subject signed informed consent) to 12 August 2018 (Date of last observation for last subject recorded as part of the database)

## Conduct of the study

There were 2 amendments to the protocol, both of which were substantial. The first amendment (14 July 2015) was implemented before study initiation and incorporated health authority feedback. The second amendment (20 April 2016) addressed health authority requests for additional data collection and included other clarifications. Changes that affected study conduct or data analyses of the induction study are detailed in the table below presents the changes that affected study conduct or data analyses of the maintenance study only.

| Table 1:             | Protocol Amendment Changes Specific to the Maintenance Study Only   | Protocol Amendment Changes Specific to the Maintenance Study Only                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|----------------------|---------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| AmendmentNumber Date | AmendmentNumber Date                                                | Protocol Amendment Changes 1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 1 14 Jul 2015        | 1 14 Jul 2015                                                       | Sample collection for anti-ustekinumab antibodies was added at the Week 4 visit during maintenance.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|                      |                                                                     | Study agent administrations at Week 20, Week 28, and Week 44 were deleted from the Time and Events Schedule for maintenance because these administrations, for placebo only, were not required to maintain the study blind for either maintenance dose regimen.                                                                                                                                                                                                                                                                                                                                                                                       |
|                      |                                                                     | Text was added to clarify that the global definition of clinical remission will be used to stratify subjects in the randomization for the maintenance study.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|                      |                                                                     | The Cochran-Mantel-Haenszel (CMH) test (rather than the logistic regression model) is to be used for the primary and major secondary efficacy analyses for the maintenance study.                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 2 20 Apr 2016        | 2 20 Apr 2016                                                       | Clarified that the United States (US) definition of clinical remission will be used to support the USsubmission only and added that each definition (global and USdefinition) will be based on the primary population.                                                                                                                                                                                                                                                                                                                                                                                                                                |
|                      |                                                                     | Clarified that if tuberculin was unavailable for the tuberculosis (TB) skin test, this method of testing was not to be considered required for Ukrainian study centers. QuantiFERON-TB Gold and chest radiograph were done if tuberculosis was suspected, along with referral to a TB specialist if possible.                                                                                                                                                                                                                                                                                                                                         |
|                      |                                                                     | The order of the third and fourth secondary objectives/major secondary endpoints in the maintenance study was reversed (new order is: corticosteroid-free remission at Week 44 followed by maintenance of clinical remission at Week 44 among subjects in clinical remission at Week 0). In addition, the analysis population for the endpoint of corticosteroid-free remission at Week 44 was updated to include all subjects randomized into the maintenance study regardless of corticosteroid use at the maintenance Week 0 visit (instead of being limited to only subjects who were receiving corticosteroids at the maintenance Week 0 visit). |
|                      |                                                                     | Clarified procedures to determine clinical flare and loss of response.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|                      |                                                                     | The recommendation for tapering budesonide was revised and tapering for beclomethasone dipropionate was incorporated.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|                      |                                                                     | Clarification of which endoscopy score was used to determine subject eligibility at baseline and for the primary and major secondary endpoints involving endoscopy subscores.                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|                      |                                                                     | The statistical methods Section was revised to specify that a fixed-sequence testing procedure will be used for submission in the US.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |

Overall, among 523 randomized subjects and 260 nonrandomized subjects, protocol deviations were reported in 40 (7.6%) subjects and 19 (7.3%) subjects, respectively. Most deviations (52 of 59 subjects) were classified as 'other'. Deviations related to withdrawal criteria, treatment, dose, or use of disallowed

<div style=\"page-break-after: always\"></div>

medications were infrequent events. Subjects who were identified to have met withdrawal criteria were promptly directed to discontinue study agent. Subjects who were identified to have received an incorrect dose received the assigned study agent and dose for the majority of visits and were analyzed in their assigned treatment groups. Subjects who were identified as having initiated disallowed medication did not initiate any medications that were prohibited and would have required discontinuation of study agent.

During the study, specific deviations were addressed at the site level as well as through study- wide site communications and trainings. Issues were addressed during the conduct of the study with appropriate corrective and preventative action before DBL.

Protocol deviations varied in nature and were determined not to have clinically relevant impact on data integrity or subject safety. Overall, assessment of efficacy was not adversely affected by these deviations, as demonstrated by similar results in the primary efficacy analyses and the per-protocol sensitivity analyses. Similarly, there was no notable effect of deviations on the safety profile of ustekinumab in this study; overall, the safety profile observed was consistent with the disease under study and the labelled safety information for ustekinumab in other indications.

## Baseline data

All subjects in this maintenance study entered from the induction study. The primary population is the population of randomized subjects. Therefore, presentation of data focuses on the randomized subjects, while presentation of data from the nonrandomized subjects is also provided with a focus on the ustekinumab induction delayed-responder group.

<div style=\"page-break-after: always\"></div>

## Comparison of baseline Demographic Baseline Data between induction and maintenance

|                                                  | Induction Study   | Maintenance Studya   |
|--------------------------------------------------|-------------------|----------------------|
| Primary efficacy analysis set                    | 961               | 523                  |
| Demographic characteristics                      |                   |                      |
| Sex,%male                                        | 582 (60.6%)       | 297 (56.8%)          |
| Race,% white                                     | 730 (76.0%)       | 387(74.0%)           |
| Median age (years)                               | 41.0              | 40.0                 |
| Median weight (kg)                               | 71.20             | 70.00                |
| UC disease characteristics                       |                   |                      |
| Median UC disease duration (years)               | 5.97              | 6.05                 |
| Median Mayo score                                | 9.0               | 9.0                  |
| Extent of disease =extensive                     | 436(45.7%)        | 246(47.1%)           |
| Median CRP(mg/L)                                 | 4.7               | 3.58                 |
| Median fecal lactoferrin （ug/g)                  | 186.7             | 182.5                |
| Median fecal calprotectin(mg/kg)                 | 1392.0            | 1437.0               |
| Endoscopy score=3(severe disease)                | 668 (69.5%)       | 350 (66.9%)          |
| UC-related concomitantmedication                 |                   |                      |
| Any UC medication                                | 867 (90.2%)       | 469 (89.7%)          |
| Corticosteroid use                               | 498(51.8%)        | 273(52.2%)           |
| Immunomodulator（6-MP/AZA,MTX)                    | 271(28.2%)        | 139(26.6%)           |
| Aminosalicylates                                 | 660 (68.7%)       | 370 (70.7%)          |
| UC-related medicationhistory                     |                   |                      |
| Subjects with inadequate response,intolerance,or |                   |                      |
| dependence tocorticosteroidsand/or6-MP/AZA       | 903 (94.0%)       | 489 (93.5%)          |
| Corticosteroids                                  | 776(80.7%)        | 405(77.4%)           |
| 6-MP/AZA                                         | 530(55.2%)        | 284(54.3%)           |
| Subjects without a history of biologic failure   | 470 (48.9%)       | 274(52.4%)           |
| Biologic-naive                                   | 443 (46.1%)       | 258(49.3%)           |
| Biologic-experienced,but not documented failure  | 27(2.8%)          | 16(3.1%)             |
| Subjects with a history of biologic failure      | 491 (51.1%)       | 249 (47.6%)          |
| Only anti-TNF (not to vedolizumab)               | 325(33.8%)        | 177(33.8%)           |
| Atleast one anti-TNF(regardlessofyedolizumab)    | 485(50.5%)        | 247(47.2%)           |
| -Primary nonresponseb                            | 235(48.5%)        | 114 (46.2%)          |
| Any anti-TNF andyedolizumab                      | 160 (16.6%)       | 70 (13.4%)           |
| Yedolizumab (regardless of anti-TNF)             | 166(17.3%)        | 72(13.8%)            |

Generally, the treatment groups were well balanced in terms of demographic, disease characteristics and of concomitant and previous therapies. No clinically relevant imbalances were observed. The inflammatory burden, as judged by faecal calprotectin, were slightly higher in the ustekinumab groups than in the placebo group. The difference is of doubtful relevance and in any instance not in favour to the test drug and as such not inducing any bias in favour of the test drug.

<div style=\"page-break-after: always\"></div>

## Discontinuation of study agent

Table 2: Nunber ofSubjectsWhoDiscontinuedStudyAgentPrior toWeek40byReasonforDiscontinuation;EnrolledSubjects (CNT01275UC03001)

|                                       |                 | Randomized subjects   | Randomized subjects   | Randomized subjects   | Randomized subjects   | Non-randomized subjects            | Non-randomized subjects                   |               |
|---------------------------------------|-----------------|-----------------------|-----------------------|-----------------------|-----------------------|------------------------------------|-------------------------------------------|---------------|
|                                       |                 |                       | Ustekinumab 90 mg SC  |                       | Total                 | Responders to placebo IV induction | Delayed responders c Ustekinumab 90 mg SC | Overall total |
| Enrolled subjects                     | Placebo SC  175 | 5S06 ql2w 172         | q8w 176               | Combined 348          | 523                   | Placebo SC b 103                   | q8w 157                                   | 783           |
| Subjectswhodiscontinued studyagent    | 43 (24.6%)      | 24 (14.0%)            | 18 (10.2%)            | 42 (12.1%)            | 85 (16.3%)            | 27 (26.2%)                         | 29 (18.5%)                                | 141 (18.0%)   |
| Reason for discontinuation            |                 |                       |                       |                       |                       |                                    |                                           |               |
| Adverse event                         | 19 (10.9%)      | 8 (4.7%)              | 4 (2.3%)              | 12 (3.4%)             | 31 (5.9%)             | 11 (10.7%)                         | 10 (6.4%)                                 | 52 (6.6%)     |
| Worsening ofUC                        | 16 (9.1%)       | 4 (2.3%)              | 0                     | 4 (1.1%)              | 20 (3.8%)             | 8 (7.8%)                           | 8 (5.1%)                                  | 36 (4.6%)     |
| Other than worsening of UC            | 3 (1.7%)        | 4 (2.3%)              | 4 (2.3%)              | 8 (2.3%)              | 11 (2.1%)             | 3 (2.9%)                           | 2 (1.3%)                                  | 16 (2.0%)     |
| Lack of efficacy                      | 15 (8.6%)       | 7 (4.1%)              | 6 (3.4%)              | 13 (3.7%)             | 28 (5.4%)             | 9 (8.7%)                           | 10 (6.4%)                                 | 47 (6.0%)     |
| Lost to follow up                     | 0               | 0                     | 0                     | 0                     | 0                     | 0                                  | 0                                         | 0             |
| Not in partial Mayo response 16 weeks |                 |                       |                       |                       |                       |                                    |                                           |               |
| following initiation of rescue meds   | 4 (2.3%)        | 2 (1.2%)              | 0                     | 2 (0.6%)              | 6 (1.1%)              | 3 (2.9%)                           | 2 (1.3%)                                  | 11 (1.4%)     |
| Death                                 | 0               | 0                     | 0                     | 0                     | 0                     | 0                                  | 1 (0.6%)                                  | 1 (0.1%)      |
| Other                                 | 5 (2.9%)        | 7 (4.1%)              | 8 (4.5%)              | 15 (4.3%)             | 20 (3.8%)             | 4 (3.9%)                           | 6 (3.8%)                                  | 30 (3.8%)     |

Subjects who were in clinical response to ustekinumab IV induction dosing and were randomized to placebo SC on enty into this maintenance study.

° Subjects who were not in clinical response to ustekinumab IV at I-8 but were in clinical response at I-16 after a SC administration of ustekinumab at I-8.

Subjects who were in clinical response to placebo IV induction dosing and received placebo SC on enhry into this maintenance study.

Subjects were randomised per clinical remission and steroid use at maintenance baseline. The proportions of patients in each arm remained similar between induction and maintenance for important variable such as UC disease characteristics, prior biological failure status. In 24.6%, 14% and 10.2% of subjects in the placebo, q12w and q8w arms respectively study treatment was discontinued. This does not appear higher than phase 3 studies for other therapies in UC.

## Numbers analysed

The Primary Efficacy Analysis Set consisted of 523 subjects who were in clinical response to IV ustekinumab induction and were randomized to ustekinumab 90 mg SC q8w, ustekinumab 90 mg SC q12w, or placebo SC. All efficacy analyses were based on the ITT principle; therefore, subjects were analyzed according to the group to which they were assigned regardless of the treatment received.

## Outcomes and estimation

## Primary and Major Secondary Results for the Maintenance Study

| Table 3: Key clinical outcome endpoints at Week 44 in the CNTO1275UCO3001 maintenance study; primary efficacy analysis set   | Table 3: Key clinical outcome endpoints at Week 44 in the CNTO1275UCO3001 maintenance study; primary efficacy analysis set   | Table 3: Key clinical outcome endpoints at Week 44 in the CNTO1275UCO3001 maintenance study; primary efficacy analysis set   | Table 3: Key clinical outcome endpoints at Week 44 in the CNTO1275UCO3001 maintenance study; primary efficacy analysis set   | Table 3: Key clinical outcome endpoints at Week 44 in the CNTO1275UCO3001 maintenance study; primary efficacy analysis set   |
|------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                              |                                                                                                                              | Ustekinumab SC                                                                                                               | Ustekinumab SC                                                                                                               | Ustekinumab SC                                                                                                               |
|                                                                                                                              | Placebo SC a                                                                                                                 | 90 mg q12w                                                                                                                   |                                                                                                                              | 90 mg q8w                                                                                                                    |
| Primary efficacy analysis set                                                                                                | 175                                                                                                                          | 172                                                                                                                          |                                                                                                                              | 176                                                                                                                          |
| PRIMARY ENDPOINT                                                                                                             |                                                                                                                              |                                                                                                                              |                                                                                                                              |                                                                                                                              |
| Subjects in clinical remission b                                                                                             | 42 (24.0%)                                                                                                                   | 66 (38.4%)                                                                                                                   |                                                                                                                              | 77 (43.8%)                                                                                                                   |
| Adjusted treatment difference (95% CI)                                                                                       |                                                                                                                              | 14.5 (5.5, 23.6)                                                                                                             | †                                                                                                                            | 19.7 (10.3, 29.0) *                                                                                                          |
| MAJOR SECONDARY ENDPOINTS                                                                                                    |                                                                                                                              |                                                                                                                              |                                                                                                                              |                                                                                                                              |
| Subjects maintaining clinical response c                                                                                     | 78 (44.6%)                                                                                                                   | 117 (68.0%)                                                                                                                  |                                                                                                                              | 125 (71.0%)                                                                                                                  |
| Adjusted treatment difference (95% CI)                                                                                       |                                                                                                                              | 23.5 (13.7, 33.3)                                                                                                            | *                                                                                                                            | 26.4 (16.6, 36.1) *                                                                                                          |
| Subjects with endoscopic healing d                                                                                           | 50 (28.6%)                                                                                                                   | 75 (43.6%)                                                                                                                   |                                                                                                                              | 90 (51.1%)                                                                                                                   |
| Adjusted treatment difference (95% CI)                                                                                       |                                                                                                                              | 15.2 (5.8, 24.6)                                                                                                             | †                                                                                                                            | 22.5 (12.8, 32.2) *                                                                                                          |
| Subjects in clinical remission and not receiving concomitant corticosteroids                                                 | 41 (23.4%)                                                                                                                   | 65 (37.8%)                                                                                                                   |                                                                                                                              | 74 (42.0%)                                                                                                                   |
| Adjusted treatment difference (95% CI)                                                                                       |                                                                                                                              | 14.5 (5.5, 23.6)                                                                                                             | †                                                                                                                            | 18.5 (9.3, 27.8) *                                                                                                           |

<div style=\"page-break-after: always\"></div>

| Table 3:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Key clinical outcome endpoints at Week 44 in the CNTO1275UCO3001 maintenance study; primary efficacy analysis set                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Key clinical outcome endpoints at Week 44 in the CNTO1275UCO3001 maintenance study; primary efficacy analysis set                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Key clinical outcome endpoints at Week 44 in the CNTO1275UCO3001 maintenance study; primary efficacy analysis set                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Ustekinumab SC                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Ustekinumab SC                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Placebo SC a                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 90 mg q12w                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 90 mg q8w                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Subjects in clinical remission at maintenance baseline                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 45 (25.7%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 40 (23.3%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 38 (21.6%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Subjects maintaining clinical remission e                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 17 (37.8%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 26 (65.0%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 22 (57.9%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Adjusted treatment difference (95% CI)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 28.4 (8.0, 48.9) ‡                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 20.3 (0.0, 40.6)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| * p<0.001. † p<0.01. ‡ p<0.05. CI=confidence interval; IV=intravenous; q8w=every 8 weeks; q12w=every 12 weeks; SC=subcutaneous. a: Subjects who were in clinical response to ustekinumab IV induction dosing and were randomized to placebo SC on entry into this maintenance study. b: A Mayo score ≤2 points, with no individual subscore >1. c: A decrease from induction baseline in the Mayo score by ≥30% and ≥3 points, with either a decrease from induction baseline in the rectal bleeding subscore ≥1 or a rectal bleeding subscore of 0 or 1. d: A Mayo endoscopy subscore of 0 or 1. | * p<0.001. † p<0.01. ‡ p<0.05. CI=confidence interval; IV=intravenous; q8w=every 8 weeks; q12w=every 12 weeks; SC=subcutaneous. a: Subjects who were in clinical response to ustekinumab IV induction dosing and were randomized to placebo SC on entry into this maintenance study. b: A Mayo score ≤2 points, with no individual subscore >1. c: A decrease from induction baseline in the Mayo score by ≥30% and ≥3 points, with either a decrease from induction baseline in the rectal bleeding subscore ≥1 or a rectal bleeding subscore of 0 or 1. d: A Mayo endoscopy subscore of 0 or 1. | * p<0.001. † p<0.01. ‡ p<0.05. CI=confidence interval; IV=intravenous; q8w=every 8 weeks; q12w=every 12 weeks; SC=subcutaneous. a: Subjects who were in clinical response to ustekinumab IV induction dosing and were randomized to placebo SC on entry into this maintenance study. b: A Mayo score ≤2 points, with no individual subscore >1. c: A decrease from induction baseline in the Mayo score by ≥30% and ≥3 points, with either a decrease from induction baseline in the rectal bleeding subscore ≥1 or a rectal bleeding subscore of 0 or 1. d: A Mayo endoscopy subscore of 0 or 1. | * p<0.001. † p<0.01. ‡ p<0.05. CI=confidence interval; IV=intravenous; q8w=every 8 weeks; q12w=every 12 weeks; SC=subcutaneous. a: Subjects who were in clinical response to ustekinumab IV induction dosing and were randomized to placebo SC on entry into this maintenance study. b: A Mayo score ≤2 points, with no individual subscore >1. c: A decrease from induction baseline in the Mayo score by ≥30% and ≥3 points, with either a decrease from induction baseline in the rectal bleeding subscore ≥1 or a rectal bleeding subscore of 0 or 1. d: A Mayo endoscopy subscore of 0 or 1. |

The primary endpoint of clinical remission was met with a treatment difference of 14.5% 19.7% for the q12w and q8w. The secondary endpoint of steroid free clinical remission was considered the key other endpoint in view of the current CHMP guidelines. This endpoint was also met and the proportions of patients meeting each guideline are &gt;95% concordant. The other controlled secondary endpoints were met, except for maintaining clinical remission for the 90 mg q8w. There was a very modest treatment benefit of the q8w versus the q12w with the exception of sustained clinical remission although of the major secondary endpoints, this endpoint had the weakest power to detect a change.

Overall, Ustekinumab SC maintenance therapy achieved significantly greater clinical remission and response through Week 44 compared to placebo and also achieved greater endoscopic healing and corticosteroid-free remission at Week 44 in this study of subjects with moderately to severely active UC who had responded to ustekinumab IV induction therapy.

<div style=\"page-break-after: always\"></div>

## Primary and Major Secondary Results for the Maintenance Study by Biological Failure Status

| Table 4:                               | Efficacy for key endpoints at Week 44 by biologic failure status in the CNTO1275UCO3001 maintenance study; primary efficacy analysis set   | Efficacy for key endpoints at Week 44 by biologic failure status in the CNTO1275UCO3001 maintenance study; primary efficacy analysis set   | Efficacy for key endpoints at Week 44 by biologic failure status in the CNTO1275UCO3001 maintenance study; primary efficacy analysis set   | Efficacy for key endpoints at Week 44 by biologic failure status in the CNTO1275UCO3001 maintenance study; primary efficacy analysis set   | Efficacy for key endpoints at Week 44 by biologic failure status in the CNTO1275UCO3001 maintenance study; primary efficacy analysis set   | Efficacy for key endpoints at Week 44 by biologic failure status in the CNTO1275UCO3001 maintenance study; primary efficacy analysis set   |
|----------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|
|                                        | Biologic Failure                                                                                                                           | Biologic Failure                                                                                                                           | Biologic Failure                                                                                                                           | Not Biologic Failure                                                                                                                       | Not Biologic Failure                                                                                                                       | Not Biologic Failure                                                                                                                       |
|                                        |                                                                                                                                            | Ustekinumab SC                                                                                                                             | Ustekinumab SC                                                                                                                             |                                                                                                                                            | Ustekinumab SC                                                                                                                             | Ustekinumab SC                                                                                                                             |
| Endpoint                               | Placebo SC a                                                                                                                               | 90 mg q12w                                                                                                                                 | 90 mg q8w                                                                                                                                  | Placebo SC a                                                                                                                               | 90 mg q12w                                                                                                                                 | 90 mg q8w                                                                                                                                  |
| Primary efficacy analysis set          | 88                                                                                                                                         | 70                                                                                                                                         | 91                                                                                                                                         | 87                                                                                                                                         | 102                                                                                                                                        | 85                                                                                                                                         |
| Clinical remission b                   | 15 (17.0%)                                                                                                                                 | 16 (22.9%) †                                                                                                                               | 36 (39.6%) *                                                                                                                               | 27 (31.0%)                                                                                                                                 | 50 (49.0%) †                                                                                                                               | 41 (48.2%) †                                                                                                                               |
| Clinical response c                    | 34 (38.6%)                                                                                                                                 | 39 (55.7%) †                                                                                                                               | 59 (64.8%) *                                                                                                                               | 44 (50.6%)                                                                                                                                 | 78 (76.5%) *                                                                                                                               | 66 (77.6%) *                                                                                                                               |
| Endoscopic healing d                   | 20 (22.7%)                                                                                                                                 | 18 (25.7%)                                                                                                                                 | 41 (45.1%) *                                                                                                                               | 30 (34.5%)                                                                                                                                 | 57 (55.9%) †                                                                                                                               | 49 (57.6%) †                                                                                                                               |
| Corticosteroid-free clinical remission | 14 (15.9%)                                                                                                                                 | 16 (22.9%) †                                                                                                                               | 34 (37.4%) *                                                                                                                               | 27 (31.0%)                                                                                                                                 | 49 (48.0%) †                                                                                                                               | 40 (47.1%) †                                                                                                                               |
| Maintenance of clinical remission e    | 8/20 (40.0%)                                                                                                                               | 3/8 (37.5%)                                                                                                                                | 10/20 (50.0%)                                                                                                                              | 9/25 (36.0%)                                                                                                                               | 23/32 (71.9%) †                                                                                                                            | 12/18 (66.7%)                                                                                                                              |
| Mucosal healing f                      | 16/87 (18.4%)                                                                                                                              | 16/70 (22.9%)                                                                                                                              | 36/89 (40.4%) *                                                                                                                            | 25/83 (30.1%)                                                                                                                              | 50/100 (50.0%) †                                                                                                                           | 43/83 (51.8%) †                                                                                                                            |

e: Among subjects in clinical remission at maintenance baseline.

- f: A combination of endoscopic healing (ie, a Mayo endoscopy subscore of 0 or 1) and histologic healing (ie, neutrophil infiltration in &lt;5% of crypts, no crypt destruction, and no erosions, ulcerations, or granulation tissue).

Adapted from Mod5.3.5.1/CNTO1275UCO3001/Maintenance/AttTEFCREM11\\_G, AttTEFCRES04, AttTEFENDO04, AttTEFCREM03C\\_G, AttTEFCREM04A\\_G, AttTEFMUCO06

The primary endpoint and key secondary endpoint of steroid free clinical remission were met in subjects with and without a history of biological failure. The other controlled secondary endpoints were met, except for maintaining clinical remission for the 90 mg q8w. There was a treatment benefit of &gt;10 percentage points for all endpoints, except clinical response, for the q8w versus the q12w in subjects with a history of biological failure. The q8w and and q12w were similar in patients without biological failure.

It is noted that subjects who were biologically naïve accounted for 94.2% of the biological non-failure group. Subjects who received at least one anti-TNF accounted for 99.2% who were biological failures regardless of vedolizumab. Only 2/249 had received vedolizumab only in this group.

## Primary and Major Secondary Results for the Maintenance Study by Biological Failure Profile

| Table 5:                               | Efficacy for key endpoints at Week 44 by biologic failure profile in the CNTO1275UCO3001 maintenance study; primary efficacy analysis set   | Efficacy for key endpoints at Week 44 by biologic failure profile in the CNTO1275UCO3001 maintenance study; primary efficacy analysis set   | Efficacy for key endpoints at Week 44 by biologic failure profile in the CNTO1275UCO3001 maintenance study; primary efficacy analysis set   | Efficacy for key endpoints at Week 44 by biologic failure profile in the CNTO1275UCO3001 maintenance study; primary efficacy analysis set   | Efficacy for key endpoints at Week 44 by biologic failure profile in the CNTO1275UCO3001 maintenance study; primary efficacy analysis set   | Efficacy for key endpoints at Week 44 by biologic failure profile in the CNTO1275UCO3001 maintenance study; primary efficacy analysis set   | Efficacy for key endpoints at Week 44 by biologic failure profile in the CNTO1275UCO3001 maintenance study; primary efficacy analysis set   | Efficacy for key endpoints at Week 44 by biologic failure profile in the CNTO1275UCO3001 maintenance study; primary efficacy analysis set   | Efficacy for key endpoints at Week 44 by biologic failure profile in the CNTO1275UCO3001 maintenance study; primary efficacy analysis set   |
|----------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------|
|                                        | Biologic naïve                                                                                                                              | Biologic naïve                                                                                                                              | Biologic naïve                                                                                                                              | Biologic failure to at least 1 anti-TNF                                                                                                     | Biologic failure to at least 1 anti-TNF                                                                                                     | Biologic failure to at least 1 anti-TNF                                                                                                     | Biologic failure to both an anti-TNF and vedolizumab                                                                                        | Biologic failure to both an anti-TNF and vedolizumab                                                                                        | Biologic failure to both an anti-TNF and vedolizumab                                                                                        |
|                                        | a                                                                                                                                           | Ustekinumab SC                                                                                                                              | Ustekinumab SC                                                                                                                              | a                                                                                                                                           | Ustekinumab SC                                                                                                                              | Ustekinumab SC                                                                                                                              | Pbo SC a                                                                                                                                    | Ustekinumab SC                                                                                                                              | Ustekinumab SC                                                                                                                              |
| Endpoint                               | Pbo SC                                                                                                                                      | q12w                                                                                                                                        | q8w                                                                                                                                         | Pbo SC                                                                                                                                      | q12w                                                                                                                                        | q8w                                                                                                                                         | Pbo SC a                                                                                                                                    | q12w                                                                                                                                        | q8w                                                                                                                                         |
| N                                      | 84                                                                                                                                          | 95                                                                                                                                          | 79                                                                                                                                          | 87                                                                                                                                          | 70                                                                                                                                          | 90                                                                                                                                          | 27                                                                                                                                          | 22                                                                                                                                          | 21                                                                                                                                          |
| Clinical remission b                   | 32.1%                                                                                                                                       | 47.4%                                                                                                                                       | 50.6%†                                                                                                                                      | 17.2%                                                                                                                                       | 22.9%†                                                                                                                                      | 38.9%*                                                                                                                                      | 14.8%                                                                                                                                       | 22.7%                                                                                                                                       | 33.3%                                                                                                                                       |
| Clinical response c                    | 52.4%                                                                                                                                       | 76.8%†                                                                                                                                      | 77.2%*                                                                                                                                      | 39.1%                                                                                                                                       | 55.7%†                                                                                                                                      | 64.4%*                                                                                                                                      | 40.7%                                                                                                                                       | 50.0%                                                                                                                                       | 66.7%                                                                                                                                       |
| Endoscopic healing d                   | 35.7%                                                                                                                                       | 54.7%†                                                                                                                                      | 58.2%†                                                                                                                                      | 23.0%                                                                                                                                       | 25.7%                                                                                                                                       | 44.4%*                                                                                                                                      | 25.9%                                                                                                                                       | 27.3%                                                                                                                                       | 38.1%                                                                                                                                       |
| Corticosteroid-free clinical remission | 32.1%                                                                                                                                       | 46.3%                                                                                                                                       | 49.4%†                                                                                                                                      | 16.1%                                                                                                                                       | 22.9%†                                                                                                                                      | 36.7%*                                                                                                                                      | 14.8%                                                                                                                                       | 22.7%                                                                                                                                       | 33.3%                                                                                                                                       |
| Maintenance of clinical remission e    | 36.0% (9/25)                                                                                                                                | 70.0%† (21/30)                                                                                                                              | 75.0%† (12/16)                                                                                                                              | 42.1% (8/19)                                                                                                                                | 37.5% (3/8)                                                                                                                                 | 50.0% (10/20)                                                                                                                               | 50.0% (2/4)                                                                                                                                 | 33.3% (1/3)                                                                                                                                 | 42.9% (3/7)                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

| Table 5:   | Efficacy for key endpoints at Week 44 by biologic failure profile in the CNTO1275UCO3001 maintenance study; primary efficacy analysis set   | Efficacy for key endpoints at Week 44 by biologic failure profile in the CNTO1275UCO3001 maintenance study; primary efficacy analysis set   | Efficacy for key endpoints at Week 44 by biologic failure profile in the CNTO1275UCO3001 maintenance study; primary efficacy analysis set   | Efficacy for key endpoints at Week 44 by biologic failure profile in the CNTO1275UCO3001 maintenance study; primary efficacy analysis set   | Efficacy for key endpoints at Week 44 by biologic failure profile in the CNTO1275UCO3001 maintenance study; primary efficacy analysis set   | Efficacy for key endpoints at Week 44 by biologic failure profile in the CNTO1275UCO3001 maintenance study; primary efficacy analysis set   | Efficacy for key endpoints at Week 44 by biologic failure profile in the CNTO1275UCO3001 maintenance study; primary efficacy analysis set   | Efficacy for key endpoints at Week 44 by biologic failure profile in the CNTO1275UCO3001 maintenance study; primary efficacy analysis set   | Efficacy for key endpoints at Week 44 by biologic failure profile in the CNTO1275UCO3001 maintenance study; primary efficacy analysis set   | Efficacy for key endpoints at Week 44 by biologic failure profile in the CNTO1275UCO3001 maintenance study; primary efficacy analysis set   |
|------------|---------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------|
|            |                                                                                                                                             |                                                                                                                                             |                                                                                                                                             | Biologic failure to at least 1 anti-TNF                                                                                                     | Biologic failure to at least 1 anti-TNF                                                                                                     | Biologic failure to at least 1 anti-TNF                                                                                                     | Biologic failure to both an anti-TNF and vedolizumab                                                                                        | Biologic failure to both an anti-TNF and vedolizumab                                                                                        | Biologic failure to both an anti-TNF and vedolizumab                                                                                        | Biologic failure to both an anti-TNF and vedolizumab                                                                                        |
|            |                                                                                                                                             | Ustekinumab SC                                                                                                                              | Ustekinumab SC                                                                                                                              |                                                                                                                                             | Ustekinumab SC                                                                                                                              | Ustekinumab SC                                                                                                                              |                                                                                                                                             | Ustekinumab SC                                                                                                                              | Ustekinumab SC                                                                                                                              | Ustekinumab SC                                                                                                                              |
| Endpoint   | Pbo SC a                                                                                                                                    | q12w                                                                                                                                        | q8w                                                                                                                                         | Pbo SC a                                                                                                                                    | q12w                                                                                                                                        | q8w                                                                                                                                         | Pbo SC                                                                                                                                      | a                                                                                                                                           | q12w                                                                                                                                        | q8w                                                                                                                                         |

The primary endpoint and key secondary endpoint of steroid free clinical remission were not met in subjects who were failures to an anti-TNF and vedolizumab. There was a trend towards a benefit of ustekinumab versus placebo (greatest effect size for the q8w) but it did not reach significance and the number were very low, less than 10 in each arm.

## Ancillary analyses

The following analyses for week 8 Non-responders are derived from the induction study only.

## Efficacy for Week 8 Non-responders who received additional treatment at Week 8

A total of 417 subjects (placebo + ustekinumab treated patients) were not in clinical response at Week 8 (as determined by the IWRS) and received an additional administration of either IV or SC ustekinumab at Week 8

The applicant discusses the demographic, baseline characteristics and relevant medical history of the Week 8 treated set and there were no significant difference/findings to note.

Subjects who did not achieve clinical response at Week 8 following IV induction dosing at Week 0 received an additional dose of study agent at Week 8 as follows:

- Subjects who received placebo (IV) at Week 0 received ustekinumab ~6 mg/kg (IV) at Week 8 (placebo → ~6 mg/kg group; n=184)
- Subjects who received ustekinumab 130 mg (IV) at Week 0 received ustekinumab 90 mg SC at Week 8 (130 mg → 90 mg SC group; n=132)
- Subjects who received ustekinumab ~6 mg/kg (IV) at Week 0 received 90 mg SC at Week 8 (~6 mg/kg → 90 mg SC group; n=101)

The following is a summary of these results based on the endpoints of Clinical Remission, Endoscopy and Histology (endoscopic, histologic and mucosal healing) and clinical Response:

## Week 8 Non-responders who received Placebo IV at Week 0 and Ustekinumab ~6 mg/kg IV at Week 8

The proportions of subjects in the placebo → ~6 mg/kg group who achieved each of the endpoints mentioned above at Week 16 were as follows:

Clinical remission (global definition): 13.0%

Clinical remission (US definition): 16.8%

Clinical response: 67.9%

Endoscopic healing: 21.7%

Mucosal healing: 16.5%

Histologic healing: 38.6%

<div style=\"page-break-after: always\"></div>

## Week 8 Non-responders Who Received IV Ustekinumab (either 130mg or ~6 mg/kg) at Week 0 and Ustekinumab 90 mg SC (combined numbers) at Week 8

Clinical remission (global definition): 9.4%

Clinical remission (US definition): 11.2%

Clinical response: 59.7%

Endoscopic healing: 16.7%

Mucosal healing: 12.1%

Histologic healing: 34.9%

## Efficacy by biologic failure status among Week 8 Non-responders who received additional treatment at Week 8

When the endpoints of clinical remission (global and US definitions), endoscopic healing, and clinical response were assessed at Week 16 by biologic failure status (based on the Week 8 treated analysis set), consistent with the analyses of these endpoints at Week 8, the proportions of subjects who achieved each endpoint were consistently lower across all treatment groups for subjects who had a history of biologic failure compared with those who did not.

## Efficacy in Delayed Responders to Induction

The ustekinumab induction delayed responders (n=157) are subjects who were not in clinical response to ustekinumab IV at induction Week 8 but were in clinical response at induction Week 16 after receiving ustekinumab 90 mg SC at induction Week 8. These subjects received ustekinumab 90 mg SC q8w during maintenance.

Benefit was observed from continued maintenance therapy with ustekinumab (at 90 mg q8w) in the ustekinumab  induction  delayed  responders,  although  this  observation  is  based  on  uncontrolled observational  data.  A  substantial  proportion  of  these  subjects  (62.4%)  maintained  clinical  response through Week 44. These subjects also achieved other measures of efficacy at Week 44, but at rates that were lower than those observed in the subjects who were responders to ustekinumab induction and were subsequently  randomized  to  ustekinumab  q8w  in  the  primary  population  of  the  maintenance  study (Table 6).

| Table 6:                                       | Key clinical outcome endpoints at Week 44 in the CNTO1275UCO3001 maintenance study in responders and delayed responders to ustekinumab induction   | Key clinical outcome endpoints at Week 44 in the CNTO1275UCO3001 maintenance study in responders and delayed responders to ustekinumab induction   | Key clinical outcome endpoints at Week 44 in the CNTO1275UCO3001 maintenance study in responders and delayed responders to ustekinumab induction   |
|------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                | Responders to ustekinumab IV induction                                                                                                             | Responders to ustekinumab IV induction                                                                                                             | Delayed responders to ustekinumab induction a                                                                                                      |
|                                                | 90 mg q12w SC                                                                                                                                      | 90 mg q8w SC                                                                                                                                       | 90 mg q8w SC                                                                                                                                       |
| N                                              | 172                                                                                                                                                | 176                                                                                                                                                | 157                                                                                                                                                |
| Clinical remission b                           | 66 (38.4%)                                                                                                                                         | 77 (43.8%)                                                                                                                                         | 47 (29.9%)                                                                                                                                         |
| Maintained clinical response c through Week 44 | 117 (68.0%)                                                                                                                                        | 125 (71.0%)                                                                                                                                        | 98 (62.4%)                                                                                                                                         |
| Endoscopic healing d                           | 75 (43.6%)                                                                                                                                         | 90 (51.1%)                                                                                                                                         | 56 (35.7%)                                                                                                                                         |
| Corticosteroid-free clinical remission b       | 65 (37.8%)                                                                                                                                         | 74 (42.0%)                                                                                                                                         | 43 (27.4%)                                                                                                                                         |
| Partial Mayo remission e                       | 107 (62.2%)                                                                                                                                        | 121 (68.8%)                                                                                                                                        | 80 (51.0%)                                                                                                                                         |
| Mucosal healing f                              | 66/170 (38.8%)                                                                                                                                     | 79/172 (45.9%)                                                                                                                                     | 50 (32.5%)                                                                                                                                         |

IV=intravenous; q8w=every 8 weeks; q12w=every 12 weeks; SC=subcutaneous.

a: Subjects who were not in clinical response to ustekinumab IV at induction Week 8 but were in clinical response

<div style=\"page-break-after: always\"></div>

| Table 6:   | Key clinical outcome endpoints at Week 44 in the CNTO1275UCO3001 maintenance study in responders and delayed responders to ustekinumab induction   | Key clinical outcome endpoints at Week 44 in the CNTO1275UCO3001 maintenance study in responders and delayed responders to ustekinumab induction   | Key clinical outcome endpoints at Week 44 in the CNTO1275UCO3001 maintenance study in responders and delayed responders to ustekinumab induction   |
|------------|----------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------|
|            |                                                                                                                                                    | Responders to ustekinumab IV induction 90 mg q12w SC 90 mg q8w SC                                                                                  | Delayed responders to ustekinumab induction a 90 mg q8w SC                                                                                         |

at induction Week 16 after an SC administration of ustekinumab at induction Week 8.

b: A Mayo score ≤2 points, with no individual subscore &gt;1.

c: A decrease from baseline in the Mayo score by ≥30% and ≥3 points, with either a decrease from baseline in the rectal bleeding subscore ≥1 or a rectal bleeding subscore of 0 or 1

d: A Mayo subscore of 0 or 1.

e: A Mayo score ≤2.

- f: A combination of endoscopic healing (Mayo endoscopy score of 0 or 1) and histologic healing (neutrophil infiltration in &lt;5% of crypts, no crypt destruction, and no erosions, ulcerations, or granulation tissue).

Adapted from Table 3; Mod5.3.5.1/CNTO1275UCO3001/Maintenance/AttTEFCREM01\\_NR\\_G,

AttTEFCREM03\\_NR\\_G, AttTEFMUCO01\\_NR, AttTEFCREM02\\_NR

A total of 233 (this number represents those subjects treated with ustekinumab at Week 0, excluding placebo) did not achieve clinical response at Week 8 after IV induction dosing with ustekinumab at Week 0 and received ustekinumab 90 mg SC at Week 8.

The results indicate that benefit was observed after patients received a second ustekinumab dose at Week 8. Approximately 60% of these subjects attained clinical response at Week 16 and benefit was also observed for other clinical outcomes at Week 16.

## Mucosal healing (endoscopic and histological)

| Table 15:                        | NunberofSubjectswithMucosal Healing atWeek44;PrimaryEfficacyAnalysisSet(CNTO1275UCO3001)   | NunberofSubjectswithMucosal Healing atWeek44;PrimaryEfficacyAnalysisSet(CNTO1275UCO3001)   | NunberofSubjectswithMucosal Healing atWeek44;PrimaryEfficacyAnalysisSet(CNTO1275UCO3001)   | NunberofSubjectswithMucosal Healing atWeek44;PrimaryEfficacyAnalysisSet(CNTO1275UCO3001)   |
|----------------------------------|--------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------|
|                                  | Placebo SC ~                                                                               | 90 mg SC ql2w                                                                              | Ustekinumab 90 mg SC q8w                                                                   | Combined                                                                                   |
| PrimaryEfficacyAnalysisSet       | 175                                                                                        | 172                                                                                        | 176                                                                                        | 348                                                                                        |
| Week 44                          |                                                                                            |                                                                                            |                                                                                            |                                                                                            |
| Nb                               | 170                                                                                        | 170                                                                                        | 172                                                                                        | 342                                                                                        |
| Subjecs with mucosal healing cds | 41 (24.1%)                                                                                 | 66 (38.8%)                                                                                 | 79 (45.9%)                                                                                 | 145 (42.4%)                                                                                |
| p-value                          |                                                                                            | 0.002                                                                                      | ≤ 0.001                                                                                    | ≤0.001                                                                                     |

## Patient related quality of life. IBDQ

At Week 44, the median changes from maintenance baseline in the total IBDQ score were 5.0 and 1.5 (improved) in the ustekinumab q8w and q12w groups, respectively, compared with -7.0 (worsened) in the placebo group (p&lt;0.001 for both comparisons).

Maintenance of the improvements attained during induction were also observed for both ustekinumab dose regimens for the IBDQ dimension scores (bowel, emotional, systemic, and social; p≤0.002 for all comparisons).

The effects of ustekinumab in maintaining mucosal healing and IBDQ improvements from the induction study are consistent with the major efficacy results.

## Hospitalization or surgery

The  proportion  of  subjects  in  the  combined  ustekinumab  group  who  had  a  UC  disease-related hospitalization or surgery (2.3% [n=8]) was less than the proportion in the placebo group (5.7% [n=10];

<div style=\"page-break-after: always\"></div>

p=0.071). The colectomy and hospitalisation rate was low in the maintenance study but there were less events in the treatment arms compared to placebo.

## Markers of inflammation

## CRP

Consistent with the efficacy observed for clinical outcomes, the reductions in both a serum-based marker of inflammation (CRP) and fecal-based markers of inflammation (fecal calprotectin and fecal lactoferrin) attained with ustekinumab induction were maintained at Week 44 for both ustekinumab dose regimens (90 mg q8w and q12w), while concentrations increased somewhat in the placebo group

At Week 44, the median changes from maintenance baseline in CRP concentrations were -0.07 mg/L and 0.38 mg/L for the ustekinumab q8w and q12w groups, respectively, compared with 1.07 mg/L in the placebo group (p&lt;0.001 for both comparisons).

The proportions of subjects with normalized CRP concentration (≤3 mg/L) at Week 44 (among subjects with abnormal CRP [&gt;3 mg/L] at induction baseline [53.5%]) were significantly greater in the ustekinumab q8w (50.0%) and q12w (44.3%) groups compared with the placebo group (27.7%; p=0.002 and p=0.019, respectively).

## Faecal Calprotectin

The reductions in fecal calprotectin concentrations attained with ustekinumab induction were maintained in both the ustekinumab 90 mg SC q8w and q12w groups (with even further reductions observed in both groups), while concentrations increased in the placebo SC group. At Week 44, the median changes from maintenance baseline in fecal calprotectin were -85.0 mg/kg and -37.5 mg/kg in the ustekinumab q8w and q12w groups, respectively, compared with 229.5 mg/kg in the placebo group (p&lt;0.001 for both comparisons); greater reductions were observed in the q8w group than in the q12w group.

The proportions of subjects with normalized fecal calprotectin (≤250 mg/kg) at Week 44 (among subjects with abnormal calprotectin [&gt;250 mg/kg] at induction baseline [81.8%]) were significantly greater in the ustekinumab q8w (44.4%) and q12w (47.1%) groups compared with the placebo group (26.0%; p=0.001 and p&lt;0.001, respectively).

## Summary of main study(ies)

The following tables summarise the efficacy results from the main studies supporting the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

<div style=\"page-break-after: always\"></div>

## Summary of efficacy for trial CNTO1275UCO3001-Maintenance (UNIFI-M)

Title: A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis

| Study identifier          | UCO3001- Maintenance (UNIFI-M)                                                  | UCO3001- Maintenance (UNIFI-M)                                                  | UCO3001- Maintenance (UNIFI-M)                                                                                                                                                                      |
|---------------------------|---------------------------------------------------------------------------------|---------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Design                    | Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study | Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study | Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study                                                                                                                     |
| Design                    | Duration of main phase: Duration of Run-in phase: Duration of Extension phase:  | Duration of main phase: Duration of Run-in phase: Duration of Extension phase:  | 44 Weeks Not Applicable 176 Weeks                                                                                                                                                                   |
| Hypothesis                | Superiority                                                                     | Superiority                                                                     | Superiority                                                                                                                                                                                         |
| Treatments groups         | Ustekinumab 90 mg Q12W                                                          | Ustekinumab 90 mg Q12W                                                          | SC administration of ustekinumab every 12 weeks; randomized n=172                                                                                                                                   |
| Treatments groups         | Ustekinumab 90 mg Q8W                                                           | Ustekinumab 90 mg Q8W                                                           | SC administration of ustekinumab every 8 weeks; randomized n=176                                                                                                                                    |
| Treatments groups         | Placebo                                                                         | Placebo                                                                         | SC administration of placebo; randomized n=175                                                                                                                                                      |
| Endpoints and definitions | Primary endpoint                                                                | Clinical Remission at Week 44                                                   | Mayo score ≤2 points, with no individual subscore >1                                                                                                                                                |
| Endpoints and definitions | Major Secondary endpoint                                                        | Maintenance of clinical response through Week 44                                | Decrease from induction baseline in the Mayo score by ≥30% and ≥3 points, with either a decrease from induction baseline in the rectal bleeding subscore ≥1 or a rectal bleeding subscore of 0 or 1 |
| Endpoints and definitions | Major Secondary endpoint                                                        | Endoscopic healing at Week 44                                                   | Defined as a Mayo endoscopy subscore of 0 or 1                                                                                                                                                      |
| Endpoints and definitions | Major Secondary endpoint                                                        | Corticosteroid-f ree clinical remission at Week 44                              | Clinical remission (Mayo score ≤2 points, with no individual subscore >1) and not receiving concomitant corticosteroids (corticosteroid-free clinical remission) at Week 44                         |
|                           | Major Secondary endpoint                                                        | Remission in remitters through Week 44                                          | Maintenance of clinical remission (Mayo score ≤2 points, with no individual subscore >1) through Week 44 among the subjects who had achieved clinical remission at maintenance baseline             |
| Database lock             | 10 Aug 2018                                                                     | 10 Aug 2018                                                                     | 10 Aug 2018                                                                                                                                                                                         |

## Results and Analysis

| Analysis description                            | Primary Analysis                                | Primary Analysis          | Primary Analysis          | Primary Analysis                  | Primary Analysis                  |
|-------------------------------------------------|-------------------------------------------------|---------------------------|---------------------------|-----------------------------------|-----------------------------------|
| Analysis population and time point description  | Intent to treat - Week 44                       | Intent to treat - Week 44 | Intent to treat - Week 44 | Intent to treat - Week 44         | Intent to treat - Week 44         |
| Descriptive statistics and estimate variability | Treatment group                                 | Ustekinumab 90 mg Q12W    | Ustekinumab 90 mg Q8W     | Ustekinumab 90 mg Q8W             | Placebo                           |
| Descriptive statistics and estimate variability | Number of subject                               | 172                       | 176                       | 176                               | 175                               |
| Descriptive statistics and estimate variability | Primary endpoint- Clinical Remission at Week 44 | 66 (38.4%)                | 77 (43.8%)                | 77 (43.8%)                        | 42 (24.0%)                        |
| Descriptive statistics and estimate variability | Adjusted treatment difference (95% CI)          | 14.5 (5.5, 23.6)          | 19.7 (10.3, 29.0)         | 19.7 (10.3, 29.0)                 | N.A                               |
| Effect estimate per comparison                  |                                                 | Comparison groups         | Comparison groups         | Ustekinumab 90 mg Q8W vs Placebo  | Ustekinumab 90 mg Q8W vs Placebo  |
| Effect estimate per comparison                  |                                                 | P-value                   | P-value                   | < 0.001                           | < 0.001                           |
| Effect estimate per comparison                  |                                                 | Comparison groups         | Comparison groups         | Ustekinumab 90 mg Q12W vs Placebo | Ustekinumab 90 mg Q12W vs Placebo |
| Effect estimate per comparison                  |                                                 | P-value                   | P-value                   | 0.002                             | 0.002                             |

<div style=\"page-break-after: always\"></div>

| Analysis description                                                                           | Major Secondary Analysis                                                     | Major Secondary Analysis               | Major Secondary Analysis               | Major Secondary Analysis               | Major Secondary Analysis               |
|------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|
| Analysis population and time point description                                                 | Intent to treat - Through Week 44                                            | Intent to treat - Through Week 44      | Intent to treat - Through Week 44      | Intent to treat - Through Week 44      | Intent to treat - Through Week 44      |
| Descriptive statistics and estimate variability                                                | Treatment group                                                              | Ustekinumab 90 mg Q12W                 | Ustekinumab 90 mg Q8W                  | Ustekinumab 90 mg Q8W                  | Placebo                                |
| Descriptive statistics and estimate variability                                                | Number of subject                                                            | 172                                    | 176                                    | 176                                    | 175                                    |
| Descriptive statistics and estimate variability                                                | Major Secondary endpoint - Maintenance of clinical response                  | 117 (68.0%)                            | 125 (71.0%)                            | 125 (71.0%)                            | 78 (44.6%)                             |
| Descriptive statistics and estimate variability                                                | through Week 44 Adjusted treatment difference (95% CI)                       | 23.5 (13.7, 33.3)                      | 26.4 (16.6, 36.1)                      | 26.4 (16.6, 36.1)                      | N.A.                                   |
| Descriptive statistics and estimate variability                                                |                                                                              | Comparison groups                      | Comparison groups                      | Ustekinumab 90 mg Q8W vs Placebo       | Ustekinumab 90 mg Q8W vs Placebo       |
| Descriptive statistics and estimate variability                                                |                                                                              | P-value                                | P-value                                | < 0.001                                | < 0.001                                |
| Descriptive statistics and estimate variability                                                |                                                                              | Comparison groups                      | Comparison groups                      | Ustekinumab 90 mg Q12W vs Placebo      | Ustekinumab 90 mg Q12W vs Placebo      |
| Descriptive statistics and estimate variability                                                |                                                                              | P-value                                | P-value                                | < 0.001                                | < 0.001                                |
| Analysis description                                                                           | Major Secondary Analysis                                                     | Major Secondary Analysis               | Major Secondary Analysis               | Major Secondary Analysis               | Major Secondary Analysis               |
| Analysis population and time point description Descriptive statistics and estimate variability | Intent to treat - Week 44                                                    | Intent to treat - Week 44              | Intent to treat - Week 44              | Intent to treat - Week 44              | Intent to treat - Week 44              |
|                                                                                                | Treatment group                                                              | Ustekinumab 90 mg Q12W                 | Ustekinumab 90 mg Q8W                  | Ustekinumab 90 mg Q8W                  | Placebo                                |
|                                                                                                | Number of subject                                                            | 172                                    | 176                                    | 176                                    | 175                                    |
|                                                                                                | Major Secondary endpoint - Endoscopic healing at Week 44                     | 75 (43.6%)                             | 90 (51.1%)                             | 90 (51.1%)                             | 50 (28.6%)                             |
|                                                                                                | Adjusted treatment difference (95% CI)                                       | 15.2 (5.8, 24.6)                       | 22.5 (12.8, 32.2)                      | 22.5 (12.8, 32.2)                      | N.A.                                   |
|                                                                                                |                                                                              | Comparison groups                      | Comparison groups                      | Ustekinumab 90 mg Q8W vs Placebo       | Ustekinumab 90 mg Q8W vs Placebo       |
|                                                                                                |                                                                              | P-value                                | P-value                                | < 0.001                                | < 0.001                                |
|                                                                                                |                                                                              | Comparison groups                      | Comparison groups                      | Ustekinumab 90 mg Q12W vs Placebo      | Ustekinumab 90 mg Q12W vs Placebo      |
| Analysis description                                                                           |                                                                              |                                        |                                        |                                        |                                        |
|                                                                                                | P-value 0.002 Major Secondary Analysis                                       | P-value 0.002 Major Secondary Analysis | P-value 0.002 Major Secondary Analysis | P-value 0.002 Major Secondary Analysis | P-value 0.002 Major Secondary Analysis |
| Analysis population and time point description                                                 | Intent to treat - Week 44                                                    | Intent to treat - Week 44              | Intent to treat - Week 44              | Intent to treat - Week 44              | Intent to treat - Week 44              |
| Descriptive statistics and estimate variability                                                | Treatment group                                                              | Ustekinumab 90 mg Q12W                 | Ustekinumab 90 mg Q8W                  | Ustekinumab 90 mg Q8W                  | Placebo                                |
| Descriptive statistics and estimate variability                                                | Number of subject                                                            | 172                                    | 176                                    | 176                                    | 175                                    |
| Descriptive statistics and estimate variability                                                | Major Secondary endpoint - Corticosteroid-free clinical remission at Week 44 | 65 (37.8%)                             | 74 (42.0%)                             | 74 (42.0%)                             | 41 (23.4%)                             |
| Descriptive statistics and estimate variability                                                | Adjusted treatment difference (95% CI)                                       | 14.5 (5.5, 23.6)                       | 18.5 (9.3, 27.8)                       | 18.5 (9.3, 27.8)                       | N.A.                                   |
| Descriptive statistics and estimate variability                                                |                                                                              | Comparison groups                      | Comparison groups                      | Ustekinumab 90 mg Q8W vs               | Ustekinumab 90 mg Q8W vs               |
| Descriptive statistics and estimate variability                                                |                                                                              | P-value                                | P-value                                | Placebo < 0.001                        | Placebo < 0.001                        |
| Descriptive statistics and estimate variability                                                |                                                                              | Comparison groups                      | Comparison groups                      | Ustekinumab 90 mg Q12W vs              | Ustekinumab 90 mg Q12W vs              |
| Descriptive statistics and estimate variability                                                |                                                                              | P-value                                | P-value                                | Placebo 0.002                          | Placebo 0.002                          |
| Analysis description                                                                           | Major Secondary Analysis                                                     | Major Secondary Analysis               | Major Secondary Analysis               | Major Secondary Analysis               | Major Secondary Analysis               |

<div style=\"page-break-after: always\"></div>

| Analysis population and time point description   | Intent to treat, all subjects in clinical remission at maintenance baseline - Through Week 44   | Intent to treat, all subjects in clinical remission at maintenance baseline - Through Week 44   | Intent to treat, all subjects in clinical remission at maintenance baseline - Through Week 44   | Intent to treat, all subjects in clinical remission at maintenance baseline - Through Week 44   | Intent to treat, all subjects in clinical remission at maintenance baseline - Through Week 44   |
|--------------------------------------------------|-------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|
| Descriptive statistics and estimate variability  | Treatment group                                                                                 | Ustekinumab 90 mg Q12W                                                                          | Ustekinumab 90 mg Q8W                                                                           | Ustekinumab 90 mg Q8W                                                                           | Placebo                                                                                         |
| Descriptive statistics and estimate variability  | Subjects in clinical remission at maintenance Baseline                                          | 40                                                                                              | 38                                                                                              | 38                                                                                              | 45                                                                                              |
| Descriptive statistics and estimate variability  | Major Secondary endpoint - Remission in remitters through Week 44                               | 26 (65.0%)                                                                                      | 22 (57.9%)                                                                                      | 22 (57.9%)                                                                                      | 17 (37.8%)                                                                                      |
| Descriptive statistics and estimate variability  | Adjusted treatment difference (95% CI)                                                          | 28.4 (8.0, 48.9)                                                                                | 20.3 (0.0, 40.6)                                                                                | 20.3 (0.0, 40.6)                                                                                | N.A.                                                                                            |
| Descriptive statistics and estimate variability  |                                                                                                 | Comparison groups                                                                               | Comparison groups                                                                               | Ustekinumab 90 mg Q8W vs Placebo                                                                | Ustekinumab 90 mg Q8W vs Placebo                                                                |
| Descriptive statistics and estimate variability  |                                                                                                 | P-value                                                                                         | P-value                                                                                         | 0.069                                                                                           | 0.069                                                                                           |
| Descriptive statistics and estimate variability  |                                                                                                 | Comparison groups                                                                               | Comparison groups                                                                               | Ustekinumab 90 mg Q12W vs Placebo                                                               | Ustekinumab 90 mg Q12W vs Placebo                                                               |
| Descriptive statistics and estimate variability  |                                                                                                 | P-value                                                                                         | P-value                                                                                         | 0.011                                                                                           | 0.011                                                                                           |

## Analysis performed across trials (pooled analyses and meta-analysis)

Efficacy data from the UCO3001 induction and maintenance studies were not pooled or compared across studies because the two studies are based on different treatment phases. Instead, efficacy and subpopulation analyses are provided separately for induction and maintenance.

## 2.4.3. Discussion on clinical efficacy

## Design and conduct of clinical studies

To support a positive risk benefit for ustekinumab for the treatment of ulcerative colitis, the Applicant has submitted two pivotal phase 3 studies, one study aiming at demonstrating safety and efficacy in the induction of remission setting (CNTO1275UCO3001 induction) and one study aiming at demonstrating safety and efficacy in the maintenance of remission setting (CNTO1275UCO3001 maintenance). Both studies were randomized, placebo-controlled and double blind. The induction study included patients with moderate to severe active ulcerative colitis having failed conventional and or biologic treatment. The maintenance therapy included patients who had finalized the induction study and achieved response on ustekinumab treatment. The duration of the induction study was 8 weeks but patients not achieving response at week 8 were given ustekinumab and allowed to enter the maintenance study if they subsequently achieved response at week 16. The duration of the maintenance study was 44 weeks making the total study duration 52 weeks (for responders at week 8 in the induction study). Overall the design of the studies are considered acceptable and in line with the current EU guideline (CHMP/EWP/18463/2006 Rev.1). The study population reflects the intended target population and is also considered acceptable. The primary endpoint in both studies was clinical remission, defined as Mayo score ≤ 2 points, with no individual subscore &gt;1, at week 8 and week 44 of the induction and maintenance studies, respectively. Major secondary endpoint (for which the overall risk of type 1 error was controlled) included endoscopic healing, clinical response and change from baseline in IBDQ (induction study) and maintenance of clinical response through Week 44, endoscopic healing at Week 44, clinical remission and not receiving concomitant corticosteroids (corticosteroid-free clinical remission) at Week 44 and maintenance of clinical remission through Week 44 among the subjects who had achieved clinical remission at maintenance baseline (maintenance study). The endpoint used are not in accordance with

<div style=\"page-break-after: always\"></div>

the current EU guideline) which recommends that symptomatic remission and endoscopic remission should be co-primary endpoints. It is acknowledged that the study was designed and conducted before the current revision of the EU guideline came into effect but still it is expected to provide evidence of efficacy in both symptoms and endoscopic appearance.

In that respect it is noted that endoscopic healing (defined as a Mayo endoscopy score of 0 or 1) was included as a major secondary endpoint (for which the overall type 1 error was controlled) and that symptomatic remission was an ordinary, secondary endpoint (for which overall type 1 error was not controlled). Furthermore, in the US application, clinical remission defined as absolute stool number ≤ 3, Mayo rectal bleeding score of 0 and Mayo endoscopy score ≤ 1 (i.e. only mild erythema and friability) was the primary endpoint. The applicant confirmed that the US definition of clinical remission does require individual subjects to achieve all 3 elements of the composite endpoint (ie, an absolute stool number ≤3, a Mayo rectal bleeding sub score of 0, and a Mayo endoscopy sub score of 0 or 1. Further, the US definition of clinical remission was a pre-specified endpoint in the protocol and statistical analysis plan for both the induction and the maintenance studies. This explanation was considered satisfactory by the CHMP as the presented data does demonstrate efficacy in the domains requested by the EU Guideline.

The statistical analysis were generally acceptable. Adequate measures to control the overall type 1 error were included. Methods for handling intercurrent events and missing values were well described and relevant sensitivity analyses to explore the impact of intercurrent events and different ways of imputing missing values were planned.

The study was carried out according to GCP. Judged by the number and type of protocol violations, the study appears to be well-conducted.

## Efficacy data and additional analyses

## Dose response

Dose-ranging was performed in two Phase 2 studies for ustekinumab in Crohn's disease. No formal dose-ranging was studied for ustekinumab in UC.  The ustekinumab dose regimens selected for the UCO3001 induction and maintenance studies in subjects with UC were the same as those that were being studied in the Phase 3 program for ustekinumab in subjects with Crohn's disease. Evaluating the same ustekinumab dose regimens in both diseases was considered reasonable by the CHMP given the similarities in the genetics and biology of UC and Crohn's disease.

## Efficacy induction

In the induction study, a total of 961 patients were randomized to either placebo (319), ustekinumab 130 mg IV (320) or ustekinumab 5 mg/kg IV (322). There were no apparent imbalances between treatment groups apart from a slightly higher baseline fecal calprotectin in patients treated with ustekinumab compared to placebo. If a bias was introduced by this, it would be in favour of placebo. Thus, this imbalance is unlikely to have had major impact on the conclusions of the study.

The study population consisted of approximately 50% extensive disease and 50 % left sided disease. There was a nearly even distribution of biologic naïve and biologic experienced patients. Patients included had moderate to severe disease activity reflected by a relatively high median Mayo score of 9 and a median fecal calprotectin of 1200-1500 mg/kg. Approximately 90 % had a fecal calprotectin above 250 mg/kg. In terms of baseline characteristics and disease activity, the included patients are considered representative of intended target population.

<div style=\"page-break-after: always\"></div>

The majority of the included patients had failed or were intolerant to standard therapy (including steroids and immunosuppressant) and/or biologics. In terms of baseline concomitant medication and previous medication history, the included patients are considered representative of intended target population.

In terms of concomitant medication and previous medication history, the treatment groups are well balanced. There are no important imbalances.

Compared to placebo (5.3 %), both doses of ustekinumab (15.6% and 15.3 % for 130 mg and 6 mg/kg, respectively) significantly increased the proportion of patients who achieved clinical remission (defined as Mayo score ≤ 2 points, with no individual subscore &gt; 1). There were slightly more patients in the placebo group than in the two ustekinumab groups who were defined as treatment failures due to use of prohibited medication or missing of all Mayo scores. In theory, this could favour ustekinumab over placebo. However, in a long row of sensitivity analyses, including a worst case scenario analysis (subjects who received placebo, had missing data at Week 8, and did not have an event of treatment failure prior to Week 8 were considered to be in clinical remission. Subjects who received ustekinumab and had missing data at Week 8 were considered not to be in clinical remission) ustekinumab was consistently statistically superior to placebo. This supports the statistical robustness of the results.

Analyses in various clinically relevant subgroups demonstrated that efficacy was maintained across these. In particular efficacy was maintained irrespective of whether the subjects received concomitant 5-ASA, oral corticosteroid, AZA/MP/MTX. Efficacy was also independent of previous medication history (e.g. biologic failure y/n).

As regards the clinical relevance, the difference between placebo and ustekinumab in terms of fraction of patients achieving clinical remission (approximately 10 percentage points for both doses) appears modest at first glance. However, it has to be acknowledged that achieving clinical remission defined as above within 8 weeks is a very demanding endpoint. It also has to be acknowledged that in previous applications for similar indications, the less demanding endpoint of response was used. This has to taken into consideration when comparing results across studies.

Considering the very demanding endpoint and the early assessment, the observed difference is considered clinically relevant.

As regards the major secondary endpoint 'endoscopic remission', both doses of ustekinumab significantly increased the fraction of patients achieving the endpoint (26.3% and 27.0 % for 130 mg and 6 mg/kg respectively) compared to placebo (13.8%). Superiority above placebo was achieved at an early time point and the difference in terms of remission rates are considered clinically relevant.

Compared to placebo, both doses of ustekinumab significantly increased the fraction of patients achieving clinical response (major secondary endpoint) defined in an identical way to what was used in the pivotal studies of infliximab in UC (51.3%, 61.8% and 31.3% for ustekinumab 130 mg, ustekinumab 6 mg/kg and placebo, respectively). Notwithstanding the many caveats associated with cross trial comparisons, the effect size for the highest dose of ustekinumab (6 mg/kg) was numerically comparable to what was achieved with infliximab (5 or 10 mg/kg) in the ACT1 and ACT2 studies. This further supports the conclusion on the clinical relevance of the observed effect size.

Albeit a secondary endpoint without correction for multiplicity, symptomatic remission (defined at a Mayo stool frequency of 0 or 1 and a rectal bleeding score of 0) is considered of major interest as according to current relevant EU guideline, this should have been a co-primary endpoint. It is noted that both doses of ustekinumab, compared to placebo, significantly increased the fraction of patients achieving symptomatic remission. Thus significantly greater proportions of subjects in the ~6 mg/kg and 130 mg groups achieved symptomatic remission (44.7% and 41.3%, respectively) compared with subjects in the placebo group (22.6%; p&lt;0.001 for both comparisons). The difference is considered clinically relevant.

<div style=\"page-break-after: always\"></div>

Thus while not formally defined as co-primary endpoints as suggested by the current EU guideline, the Applicant has indeed demonstrated clinically and statistically significant effects on both endoscopic and symptomatic remission.

As expected, compared to patients not having failed biologics, patients who had a history of failing biologic treatment had a numerically smaller effect size both in term of response and remission rates. However, the effect remained statistically and clinically significant. Notwithstanding the serious uncertainties associated with cross study comparisons, it is noted that response rates were comparable to what has been observed for other biologics.

Elevated CRP is not present in all cases of active UC. This was also reflected in the study population where 40.8% had normal CRP levels. This is considered acceptable and representative for the target population. Among patients with elevated CRP, the rate of normalisation was significantly greater in the ustekinumab treated patients than in placebo treated patients. Furthermore, faecal calprotectin was significantly reduced by ustekinumab. Both effects are considered supportive evidence of the biologic effect of the drug in UC. Subjects not achieving response/remission at week 8 were given open label ustekinumab (~6 mg/kg (to patients having received placebo at week 0) and 90 mg (to patients having received either 130 mg or ~6 mg/kg at week 0). Among patients treated with placebo at week 0 and ustekinumab ~6 mg/kg at week given at week 8, the effect at week 16 was, as expected similar to what was observed at week 8 for patients receiving ~6 mg/kg at week 0. This does not provide any new information.

Ustekinumab treated patients who were not in response at week 8 of UNIFI-I received an administration of 90 mg SC ustekinumab at week 8 (36% of patients). Of those patients, 9% of patients who were initially randomized to the recommended induction dose achieved clinical remission and 58% achieved clinical response at Week 16. Patients who were not in clinical response to ustekinumab induction at week 8 of the UNFI-I study but were in response at week 16 (157 patients) entered into the non-randomized portion of UNIFI-M and continued to receive maintenance dosing every 8 weeks; among these patients, a majority (62%) maintained response and 30% achieved remission at week 44. This information is in the SmPC.

## Efficacy maintenance

A total of 783 patients were included in the maintenance study. Only 523 of these were randomised (constituting the primary efficacy population). The rest (260 patients) were non randomised patients receiving open label ustekinumab. Among the randomised patients, 175 received placebo, 172 received ustekinumab 90 mg q12w and 176 patients received ustekinumab 90 mg q8w. In the placebo group 43 patients discontinued study agent whereas the corresponding figures for the ustekinumab groups were 24 and 18, respectively. The total number of discontinuations were almost twice as high in the placebo arm as in the two ustekinumab arms combined. The difference was primarily due to (expectedly) higher discontinuations rates in the placebo arm due to lack of efficacy, worsening of UC and failure to achieve partial Mayo response at week 16 (all of which are linked to the lack of effect of placebo). As such this is not unexpected.

Patients discontinuing treatment were considered non-responders. The applicant provided evidence of worsening UC disease activity among the majority of subjects who discontinued study agent due to an AE of worsening UC or lack of efficacy across the different treatment groups which justifies treating these subjects as non-responders in the efficacy analyses.

Generally, the treatment groups were well balanced in terms of demographic characteristics, disease characteristics and concomitant therapies. In general, no clinically relevant imbalances were observed. However, the inflammatory burden, as judged by fecal calprotectin, was slightly higher in the

<div style=\"page-break-after: always\"></div>

ustekinumab than in the placebo group. The difference is of doubtful relevance and in any instance not in favor to the test drug and as such not inducing any bias in favor of the test drug.

Compared to placebo, both doses of ustekinumab statistically significantly increased the fraction of patients who maintained clinical remission. The difference between placebo and both doses of ustekinumab was considered clinically relevant. Remission rates were numerically higher in the ustekinumab q8 group compared to the ustekinumab q12 group. No formal statistical comparison was reported.

The number of patients missing one or more Mayo subscores at week 44 was considerably higher in the placebo group compared to the two ustekinumab groups. However, this was almost entirely due to patients having discontinued study agent prior to week 40. Furthermore, among the patients with all four Mayo scores missing, the difference between placebo and ustekinumab groups were entirely due to the expected differences in term of discontinuations due to treatment failure. Thus, it is concluded that the differences in missing information is unlikely to have confounded the observed results.

Compared to placebo, both doses of ustekinumab statistically significantly increased the fraction of patients who maintained clinical remission. The difference between placebo and both doses of ustekinumab was considered clinically relevant. Remission rates were numerically higher in the ustekinumab q8 group compared to the ustekinumab q12 group. No formal statistical comparison was reported.

As expected the number of patients experiencing treatment failure were higher in the placebo group compared to the ustekinumab group (please refer to the section on statistical methods).

Compared to placebo, both doses of ustekinumab statistically and clinically significantly increased the number of subjects achieving the primary endpoint (clinical remission (global definition)) (24.0%, 38.4% and 43.8% for placebo, ustekinumab 90 mg q12w and ustekinumab q8w, respectively).

The effect was maintained in both biologic naïve and experienced patients. However, as expected the effect size was numerically smaller in the treatment-experienced patients. There was a trend for better efficacy of q8 than q12 in treatment-experienced patients.

For the very treatment resistant patients (failing both anti-TNF and vedolizumab), treatment benefit was small and not statistically persuasive. Point estimates of beneficial treatment effect over placebo were however consistent across strata including patients failing both anti-TNF and vedolizumab. The maintenance study was underpowered to demonstrate the benefit persuasively in this subgroup.

It is acknowledged that the numbers of patients in these groups are small and that the study was not powered to demonstrate statistically significant results in this subpopulation. Nevertheless, it is likely that ustekinumab will be used extensively in patients who have failed biologics including patients failing both TNF inhibitors and integrin inhibitors. Thus, the Applicant included the relevant data on these patients into 5.1 of the SmPC (at week 8 and at week 52 from initiation of the induction dose) to alert prescribers to the limited evidence of efficacy in this subpopulation .

In order to support a claim for efficacy in UC, the drug is expected to have an effect on both symptoms and endoscopic appearance of the mucosa. As outlined in the current guideline, the (co)primary endpoints should be proportion of patients in symptomatic remission and proportion of patients with endoscopic remission (for the maintenance studies this should be achieved without steroids, i.e. steroid free symptomatic and endoscopic remission). Thus, the use of clinical remission defined as a total Mayo score (which includes both symptoms, endoscopic appearance and physician's global impression) below or equal to 2 (with no subscores above 1) is not in accordance with the current guideline. Furthermore, the primary endpoint used does not exclude the use of steroids.

<div style=\"page-break-after: always\"></div>

Notwithstanding these remarks, it is noted that the study was designed and conducted prior to the release of the current version of the EU guideline. Furthermore, the results of the secondary endpoint (please see below) does indicate that ustekinumab has an effect on both symptomatic and endoscopic remission. Finally, the US definition of the primary endpoint (for which a statistically and clinically significant effect also was demonstrated), i.e. patients achieving both clinical and symptomatic response, does indicate that ustekinumab has an effect on both parameters

The results appear statistically robust as a number of sensitivity analyses supported the primary analysis. Even the 'worst case scenario' analyses did provide some support as significance was maintained in the q8 ustekinumab group and significance was borderline (p=0.055) in the q12 ustekinumab. Taken together these results supports the robustness of the primary analysis.

The major secondary endpoints all supported the primary endpoint. Compared to placebo, ustekinumab statistically and clinically significant increased the number of patients achieving, maintenance of clinical response, endoscopic healing, corticosteroid free remission and maintenance of clinical remission through week 44. The analyses of these endpoints were done in hierarchical way maintaining the overall p value below 0.05. As previously mentioned, these major secondary endpoints, in combination with the US defined primary endpoint, are considered to support that ustekinumab has efficacy in the two domains (symptoms and endoscopy) requested by the current EU guideline.

## 2.4.4. Conclusions on the clinical efficacy

The efficacy of utekinumab has been adequately demonstrated in both the induction and maintenance pivotal studies. Superior efficacy over placebo has been demonstrated in subjects for the primary and key secondary outcomes in subjects who were biological and non-biological failures. Efficacy has been demonstrated in biological failures in terms of patients failing either anti-TNF agents or vedolizumab. The company have applied for the following indication ' Extension of Indication for Stelara to include treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic or have medical contraindications to such therapies' .  During the procedure, the CHMP noted that efficacy in severely treatment refractory patients (i.e. refractory to both TNF-inhibitors and vedolizumab)  was based on small numbers of and the study was not powered to demonstrate statistically significant results in this subpopulation. As it is likely that ustekinumab will be used extensively in patients who have failed biologics including patients failing both TNF inhibitors and integrin inhibitors the MAH agreed at the CHMP's request to add in Section 5.1 of the SmPC at statement to inform  prescribers about  the limited evidence of efficacy in this subpopulation.

## 2.5. Clinical safety

## Introduction

Ustekinumab was first authorised in the EU in 2009 for the indication of plaque psoriasis. Since that original licence, extensions to the indication include psoriatic arthropathy, paediatric plaque psoriasis in subjects aged 12yrs and older and most recently moderately to severely active Crohn's disease in patients who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a TNFα antagonist or have medical contraindications to such therapies.

The most common adverse reactions (&gt; 5%) in controlled periods of the adult psoriasis, psoriatic arthritis and Crohn's disease clinical studies with ustekinumab were nasopharyngitis and headache. Based on the postmarketing safety surveillance, hypersensitivity reactions (including rash and urticaria), serious hypersensitivity reactions (including anaphylaxis and angioedema), lower respiratory tract infection,

<div style=\"page-break-after: always\"></div>

allergic alveolitis, eosinophilic pneumonia, erythrodermic psoriasis, and pustular psoriasis, were identified as ADRs.

Serious infections (including mycobacterial and salmonella infections) and malignancies represent important potential risks due to the mechanism of action. Current post-marketing registries for patients with moderate to severe psoriasis and Crohn's disease aim to further characterise long term safety for these indications.

The clinical development program for ustekinumab in UC consisted of a placebo-controlled induction study and a randomised-withdrawal maintenance study, conducted under a single protocol.

The safety data for UC were presented and analysed separately for:

- The placebo-controlled induction period (ie, Week 0 to Week 8 of induction and the final safety visit) in treated subjects.
- The maintenance phase of treatment (Week 0 of maintenance up to week 44).
- Combined induction and maintenance phase of treatment, to assess the overall safety experience from induction though maintenance, representing a total of up to 52 weeks of exposure (8 weeks exposure in induction studies and 44 weeks exposure in the maintenance study).

Supportive analyses were also presented including:

- An analysis of the placebo-controlled induction period and Week 0 through Week 44 of the maintenance studies from the pooled Phase 3 IBD (UC and Crohn's disease induction and maintenance studies) population
- An analysis of global pooled Phase 2 and Phase 3 safety data across diseases (IBD [UC and Crohn's disease] and psoriatic diseases [psoriasis and PsA]), and a range of doses, for all treated subjects analyzed separately for the placebo-controlled period and through approximately 1 year of treatment.

Safety was evaluated via descriptive statistics, counts and percentages (subject incidence, numbers of events and numbers of subjects with events both per 100 subject-years of follow-up). All subjects who receive at least 1 administration of study agent were included in the Safety Analysis Set (including randomised and non-randomised patients).

The following treatment emergent safety parameters were analysed by treatment group: adverse reactions (AEs), serious adverse reactions (SAEs), reasonably-related AEs (any event with an investigator-assigned relationship to study agent of 'Very Likely', 'Probable', or 'Possible' or if the relationship to study agent is missing), discontinuations of study agent due to AEs, deaths, infections, serious infections, treated infections, AEs within 1 hour of infusion and injection-site reactions. Analysis of laboratory evaluations, vital signs and safety in special groups was also presented.

Protocol specified events of special interest included any newly identified malignancy or case of active TB occurring after the first administration of study agent. The targeted AEs of serious infections, TB, malignancies, and serious MACE were analysed for the UC safety data set and compared across the IBD and approved psoriatic diseases populations. In addition, targeted AEs that occurred infrequently (anaphylactic and delayed hypersensitivity [serum sickness-like] reactions, TB and opportunistic infections, and serious neurological disorders) are also described.

Subgroup analyses were conducted to evaluate whether demographic characteristics, UC disease characteristics, concomitant UC medication, or UC medication history factors had a differential effect on safety in subjects with UC.

<div style=\"page-break-after: always\"></div>

## Patient exposure

## Patient exposure - Induction study

In the Phase 3 UC induction study, a total of 641 subjects received a single IV induction dose of ustekinumab at Week 0; 321 subjects received IV ustekinumab 130 mg and 320 subjects received IV ustekinumab ~6 mg/kg. The average length of follow-up was 8, 8.1 and 8.2 weeks for the placebo, the 130 mg and ~6 mg/kg treatment groups through week 8 and 8.7, 8.6 and 8.6 weeks through the final safety visit.

Figure 4: Subject Disposition - Randomized Subjects (CNTO1275UC03001)

<!-- image -->

## Patient exposure - Maintenance phase

The safety database from the two Phase 3 Ulcerative Colitis clinical studies (UCO3001 induction and maintenance studies) comprises 825 ustekinumab-treated subjects. All 825 subjects received a single IV dose of ustekinumab.

Subjects in whom the duration between the first and last ustekinumab administration was at least 14 weeks were counted as having 6 months of exposure, and subjects in whom the duration between the first and last ustekinumab administration was at least 38 weeks (accounting for 2-week visit windows) were counted as having 1 year of exposure. This definition of exposure was used in submissions supporting the psoriatic disease indications and was also subsequently applied for the Crohn's disease submission. A total of 491 (59.5%) subjects were exposed to ustekinumab (IV and SC) for at least 6 months and 442 (53.6%) subjects were exposed to ustekinumab (IV and SC) for at least 1 year, with a total of 250 subject-years of follow up, as summarised in the following table:

<div style=\"page-break-after: always\"></div>

Table 8: Summary of Duration of UstekinumabExposure Through OneYear\" of Follow-Up; TreatedSubjectsinCNTO1275UCO3001InductionandMaintenanceStudies

|                                   | Ustekinumabb   |
|-----------------------------------|----------------|
| Subjectstreatedwithustekinumab    | 825            |
| Durationofustekinumabexposure     |                |
| Single IV                         | 825 (100.0%)   |
| Atleast6months                    | 491 (59.5%)    |
| At least 1 yeard                  | 442 (53.6%)    |
| Avg duration of treatment (weeks) | 28.82          |
| Total subject-yearsoffollow-up°   | 250            |
| Total dose (mg)                   |                |
| N                                 | 825            |
| Mean (SD)                         | 587.8 (276.49) |
| Median                            | 580.0          |
| IQ range                          | (390.0; 760.0) |
| Range                             | (86; 1280)     |

- The duration between the first and last ustekinumab administration was at least 14 weeks.

* Through 60 weeks for subjects who entered maintenance at Week 16 of the CNTO1275UCO3001 induction study b CNTO1275UCO3001 (through induction Week 20 for subjects who did not enter maintenance and did not receive treatment at induction Week 8; through induction Week 28 for subjects who did not enter maintenance and received treatmentatinductionWeek8;throughmaintenanceWeek44forsubjectswhoenteredmaintenance)

- d The duration between the first and last ustekinumab administration was at least 38 weeks.

e Through 1 year of treatment, 60 weeks for subjects who entered maintenance at Week 16 of the CNTO1275UCO3001 inductionstudy

Adaptedffom:[TSFAE12D.RTF][CNTO1275\\Z\\_SCS\\DBR\\_2017\\_12\\RE\\_2017\\_12\\PROD\\TSFAE12D.SAS]14AUG2018,19:21

## Demographics

The demographic characteristics of subjects at baseline in UCO3001 and across all diseases pooled are summarised in the following table:

<div style=\"page-break-after: always\"></div>

| TSIDEMOID: Summaryof Demographics,ConcomitantMfedicationsatBaseline;RandomizedSubjectsinInflainmatoryBowrel Disease (UlcerativeColitisand Crohn'sDisease)andPsoriaticDiseases(PsoriasisandPsoriaticArthritis)Studies   | TSIDEMOID: Summaryof Demographics,ConcomitantMfedicationsatBaseline;RandomizedSubjectsinInflainmatoryBowrel Disease (UlcerativeColitisand Crohn'sDisease)andPsoriaticDiseases(PsoriasisandPsoriaticArthritis)Studies   | TSIDEMOID: Summaryof Demographics,ConcomitantMfedicationsatBaseline;RandomizedSubjectsinInflainmatoryBowrel Disease (UlcerativeColitisand Crohn'sDisease)andPsoriaticDiseases(PsoriasisandPsoriaticArthritis)Studies   | TSIDEMOID: Summaryof Demographics,ConcomitantMfedicationsatBaseline;RandomizedSubjectsinInflainmatoryBowrel Disease (UlcerativeColitisand Crohn'sDisease)andPsoriaticDiseases(PsoriasisandPsoriaticArthritis)Studies   | TSIDEMOID: Summaryof Demographics,ConcomitantMfedicationsatBaseline;RandomizedSubjectsinInflainmatoryBowrel Disease (UlcerativeColitisand Crohn'sDisease)andPsoriaticDiseases(PsoriasisandPsoriaticArthritis)Studies   | TSIDEMOID: Summaryof Demographics,ConcomitantMfedicationsatBaseline;RandomizedSubjectsinInflainmatoryBowrel Disease (UlcerativeColitisand Crohn'sDisease)andPsoriaticDiseases(PsoriasisandPsoriaticArthritis)Studies   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                                                        | Ulcerative Colitis                                                                                                                                                                                                     | Crohn's Disease\"                                                                                                                                                                                                       | InflammatoryBowel                                                                                                                                                                                                      | PsoriaticDiseases\"                                                                                                                                                                                                     | All Diseases Pooled\"                                                                                                                                                                                                   |
| Subjectsrandomized                                                                                                                                                                                                     | 196                                                                                                                                                                                                                    | 1988                                                                                                                                                                                                                   | Disease\" 2949                                                                                                                                                                                                          | 4292                                                                                                                                                                                                                   | 7241                                                                                                                                                                                                                   |
| Age(years)                                                                                                                                                                                                             |                                                                                                                                                                                                                        |                                                                                                                                                                                                                        |                                                                                                                                                                                                                        |                                                                                                                                                                                                                        |                                                                                                                                                                                                                        |
| N                                                                                                                                                                                                                      | 196                                                                                                                                                                                                                    | 1988                                                                                                                                                                                                                   | 2949                                                                                                                                                                                                                   | 4292                                                                                                                                                                                                                   | 7241                                                                                                                                                                                                                   |
| Mean (SD)                                                                                                                                                                                                              | 41.7(13.70)                                                                                                                                                                                                            | 38.6(12.73)                                                                                                                                                                                                            | 39.6 (13.13)                                                                                                                                                                                                           | 46.1 (12.28)                                                                                                                                                                                                           | 43.5(13.03)                                                                                                                                                                                                            |
| Median                                                                                                                                                                                                                 | 41.0                                                                                                                                                                                                                   | 37.0                                                                                                                                                                                                                   | 38.0                                                                                                                                                                                                                   | 46.0                                                                                                                                                                                                                   | 44.0                                                                                                                                                                                                                   |
| IQrange                                                                                                                                                                                                                | (30.0;51.0)                                                                                                                                                                                                            | (28.0;47.0)                                                                                                                                                                                                            | (29.0;49.0)                                                                                                                                                                                                            | (37.0;55.0)                                                                                                                                                                                                            | (33.0;53.0)                                                                                                                                                                                                            |
| Range                                                                                                                                                                                                                  | (18;84)                                                                                                                                                                                                                | (18;77)                                                                                                                                                                                                                | (18;84)                                                                                                                                                                                                                | (18;86)                                                                                                                                                                                                                | (18;86)                                                                                                                                                                                                                |
| Sex                                                                                                                                                                                                                    |                                                                                                                                                                                                                        |                                                                                                                                                                                                                        |                                                                                                                                                                                                                        |                                                                                                                                                                                                                        |                                                                                                                                                                                                                        |
| N                                                                                                                                                                                                                      | 961                                                                                                                                                                                                                    | 1988                                                                                                                                                                                                                   | 2949                                                                                                                                                                                                                   | 4292                                                                                                                                                                                                                   | 7241                                                                                                                                                                                                                   |
| Male                                                                                                                                                                                                                   | 582 (60.6%)                                                                                                                                                                                                            | 871(43.89)                                                                                                                                                                                                             | 1453 (49.3%)                                                                                                                                                                                                           | 2767 (64.59)                                                                                                                                                                                                           | 4220(58.3%)                                                                                                                                                                                                            |
| Female                                                                                                                                                                                                                 | 379 (39.4%)                                                                                                                                                                                                            | 1117 (56.2%)                                                                                                                                                                                                           | 1496 (50.7%)                                                                                                                                                                                                           | 1525 (35.5%)                                                                                                                                                                                                           | 3021 (41.7%)                                                                                                                                                                                                           |
| Race                                                                                                                                                                                                                   |                                                                                                                                                                                                                        |                                                                                                                                                                                                                        |                                                                                                                                                                                                                        |                                                                                                                                                                                                                        |                                                                                                                                                                                                                        |
| N                                                                                                                                                                                                                      | 961                                                                                                                                                                                                                    | 1988                                                                                                                                                                                                                   | 2949                                                                                                                                                                                                                   | 4291                                                                                                                                                                                                                   | 7240                                                                                                                                                                                                                   |
| White                                                                                                                                                                                                                  | 730 (76.0%)                                                                                                                                                                                                            | 1729 (87.0%)                                                                                                                                                                                                           | 2459 (83.4%)                                                                                                                                                                                                           | 3998(93.2%)                                                                                                                                                                                                            | 6457(89.2%)                                                                                                                                                                                                            |
| Black orAfican American                                                                                                                                                                                                | 9(0.9%)                                                                                                                                                                                                                | 65 (3.3%)                                                                                                                                                                                                              | 74(2.5%)                                                                                                                                                                                                               | 73 (1.7%)                                                                                                                                                                                                              | 147 (2.0%)                                                                                                                                                                                                             |
| Asian                                                                                                                                                                                                                  | 144 (15.0%)                                                                                                                                                                                                            | 122 (6.1%)                                                                                                                                                                                                             | 266 (9.0%)                                                                                                                                                                                                             | 121 (2.8%)                                                                                                                                                                                                             | 387 (5.39)                                                                                                                                                                                                             |
| AmericanIndian orAlaska native                                                                                                                                                                                         | 0                                                                                                                                                                                                                      | 1 (0.1%)                                                                                                                                                                                                               | 1 (-0.1%)                                                                                                                                                                                                              | 0                                                                                                                                                                                                                      | (%10>）1                                                                                                                                                                                                                |
| NativeHawaiian orotherPacificIslander                                                                                                                                                                                  | 0                                                                                                                                                                                                                      | 2 (0.1%)                                                                                                                                                                                                               | 2(0.19)                                                                                                                                                                                                                | 0                                                                                                                                                                                                                      | 2(<0.1%)                                                                                                                                                                                                               |
| Other                                                                                                                                                                                                                  | 29 (3.0%)                                                                                                                                                                                                              | 45 (2.3%)                                                                                                                                                                                                              | 74 (2.5%)                                                                                                                                                                                                              | 99(2.3%)                                                                                                                                                                                                               | 173 (2.4%)                                                                                                                                                                                                             |
| Unknown                                                                                                                                                                                                                | 3(0.3%)                                                                                                                                                                                                                | 4(0.2%)                                                                                                                                                                                                                | 7(0.2%)                                                                                                                                                                                                                | 0                                                                                                                                                                                                                      | 7(0.1%)                                                                                                                                                                                                                |
| Notreported                                                                                                                                                                                                            | 46 (4.8%)                                                                                                                                                                                                              | 20 (1.0%)                                                                                                                                                                                                              | 66(2.2%)                                                                                                                                                                                                               | 0                                                                                                                                                                                                                      | (%60)99                                                                                                                                                                                                                |
| Weight (kg)                                                                                                                                                                                                            |                                                                                                                                                                                                                        |                                                                                                                                                                                                                        |                                                                                                                                                                                                                        |                                                                                                                                                                                                                        |                                                                                                                                                                                                                        |
| N                                                                                                                                                                                                                      | 196                                                                                                                                                                                                                    | 1988                                                                                                                                                                                                                   | 2949                                                                                                                                                                                                                   | 4289                                                                                                                                                                                                                   | 7238                                                                                                                                                                                                                   |
| Mean (SD)                                                                                                                                                                                                              | 73.20 (17.638)                                                                                                                                                                                                         | 72.17 (19.640)                                                                                                                                                                                                         | 72.51 (19.014)                                                                                                                                                                                                         | 91.21(21.908)                                                                                                                                                                                                          | 83.59 (22.717)                                                                                                                                                                                                         |
| Mecian                                                                                                                                                                                                                 | 71.20                                                                                                                                                                                                                  | 69.00                                                                                                                                                                                                                  | 70.00                                                                                                                                                                                                                  | 88.90                                                                                                                                                                                                                  | 81.20                                                                                                                                                                                                                  |
| IQrange                                                                                                                                                                                                                | (60.50;83.50)                                                                                                                                                                                                          | (57.95;82.50)                                                                                                                                                                                                          | (58.50;83.00)                                                                                                                                                                                                          | (76.00;104.00)                                                                                                                                                                                                         | (67.00;96.90)                                                                                                                                                                                                          |
| Range                                                                                                                                                                                                                  | (36.5;177.2)                                                                                                                                                                                                           | (35.0; 184.0)                                                                                                                                                                                                          | (35.0;184.0)                                                                                                                                                                                                           | (37.4; 220.4)                                                                                                                                                                                                          | (35.0;220.4)                                                                                                                                                                                                           |
| Height (cm)                                                                                                                                                                                                            |                                                                                                                                                                                                                        |                                                                                                                                                                                                                        |                                                                                                                                                                                                                        |                                                                                                                                                                                                                        |                                                                                                                                                                                                                        |
| N                                                                                                                                                                                                                      | 961                                                                                                                                                                                                                    | 1988                                                                                                                                                                                                                   | 2949                                                                                                                                                                                                                   | 4287                                                                                                                                                                                                                   | 7236                                                                                                                                                                                                                   |
| Mean (SD)                                                                                                                                                                                                              | 171.69 (9.707)                                                                                                                                                                                                         | 169.70 (9.678)                                                                                                                                                                                                         | 170.35 (9.730)                                                                                                                                                                                                         | 171.74 (9.872)                                                                                                                                                                                                         | 171.17 (9.838)                                                                                                                                                                                                         |
| Median                                                                                                                                                                                                                 | 172.00                                                                                                                                                                                                                 | 169.30                                                                                                                                                                                                                 | 170.00                                                                                                                                                                                                                 | 172.70                                                                                                                                                                                                                 | 171.00                                                                                                                                                                                                                 |
| IQrange                                                                                                                                                                                                                | (165.00;179.00)                                                                                                                                                                                                        | (162.60;176.35)                                                                                                                                                                                                        | (163.00;177.50)                                                                                                                                                                                                        | (165.00;179.00)                                                                                                                                                                                                        | (164.00;178.00)                                                                                                                                                                                                        |
| Range                                                                                                                                                                                                                  | (145.0;205.7)                                                                                                                                                                                                          | (132.6;202.0)                                                                                                                                                                                                          | (132.6;205.7)                                                                                                                                                                                                          | (125.0;208.0)                                                                                                                                                                                                          | (125.0;208.0)                                                                                                                                                                                                          |
| BMI (kg/m²)                                                                                                                                                                                                            |                                                                                                                                                                                                                        |                                                                                                                                                                                                                        |                                                                                                                                                                                                                        |                                                                                                                                                                                                                        |                                                                                                                                                                                                                        |
| N                                                                                                                                                                                                                      | 961                                                                                                                                                                                                                    | 1988                                                                                                                                                                                                                   | 2949                                                                                                                                                                                                                   | 4285                                                                                                                                                                                                                   | 7234                                                                                                                                                                                                                   |
| Mean (SD)                                                                                                                                                                                                              | 24.72(5.103)                                                                                                                                                                                                           | 24.98 (6.218)                                                                                                                                                                                                          | 24.90 (5.878)                                                                                                                                                                                                          | 30.91 (7.026)                                                                                                                                                                                                          | 28.46(7.215)                                                                                                                                                                                                           |
| Median                                                                                                                                                                                                                 | 24.11                                                                                                                                                                                                                  | 23.85                                                                                                                                                                                                                  | 23.95                                                                                                                                                                                                                  | 29.73                                                                                                                                                                                                                  | 27.45                                                                                                                                                                                                                  |
| IQrange                                                                                                                                                                                                                | (21.16;27.46)                                                                                                                                                                                                          | (20.43;28.09)                                                                                                                                                                                                          | (20.74;27.86)                                                                                                                                                                                                          | (26.00;34.72)                                                                                                                                                                                                          | (23.30;32.30)                                                                                                                                                                                                          |

## Adverse events

## Adverse events - Induction study

Through Week 8, 50.0%, 41.4%, and 48.0% of subjects had 1 or more AEs in the ~6 mg/kg, 130 mg, and placebo groups, respectively. Adverse events in the Infections and infestations, and Gastrointestinal (GI) disorders SOCs were most frequently reported. The most frequently reported AE in the Infections and infestations SOC was viral upper respiratory tract infection (5.0%, 4.0% and 2.5% in the ~6 mg/kg, 130 mg and placebo groups, respectively). In the GI disorders SOC, the most frequently reported AEs were ulcerative colitis (2.2%, 2.8%, and 5.6% of subjects, respectively), nausea (2.2%, 2.5%, 1.9% of subjects, respectively), and abdominal pain (1.9%, 2.5%, 2.2% of subjects, respectively).

<div style=\"page-break-after: always\"></div>

Table 14: Number of Subjects with 1 or More Treatment-emergent AdverseEvents withFrequency of ≥2%in AnyGroupThroughWeek8by MedDRAPreferred Term;SafetyAnalysisSet (CNT01275UC03001)

|                                              |             | Ustekinumab IV   | Ustekinumab IV   | Ustekinumab IV   |
|----------------------------------------------|-------------|------------------|------------------|------------------|
|                                              | Placebo IV  | 130 mg           | 6 mg/kg          | Combined         |
| Safety Analysis Set                          | 319         | 321              | 320              | 641              |
| Average duration of follow-up (weeks)        | 8.0         | 8.1              | 8.2              | 8.1              |
| Average exposure (number of administrations) | 1.0         | 1.0              | 1.0              | 1.0              |
| Subjects with 1 or more                      |             |                  |                  |                  |
| treatment-emergent adverse events            | 153 (48.0%) | 133 (41.4%)      | 160 (50.0%)      | 293 (45.7%)      |
| Preferred term                               |             |                  |                  |                  |
| Headache                                     | 14 (4.4%)   | 22 (6.9%)        | 13 (4.1%)        | 35 (5.5%)        |
| Viral upper respiratory tract infection      | 8 (2.5%)    | 13 (4.0%)        | 16 (5.0%)        | 29 (4.5%)        |
| Colitis ulcerative                           | 18 (5.6%)   | 9 (2.8%)         | 7 (2.2%)         | 16 (2.5%)        |
| Anaemia                                      | 11 (3.4%)   | 7 (2.2%)         | 8 (2.5%)         | 15 (2.3%)        |
| Nausea                                       | 6 (1.9%)    | 8 (2.5%)         | 7 (2.2%)         | 15 (2.3%)        |
| Abdominal pain                               | 7 (2.2%)    | 8 (2.5%)         | 6 (1.9%)         | 14 (2.2%)        |
| Fatigue                                      | 5 (1.6%)    | 6 (1.9%)         | 8 (2.5%)         | 14 (2.2%)        |
| Pruritus                                     | 4 (1.3%)    | 8 (2.5%)         | 3 (0.9%)         | 11 (1.7%)        |
| Oropharyngeal pain                           | 1 (0.3%)    | 1 (0.3%)         | 8 (2.5%)         | 9 (1.4%)         |

For analyses of all data through the final safety visit (20 weeks after the last administration of study agent), a subject with an AE was counted in a group based on the study agent the subject was receiving at the time of onset of the event and therefore may be counted in more than 1 column in a table.

<div style=\"page-break-after: always\"></div>

Includes data for the following groups:

- The placebo IV group included subjects randomized to placebo at Week 0.
- o Safety summaries include data:
-  Through the final safety visit, OR
-  Through Week 8 for subjects who were not in clinical response to placebo IV and received ustekinumab ~6 mg/kg IV at Week 8.
- The ustekinumab IV group (~6 mg/kg or 130 mg) included subjects randomized to ustekinumab IV (~6 mg/kg or 130 mg) at Week 0.
- o Safety summaries include data:
-  Through the final safety visit, OR
-  Through Week 8 for subjects who were not in clinical response to ustekinumab IV and received ustekinumab 90 mg SC at Week 8.
- The placebo IV (I-0) → ustekinumab ~6 mg/kg IV (I-8) group (referred to as placebo → ~6 mg/kg, hereafter) included subjects who were not in clinical response to placebo IV and received ustekinumab ~6 mg/kg IV at Week 8.
- o Safety summaries include data from Week 8 through the final safety visit.
- The ustekinumab IV(I-0) → ustekinumab 90 mg SC (I-8) group included subjects who were not in clinical response to ustekinumab IV (~6 mg/kg or 130 mg) and received ustekinumab 90 mg SC at Week 8.
- o Safety summaries include data from Week 8 through the final safety visit.
- The combined ustekinumab IV group included subjects randomized to ustekinumab ~6 mg/kg or 130 mg IV at Week 0, as well as subjects who were not in clinical response to placebo and received ustekinumab ~6 mg/kg IV at Week 8.
- o Safety summaries include data:
-  Through the final safety visit, OR
-  Data from Week 0 to Week 8 for subjects who were not in clinical response to ustekinumab IV and received ustekinumab 90 mg SC at Week 8, OR
-  Data from Week 8 through the final safety visit for subjects who were not in clinical response to placebo IV and received ustekinumab ~6 mg/kg IV at Week 8.
- The all ustekinumab group included subjects who received ustekinumab at any time during the study.
- o Safety summaries include data from the first ustekinumab dose through the final safety visit.

Through the final safety visit, 42.4% of subjects in the combined ustekinumab IV group had 1 or more AEs compared with 48.0% of subjects in the placebo group.

Adverse events in the Infections and infestations, and GI disorders SOCs were most frequently reported and were reported for similar proportions of subjects in both groups (13.7% and 13.2%, and 11.5% and 12.9%, respectively). Viral upper respiratory tract infection was the most frequently reported AE in the

<div style=\"page-break-after: always\"></div>

Infection and infestation SOC (4.4% and 2.5% in the combined ustekinumab IV group and placebo group, respectively). Within the GI disorders SOC, ulcerative colitis was the most frequently reported AE (2.8% and 5.6% in the combined ustekinumab IV group and placebo group, respectively).

Overall, through the final safety visit, the 2 most frequently reported AEs were headache (4.5% and 4.4% in the combined ustekinumab IV group and placebo group, respectively) and viral upper respiratory infection (4.4% and 2.5% in the combined ustekinumab IV group and placebo group, respectively.

## Adverse events - Maintenance study

The company conducted analyses of safety in the maintenance study for the primary population (ie, subjects who were in clinical response to IV ustekinumab induction and were randomised in the maintenance study).  Safety data for subjects who were not in the randomized primary population in UCO3001, including responders to placebo IV induction and delayed responders (ie, subjects who were not in clinical response to ustekinumab at Week 8 of induction but were in clinical response at Week 16 of induction after a SC administration of ustekinumab at Week 8 of the induction study), were summarised separately.

In the maintenance phase the proportions of subjects experiencing a treatment emergent AEs was comparable amongst groups. There was no evidence of a dose effect between the 2 ustekinumab dose groups (78.9% of patients experienced a TEAE in the placebo group versus 69.2% in the ustekinumab 90 mg SC q12w group, and 77.3% in the ustekinumab 90 mg SC q8w group).

The SOCs with the highest proportions of AEs in the combined ustekinumab group during maintenance were Infections and Infestations (48.9% of subjects in the placebo group and 46.8% of subjects in the combined ustekinumab group) and Gastrointestinal Disorders (47.4% of subjects in the placebo group and 39.2% of subjects in the combined ustekinumab group).

Of the 523 subjects who were randomised at maintenance Week 0 and received at least 1 administration of study agent, 1 or more AEs was reported through Week 44 for 77.3%, 69.2%, and 78.9% of subjects in the ustekinumab q8w, ustekinumab q12w, and placebo groups, respectively as summarised in the following table:

<div style=\"page-break-after: always\"></div>

| Table17:                                                 | Summaryof KeySafetyFindingsThroughWeek44byRandomizationStatus;SafetyAnalysisSet(CNTO1275UCO3001)   | Summaryof KeySafetyFindingsThroughWeek44byRandomizationStatus;SafetyAnalysisSet(CNTO1275UCO3001)   | Summaryof KeySafetyFindingsThroughWeek44byRandomizationStatus;SafetyAnalysisSet(CNTO1275UCO3001)   | Summaryof KeySafetyFindingsThroughWeek44byRandomizationStatus;SafetyAnalysisSet(CNTO1275UCO3001)   | Summaryof KeySafetyFindingsThroughWeek44byRandomizationStatus;SafetyAnalysisSet(CNTO1275UCO3001)   | Summaryof KeySafetyFindingsThroughWeek44byRandomizationStatus;SafetyAnalysisSet(CNTO1275UCO3001)   |
|----------------------------------------------------------|----------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------|
|                                                          | Randomized subjects Responders to ustekinumabIVinduction                                           | Randomized subjects Responders to ustekinumabIVinduction                                           | Randomized subjects Responders to ustekinumabIVinduction                                           | Randomized subjects Responders to ustekinumabIVinduction                                           | Non-randomizedsubjects                                                                             | Non-randomizedsubjects                                                                             |
| Safety Analysis Set                                      | Placebo SC* 175                                                                                    | 90mgSCq12w 172                                                                                     | Ustekinumab 90mgSCq8w 176                                                                          | Combined 348                                                                                       | Responders to placeboIV induction Placebo SCb 103                                                  | Delayed responders\" Ustekinumab90 mg SCq8w 157                                                     |
| Avg durationoffollow-up(weeks)                           | 42.3                                                                                               | 41.8                                                                                               | 42.2                                                                                               | 42.0                                                                                               | 40.8                                                                                               | 41.8                                                                                               |
| Avgexposure(mumberofadministrations)                     | 7.1                                                                                                | 7.3                                                                                                | 7.4                                                                                                | 7.4                                                                                                | 6.9                                                                                                | 7.2                                                                                                |
| Subjects who died                                        | 0                                                                                                  | 0                                                                                                  | 0                                                                                                  | 0                                                                                                  | 0                                                                                                  | 1(0.6%)                                                                                            |
| Subjectswithlormore                                      |                                                                                                    |                                                                                                    |                                                                                                    |                                                                                                    |                                                                                                    |                                                                                                    |
| Adverse events                                           | 138(78.9%)                                                                                         | 119 (69.2%)                                                                                        | 136 (77.3%)                                                                                        | 255(73.3%)                                                                                         | 79 (76.7%)                                                                                         | 117 (74.5%)                                                                                        |
| Senous adverseevents                                     | 17 (9.7%)                                                                                          | 13 (7.6%)                                                                                          | 15(8.5%)                                                                                           | 28 (8.0%)                                                                                          | 8(7.8%)                                                                                            | 11 (7.0%)                                                                                          |
| Infections\"                                              | 81 (46.3%)                                                                                         | 58 (33.7%)                                                                                         | 86 (48.9%)                                                                                         | 144 (41.4%)                                                                                        | 44 (42.7%)                                                                                         | 58 (36.9%)                                                                                         |
| Senous Infections                                        | 4 (2.3%)                                                                                           | 6(3.5%)                                                                                            | 3 (1.7%)                                                                                           | 9 (2.6%)                                                                                           | (%6                                                                                                | 2(1.3%)                                                                                            |
| Adverse events leading to discontinuation of study agent | 20 (11.4%)                                                                                         | 9(5.2%)                                                                                            | 5 (2.8%)                                                                                           | 14 (4.0%)                                                                                          | 13 (12.6%)                                                                                         | 12 (7.6%)                                                                                          |
| Malignancies(excludingnonmelanomaskin cancer)            | 0                                                                                                  | 1(0.6%)                                                                                            | 1 (0.6%)                                                                                           | 2(0.6%)                                                                                            | 11.0%                                                                                              | 0                                                                                                  |

Subjectswhowere inclinicalresponse to ustekinumabIVinductiondosing and were randomized toplaceboSConentyinto thismaintenance study.

Subjectswho were not in clinical response to ustekinumab at I-8 butwere n clinical response at I-16 aftera SC administration of ustekinummab at I-8.

Subjectswhowere in clinical response to placebo IV induction dosing andreceived placebo SC on enty into this maintenance study.

Infection as assessed by the investigator.

## Sinusitis

A new non-serious ADR of sinusitis (with a frequency of common [≥1/100 and &lt;1/10]) has been proposed for inclusion in section 4.8 of the SmPC by the company.

## Sinusitis - Induction study

Sinusitis occurred in 1 (0.3%), 5 (1.6%), and 1 (0.3%) of subjects in the ustekinumab ~6 mg/kg, ustekinumab 130 mg, and placebo groups, respectively.

## Sinusitis - Maintenance study

During the placebo controlled period of the UCO3001 maintenance study, sinusitis was reported in 7 (4.0%), 2 (1.2%), and 2 (1.1%) subjects in the ustekinumab q8w, ustekinumab q12w, and placebo groups, respectively, equating to approximate 4.5-fold increase in the number of subjects reporting sinusitis in the combined ustekinumab-treated group (9 subjects) compared with the placebo group (2 subjects). When evaluated in conjunction with Crohn's disease data alone, and in the context of pooled Phase 3 IBD data, as well as pooled results inclusive of psoriatic disease, a less pronounced though similar trend is observed.

<div style=\"page-break-after: always\"></div>

## Extracts of tables TSFAE01B and TSFAE03C which show the frequency of sinusitis are shown below:

TSFAE0lB:Numberof Subjectswith1orMoreTreatinent-EmergentAdverseEventsfromMaintenanceWeek 0ThroughWeek44byMedDRASystem-OrganClass andPreferred Terin;TreatedSubjectsWhoWereRandomizedinInflammatoryBowelDisease(UlcerativeColitisand Crohn'sDisease)Phase3

MaintenanceStudies\"

|                                       | Ulcerative Colitis   | Ulcerative Colitis   | Ulcerative Colitis     | Ulcerative Colitis   | Crohn's Disease\"   | Crohn's Disease\"   | Crohn's Disease\"   | Crohn's Disease\"   | InflammatoryBowelDisease   | InflammatoryBowelDisease   | InflammatoryBowelDisease   | InflammatoryBowelDisease                                                                                                 |
|---------------------------------------|----------------------|----------------------|------------------------|----------------------|--------------------|--------------------|--------------------|--------------------|----------------------------|----------------------------|----------------------------|--------------------------------------------------------------------------------------------------------------------------|
|                                       | Placebo SCb          | 90mgSC q12w          | Ustekinumab 90mgSC q8w | Combined             | Placebo SCb        | q12w               | Ustekinumab 0 q8w  | Combined           | PlaceboSC                  | 90mg SC ql2w               | Ustekinmab 90mgSC q8w      | Combined                                                                                                                 |
| Subjects treated                      | 175                  | 172                  | 176                    | 348                  | 133                | 132                | 131                | 263                | 308                        | 304                        | 307                        | 611                                                                                                                      |
| Avgduation of follow-up(weeks)        | 42.30                | 41.80                | 42.20                  | 42.00                | 31.96              | 36.73              | 35.21              | 35.97              | 37.84                      | 39.60                      | 39.22                      | 39.40                                                                                                                    |
| Avg duration of treatment(weeks)      | 35.30                | 32.53                | 37.29                  | 34.94                | 26.62              | 26.52              | 28.99              | 27.75              | 31.56                      | 29.92                      | 33.75                      | 31.84                                                                                                                    |
| Subjects with lor more adverse events |                      |                      |                        |                      |                    |                    |                    |                    |                            |                            |                            | 138（78.9%)119(69.2%)136(77.3%)255（73.39)111（83.59)106（80.3%)107(81.7%)213(81.0%)249(80.8%)225（74.0%)243（79.2%)468(76.6%) |
| System-organ class/prefened tem       |                      |                      |                        |                      |                    |                    |                    |                    |                            |                            |                            |                                                                                                                          |
| Infections and infestations           | 78 (44.6%)           | 61(35.5%)            | 83(47.2%)              | 144(41.4%)           | 63 (47.4%)         | 61 (46.2%)         | 64(48.9%)          |                    |                            |                            |                            | 125(47.5%)141(45.8%)122(40.1%)147(47.9%)269(44.0%)                                                                       |
| Nasopharyngitis Upper                 | 28 (16.0%)           | 31(18.0%)            | 26 (14.89)             | 57 (16.4%)           | 10 (7.5%)          | 17(12.9%)          | 14 (10.7%)         | 31 (11.8%)         | 38(12.39)                  | 48(15.89)                  | 40(13.0%)                  | 88(14.4%)                                                                                                                |
| respuratory tractinfection            | 8(4.6%)              | 5(2.9%)              | 16 (9.1%)              | 21 (6.0%)            | 21 (15.8%)         | 9 (6.89)           | 13 (9.9%)          | 22 (8.4%)          | 29(9.4%)                   | 14 (4.6%)                  | 29 (9.4%)                  | 43 (7.0%)                                                                                                                |
| Influenza                             | 8 (4.6%)             | 6(3.5%)              | 10 (5.7%)              | 16 (4.6%)            | 4(3.0%)            | 8 (6.1%)           | 5 (3.8%)           | 13 (4.9%)          | 12(3.99)                   | 14 (4.6%)                  | 15 (4.9%)                  | 29(4.7%)                                                                                                                 |
| Gastroenteritis                       | 6(3.4%)              | 5(2.9%)              | 8(4.59%)               | 13 (3.7%)            | 5(3.8%)            | 4(3.0%)            | 43.1%)             | 8(3.0%)            | 11 (3.6%)                  | 9(3.0%)                    | 12(3.9%)                   | 21 (3.4%)                                                                                                                |
| Sinusitis                             | 2 (1.1%)             | 2(1.2%)              | 7(4.0%)                | 9 (2.6%)             | 2(1.5%)            | 6 (4.5%)           | 4(3.1%)            | 10(3.8%)           | 4(1.3%)                    | 8(2.6%)                    | 11 (3.6%)                  | 19 (3.1%)                                                                                                                |
| Bronchitis                            | 6 (3.4%)             | 5 (2.9%)             | (%）9                   | 11 (3.2%)            | 4(3.0%)            | 1 (0.8%)           | (%9)9              | 7 (2.7%)           | 10 (3.2%)                  | 6 (2.0%)                   | 12 (3.9%)                  | 18 (2.9%)                                                                                                                |
| Urinary tact infection                | 4 (2.3%)             | 3 (1.7%)             | 2 (1.1%)               | 5(1.4%)              | 3 (2.39)           | 9 (6.8%)           | 4(3.1%)            | 13 (4.9%)          | 7(2.3%)                    | 12 (3.9%)                  | 6(2.0%)                    | 18 (2.9%)                                                                                                                |
| Gastroenteritis vial                  | 2(1.1%)              | 0                    | 2(1.1%)                | 2 (0.6%)             | 1 (0.8%)           | 5(3.8%)            | 4(3.1%)            | 9(3.4%)            | 3 (1.0%)                   | 5(1.6%)                    | 6 (2.0%)                   | 11 (1.8%)                                                                                                                |
| Pharyngitis                           | 2(1.1%)              | 3 (1.7%)             | 2(1.1%)                | 5(1.4%)              | 1(0.8%)            | 2(1.5%)            | 2(1.5%)            | 4(1.5%)            | 3(1.0%)                    | 5(1.6%)                    | 4(1.39)                    | (%5D6                                                                                                                    |
| Rhinitis                              | 2 (1.1%)             | 2(1.2%)              | 4(2.3%)                | (%LD)9               | 0                  | 0                  | 3(2.3%)            | 3(1.1%)            | 2(0.6%)                    | 2 (0.7%)                   | 7(2.3%)                    | (%5D6                                                                                                                    |
| Vuralinfection                        | 3 (1.7%)             | 2(1.2%)              | 3(1.7%)                | 5(1.4%)              | 1 (0.8%)           | 1 (0.8%)           | (%SD)              | 3 (1.1%)           | 4(1.3%)                    | 3(1.0%)                    | 5 (1.6%)                   | 8(1.3%)                                                                                                                  |
| Vulvovaginal mycotic infection        | 2(1.1%)              | 0                    | 1(0.6%)                | 1(0.3%)              | 1(0.8%)            | 1 (0.8%)           | 4(3.1%)            | 5 (1.9%)           | 3 (1.0%)                   | 1(0.3%)                    | 5 (1.6%)                   | (%0T)9                                                                                                                   |
| Conjunctivitis                        | 1 (0.6%)             | 0                    | 2(1.19)                | 2(0.6%)              | 0                  | 3(2.3%)            | 0                  | 3 (1.1%)           | 1(0.3%)                    | 3(1.0%)                    | 2(0.7%)                    | 5(0.8%)                                                                                                                  |

<div style=\"page-break-after: always\"></div>

TSFAE03C:NunberofSubjectswith1orMoreTreatnent-EmergentAdverseEventsPerHundredSubject-YearsofFollow-UponInduction andMaintenanceTherapy(Upto52WeeksTotal')byMfedDRASystem-OrganClassandPreferredTerim;TreatedSubjectsWho Were Randomized in InflammatoryBowel Disease (Ulcerative Colitis and Crohn's Disease)Phase 3 Maintenance Studiesb

|                                                             | Ulcerative Colithis     | Ulcerative Colithis     | Ulcerative Colithis     | Ulcerative Colithis     | Ctohn'sDisease\"         | Ctohn'sDisease\"         | Ctohn'sDisease\"         | Ctohn'sDisease\"         | InflannmatoryBowel Disease   | InflannmatoryBowel Disease   | InflannmatoryBowel Disease   | InflannmatoryBowel Disease   |
|-------------------------------------------------------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|------------------------------|------------------------------|------------------------------|------------------------------|
|                                                             |                         | Ustekinumab Maintenance | Ustekinumab Maintenance | Ustekinumab Maintenance |                         | Ustekinumab Maintenance | Ustekinumab Maintenance | Ustekinumab Maintenance |                              | Ustekinumab Maintenance      | Ustekinumab Maintenance      | Ustekinumab Maintenance      |
|                                                             | Placebo SCMain tenanced | ql2w                    | 90mgSC90mgSC            | Combined                | Placebo SCMain tenance\" | 90mgSC90mgSC ql2w       | q8w                     | Combined                | Placebo SCMain tenance\"      | ql2w                         | 90mgSC90mgSC q8w             | Combined                     |
| Subjects treated                                            | 175                     | 172                     | 176                     | 348                     | 133                     | 132                     | 131                     | 263                     | 308                          | 304                          | 307                          | 611                          |
| Avgduation of                                               |                         |                         |                         |                         |                         |                         |                         |                         |                              |                              |                              |                              |
| follow-up (weeks)                                           | 52.73                   | 52.18                   | 52.56                   | 52.37                   | 40.10                   | 44.85                   | 43.27                   | 44.06                   | 47.27                        | 49.00                        | 48.60                        | 48.80                        |
| Avgduation of treatment (weeks)                             | 45.73                   | 40.70                   | 45.43                   | 43.09                   | 34.75                   | 34.64                   | 37.06                   | 35.85                   | 40.99                        | 38.07                        | 41.86                        | 39.97                        |
| Total subject-years of follow-up                            | 177                     | 173                     | 178                     | 350                     | 103                     | 114                     | 109                     |                         | 280                          | 286                          | 287                          | 573                          |
| Number of subjects with adverse events                      | 144                     | 130                     | 148                     | 278                     | 115                     | 115                     | 116                     | 231                     | 259                          | 245                          | 264                          | 509                          |
| Number of subjects with adverse events per 100subject-years | 81.15                   | 75.32                   | 83.19                   | 79.32                   | 112.14                  | 101.02                  | 106.41                  | 103.65                  | 92.50                        | 85.53                        | 92.01                        | 88.78                        |
| System-organ class/prefered teim                            |                         |                         |                         |                         |                         |                         |                         |                         |                              |                              |                              |                              |
| Infections and                                              |                         |                         |                         |                         |                         |                         |                         |                         |                              |                              |                              |                              |
| infestations                                                | 52.97                   | 40.56                   | 51.15                   | 45.94                   | 73.13                   | 63.25                   | 72.47                   | 67.76                   | 60.36                        | 49.57                        | 59.25                        | 54.42                        |
| Nasopharyngitis                                             | 21.42                   | 19.12                   | 17.43                   | 18.26                   | 11.70                   | 19.33                   | 15.59                   | 17.50                   | 17.86                        | 19.20                        | 16.73                        | 17.96                        |
| Upperrespiratory tractinfection                             | 5.07                    | 4.06                    | 8.99                    | 6.56                    | 25.35                   | 12.30                   | 12.84                   | 12.56                   | 12.50                        | 7.33                         | 10.46                        | 8.90                         |
| Influenza                                                   | 4.51                    | 4.06                    | 5.62                    | 4.85                    | 5.85                    | 7.03                    | 6.42                    | 6.73                    | 5.00                         | 5.24                         | 5.93                         | 5.58                         |
| Gastroentenitis                                             | 3.38                    | 4.64                    | 4.50                    | 4.56                    | 4.88                    | 5.27                    | 4.59                    | 4.94                    | 3.93                         | 4.89                         | 4.53                         | 4.71                         |
| Bronchitis                                                  | 3.94                    | 2.90                    | 5.06                    | 3.99                    | 4.88                    | 2.64                    | 6.42                    | 4.49                    | 4.29                         | 2.79                         | 5.58                         | 4.19                         |
| Sinusitis                                                   | 1.69                    | 1.74                    | 5.06                    | 3.42                    | 4.88                    | 5.27                    | 5.50                    | 5.38                    | 2.86                         | 3.14                         | 5.23                         | 4.19                         |
| Urinarytract infection                                      | 2.82                    | 1.74                    | 1.69                    | 1.71                    | 3.90                    | 8.78                    | 4.59                    | 6.73                    | 3.21                         | 4.54                         | 2.79                         | 3.66                         |
| Gastroentenitis                                             |                         |                         |                         |                         |                         |                         |                         |                         |                              |                              |                              |                              |
| vial                                                        | 1.13                    | 0.58                    | 1.12                    | 0.86                    | 1.95                    | 4.39                    | 3.67                    | 4.04                    | 1.43                         | 2.09                         | 2.09                         | 2.09                         |

<div style=\"page-break-after: always\"></div>

## Serious adverse event/deaths/other significant events

Through Week 8, 3.1%, 3.7%, and 6.6% of subjects reported 1 or more SAEs in the ~6 mg/kg, 130 mg, and placebo groups, respectively. Serious AEs in the GI disorders SOC were the most frequently reported (1.6%, 1.2% and 4.1% in the ~6 mg/kg and 130 mg and placebo groups, respectively). Ulcerative colitis was the most frequently reported SAE in this SOC (0.9%, 1.2% and 3.4%, respectively). Except for ulcerative colitis, most SAEs were reported for only 1 subject each with the exception of the following SAEs that were reported for 2 subjects each of hyperventilation (2 subjects in the 130 mg group) and Deep vein thrombosis (DVT, 2 subjects in the ~6 mg/kg group)

Through the final safety visit, 3.6% of subjects in the combined ustekinumab IV group and 6.9% of subjects in the placebo group reported SAEs. In both groups, the most frequently reported SAEs were in the GI disorders SOC (1.8% and 4.1%, respectively); ulcerative colitis was the most frequently reported SAE in this SOC (1.6% and 3.4%, respectively).

<div style=\"page-break-after: always\"></div>

TSFAEo4B: Number of subjects with 1 or more treatment-emergent serious adverse events through the final safety visit by MedDRA system-organ class and preferred term; Safety Analysis Set

| Ustekinumb IV a                            | Ustekinumb IV a   | Ustekinumb IV a   | Ustekinumb IV a   | Ustekinumb IV a   | Ustekinumb IV a                                    | Ustekinumb IV a                                    | Ustekinumb IV a           | Ustekinumb IV a   |
|--------------------------------------------|-------------------|-------------------|-------------------|-------------------|----------------------------------------------------|----------------------------------------------------|---------------------------|-------------------|
|                                            | Placebo IV a      | 130 mg            | 6 mg/kg           | Combined          | Placebo IV (1-0)→ Ustekinumab 6 mg/kg IV (I-8) b,c | Ustekinumab IV (1-0)→ Ustekinumab 90 mg SC (I-8) c | Combined Ustekinumab IV d | All Ustekinumab e |
| Safety Analysis Set                        | 319               | 321               | 320               | 641               | 184                                                | 233                                                | 825                       | 825               |
| Average duration of follow-up (weeks)      | 8.7               | 8.6               | 8.6               | 8.6               | 10.2                                               | 11.5                                               | 8.9                       | 12.2              |
| Averageexposure(numberof administrations)  | 1.0               | 1.0               | 1.0               | 1.0               | 1.0                                                | 1.0                                                | 1.0                       | 1.3               |
| Subjectswith 1ormoreserious adverse events | 22 (6.9%)         | 12 (3.7%)         | 11 (3.4%)         | 23 (3.6%)         | 7 (3.8%)                                           | 12 (5.2%)                                          | 30 (3.6%)                 | 41 (5.0%)         |
| System-organ class/preferred term          |                   |                   |                   |                   |                                                    |                                                    |                           |                   |
| Gastrointestinal disorders                 | 13 (4.1%)         | 4 (1.2%)          | 6 (1.9%)          | 10 (1.6%)         | 5 (2.7%)                                           | 6 (2.6%)                                           | 15 (1.8%)                 | 21 (2.5%)         |
| Colitis ulcerative                         | 11 (3.4%)         | 4 (1.2%)          | 4 (1.3%)          | 8 (1.2%)          | 5 (2.7%)                                           | 4 (1.7%)                                           | 13 (1.6%)                 | 17 (2.1%)         |
| Abdominal pain                             | 0                 | 0                 | 1 (0.3%)          | 1 (0.2%)          | 0                                                  | 0                                                  | 1 (0.1%)                  | 1 (0.1%)          |
| Colon dysplasia                            | 0                 | 0                 | 0                 | 0                 | 0                                                  | 1 (0.4%)                                           | 0                         | 1 (0.1%)          |
| Diarrhoea haemorrhagic                     | 0                 | 0                 | 1 (0.3%)          | 1 (0.2%)          | 0                                                  | 0                                                  | 1 (0.1%)                  | 1 (0.1%)          |
| Large intestine polyp                      | 0                 | 0                 | 0                 | 0                 | 0                                                  | 1 (0.4%)                                           | 0                         | 1 (0.1%)          |
| Oesophageal varices haemorrhage            | 0                 | 0                 | 1 (0.3%)          | 1 (0.2%)          | 0                                                  | 0                                                  | 1 (0.1%)                  | 1 (0.1%)          |
| Anal fissure                               | 1 (0.3%)          | 0                 | 0                 | 0                 | 0                                                  | 0                                                  | 0                         | 0                 |
| Large intestine perforation                | 1 (0.3%)          | 0                 | 0                 | 0                 | 0                                                  | 0                                                  | 0                         | 0                 |
| Infections and infestations                | 4 (1.3%)          | 2 (0.6%)          | 0                 | 2 (0.3%)          | 3 (1.6%)                                           | 2 (0.9%)                                           | 5 (0.6%)                  | 7 (0.8%)          |
| Gastroenteritis                            | 0                 | 1 (0.3%)          | 0                 | 1 (0.2%)          | 0                                                  | 1 (0.4%)                                           | 1 (0.1%)                  | 2 (0.2%)          |
| Pneumonia                                  | 0                 | 1 (0.3%)          | 0                 | 1 (0.2%)          | 1 (0.5%)                                           | 0                                                  | 2 (0.2%)                  | 2 (0.2%)          |
| Gastroenteritissalmonella                  | 0                 | 0                 | 0                 | 0                 | 1 (0.5%)                                           | 0                                                  | 1 (0.1%)                  | 1 (0.1%)          |
| Pneumonialegionella                        | 0                 | 0                 | 0                 | 0                 | 1 (0.5%)                                           | 0                                                  | 1 (0.1%)                  | 1 (0.1%)          |
| Pyelonephritis                             | 0                 | 0                 | 0                 | 0                 | 0                                                  | 1 (0.4%)                                           | 0                         | 1 (0.1%)          |
| Anal abscess                               | 1 (0.3%)          | 0                 | 0                 | 0                 | 0                                                  | 0                                                  | 0                         | 0                 |
| Clostridiumdifficileinfection              | 1 (0.3%)          | 0                 | 0                 | 0                 | 0                                                  | 0                                                  | 0                         | 0                 |
| Hepatitis C                                | 1 (0.3%)          | 0                 | 0                 | 0                 | 0                                                  | 0                                                  | 0                         | 0                 |
| Subcutaneous abscess                       | 1 (0.3%)          | 0                 | 0                 | 0                 | 0                                                  | 0                                                  | 0                         | 0                 |

<div style=\"page-break-after: always\"></div>

system-organ class and preferred term; Safety Analysis Set

|                                                            | Placebo IV a   | 130 mg   | 6 mg/kg b   | Combined   | Placebo IV (1-0)→ Ustekinumab 6 mg/kg IV (I-8) b,c   | Ustekinumab IV (1-0)→ Ustekinumab 90 mg SC (I-8) c   | Combined Ustekinumab IVd   | All Ustekinumab e   |
|------------------------------------------------------------|----------------|----------|-------------|------------|------------------------------------------------------|------------------------------------------------------|----------------------------|---------------------|
| Renal and urinary disorders                                | 0              | 1 (0.3%) | 1 (0.3%)    | 2 (0.3%)   | 1 (0.5%)                                             | 2 (0.9%)                                             | 3 (0.4%)                   | 5 (0.6%)            |
| Nephrolithiasis                                            | 0              | 1 (0.3%) | 0           | 1 (0.2%)   | 1 (0.5%)                                             | 1 (0.4%)                                             | 2 (0.2%)                   | 3 (0.4%)            |
| Ureterolithiasis                                           | 0              | 0        | 1 (0.3%)    | 1 (0.2%)   | 0                                                    | 0                                                    | 1 (0.1%)                   | 1 (0.1%)            |
| Urinary incontinence                                       | 0              | 0        | 0           | 0          | 0                                                    | 1 (0.4%)                                             | 0                          | 1 (0.1%)            |
| Respiratory, thoracic and mediastinal disorders            | 1 (0.3%)       | 2 (0.6%) | 1 (0.3%)    | 3 (0.5%)   | 0                                                    | 1 (0.4%)                                             | 3 (0.4%)                   | 4 (0.5%)            |
| Hyperventilation                                           | 0              | 2 (0.6%) | 0           | 2 (0.3%)   | 0                                                    | 0                                                    | 2 (0.2%)                   | 2 (0.2%)            |
| Pulmonary embolism                                         | 0              | 0        | 1 (0.3%)    | 1 (0.2%)   | 0                                                    | 0                                                    | 1 (0.1%)                   | 1 (0.1%)            |
| Pulmonary eosinophilia                                     | 0              | 0        | 0           | 0          | 0                                                    | 1 (0.4%)                                             | 0                          | 1 (0.1%)            |
| Pleurisy                                                   | 1 (0.3%)       | 0        | 0           | 0          | 0                                                    | 0                                                    | 0                          | 0                   |
| Nervous system disorders                                   | 2 (0.6%)       | 1 (0.3%) | 1 (0.3%)    | 2 (0.3%)   | 0                                                    | 1 (0.4%)                                             | 2 (0.2%)                   | 3 (0.4%)            |
| Aphasia                                                    | 0              | 1 (0.3%) | 0           | 1 (0.2%)   | 0                                                    | 0                                                    | 1 (0.1%)                   | 1 (0.1%)            |
| Cognitive disorder                                         | 0              | 1 (0.3%) | 0           | 1 (0.2%)   | 0                                                    | 0                                                    | 1 (0.1%)                   | 1 (0.1%)            |
| Migraine                                                   | 0              | 0        | 1 (0.3%)    | 1 (0.2%)   | 0                                                    | 0                                                    | 1 (0.1%)                   | 1 (0.1%)            |
| Motor dysfunction                                          | 0              | 1 (0.3%) | 0           | 1 (0.2%)   | 0                                                    | 0                                                    | 1 (0.1%)                   | 1 (0.1%)            |
| Presyncope                                                 | 0              | 0        | 0           | 0          | 0                                                    | 1 (0.4%)                                             | 0                          | 1 (0.1%)            |
| Epilepsy                                                   | 1 (0.3%)       | 0        | 0           | 0          | 0                                                    | 0                                                    | 0                          | 0                   |
| Ischaemic stroke                                           | 1 (0.3%)       | 0        | 0           | 0          | 0                                                    | 0                                                    | 0                          | 0                   |
| Neoplasmsbenign, malignant and unspecified (incl cysts and | 0              | 0        | 0           | 0          | 0                                                    | 2 (0.9%)                                             | 0                          | 2 (0.2%)            |
| polyps) Prostate cancer                                    | 0              | 0        | 0           | 0          | 0                                                    | 1 (0.4%)                                             | 0                          | 1 (0.1%)            |
| Rectal adenocarcinoma                                      | 0              | 0        | 0           | 0          | 0                                                    | 1 (0.4%)                                             | 0                          | 1 (0.1%)            |
| Skin and subcutaneous tissue                               |                |          |             |            |                                                      |                                                      |                            |                     |
| disorders                                                  | 1 (0.3%)       | 1 (0.3%) | 1 (0.3%)    | 2 (0.3%)   | 0                                                    | 0                                                    | 2 (0.2%)                   | 2 (0.2%)            |
| Pyoderma gangrenosum                                       | 1 (0.3%)       | 0        | 1 (0.3%)    | 1 (0.2%)   | 0                                                    | 0                                                    | 1 (0.1%)                   | 1 (0.1%)            |
| Rash                                                       | 0              | 1 (0.3%) | 0           | 1 (0.2%)   | 0                                                    | 0                                                    | 1 (0.1%)                   | 1 (0.1%)            |
| Vascular disorders                                         | 0              | 0        | 2 (0.6%)    | 2 (0.3%)   | 0                                                    | 1 (0.4%)                                             | 2 (0.2%)                   | 2 (0.2%)            |
| Deep vein thrombosis                                       | 0              | 0        | 2 (0.6%)    | 2 (0.3%)   | 0                                                    | 1 (0.4%)                                             | 2 (0.2%)                   | 2 (0.2%)            |
| Blood and lymphatic system                                 |                |          |             |            |                                                      |                                                      |                            |                     |
| disorders                                                  | 0              | 1 (0.3%) | 0           | 1 (0.2%)   | 0                                                    | 0                                                    | 1 (0.1%)                   | 1 (0.1%)            |

<div style=\"page-break-after: always\"></div>

TSFAE04B: Number of subjects with 1 or more treatment-emergent serious adverse events through the final safety visit by MedDRA system-organ class and preferred term; Safety Analysis Set

|                                                | Ustekinumb IV a   | Ustekinumb IV a   | Ustekinumb IV a   | Ustekinumb IV a   | Ustekinumb IV a                                    | Ustekinumb IV a                                  | Ustekinumb IV a          | Ustekinumb IV a   |
|------------------------------------------------|-------------------|-------------------|-------------------|-------------------|----------------------------------------------------|--------------------------------------------------|--------------------------|-------------------|
|                                                | Placebo IV a      | 130 mg            | 6 mg/kg           | Combined          | Placebo IV (1-0)→ Ustekinumab 6 mg/kg IV (I-8) b,c | Ustekinumab IV (1-0)→ Ustekinumab 90 mg SC (8-1) | Combined Ustekinumab IVd | All Ustekinumab e |
| Autoimmune haemolytic anaemia                  | 0                 | 1 (0.3%)          | 0                 | 1 (0.2%)          | 0                                                  | 0                                                | 1 (0.1%)                 | 1 (0.1%)          |
| Injury, poisoning and procedural complications | 2 (0.6%)          | 0                 | 1 (0.3%)          | 1 (0.2%)          | 0                                                  | 0                                                | 1 (0.1%)                 | 1 (0.1%)          |
| Ankle fracture                                 | 0                 | 0                 | 1 (0.3%)          | 1 (0.2%)          | 0                                                  | 0                                                | 1 (0.1%)                 | 1 (0.1%)          |
| Limb injury                                    | 1 (0.3%)          | 0                 | 0                 | 0                 | 0                                                  | 0                                                | 0                        | 0                 |
| Proceduralintestinal perforation               | 1 (0.3%)          | 0                 | 0                 | 0                 | 0                                                  | 0                                                | 0                        | 0                 |
| Ear and labyrinth disorders                    | 1 (0.3%)          | 0                 | 0                 | 0                 | 0                                                  | 0                                                | 0                        | 0                 |
| Sudden hearing loss                            | 1 (0.3%)          | 0                 | 0                 | 0                 | 0                                                  | 0                                                | 0                        | 0                 |
| Immune system disorders                        | 1 (0.3%)          | 0                 | 0                 | 0                 | 0                                                  | 0                                                | 0                        | 0                 |
| Anaphylacticreaction                           | 1 (0.3%)          | 0                 | 0                 | 0                 | 0                                                  | 0                                                | 0                        | 0                 |

[TSFAE04B.RTF] [/SAS/2709/CNTO1275UCO3001/FILES/RE/CSRINDUCTIONFINAL/PR0GRAMS/TSFAE04B.SAS]06FEB2018,05:19

e From the first ustekinumab dose onward.

<div style=\"page-break-after: always\"></div>

## Serious adverse events - Maintenance study

In randomised patients, serious AEs were reported in 8.5%, 7.6%, and 9.7% of subjects in the ustekinumab q8w, ustekinumab q12w, and placebo groups, respectively. Ulcerative colitis was the most commonly reported SAE across these randomized treatment groups, in 2 (1.1%), 1 (0.6%), and 8 (4.6%) subjects in the ustekinumab q8w, ustekinumab q12w, and placebo groups.

The next most commonly reported SAEs (ie, reported for 2 ustekinumab-treated subjects each) were:

- Cytomegalovirus colitis (2 subjects in the ustekinumab q12w group)
- Spontaneous abortion (2 subjects in the ustekinumab q8w group)
- Diverticulitis (1 subject each in the ustekinumab q8w and q12w groups)
- Anaemia (2 subjects in the ustekinumab q12w group)

<div style=\"page-break-after: always\"></div>

## Results are shown below:

TSFSAEOIB: NumberofSubjectswithIorMoreTreatnent-EmergentSeriousAdverseEventsfroinMaintenanceWeek0ThroughWeek4byMedDRA System-OrganClass andPreferred Term;TreatedSubjectsWhoWereRandomized inInflammatoryBowel Disease(Ulcerative Colitisand Crohn'sDisease) Phase 3MfaintenanceStudies

|                                                    | Ulcerative Colitis   | Ulcerative Colitis   | Ulcerative Colitis   | Ulcerative Colitis   | Crohn's Disease\"   | Crohn's Disease\"   | Crohn's Disease\"       | Crohn's Disease\"   | InflammatoryBowel Disease   | InflammatoryBowel Disease   | InflammatoryBowel Disease   | InflammatoryBowel Disease   |
|----------------------------------------------------|----------------------|----------------------|----------------------|----------------------|--------------------|--------------------|------------------------|--------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|
|                                                    | Placebo SC           | 90mgSC q12w          | Ustekinumab q8w      | Combined             | Placebo SC         | 90mgSC q12w        | Ustekinumab 90mgSC q8w | Combined           | Placebo SC                  | 90mgSC q12w                 | Ustekinumab 90mgSC q8w      | Combined                    |
| Subjects treated                                   | 175                  | 172                  | 176                  | 348                  | 133                | 132                | 131                    | 263                | 308                         | 304                         | 307                         | 119                         |
| Avgduration of follow-up (syoam)                   | 42.30                | 41.80                | 42.20                | 42.00                | 31.96              | 36.73              | 35.21                  | 35.97              | 37.84                       | 39.60                       | 39.22                       | 39.40                       |
| Avg duration of treatment (weeks)                  | 35.30                | 32.53                | 37.29                | 34.94                | 26.62              | 26.52              | 28.99                  | 27.75              | 31.56                       | 29.92                       | 33.75                       | 31.84                       |
| Subjectswith 1or more serious adverseevents        | 17 (9.7%)            | 13 (7.6%)            | 15 (8.5%)            | 28 (8.0%)            | 20 (15.0%)         | 16(12.1%)          | 13(9.9%)               |                    | 29(11.0%)37(12.0%)          | 29(9.5%)                    | 28 (9.1%)                   | 57(9.3%)                    |
| System-organ class/preferred tenm Gastrointestinal |                      |                      |                      |                      |                    |                    |                        |                    |                             |                             |                             |                             |
| disorders                                          | 11 (6.3%)            | 4(2.3%)              | 4(2.3%)              | 8(2.3%)              | 11(8.3%)           | 6(4.5%)            | 8(6.1%)                | 14 (5.3%)          | 22(7.1%)                    | 10 (3.3%)                   | 12(3.9%)                    | 22(3.6%)                    |
| Crohn's disease                                    | 0                    | 0                    | 0                    | 0                    | 7(5.3%)            | 5(3.8%)            | 4(3.1%)                | 9(3.4%)            | 7(2.3%)                     | 5(1.6%)                     | 4(1.3%)                     | 9(1.5%)                     |
| Colitis ulcerative                                 | 8(4.6%)              | 1 (0.6%)             | 2(1.1%)              | 3 (0.9%)             | 0                  | 0                  | 0                      | 0                  | 8(2.6%)                     | 1(0.3%)                     | 2 (0.7%)                    | 3 (0.5%)                    |
| Large intestinal stenosis                          | 0                    | 0                    | 0                    | 0                    | 0                  | 0                  | 2 (1.5%)               | 2(0.8%)            | 0                           | 0                           | 2 (0.7%)                    | 2 (0.39)                    |
| Small intestinal                                   | 0                    | 0                    | 0                    | 0                    | 0                  | 1 (0.8%)           | 1(0.8%)                | 2(0.8%)            | 0                           | 1(0.3%)                     | 1 (0.3%)                    | 2(0.3%)                     |
| obstruction Abdominal pain                         | 1(0.6%)              | 0                    | 0                    | 0                    | 0                  | 0                  | 1(0.8%)                | 1(0.4%)            | 1(0.3%)                     | 0                           | 1 (0.3%)                    | 1 (0.2%)                    |
| Enteritis                                          | 0                    | 1 (0.6%)             | 0                    | 1(0.3%)              | 0                  | 0                  | 0                      | 0                  | 0                           | 1 (0.3%)                    | 0                           | 1 (0.2%)                    |
| Enterovesical fistula                              | 0                    | 0                    | 1(0.6%)              | 1 (0.3%)             | 1 (0.8%)           | 0                  | 0                      | 0                  | 1(0.3%)                     | 0                           | 1 (0.3%)                    | 1 (0.2%)                    |
| Large intestinal obstuction                        | 0                    | 0                    | 0                    | 0                    | 0                  | 0                  | 1(0.8%)                | 1(0.4%)            | 0                           | 0                           | 1 (0.39)                    | 1(0.2%)                     |
| Lumbar henmia                                      | 0                    | 1 (0.6%)             | 0                    | 1(0.3%)              | 0                  | 0                  | 0                      | 0                  | 0                           | 1 (0.3%)                    | 0                           | 1(0.2%)                     |
| Mesentenic fibrosis                                | 0                    | 1(0.6%)              | 0                    | 1(0.3%)              | 0                  | 0                  | 0                      | 0                  |                             | 1 (0.3%)                    | 0                           | 1(0.2%)                     |
| Vomiting                                           | 0                    | 0                    | 1(0.6%)              | 1 (0.3%)             | 0                  | 0                  | 0                      | 0                  |                             | 0                           | 1 (0.3%)                    | 1 (0.2%)                    |
| Abdominal painupper                                | 1 (0.6%)             | 0                    | 0                    | 0                    | 0                  | 0                  | 0                      | 0                  | 1(0.3%)                     | 0                           | 0                           | 0                           |
| Anal fistula                                       | 0                    | 0                    | 0                    | 0                    | 2(1.5%)            | 0                  |                        | 0                  | 2 (0.69)                    | 0                           | 0                           | 0                           |
| Anorectal disorder                                 | 1 (0.6%)             | 0                    | 0                    | 0                    | 0                  | 0                  | 0 0                    | 0                  | 1 (0.3%)                    | 0                           | 0                           | 0                           |
| Colon dysplasia                                    | 1(0.6%)              | 0                    | 0                    | 0                    | 0                  | 0                  | 0                      | 0                  | 1(0.3%)                     | 0                           | 0                           | 0                           |

<div style=\"page-break-after: always\"></div>

TSFSAE0IB:1 NunberofSubjectswith1orMforeTreatment-EmergentSeriousAdverseEventsfromMaintenanceWeek0ThroughWeek4byMedDRA System-OrganClassandPreferredTerin;Treated SubjectsWhoWereRandomized inInflainmatoryBowel Disease(Ulcerative Colitisand Crohn'sDisease) Phase3MaintenanceStudies

|                                                       | Ulcerative Colitis   | Ulcerative Colitis   | Ulcerative Colitis    | Crohn's Disease\"   | Crohn's Disease\"   | Crohn's Disease\"   | Crohn's Disease\"   | InflammatoryBowel Disease   | InflammatoryBowel Disease   | InflammatoryBowel Disease   | InflammatoryBowel Disease   |
|-------------------------------------------------------|----------------------|----------------------|-----------------------|--------------------|--------------------|--------------------|--------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|
|                                                       | Placebo SC           | 90mgSC ql2w          | Ustekinmab 90mgSC q8w | Combined           | Placebo SC         | 90mgSC q12w        | Ustekinumab 06 q8w | Combined Placebo SC         | 90mgSC q12w                 | Ustekinumab 90mgSC qSw      | Combined                    |
| Large intestine perforation                           | 0                    | 0                    | 0                     | 0                  | 1 (0.8%)           | 0                  | 0                  | 0 1 (0.3%)                  | 0                           | 0                           | 0                           |
| Infections and imfestations                           | 4(2.3%)              | 5(2.9%)              | 4(2.3%)               | 9 (2.6%)           | 3(2.3%)            | 7(5.3%)            | 3(2.3%)            | 10 (3.8%) 7(2.3%)           | 12(3.9%)                    | 7 (2.3%)                    | 19(3.1%)                    |
| Appendicitis                                          | 1 (0.6%)             | 0                    | 0                     | 0                  | 0                  | 2(1.5%)            | 0                  | 2(0.8%) 1(0.3%)             | 2 (0.7%)                    | 0                           | 2(0.3%)                     |
| Cytomegalovius colitis                                | 0                    | 2 (1.2%)             | 0                     | 2 (0.6%)           |                    | 0                  | 0                  | 0 0                         | 2(0.7%)                     | 0                           | 2 (0.3%)                    |
| Diverticulitis                                        | 0                    | 1 (0.6%)             | 1 (0.6%)              | 2 (0.6%)           | 0                  | 0                  | 0                  | 0 0 1 (0.4%)                | 1(0.3%)                     | 1 (0.3%)                    | 2(0.3%)                     |
| Gastroenteritis                                       | 1(0.6%)              | 0                    | 1 (0.6%)              | 1 (0.39)           | 0                  | 1 (0.8%)           | 0                  | 1(0.3%)                     | 1(0.3%)                     | 1 (0.3%)                    | 2(0.3%)                     |
| Abdominal infection                                   | 0                    | 0                    | 0                     | 0                  | 0                  | 1(0.8%)            | 0                  | 0                           | 1 (0.3%)                    | 0                           | 1(0.2%)                     |
| Anal abscess                                          | 1(0.6%)              | 0                    | 0                     | 0                  | 1 (0.8%)           | 1(0.8%)            | 0                  | 1(0.4%) 1 (0.4%) 1 (0.4%)   | 1(0.3%)                     | 0                           | 1(0.2%)                     |
| Bacteraemia                                           | 0                    | 0                    | 0                     | 0                  | 0                  | 1 (0.8%)           | 0                  | 2(0.69) 0                   | 1 (0.3%)                    | 0                           | 1 (0.2%)                    |
| Canpylobacter gastoententis                           | 0                    | 0                    | 0                     | 0                  | 0                  | 1(0.8%)            | 0                  | 1 (0.4%) 0                  | 1 (0.3%)                    | 0                           | 1(0.2%)                     |
| Gastroenteritisviral                                  | 0                    | 0                    | 0                     | 0                  | 0                  | 1(0.8%)            | 0                  | 1(0.4%) 0                   | 1 (0.3%)                    | 0                           | 1(0.2%)                     |
| Influenza                                             | 0                    | 1 (0.6%)             | 0                     | 1 (0.3%)           | 0                  | 0                  | 0                  | 0 0                         | 1 (0.3%)                    | 0                           | 1(0.2%)                     |
| Ophthalnic herpes zoster                              | 0                    | 0                    | 0                     | 0                  | 0                  | 0                  | 1 (0.8%)           | 1(0.4%) 0                   | 0                           | 1 (0.3%)                    | 1(0.2%)                     |
| Periorbital cellulitis                                | 0                    | 0                    | 1 (0.6%)              | 1 (0.3%)           | 0                  | 0                  | 0                  | 0 0                         | 0                           | 1 (0.3%)                    | 1(0.2%)                     |
| Pneumonia                                             | 0                    | 0                    | 0                     | 0                  | 2(1.5%)            | 0                  | 1(0.8%)            | 1(0.4%) 2(0.6%)             | 0                           | 1 (0.3%)                    | 1(0.2%)                     |
| Postoperative wound infection                         | 0                    | 0                    | 0                     | 0                  | 0                  | 1(0.8%)            | 0                  | 1(0.4%) 0                   | 1(0.3%)                     | 0                           | 1(0.2%)                     |
| Pyelonephnitis                                        | 0                    | 1 (0.6%)             | 0                     | 1(0.3%)            | 0                  | 0                  | 0                  | 0 0                         | 1 (0.3%)                    | 0                           | 1(0.2%)                     |
| Salpingitis                                           | 0                    | 0                    | 1 (0.6%)              | 1(0.3%)            | 0                  | 0                  | 0                  | 0 0                         | 0                           | 1 (0.3%)                    | 1(0.2%)                     |
| Vural infection                                       | 0                    | 0                    | 0                     | 0                  | 0                  | 0                  | 1(0.8%)            | 1(0.4%)                     | 0                           | 1 (0.3%)                    | 1(0.2%)                     |
| Pharyngeal abscess                                    | 1(0.6%)              | 0                    | 0                     | 0                  | 0                  | 0                  | 0                  | 0 0 1 (0.3%)                | 0                           | 0                           | 0                           |
| Neoplasms benign, maligmant and uspecified(incl cysts |                      |                      |                       |                    |                    |                    |                    |                             |                             |                             |                             |
| (sdkyod pue                                           | 1(0.6%)              | (%)                  | 2(1.1%)               | 4(1.1%)            | 1(0.8%)            | 0                  | 1 (0.8%)           | 1 (0.4%) 2(0.6%)            | 2 (0.7%)                    | 3 (1.0%)                    | 5(0.8%)                     |
| Colon cancer                                          | 0                    | 0                    | 1 (0.6%)              | 1 (0.3%)           | 0                  | 0                  | 0                  | 0 0                         | 0                           | 1 (0.3%)                    | 1(0.2%)                     |
| Intraductalpapilloma ofbreast                         | 0                    | 1 (0.6%)             | 0                     | 1 (0.3%)           | 0                  | 0                  | 0                  | 0 0                         | 1 (0.3%)                    | 0                           | 1 (0.2%)                    |
| Ovanian adenoma                                       | 1 (0.6%)             | 0                    | 0                     | 0                  | 0                  | 0                  | 1 (0.8%)           | 1 (0.4%) 1 (0.3%)           | 0                           | 1 (0.3%)                    | 1 (0.2%)                    |

<div style=\"page-break-after: always\"></div>

TSFSAE0IB: Numberof SubjectswithlorMoreTreatment-EmergentSeriousAdverseEventsfromMfaintenanceWeek0ThroughWeek4byMedDRA System-OrganClassandPreferredTerm:Treated SubjectsWhoWereRandomizedinInflammatoryBowel Disease(UlcerativeColitisandCrohn'sDisease) Pliase3MaintenanceStudies

|                                              | Ulcerative Colitis   | Ulcerative Colitis   | Ulcerative Colitis   | Crohn's Disease   | Crohn's Disease   | Crohn's Disease   | Crohn's Disease        | Crohn's Disease   | InflammatoryBowel Disease   | InflammatoryBowel Disease   | InflammatoryBowel Disease   | InflammatoryBowel Disease   |
|----------------------------------------------|----------------------|----------------------|----------------------|-------------------|-------------------|-------------------|------------------------|-------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|
|                                              | PlaceboSC            | 90mg SC q12w         | Ustekinmab 06 q8w    | Combined          | Placebo SC        | 90mgSC ql2w       | Uatekimumab 90mgSC q8w | Combined          | Placebo SC                  | 90mgSC q12w                 | Ustekinumab 90mgSC q8w      | Combined                    |
| Rectal adenoma                               | 0                    | 0                    | 1 (0.6%)             | 1(0.3%)           | 0                 | 0                 | 0                      | 0                 |                             | 0                           | 1(0.3%)                     | 1(0.2%)                     |
| Skin papilloma                               | 0                    | 1 (0.6%)             | 0                    | 1 (0.3%)          | 0                 | 0                 | 0                      | 0                 | 0                           | 1 (0.3%)                    | 0                           | 1 (0.2%)                    |
| Meningioma                                   | 0                    | 0                    | 0                    | 0                 | 1(0.8%)           | 0                 | 0                      | 0                 | 1(0.3%)                     | 0                           | 0                           | 0                           |
| Injuy,poisoningand procedural                |                      |                      |                      |                   |                   |                   |                        |                   |                             |                             |                             |                             |
| complications                                | 0                    | 0                    | 2 (1.1%)             | 2(0.6%)           | 0                 | 1 (0.8%)          | 0                      | 1 (0.4%)          |                             | 1 (0.3%)                    | 2 (0.7%)                    | 3(0.5%)                     |
| Allergic transfusion reaction                | 0                    | 0                    | 0                    | 0                 | 0                 | 1 (0.8%)          | 0                      | 1 (0.4%)          | 0                           | 1 (0.3%)                    | 0                           | 1(0.2%)                     |
| Hip fracture                                 | 0                    | 0                    | 1(0.6%)              | 1(0.3%)           | 0                 | 0                 | 0                      | 0                 | 0                           | 0                           | 1 (0.3%)                    | 1(0.2%)                     |
| Lambar vertebral fiacture                    | 0                    | 0                    | 1 (0.6%)             | 1(0.3%)           | 0                 | 0                 | 0                      | 0                 | 0                           | 0                           | 1 (0.3%)                    | 1(0.2%)                     |
| Blood and lymphatic system disorders         | 0                    | 2(1.2%)              | 0                    | 2(0.6%)           | 0                 | 0                 | 0                      | 0                 | 0                           | 2 (0.7%)                    | 0                           | 2(0.3%)                     |
| Anaemia                                      | 0                    | 2 (1.2%)             | 0                    | 2(0.6%)           | 0                 | 0                 | 0                      | 0                 | 0                           | 2 (0.7%)                    | 0                           | 2(0.3%)                     |
| Pregnancy,pueipenum and perinatal conditions | 0                    |                      | (%1D                 | 2 (0.6%)          | 0                 | 0                 | 0                      | 0                 |                             | 0                           | 2 (0.7%)                    | 2(0.3%)                     |
| Abortionspontaneous                          | 0                    | 0                    | 2(1.1%)              | 2 (0.6%)          | 0                 | 0                 | 0                      | 0                 |                             | 0                           | 2 (0.7%)                    | 2(0.3%)                     |
| Vascular disorders                           | 1 (0.6%)             | 0                    | 0                    | 0                 | 0                 | 2(1.5%)           | 0                      | 2(0.8%)           | 1(0.3%)                     | 2(0.7%)                     | 0                           | 2(0.3%)                     |
| Deep vein thrombosis                         | 0                    | 0                    | 0                    | 0                 | 0                 | 1(0.8%)           | 0                      | 1(0.4%)           |                             | 1(0.3%)                     | 0                           | 1(0.2%)                     |
| Essentialhypertension                        | 0                    | 0                    | 0                    | 0                 | 0                 | 1(0.8%)           | 0                      | 1 (0.4%)          | 0                           | 1 (0.3%)                    | 0                           | 1(0.2%)                     |
| Haemonhage                                   | 1 (0.6%)             | 0                    | 0                    | 0                 | 0                 | 0                 | 0                      | 0                 | 1(0.3%)                     | 0                           | 0                           | 0                           |
| Cardiac disorders                            | 1 (0.6%)             | 0                    | 1(0.6%)              | 1(0.3%)           | 0                 | 0                 | 0                      | 0                 | 1 (0.3%)                    | 0                           | 1 (0.3%)                    | 1(0.2%)                     |
| Penicarditis                                 | 0                    | 0                    | 1 (0.6%)             | 1 (0.39)          | 0                 | 0                 | 0                      | 0                 | 0                           | 0                           | 1(0.3%)                     | 1(0.2%)                     |
| Cardiac arest                                | 1 (0.6%)             | 0                    | 0                    | 0                 | 0                 | 0                 | 0                      | 0                 | 1(0.3%)                     | 0                           | 0                           | 0                           |
| General disorders and                        |                      |                      |                      |                   |                   |                   |                        |                   |                             |                             |                             |                             |
| adminishation site conditions                | 0                    | 0                    | 1(0.6%)              | 1 (0.3%)          | 0                 | 0                 | 0                      | 0                 |                             | 0                           | 1(0.3%)                     | 1(0.2%)                     |
| Pyrexia                                      | 0                    | 0                    | 1(0.6%)              | 1(0.3%)           | 0                 | 0                 | 0                      | 0                 | 0                           | 0                           | 1(0.3%)                     | 1(0.2%)                     |
| Nervous system                               |                      |                      |                      |                   |                   |                   |                        |                   |                             |                             |                             |                             |
| disorders                                    | 1 (0.6%)             | 0                    | 0                    | 0                 | 1(0.8%)           | 0                 | 1 (0.8%)               | 1(0.4%)           | 2 (0.6%)                    | 0                           | 1 (0.3%)                    | 1(0.2%)                     |
| Migraine                                     | 0                    | 0                    | 0                    | 0                 | 0                 | 0                 | 1 (0.8%)               | 1(0.4%)           | 0                           | 0                           | 1 (0.3%)                    | 1(0.2%)                     |
| Generalised tonic-clonic seizure             | 1 (0.6%)             | 0                    | 0                    | 0                 | 0                 | 0                 | 0                      | 0                 | 1 (0.3%)                    | 0                           | 0                           | 0                           |
| Headache                                     | 0                    | 0                    | 0                    | 0                 | 1 (0.8%)          | 0                 | 0                      | 0                 | 1 (0.3%)                    | 0                           | 0                           | 0                           |

<div style=\"page-break-after: always\"></div>

TSFSAE0IB: NumberofSubjectswithlorMoreTreatment-EmergentSeriousAdverseEventsfromMaintenanceWeek0ThroughWeek4byMfedDRA System-OrganClassandPreferredTerm;TreatedSubjectsWhoVereRandomizedinInflammatoryBowrelDisease(UlcerativeColitisand Crohn'sDisease) Phase3MaintenanceStudies'

|                                               | Ulcerative Colitis   | Ulcerative Colitis   | Ulcerative Colitis     | Ulcerative Colitis   | Crohn's Disease\"   | Crohn's Disease\"   | Crohn's Disease\"       | Crohn's Disease\"   | InflammatoryBowelDisease   | InflammatoryBowelDisease   | InflammatoryBowelDisease   | InflammatoryBowelDisease   |
|-----------------------------------------------|----------------------|----------------------|------------------------|----------------------|--------------------|--------------------|------------------------|--------------------|----------------------------|----------------------------|----------------------------|----------------------------|
|                                               | PlaceboSC            | 90mgSC q12w          | Ustekinumab 90mgSC q8w | Combined             | Placebo SC         | 90mg SC q12w       | Ustekinumab 90mgSC qSw | Combined           | Placebo SC                 | 90ng SC ql2w               | Ustekinumab 90mgSC qSw     | Combined                   |
| Psychiatic disorders                          | 0                    | 0                    | 0                      | 0                    |                    | 1 (0.8%)           | 0                      | 1 (0.4%)           | 0                          | 1(0.39)                    | 0                          | 1 (0.2%)                   |
| Suicidal ideation                             | 0                    | 0                    | 0                      | 0                    | 0                  | 1 (0.8%)           | 0                      | 1 (0.49)           | 0                          | 1 (0.3%)                   | 0                          | 1 (0.2%)                   |
| Respiatory,thoracic and mediastinal disorders | 0                    | 1(0.6%)              | 0                      | 1 (0.3%)             | 0                  | 0                  | 0                      | 0                  | 0                          | 1(0.3%)                    | 0                          | 1 (0.2%)                   |
| Pulmonary embolism                            | 0                    | 1 (0.6%)             | 0                      | 1(0.3%)              | 0                  | 0                  | 0                      | 0                  | 0                          | 1 (0.3%)                   | 0                          | 1 (0.2%)                   |
| Skin and subcutaneous tissue disorders        | 0                    | 0                    | 1 (0.6%)               | 1 (0.3%)             | 0                  | 0                  | 0                      | 0                  | 0                          | 0                          | 1(0.3%)                    | 1 (0.2%)                   |
| Dematitis                                     | 0                    | 0                    | 1(0.6%)                | 1(0.3%)              | 0                  | 0                  | 0                      |                    | 0                          | 0                          | 1 (0.3%)                   | 1(0.2%)                    |
| Ear and labyrinth disorders                   | 1 (0.6%)             | 0                    | 0                      | 0                    | 0                  | 0                  | 0                      | 0                  | 1 (0.3%)                   | 0                          | 0                          | 0                          |
| Deafness neurosensory                         | 1 (0.6%)             | 0                    | 0                      | 0                    | 0                  | 0                  | 0                      | 0                  | 1(0.39)                    | 0                          |                            | 0                          |
| Hepatobiliary disorders                       | 1 (0.6%)             | 0                    | 0                      | 0                    | 0                  | 0                  | 0                      |                    | 1(0.3%)                    | 0                          | 0                          | 0                          |
| Liver disorder                                | 1 (0.6%)             | 0                    | 0                      | 0                    | 0                  | 0                  | 0                      | 0                  | 1(0.3%)                    | 0                          | 0                          | 0                          |
| Metabolism and nuhition disorders             | 1 (0.6%)             | 0                    | 0                      | 0                    | 0                  | 0                  | 0                      | 0                  | 1(0.3%)                    | 0                          | 0                          | 0                          |
| Diabetic metabolic decompensation             | 1 (0.6%)             |                      | 0                      | 0                    | 0                  | 0                  | 0                      | 0                  | 1 (0.3%)                   | 0                          | 0                          | 0                          |
| Musculoskeletal and connective tissue         | 0                    |                      | 0                      |                      | 3(2.3%)            | 0                  | 0                      |                    | 3(1.0%)                    | 0                          | 0                          | 0                          |
| disorders Arthuralgia                         | 0                    | 0                    | 0                      | 0                    | 1 (0.8%)           | 0                  | 0                      | 0                  | 1 (0.3%)                   | 0                          | 0                          | 0                          |
| Fibromyalgia                                  | 0                    | 0                    | 0                      | 0                    | 1 (0.8%)           | 0                  | 0                      | 0                  | 1(0.3%)                    | 0                          | 0                          | 0                          |
| Lumbar spinal stenosis                        | 0                    | 0                    | 0                      | 0                    | 1(0.8%)            | 0                  | 0                      | 0                  | 1(0.3%)                    | 0                          | 0                          | 0                          |
| Renal and winary disorders                    | 1 (0.6%)             | 0                    | 0                      | 0                    | 0                  | 0                  | 0                      | 0                  | 1(0.3%)                    | 0                          | 0                          | 0                          |
| Acute kidney injny Social circumstances       | 1 (0.6%)             | 0                    | 0                      | 0                    | 0                  | 0                  | 0                      | 0                  | 1(0.3%)                    | 0                          | 0                          | 0                          |
|                                               | 0                    | 0                    | 0                      | 0                    | 1 (0.8%)           | 0                  | 0                      | 0                  | 1 (0.3%)                   | 0                          | 0                          | 0                          |
|                                               |                      |                      |                        |                      |                    |                    |                        |                    | 1 (0.3%)                   |                            |                            |                            |
| Substance abuser                              | 0                    | 0                    | 0                      | 0                    | 1 (0.8%)           | 0                  | 0                      | 0                  |                            | 0                          | 0                          | 0                          |

<div style=\"page-break-after: always\"></div>

Of note, there was 1 reported SAE of pulmonary embolism (though no reports of deep venous thrombosis) in the UCO3001 maintenance study through Week 44.

- Pulmonary embolism (1 subject in the ustekinumab q12w group) - Bilateral pulmonary artery embolism complicated by pulmonary infarction was reported on Day 229 post first administration. The subject had a prior history of brachial artery thrombosis, thrombophilia-heterozygous form of MTHFR gene mutation, ulcerative haemorrhagic retrocolitis and severe iron-deficiency anaemia.

## Deaths - Induction study

There was 1 death reported through the final safety visit; a subject in the ~6 mg/kg group experienced sudden death on Study Day 42 attributed to an SAE of oesophageal varices haemorrhage. The event was considered not to be related to study agent by the investigator. The subject had no reported history of portal hypertension or cirrhosis.

## Deaths - Maintenance study

There was 1 death prior to Week 44 of the maintenance study in a subject who was in the ustekinumab induction delayed-responder group (receiving ustekinumab q8w). The death (maintenance Day 85) was attributed to acute respiratory failure that occurred during thyroid surgery for a multinodular goiter. The event was considered to be unrelated to study agent by the investigator.

The sponsor also highlights an additional death that occurred during the ongoing LTE (after maintenance Week 44) in an elderly subject with multiple comorbidities died on Day 573 post first administration of study agent; the death was attributed to failure to thrive. The subject received placebo IV at Week 0 of induction followed by ustekinumab ~6 mg/kg IV at Week 8 of induction and was randomized to the placebo group at Week 0 of maintenance. The patient received ustekinumab 90 mg (receiving only 1 dose) approximately 10 days prior to hospitalisation for diarrhoea secondary to ulcerative colitis, complicated by CMV colitis. However the initial event of diarrhoea had been reported 10 days prior to the second dose of ustekinumab. The patient was discharged but eventually readmitted with a lumbar compression fracture and was continuing to have active diarrhoea with blood. The subject eventually died 573 days after first administration of the study agent. Death was attributed to failure to thrive.

## Serious Infections, including TB and Opportunistic infections - Induction study

Through Week 8, a total of 7 subjects had 1 or more serious infection as identified by the investigator (0.3% [1 subject], 0.6% [2 subjects], and 1.3% [4 subjects] in the ~6 mg/kg, 130 mg, and placebo groups, respectively).

No cases of active TB were reported through the final safety visit.

The only serious infection that was reported in the ~6 mg/kg group was pyoderma gangrenosum (which the investigator designated as an infection on the eCRF). The only serious infections that were reported in the 130 mg group were gastroenteritis and pneumonia (reported by 1 subject ach).

A life threatening opportunistic infection of legionella pneumonia was reported for a subject in the placebo → ~6 mg/kg group. At the time of the event the subject was receiving concomitant therapy with methylprednisolone (8 mg daily). The subject was hospitalised with dyspnea and tachypnea approximately 4 weeks after her first dose of ustekinumab at week 8 and transferred to ICU the next day due to respiratory insufficiency which required intubation and artificial ventilation. Following extended hospitalisation the patient recovered with sequelae from the event; which considered very likely related to study agent by the investigator.

Through the final safety visit, 0.7% and 1.6 % of subjects in the combined ustekinumab IV group and placebo group, respectively, reported at least 1 serious infection. Serious infections of pneumonia were

<div style=\"page-break-after: always\"></div>

reported for 2 subjects in the combined ustekinumab IV group (no subjects in the placebo group reported pneumonia). The remaining serious infections were reported for no more than 1 subject each.

## Serious infections, including TB and Opportunistic infections - Maintenance study

Among randomised subjects, serious AEs of infection were reported in 3 (1.7%), 6 (3.5%), and 4 (2.3%) subjects in the ustekinumab q8w, ustekinumab q12w, and placebo groups, respectively.

No cases of active TB were reported among ustekinumab-treated subjects through Week 44.

Opportunistic infections were identified in 3 subjects (all in the randomised population).

There were two cases of CMV colitis. Both events were of moderate intensity and resulted in hospitalization. There was also a case of ophthalmic and oral herpes simplex in a patient who was not receiving concomitant corticosteroid or immunomodulator therapy at the time of the event.

## Possible Anaphylactic and Possible Delayed Hypersensitivity (Serum Sickness-Like) Reactions -Induction study

Through the final safety visit, 1 SAE of anaphylactic reaction in the placebo group occurred on Study Day 1; this event occurred within minutes of starting the infusion, and resulted in the subject being terminated from study participation. There were no cases of delayed hypersensitivity or serum sickness-like reaction through the final safety visit.

## Possible Anaphylactic and Possible Delayed Hypersensitivity (Serum Sickness-Like) Reactions -Maintenance study

There were no cases of anaphylactic or delayed hypersensitivity reactions reported through Week 44

## Malignancies - Induction Study

No malignancies were reported through Week 8. However, through the final safety visit,2 malignancies (both SAEs) of prostate cancer and rectal adenocarcinoma were reported for 1 subject each, in the 130 mg IV → 90 mg SC group.

## Malignancies - Maintenance Study

Seven subjects in the treatment group versus 1 in the placebo group developed malignancy. Most of these malignancies were diagnosed within 6 months of study treatment. The standardised incidence ratios (excluding in situ cervical cancer and non-melanoma skin cancer) using epidemiological data from the SEER database, adjusting for age and race, is presented to place these occurrences into context of what might be expected for the population. The SIR obtained is 1.7 for UC which is almost three times the SIRs obtained for previous indications.

## Cardiovascular events - Induction study

No serious cases of MACE (ie, nonfatal myocardial infarction, nonfatal stroke, and cardiovascular death) were reported for ustekinumab-treated subjects through the final safety visit. Through Week 8, there was 1 SAE of ischemic stroke reported for 1 subject in the placebo group.

## Cardiovascular events - Maintenance study

There were two reports of serious MACE (ie, nonfatal myocardial infarction, nonfatal stroke, and cardiovascular death) in the maintenance study:

- A case of nonfatal cardiac arrest in a 45 year old male patient (maintenance Day 143; 199 days after last dose of ustekinumab [during induction study]) in the perioperative period following a

<div style=\"page-break-after: always\"></div>

total laparoscopic coloproctocoletomy with ileostomy; the subject was successfully resuscitated. The subject had a medical history of essential hypertension and ischemic heart disease.

- A postoperative anterior wall myocardial infarction in a following a thyroid surgery complicated by acute respiratory failure in a 54 year old male patient who died of complications of ARDS that began with acute respiratory failure (discussed above in Deaths).

Overall, up to 1 year, there is no consistent evidence that ustekinumab increases cardiovascular risk.

## Immunogenicity - Induction study

Of the 822 subjects who received ustekinumab at any time through the final safety visit, and who had appropriate samples for the assessment of anti-drug antibodies, 18 subjects (2.2%) were positive for antibodies to ustekinumab from Week 0 through the final safety visit with subject peak titers ranging from 1:100 to 1:3200. This included 1 subject in the placebo group tested positive for antibodies to ustekinumab at Week 0. Of these 18 subjects who were positive for antibodies to ustekinumab, 15 were evaluable for NAbs. Of these 15 subjects, 4 (26.7%) were positive for NAbs through the final safety visit.

## Immunogenicity - Maintenance study

Among 680 treated subjects with appropriate samples for the assessment of antibodies to ustekinumab, 39 (5.7%) were positive for antibodies to ustekinumab through 52 weeks of treatment, the majority with antibody titers ≤1:800. Of the 39 treated subjects who were positive for antibodies to ustekinumab in this maintenance study, 11 (28.2%) were positive for neutralizing antibodies (NAbs).

Among randomized subjects in this maintenance study, the incidence of antibodies to ustekinumab was similar among subjects in the ustekinumab q8w and q12w groups (3.4% and 3.5%, respectively) but higher among subjects in the placebo group (9.1%). During the UCO3001 maintenance study, none of the subjects who were positive for antibodies to ustekinumab through Week 44 reported an injection-site reaction.

<div style=\"page-break-after: always\"></div>

Table5: SuminaryofAntibodytoUstekinumabStatusThroughWeek44ofthisMaintenanceStudy;PKAnalysisSet(CNTOl275UCO3001)

|                                                         |                | Randomized subjects        |                          | Non- randomized subjects                     |                                    |                          |            |
|---------------------------------------------------------|----------------|----------------------------|--------------------------|----------------------------------------------|------------------------------------|--------------------------|------------|
| PK Analysis Set                                         | Placebo SC 175 | Ustekinmab 90mgSC q12w 172 | Ustekimmab 90mgSCq8w 176 | Delayed respondersb Ustekimmab 90mgSCq8w 157 | Combined Ustekinunab 90mgSCq8w 333 | Combined Ustekinumab 505 | Total 680  |
| Subjectswithappropriatesamples                          | 175            | 172                        | 176                      | 157                                          | 333                                | 505                      | 680        |
| Subjectspositiveforantibodiesto ustekimmab at any timed | 16(9.1%)       | 6(3.5%)                    | 6(3.4%)                  | 11 (7.0%)                                    | 17(5.1%)                           | 23 (4.6%)                | 39 (5.7%)  |
| Titers                                                  |                |                            |                          |                                              |                                    |                          |            |
| 1:50                                                    |                | 0                          | 0                        | 1                                            | 1                                  | 1                        | 3          |
| 1:100                                                   | 3              | 2                          | 0                        |                                              | 3                                  | 5                        | 8          |
| 1:200                                                   | 3              | 1                          | 2                        | 0                                            | 2533                               | 3                        | 6          |
| 1:400                                                   | 5              | 2                          | 1                        | 4                                            |                                    | 7                        | 12         |
| 1:800                                                   | 1              | 0                          | 1                        |                                              |                                    |                          | 4          |
| 1:1600                                                  | 0              | 0                          | 2                        | 1                                            |                                    | 3                        |            |
| 1:3200                                                  | 2              | 0                          | 0                        | 0                                            | 0                                  | 0                        | 32         |
| 1:12800                                                 | 0              | 1                          | 0                        | 0                                            | 0                                  | 1                        | 1          |
| Subjectsnegativefor antibodiesto ustekimunab            | 159 (90.9%)    | 166 (96.5%)                | 170 (96.6%)              | 146(93.0%)                                   | 316(94.9%)                         | 482(95.4%)               | 641(94.3%) |

Subjects whowere in clinical response to ustekinumabIVincductiondosing andwererandomized toplaceboSConentry into thismaintenance study.

Subjectswhohad1 ormore samples obtained after theirfirst study agent administration of theinduction study through theevaluationvisit.

Subjectswhowere not in clinical response to ustekinumab at I-8but were in clinical response at I-16 afteraSC administration of ustekinumab at I-8.

dSubjectswhohad atleast positivesample in theanalysisat anytimefromWeekOofinductionstudyup to theevaluationvisitDenominatorissubjectswithappropriate samplesthroughthe evaluationvisit inthe inductionstudy.

- DenominatorissubjectsevaluableforeutralizingantibodiesfromWeekOofinductionstudytroughheevaluationvisit.

## Laboratory findings

## Laboratory findings- Induction phase

At baseline, haematology values were generally similar across all treatment groups. Changes in selected haematology values through Week 8 were consistent with the decrease in inflammatory disease activity observed in the ~6 mg/kg and 130 mg groups; namely, increases in median haemoglobin and haematocrit values, and small decreases in median WBC and neutrophils were noted.

At baseline, chemistry values were generally similar across all treatment groups. Through Week 8, except for serum albumin which was increased in both ustekinumab groups compared with placebo, changes in chemistry values did not appear to be clinically important. As was observed for selected hematologic parameters, the observed increase in serum albumin is consistent with a decrease in inflammatory activity with ustekinumab treatment.

## Laboratory finding - Maintenance phase

Haematology and clinical chemistry results were comparable among treatment groups and no trends were observed indicating an association between ustekinumab and changes in routine laboratory parameters.

No clinically relevant changes in vital signs were reported during the study.

## Safety in special populations

Anevaluablesubjectisasubjectwhohadnodemonstratedinterference intheneutralizingantibody assaywithinone tested sample.Denominatorissubjectspositive for antibodies toustekinumabatany timefromWeekOofinductionstudyupto the evaluationvisit.

[Adaptedfrom:TPKIR01RTF][CNTO1275\\UCO3001DBR\\_CSRWEEK44RE\\_CSRWEEK44PRODITPKIR01.SAS]12SEP2018,16:05

<div style=\"page-break-after: always\"></div>

## Pregnancy - Induction phase

Through the final safety visit, 2 pregnancies were reported (1 female subject in the ~6 mg/kg group and another in the 130 mg group). Both pregnancies resulted in the delivery of healthy newborns.

## Pregnancy - Maintenance phase

There were 6 pregnancies in reported through to week 44 (2 subject pregnancies in the q8w group,1 subject pregnancy and 1 partner pregnancy in the ustekinumab q12w group, 1 subject pregnancy from the placebo group (received IV ustekinumab during induction), and 1 partner pregnancy in the ustekinumab induction delayed-responder group (received ustekinumab q8w during maintenance). There were 2 first trimester miscarriages in the q8w group pregnancies. One of the mothers had a previous healthy pregnancy and no identified risk factors and the second mother is noted to have heterozygous factor v leiden mutation and three previous pregnancies (a spontaneous abortion, live birth at 24 weeks and stillborn at 28 weeks)).

The remaining 4 pregnancies resulted in healthy newborns.

Pregnancies across ustekinumab studies:

As of 31 August 2018, 154 reports of pregnancy were identified in studies of ustekinumab in UC, Crohn's disease, psoriasis, PsA, MS, ankylosing spondylitis, and healthy volunteers:

81 maternal pregnancies and 73 pregnancies with paternal exposure.

In general, the outcomes seen in the ustekinumab pregnancies are comparable with what is expected in the general population.

Table 15: Pregnancy Outcomes with Maternal Exposure (Cumulatively Through 31 August 2018)

| Pregnancy Outcome                     | Indication   | Indication   | Indication   | Indication   | Indication   | Indication   |
|---------------------------------------|--------------|--------------|--------------|--------------|--------------|--------------|
|                                       | PSO          | PsA          | CD           | UC           | Othera       | Total        |
| Live birth                            | 15           | 0            | 16           | 4            | 2            | 37           |
| Congenital anomaly/birth defect       | 0            | 0            | 0            | 0            | 0            | 0            |
| Other AEs                             | 2            | 0            | 0            | 1            | 0            | 3            |
| No AE/congenital anomaly/birth defect | 13           | 0            | 16           | 3            | 2            | 34           |
| Spontaneousabortion                   | 5            | 0            | 5            | 2            | 0            | 12           |
| Elective abortion                     | 10           | 1            | 4            | 0            | 0            | 15           |
| Abortion (Unspecified)                | 0            | 0            | 0            | 0            | 1            | 1            |
| Premature birth                       | 1            | 0            | 1            | 0            | 0            | 2            |
| Ectopic pregnancy                     | 2            | 0            | 0            | 0            | 0            | 2            |
| NR/continuing                         | 6            | 1            | 3            | 2            | 0            | 12           |
| Totalnunberofcases b                  | 39           | 2            | 29           | 8            | 3            | 81           |

Abbreviations: AE=Adverse Event; CD=Crohn's Disease; NR=Not Reported; PsA=Psoriatic Arthritis;

PSO=Psoriasis; UC=Ulcerative Colitis.

<div style=\"page-break-after: always\"></div>

Table 16: PregnancyOutcomeswithPaternalExposure(CumulativelyThrough31August 2018)

|                                       | Indication   | Indication   | Indication   | Indication   | Indication   | Indication   |
|---------------------------------------|--------------|--------------|--------------|--------------|--------------|--------------|
| Pregnancy Outcome                     | PSO          | PsA          | CD           | UC           | Other?       | Total        |
| Live birth                            | 32           | 0            | 7            | 3            | 0            | 42           |
| Congenital anomaly/birth defect       | 1            | 0            | 0            | 0            | 0            | 1            |
| Other AEs                             | 4            | 0            | 0            | 0            | 0            | 4            |
| No AE/congenital anomaly/birth defect | 27           | 0            | 7            | 3            | 0            | 37           |
| Prematurebirth                        | 6            | 0            | 0            | 0            | 0            | 6            |
| Elective abortion                     | 2            | 0            | 1            | 0            | 0            | 3            |
| Spontaneousabortion                   | 3            | 1            | 2            | 0            | 0            | 6            |
| NR/continuing                         | 5            | 2            | 3            | 1            | 5            | 16           |
| Totalb                                | 48           | 3            | 13           | 4            | 5            | 73           |

Abbreviations: AE=Adverse Event; CD=Crohn's Disease; NR=Not Reported; PsA=Psoriatic Arthritis;

PSO=Psoriasis; UC=Ulcerative Colitis.

## Elderly - Induction phase

During the induction study, within the ≥65 years of age population, there appeared to be an increase in the proportions of ustekinumab-treated subjects reporting AEs, SAEs, and infections compared with placebo-treated subjects (ie, for AEs 21 [61.8%] and 5 [31.3%] subjects with 1 or more AEs, for the ustekinumab and placebo groups respectively, for SAEs 2 [5.9%] and 0 subjects with 1 or more AEs for the ustekinumab and placebo groups respectively, and for infections 9 [26.5%] and 0 subjects with 1 or more infections for the ustekinumab and placebo groups respectively); this pattern was not observed in the &lt;65 years of age population. On review of the specific events, the most frequent AEs and infections in the ≥65 years of age group involved the upper respiratory tract (ie, nasopharyngitis, upper respiratory tract infection, sinusitis, and pharyngitis) which is consistent with the overall population. Several of these AEs (ie, nasopharyngitis and upper respiratory tract infections) are established ADRs while sinusitis is a newly identified ADR in the overall population. All AEs were reported as mild events and generally resolved without treatment. Two ustekinumab-treated subjects reported SAEs; 1 subject reported 3 concurrent SAEs (ie, aphasia, cognitive disorder, and motor dysfunction) and the second subject reported 1 SAE of ulcerative colitis. However, given the low number of subjects in the ≥65 years of age subpopulation, particularly in the placebo group, and some imbalances in concomitant immunomodulators use between the treatment groups, definitive conclusions of the impact of ustekinumab on the risk of AEs and infections in elderly patients cannot be drawn.

<div style=\"page-break-after: always\"></div>

## Elderly - Maintenance study

<!-- image -->

TSFSUB24B:Numberof Treatment-EinergentAdverseEventsLeadingtoDiscontinuationon MaintenanceTherapy(Upto44Weeks)PerHundredSubject-YearsofFollow-Upby DemographicFactors:TreatedSubjectsWhoWereRandomizedinPhase3Ulcerative ColitisCNTO1275UCO3001MaintenanceStudy

|                                  | Placebo    | Uatekinumab'   |
|----------------------------------|------------|----------------|
| Subjects treated                 | 175        | 348            |
| Weight(kg) 70.0                  |            |                |
| N                                | 81         | 172            |
| Avgduration of follow-up（weeks)  | 41.50      | 41.09          |
| Avgduration oftreatment(weeks)   | 34.16      | 33.60          |
| Subjectswith adverseevents       | 11 (13.6%) | 10 (5.8%)      |
| Total subject-yearsof follow-up  | 65         | 136            |
| Numberofadverseevents            | 11         | 10             |
| Eventrateper100subject-years     | 17.02      | 7.36           |
| ≥70.0°                           |            |                |
| N                                | 94         | 176            |
| Avgduration of follow-up(weeks)  | 42.99      | 42.89          |
| Avgduration of treatment(weeks)  | 36.29      | 36.25          |
| Subjectswith adverse events      | 9 (9.6%)   | 4(2.3%)        |
| Total subject-years of follow-up | 78         | 145            |
| Numberofadverseevents            | 9          | 4              |
| Erentrateper100subject-years     | 11.58      | 2.76           |
| Age (yrs) 65                     |            |                |
| N                                | 164        | 333            |
| Avgdurationoffollow-up(weeks)    | 42.16      | 42.15          |
| Avgduration of treatment(weeks)  | 35.07      | 35.24          |
| Subjectswith adverseevents       | 20 (12.2%) | 11(3.3%)       |
| Totalsubject-yearsof follow-up   | 133        | 270            |
| Number of adverseevents          | 20         | 11             |
| Eventrateper100 subject-years    | 15.04      | 4.07           |
| 65                               |            |                |
| N                                | 11         | 15             |
| Avg durationoffollow-up(weeks)   | 44.35      | 38.60          |
| Avg duration of teatment（weels)  | 38.82      | 28.30          |
| Subjects with adverse events     | 0          | 3(20.0%)       |
| Total subject-years of follow-up | 9          |                |
| Number of adverseevents          | 0          | 3              |
| Eventrateper100subject-years     | 0.00       | 26.94          |

Unlike the observations from the induction study, no trends were observed with regards to differences in the event rates per 100 subject-years for AEs, SAEs, infections, or discontinuations of study agent due to AEs, when evaluated according to the subject's age during the maintenance study. While it is acknowledged that the numbers are very low, it is noted that the proportion of patients discontinuing due to TAES in the maintenance phase is larger (3% in those &lt;65 years versus 20% in those &gt;65 years - as illustrated in the table above.

## Sex, Race, Weight

The company state that no trends were observed with regards to differences in the proportions of subjects reporting AEs, SAEs, or infections, when evaluated according to the subject's sex, race or weight during the induction study.

The number of TEAEs up to 44 weeks per 100 Subject-years of follow-up by demographic factors in patients randomised in the maintenance study is presented in the following table:

<div style=\"page-break-after: always\"></div>

TSFSUB22B: Number of Treatment-Emergent Serious Adverse Events on Maintenance Therapy (Up to 44 Weeks)Per Hundred Subject-Year's of Follow-Up byDemographic Factors; Treated SubjectsWhoWereRandomized inPhase 3 Ulcerative Colitis CNTOl275UCO300l Maintenance Studya

|                                   | Placebo    | Ustekinumab   |
|-----------------------------------|------------|---------------|
| Subjects treated                  | 175        | 348           |
| Weight (kg)                       |            |               |
| <70.0                             |            |               |
| N                                 | 81         | 172           |
| Avg duration of follow-up (weeks) | 41.50      | 41.09         |
| Avg duration of treatment (weeks) | 34.16      | 33.60         |
| Subjects with adverse events      | 10 (12.3%) | 18 (10.5%)    |
| Total subject-years of follow-up  | 65         | 136           |
| Number of adverse events          | 12         | 18            |
| Event rate per 100 subject-years  | 18.56      | 13.24         |
| ≥70.0 c                           |            |               |
| N                                 | 94         | 176           |
| Avg duration of follow-up (weeks) | 42.99      | 42.89         |
| Avg duration of treatment (weeks) | 36.29      | 36.25         |
| Subjects with adverse events      | 7 (7.4%)   | 10 (5.7%)     |
| Total subject-years of follow-up  | 78         | 145           |
| Number of adverse events          | 12         | 15            |
| Event rate per 100 subject-years  | 15.44      | 10.33         |
| Age (yrs)                         |            |               |
| 9                                 |            |               |
| N                                 | 164        | 333           |
| Avg duration of follow-up (weeks) | 42.16      | 42.15         |
| Avg duration of treatment (weeks) | 35.07      | 35.24         |
| Subjects with adverse events      | 17 (10.4%) | 26 (7.8%)     |
| Total subject-years of follow-up  | 133        | 270           |
| Number of adverse events          | 24         | 31            |
| Event rate per 100 subject-years  | 18.05      | 11.48         |
| 265                               |            |               |
| N                                 | 11         | 15            |
| Avg duration of follow-up (weeks) | 44.35      | 38.60         |
| Avg duration of treatment (weeks) | 38.82      | 28.30         |
| Subjects with adverse events      | 0          | 2 (13.3%)     |
| Total subject-years of follow-up  | 6          | 11            |
| Number of adverse events          | 0          | 2             |
| Event rate per 100 subject-years  | 0.00       | 17.96         |
| Sex                               |            |               |
| Male                              |            |               |
| N                                 | 107        | 190           |
| Avg duration of follow-up (weeks) | 42.75      | 42.47         |
| Avg duration of treatment (weeks) | 36.10      | 35.64         |
| Subjects with adverse events      | 9 (8.4%)   | 10 (5.3%)     |
| Total subject-years of follow-up  | 88         | 155           |
| Number of adverse events          | 14         | 11            |
| Event rate per 100 subject-years  | 15.91      | 7.09          |
| Female                            |            |               |
| N                                 | 68         | 158           |
| Avg duration of follow-up (weeks) | 41.59      | 41.44         |
| Avg duration of treatment (weeks) | 34.05      | 34.09         |
| Subjects with adverse events      | 8 (11.8%)  | 18 (11.4%)    |
| Total subject-years of follow-up  | 54         | 126           |
| Number of adverse events          | 10         | 22            |

<div style=\"page-break-after: always\"></div>

TSFSUB22B: Number of Treatment-Emergent Serious Adverse Events on MIaintenance Therapy (Up to 44 Weeks) Per Hundred Subject-Years of Follow-Up by Demographic Factors; Treated Subjects WhoWere Randomized in Phase 3 Ulcerative Colitis CNTO1275UCO3001 Maintenance Studya

| Event rate per 100 subject-years   | Placebo 18.39   | Ustekinumabb 17.47   |
|------------------------------------|-----------------|----------------------|
| Race                               |                 |                      |
| White                              |                 |                      |
| N                                  | 125             | 262                  |
| Avg duration of follow-up (weeks)  | 41.73           | 42.33                |
| Avg duration of treatment (weeks)  | 34.71           | 35.20                |
| Subjects with adverse events       | 11 (8.8%)       | 20 (7.6%)            |
| Total subject-years of follow-up   | 100             | 213                  |
| Number of adverse events           | 18              | 23                   |
| Event rate per 100 subject-years   | 17.94           | 10.78                |
| Black or African American          |                 |                      |
| N                                  | 3               | 3                    |
| Avg duration of follow-up (weeks)  | 46.90           | 45.10                |
| Avg duration of treatment (weeks)  | 35.05           | 40.71                |
| Subjects with adverse events       | 0               | 1 (33.3%)            |
| Total subject-years of follow-up   | 3               | 3                    |
| Number of adverse events           | 0               | 2                    |
| Event rate per 100 subject-years   | 0.00            | 76.87                |
| Asian                              |                 |                      |
| N                                  | 34              | 53                   |
| Avg duration of follow-up (weeks)  | 43.33           | 39.77                |
| Avg duration of treatment (weeks)  | 37.29           | 32.64                |
| Subjects with adverse events       | 6 (17.6%)       | 6 (11.3%)            |
| Total subject-years of follow-up   | 28              | 41                   |
| Number of adverse events           | 6               | 7                    |
| Event rate per 100 subject-years   | 21.18           | 17.27                |
| Other                              |                 |                      |
| N                                  | 13              | 30                   |
| Avg duration of follow-up (weeks)  | 44.02           | 42.73                |
| Avg duration of treatment (weeks)  | 35.92           | 36.15                |
| Subjects with adverse events       | 0               | 1 (3.3%)             |
| Total subject-years of follow-up   | 11              | 25                   |
| Number of adverse events           | 0               | 1                    |
| Event rate per 100 subject-years   | 0.00            | 4.06                 |

[TSFSUB22B.RIF][CNI01275\\Z\\_SCSDBR\\_2017\\_12RE\\_2017\\_12PRODITSFSUB22B.SAS]14AUG2018,19:36

## Disease severity

Overall, the safety profile of ustekinumab was not affected by UC disease severity.

## Safety related to drug-drug interactions and other interactions

The sponsor has not performed any specific drug-drug interactions however no new drug-drug interactions are expected based on the proposed new indication.

## Discontinuation due to adverse events

## Discontinuation due to adverse events - Induction study

Study agent was administered as a single IV infusion at Week 0; therefore, subjects could not be discontinued from further study agent administration.

<div style=\"page-break-after: always\"></div>

## Discontinuation due to adverse events - Maintenance study

Adverse events leading to discontinuation of study agent in randomised patients were reported in 5 (2.8%), 9 (5.2%), and 20 (11.4%) subjects in the ustekinumab q8w, ustekinumab q12w, and placebo groups, respectively.

Ulcerative colitis was the most frequently reported AE that resulted in discontinuation of study agent among randomized subjects, in 15 (8.6%) subjects in the placebo group, 4 (2.3%) subjects in the q12w group, and none in the q8w group.

## Pooled analysis

There are pathophysiologic similarities between UC and Crohn's disease (an approved ustekinumab indication). Furthermore, medications used to treat UC are generally similar to those used to treat Crohn's disease. In addition, other approved biologics typically use a similar posology for the treatment of Crohn's disease and UC. Because of these considerations, the same induction and maintenance dose regimens were used in the Phase 3 studies in UC and Crohn's disease. Also of note, the UC and Crohn's disease programs employed a similar design strategy of placebo controlled induction and randomized-withdrawal maintenance Phase 3 studies and had similar target populations. Therefore, the pooling of the data from the Phase 3 UC and Crohn's disease studies into the pooled Phase 3 IBD population is appropriate and will increase the power to identify safety signals.

Only the Phase 3 Crohn's disease studies were included in these assessments, as it is the most rigorous analysis of the 130 mg and ~6 mg/kg doses. The Phase 2 Crohn's disease studies (C0379T07 and C0743T26) were not included since they could introduce bias. Except for the ~6 mg/kg dose used in C0743T26, different doses were studied in C0379T07 and C0743T26 than were studied in the Phase 3 Crohn's disease studies. Furthermore, the ~6 mg/kg group in C0743T26 had a greater proportion of TNF antagonist refractory subjects than the Phase 3 Crohn's disease studies as the study enrolled only TNF refractory subjects.

Of note, the duration of follow-up in ustekinumab-treated subjects (ie, 90 mg SC q8w and 90 mg SC q12w combined) in the UCO3001 maintenance study was approximately 6 weeks longer than in the CRD3003 maintenance study. Therefore, to allow for more informative comparisons, the primary presentations for the analyses of safety in the pooled Phase 3 IBD maintenance studies are subjects with events per 100 subject-years of follow-up; supportive analyses of events per 100 subject-years and proportions of subjects with events are also provided.

## Inflammatory Bowel Disease Pooled with Psoriatic Diseases

Extensive clinical safety data supported the approval of ustekinumab for Crohn's disease, psoriasis, and PsA. Therefore, the safety experience of ustekinumab across the global Phase 2 and Phase 3 IBD studies (UC and Crohn's disease) was assessed alongside the safety experience from the global Phase 2 and Phase 3 psoriatic diseases (psoriasis and PsA) studies, as well as all diseases pooled (IBD [UC and Crohn's disease] and psoriatic diseases [psoriasis and PsA]), for both the placebo-controlled period and through approximately 1 year of treatment.

A total of 6,709 subjects were treated with ustekinumab (2,574 subjects in the Phase 2 and Phase 3 IBD studies [825 subjects in the Phase 3 UC studies, 1,749 subjects in the Phase 2 and Phase 3 Crohn's disease studies] and 4,135 subjects in the Phase 2 and Phase 3 psoriatic diseases studies). Of these 6,709 subjects, 4,577 subjects were exposed to ustekinumab (IV and SC) for at least 6 months and 2,540 subjects were exposed to ustekinumab (IV and SC) for at least 1 year.

Data on all diseases include results from the following trials:

<div style=\"page-break-after: always\"></div>

## Crohn's disease

Three Phase 3 studies (CRD3001 [induction], CRD3002 [induction] and CRD3003 [maintenance])

Two Phase 2 studies (C0379T07 and C0743T26)

- For C0379T07, only subjects who received placebo-controlled IV study agent are included; data from subjects who received placebo-controlled SC induction study agent are excluded (as are data from the non-placebo-controlled groups in C0379T07).

## Psoriasis

- One Phase 2 study (C0379T04)
- Three Phase 3 studies (C0743T08, C0743T09, and C0743T12)

## PsA

- One Phase 2 study (C0743T10)
- Two Phase 3 studies (CNTO1275PSA3001 and CNTO1275PSA3002)

## Pooled all indications:

Through 1 year of follow-up across all diseases pooled, a total of 6,709 subjects were treated with ustekinumab (2,574 subjects in the Phase 2 and Phase 3 IBD studies [825 subjects in the UC studies and 1,749 subjects in the Crohn's disease studies] and 4,135 subjects in the Phase 2 and Phase 3 psoriatic diseases studies [Table 14]) with a total of 5,149 subject-years of follow-up. Of these 6,709 subjects, 4,577 subjects were exposed to ustekinumab (IV and SC) for at least 6 months and 2,540 subjects were exposed to ustekinumab (IV and SC) for at least 1 year. The mean (SD) total dose of ustekinumab in all diseases pooled was 350.7 mg (216.90 mg). Data are summarised in the following table:

<div style=\"page-break-after: always\"></div>

Table 14: SunmaryofDurationofUstekinumnbExposureandTotalUstelinumabDoseThroughOneYearofFollow-Up:TreatedSubjectsin InflaminatoryBowrel Disease(Ulcerative Colitisand Crohn'sDisease)and PsoriaticDiseases(PsoriasisandPsoriaticArthritis) Studiesb

|                                 | Ulcerative Colitis Ustekinumab\"   | Crohn's Disease Ustekinumab\"   | InflammatoryBowel Disease Ustekimmabs   | PsoriaticDiseases Ustekinuumabd   | All DiseasesPooled Ustekinuumab.d   |
|---------------------------------|-----------------------------------|--------------------------------|-----------------------------------------|-----------------------------------|-------------------------------------|
| Subjectstreatedwith ustekinumab | 825                               | 1749                           | 2574                                    | 4135                              | 6709                                |
| Duration of ustekimmab exposure |                                   |                                |                                         |                                   |                                     |
| SingleIV                        | 825(100.0%)                       | 1664 (95.1%)                   | 2489 (96.7%)                            | 0                                 | 2489 (37.1%)                        |
| Atleast6months                  | 491 (59.5%)                       | 831(47.5%)                     | 1322(51.4%)                             | 3255 (78.79)                      | 4577 (68.2%)                        |
| Atleast 1years                  | 442(53.6%)                        | 429 (24.5%)                    | 871(33.8%)                              | 1669 (40.4%)                      | 2540 (37.9%)                        |
| Avgdurationof treatment(weeks)  | 28.82                             | 18.80                          | 22.01                                   | 26.78                             | 24.95                               |
| Total dose(mg)                  |                                   |                                |                                         |                                   |                                     |
| N                               | 825                               | 1749                           | 2574                                    | 4135                              | 6709                                |
| Mean (SD)                       | 587.8(276.49)                     | 432.2(243.96)                  | 482.0 (264.93)                          | 268.9 (123.38)                    | 350.7 (216.90)                      |
| Median                          | 580.0                             | 399.6                          | 418.1                                   | 225.0                             | 270.0                               |
| IQrange                         | (390.0;760.0)                     | (219.6;619.2)                  | (259.2;669.6)                           | (180.0;360.0)                     | (180.0,450.0)                       |
| Range                           | (86;1280)                         | 3:1060)                        | (3;1280)                                | (45;630)                          | (3:1280)                            |

<div style=\"page-break-after: always\"></div>

Key Safety Events for Ulcerative Colitis, Pooled with Crohn's Disease, and Psoriatic Diseases (Psoriasis and Psoriatic Arthritis): Through 1 Year of Treatment

Table 4: Bowel Disease (Ulcerative Colitis and Crohn'sDisease)and PsoriaticDiseases (Psoriasis andPsoriaticArthritis)Studies

|                                                                             | Ulcerative Colitis                                                          | Ulcerative Colitis                                                          | Crohn's Disease                                                             | Crohn's Disease                                                             | InflammatoryBowelDisease                                                    | InflammatoryBowelDisease                                                    | Psoriatic Diseases                                                          | Psoriatic Diseases                                                          | AllDiseasesPooled                                                           | AllDiseasesPooled                                                           |
|-----------------------------------------------------------------------------|-----------------------------------------------------------------------------|-----------------------------------------------------------------------------|-----------------------------------------------------------------------------|-----------------------------------------------------------------------------|-----------------------------------------------------------------------------|-----------------------------------------------------------------------------|-----------------------------------------------------------------------------|-----------------------------------------------------------------------------|-----------------------------------------------------------------------------|-----------------------------------------------------------------------------|
|                                                                             | Placeboc                                                                    | Ustekinumabd                                                                | Placebo~                                                                    | Ustekinumabd                                                                | Placebo~                                                                    | Ustekinumabd                                                                | Placebo°                                                                    | Ustekinumab                                                                 | Placeboce                                                                   | Ustekinumabdf                                                               |
| Subjects treated                                                            | 446                                                                         | 825                                                                         | 943                                                                         | 1749                                                                        | 1389                                                                        | 2574                                                                        | 1112                                                                        | 4135                                                                        | 2501                                                                        | 6709                                                                        |
| Avg duration of follow-up (weeks)                                           | 29.14                                                                       | 39.53                                                                       | 19.11                                                                       | 32.89                                                                       | 22.33                                                                       | 35.02                                                                       | 15.30                                                                       | 42.95                                                                       | 19.20                                                                       | 39.91                                                                       |
| Avg duration of treatment (weeks)                                           | 20.28                                                                       | 28.82                                                                       | 9.87                                                                        | 18.80                                                                       | 13.46                                                                       | 22.01                                                                       | 7.31                                                                        | 26.78                                                                       | 10.60                                                                       | 24.95                                                                       |
| Total subject-years of follow-up                                            | 250                                                                         | 627                                                                         | 347                                                                         | 1106                                                                        | 596                                                                         | 1733                                                                        | 327                                                                         | 3415                                                                        | 924                                                                         | 5149                                                                        |
| Numberofsubjects with events per 100 subject-years (number of subjects with | Numberofsubjects with events per 100 subject-years (number of subjects with | Numberofsubjects with events per 100 subject-years (number of subjects with | Numberofsubjects with events per 100 subject-years (number of subjects with | Numberofsubjects with events per 100 subject-years (number of subjects with | Numberofsubjects with events per 100 subject-years (number of subjects with | Numberofsubjects with events per 100 subject-years (number of subjects with | Numberofsubjects with events per 100 subject-years (number of subjects with | Numberofsubjects with events per 100 subject-years (number of subjects with | Numberofsubjects with events per 100 subject-years (number of subjects with | Numberofsubjects with events per 100 subject-years (number of subjects with |
| events) Adverse events Serious adverse                                      | 121.65 (304)                                                                | 95.03 (596)                                                                 | 197.97 (686)                                                                | 131.52 (1455)                                                               | 165.99 (990)                                                                | 118.32 (2051)                                                               | 181.81 (595)                                                                | 93.38 (3189)                                                                | 171.60 (1585)                                                               | 101.77 (5240)                                                               |
| events                                                                      | 18.41 (46)                                                                  | 12.91 (81)                                                                  | 34.05 (118)                                                                 | 25.94 (287)                                                                 | 27.50 (164)                                                                 | 21.23 (368)                                                                 | 8.25 (27)                                                                   | 6.06 (207)                                                                  | 20.68 (191)                                                                 | 11.17 (575)                                                                 |
| Infections                                                                  | 59.23 (148)                                                                 | 49.75 (312)                                                                 | 95.52 (331)                                                                 | 72.59 (803)                                                                 | 80.31 (479)                                                                 | 64.32 (1115)                                                                | 84.64 (277)                                                                 | 65.33 (2231)                                                                | 81.85 (756)                                                                 | 64.99 (3346)                                                                |
| Serious infectionss.h                                                       | 4.00 (10)                                                                   | 3.19 (20)                                                                   | 6.64 (23)                                                                   | 6.06 (67)                                                                   | 5.53 (33)                                                                   | 5.02 (87)                                                                   | 1.22 (4)                                                                    | 1.20 (41)                                                                   | 4.01 (37)                                                                   | 2.49 (128)                                                                  |
| Serious MACEi                                                               | 0.80 (2)                                                                    | 0.16 (1)                                                                    | 0.00 (0)                                                                    | 0.09 (1)                                                                    | 0.34 (2)                                                                    | 0.12 (2)                                                                    | 0.61 (2)                                                                    | 0.59 (20)                                                                   | 0.43 (4)                                                                    | 0.43 (22)                                                                   |
| Discontinuation of study agents because of 1 or more adverse events         | 13.21 (33)                                                                  | 4.15 (26)                                                                   | 13.56 (47)                                                                  | 9.76 (108)                                                                  | 13.41 (80)                                                                  | 7.73 (134)                                                                  | 11.92 (39)                                                                  | 3.43 (117)                                                                  | 12.88 (119)                                                                 | 4.88 (251)                                                                  |
| Death Malignancies                                                          | 0.00 (0)                                                                    | 0.32 (2)                                                                    | 0.00 (0)                                                                    | 0.00 (0)                                                                    | 0.00 (0)                                                                    | 0.12 (2)                                                                    | 0.00 (0)                                                                    | 0.15 (5)                                                                    | 0.00 (0)                                                                    | 0.14 (7)                                                                    |
| (excluding NMSC)                                                            | 0.40 (1)                                                                    | 0.64 (4)                                                                    | 0.00 (0)                                                                    | 0.27 (3)                                                                    | 0.17 (1)                                                                    | 0.40 (7)                                                                    | 0.31 (1)                                                                    | 0.35 (12)                                                                   | 0.22 (2)                                                                    | 0.37 (19)                                                                   |

<div style=\"page-break-after: always\"></div>

a Through 60 weeks for subjects who entered maintenance at Week 16 of the induction study in Ulcerative Colitis CNTO1275UCO3001.

Ulcerative Colitis: CNTO1275UCO3001 (through induction Week 20 for subjects who did not enter maintenance and did not receive treatment at induction Week 8; through induction Week 28 for subjectswhodidnotentermaintenanceandreceivedtreatmentatinductionWeek8;throughmaintenanceWeek44forsubjectswhoenteredmaintenance);Crohn's:C0379T07(onlyplacebo-controlled IV population inpopulation1; throughWeek 28),C0743T26(throughWeek 36),CNTO1275CRD3001 (through Week8 for subjectswhoentered CNTO1275CRD3003; through Week 20for subjects who did not enter CNTO1275CRD3003), CNTO1275CRD3002 (through Week 8 for subjects who entered CNTO1275CRD3003; through Week 20 for subjects who did not enter CNTO1275CRD3003),CNTO1275CRD3003(throughWeek44);Ps0riasis:C0379T04(throughWeek52),C0743T08(throughWeek52),C0743T09(throughWeek52),C0743T12(throughWeek 52);PsA:C0743T10(throughWeek36),CNTO1275PSA3001(throughWeek52),CNTO1275PSA3002(throughWeek60).

Ulcerative Colitis and Crohn's disease:includes dataup to the first ustekinumabdosefor subjectswhowere initially treated with placebo;includes data at or after 16weeks from the first ustekinumab doseforsubjectswhoweretreatedwithustekinumabininductionandwerecrossedoverorrerandomizedtoplacebomaintenance.

Psoriatic diseases:includesdata upto the time of early escape or crossover.

d Ulcerative Colitis and Crohn's disease: includes data up to 16 weeks from the first ustekinumab dose for subjects who were crossed over or rerandomized to placebo maintenance.

f Psoriatic diseases: includes data from the first ustekinumab dose onward for subjects who early escaped or crossed over from placebo.

The events of serious infection were reviewed by clinical.

Infection as assessed by the investigator.

'MACE events independently adjudicated for Psoriasis, PsA, and Crohn's indications. For the UC indication, MACE events were identified by clinical review and were not independently adjudicated

<div style=\"page-break-after: always\"></div>

## Serious infections

TSFINFEo2D:Numberof Treatment-EmergentSeriousInfectionsPerHundredSubject-Year'sofFollow-UpDuringPlacebo-ControlledPortionbyMedDRA System-Organ Class andPreferred Term; Treated Subjects inInflammatoryBowel Disease(Ulcerative Colitis and Crohn's Disease)andPsoriatic Diseases (Psoriasis and Psoriatic Arthritis) Studiesa

|                                        | Ulcerative Colitis (0-8 weeks)   | Ulcerative Colitis (0-8 weeks)   | Crohn's Disease (0-8 weeks)   | Crohn's Disease (0-8 weeks)   | InflammatoryBowelDisease   | InflammatoryBowelDisease   | PsoriaticDiseases (0-12 or 16 weeks)   | PsoriaticDiseases (0-12 or 16 weeks)   | All Diseases Pooled   | All Diseases Pooled   |
|----------------------------------------|----------------------------------|----------------------------------|-------------------------------|-------------------------------|----------------------------|----------------------------|----------------------------------------|----------------------------------------|-----------------------|-----------------------|
|                                        | Placebo                          | Ustekinumab                      | Placebo                       | Ustekinumab                   | Placebo                    | Ustekinumab                | Placebo                                | Ustekinumab                            | Placebo               | Ustekinumab           |
| Subjects treated                       | 319                              | 641                              | 624                           | 1362                          | 943                        | 2003                       | 1111                                   | 2274                                   | 2054                  | 4277                  |
| Avgdurationoffollow-up (weeks)         | 7.96                             | 8.13                             | 8.15                          | 8.16                          | 8.08                       | 8.15                       | 13.45                                  | 14.08                                  | 10.98                 | 11.30                 |
| Avgexposure(numberof administrations)b | 1.00                             | 1.00                             | 1.00                          | 1.00                          | 1.00                       | 1.00                       | 2.24                                   | 2.37                                   | 1.67                  | 1.73                  |
| Totalsubject-yearsof follow-up         | 49                               | 100                              | 98                            | 214                           | 147                        | 314                        | 287                                    | 616                                    | 434                   | 930                   |
| Number of serious infectionss          | 4                                | 3                                |                               | 22                            | 11                         | 25                         | 4                                      | 5                                      | 15                    | 30                    |
| Event rate per 100 subject-years       | 8.19                             | 2.99                             | 7.16                          | 10.29                         | 7.50                       | 7.96                       | 1.39                                   | 0.81                                   | 3.46                  | 3.23                  |

<div style=\"page-break-after: always\"></div>

TSFINFE73C:NumberofSeriousInfectionsPerHundredSubject-Year'sofFollow-UpThroughOneYear\"ofFollowUpforInflammatoryBowel Disease (Ulcerative Colitis and Crohn's Disease) and PsA Studies and Through Five Year's of Follow Up for PSO Studies; Treated Subjects in Inflammatory Bowel Disease (Ulcerative Colitis and Crohn's Disease) and Psoriatic Diseases (Psoriasis and Psoriatic Arthritis) Studiesb

|                                             | Ulcerative Colitis   | Ulcerative Colitis   | Crohn's Disease   | Crohn's Disease   | InflammatoryBowelDisease   | InflammatoryBowelDisease   | Psoriatic Diseases   | Psoriatic Diseases   | AllDiseasesPooled   | AllDiseasesPooled   |
|---------------------------------------------|----------------------|----------------------|-------------------|-------------------|----------------------------|----------------------------|----------------------|----------------------|---------------------|---------------------|
|                                             | Placeboc             | Ustekinumabd         | Placeboc          | Ustekinumabd      | Placeboc                   | Ustekinumabd               | Placeboe             | Ustekinumabf         | Placeboce           | Ustekinumabd.f      |
| Subjects treated                            | 446                  | 825                  | 943               | 1749              | 1389                       | 2574                       | 1112                 | 4135                 | 2501                | 6709                |
| Number of subjects with serious infectionss | 10 (2.2%)            | 20 (2.4%)            | 23 (2.4%)         | 67 (3.8%)         | 33 (2.4%)                  | 87 (3.4%)                  | 4 (0.4%)             | 95 (2.3%)            | 37 (1.5%)           | 182 (2.7%)          |
| Totalsubject-yearsof follow-up              | 250                  | 627                  | 347               | 1106              | 596                        | 1733                       | 327                  | 9847                 | 924                 | 11581               |
| Median subject-years of follow-up           | 0.7                  | 1.0                  | 0.2               | 0.6               | 0.3                        | 0.7                        | 0.2                  | 1.1                  | 0.2                 | 1.0                 |
| Number of serious infections.h              | 10                   | 21                   | 25                | 71                | 35                         | 92                         | 4                    | 107                  | 39                  | 199                 |
| Event rate per 100 subject-years            | 4.00                 | 3.35                 | 7.21              | 6.42              | 5.87                       | 5.31                       | 1.22                 | 1.09                 | 4.22                | 1.72                |
| 95% confidence interval'                    | (1.92, 7.36)         | (2.07, 5.12)         | (4.67, 10.65)     | (5.01, 8.10)      | (4.09, 8.16)               | (4.28, 6.51)               | (0.33, 3.13)         | (0.89, 1.31)         | (3.00, 5.77)        | (1.49, 1.97)        |

<div style=\"page-break-after: always\"></div>

## Malignancies

|                                                          | Ulcerative Colitis (0-8 weeks)                | Ulcerative Colitis (0-8 weeks)                | Crohn's Disease (0-8 weeks)                   | Crohn's Disease (0-8 weeks)                   | InflammatoryBowel Disease                     | InflammatoryBowel Disease                     | Psoriatic Diseases (0-12 or 16 weeks)         | Psoriatic Diseases (0-12 or 16 weeks)         | All DiseasesPooled                            | All DiseasesPooled                            |
|----------------------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|
|                                                          | Placebo                                       | Ustekinumab                                   | Placebo                                       | Ustekinumab                                   | Placebo                                       | Ustekinumab                                   | Placebo                                       | Ustekinumab                                   | Placebo                                       | Ustekinumab                                   |
| Subjects treated                                         | 319                                           | 641                                           | 624                                           | 1362                                          | 943                                           | 2003                                          | 1111                                          | 2274                                          | 2054                                          | 4277                                          |
| Type of malignancy                                       | Type of malignancy                            | Type of malignancy                            | Type of malignancy                            | Type of malignancy                            | Type of malignancy                            | Type of malignancy                            | Type of malignancy                            | Type of malignancy                            | Type of malignancy                            | Type of malignancy                            |
| Nonmelanoma skin cancer                                  | Nonmelanoma skin cancer                       | Nonmelanoma skin cancer                       | Nonmelanoma skin cancer                       | Nonmelanoma skin cancer                       | Nonmelanoma skin cancer                       | Nonmelanoma skin cancer                       | Nonmelanoma skin cancer                       | Nonmelanoma skin cancer                       | Nonmelanoma skin cancer                       | Nonmelanoma skin cancer                       |
| Total subject-years of follow-up                         | 49                                            | 100                                           | 98                                            | 214                                           | 147                                           | 314                                           | 287                                           | 615                                           | 433                                           | 929                                           |
| Median subject-years of follow-up                        | 0.2                                           | 0.2                                           | 0.2                                           | 0.2                                           | 0.2                                           | 0.2                                           | 0.2                                           | 0.2                                           | 0.2                                           | 0.2                                           |
| Observed number of subjects with event                   | 0                                             | 0                                             | 0                                             | 0                                             | 0                                             | 0                                             | 2                                             | 4                                             | 2                                             | 4                                             |
| Incidence per 100 subject-years                          | 0.00                                          | 0.00                                          | 0.00                                          | 0.00                                          | 0.00                                          | 0.00                                          | 0.70                                          | 0.65                                          | 0.46                                          | 0.43                                          |
| 95% confidence intervalb                                 | (0.00, 6.13)                                  | (0.00, 2.99)                                  | (0.00,3.06)                                   | (0.00, 1.40)                                  | (0.00, 2.04)                                  | (0.00, 0.95)                                  | (0.08, 2.52)                                  | (0.18, 1.67)                                  | (0.06, 1.67)                                  | (0.12, 1.10)                                  |
| Malignancies other than nonmelanomaskincancer            | Malignancies other than nonmelanomaskincancer | Malignancies other than nonmelanomaskincancer | Malignancies other than nonmelanomaskincancer | Malignancies other than nonmelanomaskincancer | Malignancies other than nonmelanomaskincancer | Malignancies other than nonmelanomaskincancer | Malignancies other than nonmelanomaskincancer | Malignancies other than nonmelanomaskincancer | Malignancies other than nonmelanomaskincancer | Malignancies other than nonmelanomaskincancer |
| Totalsubject-yearsoffollow-up                            | 49                                            | 100                                           | 98                                            | 214                                           | 147                                           | 314                                           | 287                                           | 615                                           | 434                                           | 929                                           |
| Median subject-years of follow-up                        | 0.2                                           | 0.2                                           | 0.2                                           | 0.2                                           | 0.2                                           | 0.2                                           | 0.2                                           | 0.2                                           | 0.2                                           | 0.2                                           |
| Observed number of subjects with event                   | 0                                             | 0                                             | 0                                             | 0                                             | 0                                             | 0                                             | 1                                             | 1                                             | 1                                             | 1                                             |
| Incidenceper1oosubject-years 95% confidence intervalb    | 0.00 (0.00, 6.13)                             | 0.00 (0.00, 2.99)                             | 0.00 (0.00, 3.06)                             | 0.00 (0.00, 1.40)                             | 0.00 (0.00, 2.04)                             | 0.00 (0.00, 0.95)                             | 0.35 (0.01, 1.94)                             | 0.16 (0.00, 0.91)                             | 0.23 (0.01, 1.28)                             | 0.11 (0.00, 0.60)                             |
| All malignancies                                         | All malignancies                              | All malignancies                              | All malignancies                              | All malignancies                              | All malignancies                              | All malignancies                              | All malignancies                              | All malignancies                              | All malignancies                              | All malignancies                              |
| Total subject-years of follow-up                         | 49                                            | 100                                           | 98                                            | 214                                           | 147                                           | 314                                           | 287                                           | 615                                           | 433                                           | 929                                           |
| Median subject-years of follow-up                        | 0.2                                           | 0.2                                           | 0.2                                           | 0.2                                           | 0.2                                           | 0.2                                           | 0.2                                           | 0.2                                           | 0.2                                           | 0.2                                           |
| Observed number ofsubjects with event                    | 0                                             | 0                                             | 0                                             | 0                                             | 0                                             | 0                                             | 3                                             | 5                                             | 3                                             | 5                                             |
| Incidence per 100 subject-years 95% confidence intervalb | 0.00 (0.00, 6.13)                             | 0.00 (0.00, 2.99)                             | 0.00 (0.00, 3.06)                             | 0.00 (0.00, 1.40)                             | 0.00 (0.00, 2.04)                             | 0.00 (0.00, 0.95)                             | 1.05 (0.22, 3.06)                             | 0.81 (0.26, 1.90)                             | 0.69 (0.14, 2.02)                             | 0.54 (0.17, 1.26)                             |

<div style=\"page-break-after: always\"></div>

TSFMAL74C:Numberof Subjectswith1orMoreMalignanciesPerHundredSubject-Year'sof Follow-UpThroughOneYear?ofFollowUpforInflammatoryBowel Disease(UlcerativeColitisandCrohn'sDisease)andPsAStudiesandThroughFiveYearsofFollowUpforPSOStudies;TreatedSubjectsinInflammatory Bowel Disease (Ulcerative Colitis and Crohn's Disease) and Psoriatic Diseases (Psoriasis and Psoriatic Arthritis) Studiesb

|                                                          | Ulcerative Colitis   | Ulcerative Colitis   | Crohn's Disease   | Crohn's Disease   | InflammatoryBowel Disease   | InflammatoryBowel Disease   | PsoriaticDiseases   | PsoriaticDiseases   | All Diseases Pooled   | All Diseases Pooled   |
|----------------------------------------------------------|----------------------|----------------------|-------------------|-------------------|-----------------------------|-----------------------------|---------------------|---------------------|-----------------------|-----------------------|
| Subjects treated                                         | Placeboc 446         | Ustekinumabd 825     | Placeboc 943      | Ustekinumabd 1749 | Placeboc 1389               | Ustekinumabd 2574           | Placebo² 1112       | Ustekinumabf 4135   | Placeboce 2501        | Ustekinumabd.f 6709   |
| Type of malignancy Nonmelanoma skin cancer               |                      |                      |                   |                   |                             |                             |                     |                     |                       |                       |
| Total subject-years of follow-up                         | 250                  | 626                  | 346               | 1105              | 596                         | 1731                        | 327                 | 9814                | 923                   | 11545                 |
| Median subject-years of follow-up                        | 0.7                  | 1.0                  | 0.2               | 0.6               | 0.3                         | 0.7                         | 0.2                 | 1.1                 | 0.2                   | 1.0                   |
| Observed number of subjects with event Incidence per 100 | 0                    | 3                    | 2                 | 4                 | 2                           | 7                           | 2                   | 49                  | 4                     | 56                    |
| subject-years 95% confidence intervale                   | 0.00 (0.00, 1.20)    | 0.48 (0.10, 1.40)    | 0.58 (0.07, 2.09) | 0.36 (0.10, 0.93) | 0.34 (0.04, 1.21)           | 0.40 (0.16, 0.83)           | 0.61 (0.07,2.21)    | 0.50 (0.37, 0.66)   | 0.43 (0.12, 1.11)     | 0.49 (0.37, 0.63)     |
| Malignanciesotherthan nonmelanomaskincancer              |                      |                      |                   |                   |                             |                             |                     |                     |                       |                       |
| Total subject-years of follow-up                         | 250                  | 626                  | 347               | 1106              | 596                         | 1732                        | 327                 | 9829                | 923                   | 11561                 |
| Median subject-years of follow-up                        | 0.7                  | 1.0                  | 0.2               | 0.6               | 0.3                         | 0.7                         | 0.2                 | 1.1                 | 0.2                   | 1.0                   |
| Observed number of subjectswithevent                     |                      | 4                    | 0                 | 3                 | 1                           | 7                           |                     | 55                  | 2                     | 62                    |
| Incidence per 100 subject-years 95% confidence intervale | 0.40 (0.01,2.23)     | 0.64 (0.17, 1.64)    | 0.00 (0.00, 0.86) | 0.27 (0.06, 0.79) | 0.17 (0.00, 0.93)           | 0.40 (0.16, 0.83)           | 0.31 (0.01, 1.70)   | 0.56 (0.42, 0.73)   | 0.22 (0.03, 0.78)     | 0.54 (0.41, 0.69)     |
| All malignancies                                         |                      |                      |                   |                   |                             |                             |                     |                     |                       |                       |
| Total subject-years of follow-up                         | 250                  | 625                  | 346               | 1105              | 596                         | 1730                        | 326                 | 9796                | 922                   | 11526                 |
| Median subject-years of follow-up                        | 0.7                  | 1.0                  | 0.2               | 0.6               | 0.3                         | 0.7                         | 0.2                 | 1.1                 | 0.2                   | 1.0                   |
| Observednumber of subjects with event                    |                      | 7                    | 2                 | 7                 | 3                           | 14                          | 3                   | 104                 | 6                     | 118                   |
| Incidence per 100 subject-years 95% confidence interval= | 0.40 (0.01, 2.23)    | 1.12 (0.45, 2.31)    | 0.58 (0.07, 2.09) | 0.63 (0.25, 1.30) | 0.50 (0.10, 1.47)           | 0.81 (0.44, 1.36)           | 0.92 (0.19, 2.69)   | 1.06 (0.87, 1.29)   | 0.65 (0.24, 1.42)     | 1.02 (0.85, 1.23)     |

<div style=\"page-break-after: always\"></div>

For malignancies other than cervical cancer in situ and nonmelanoma skin cancer (NMSC), comparisons with an external database were conducted to determine whether event rates across indications were consistent with those rates expected for the general population. The National Institutes of Health Surveillance, Epidemiology, and End Results (SEER) database (2000-2010) was selected to estimate expected event rates of noncutaneous malignancies in the general US population adjusting for age, sex, and race. Selection of the SEER database was based on the ability of the database to identify the targeted events of interest. The SEER database contains information on over 3 million malignancies based upon population information from US census data, and malignancy data are collected and categorized in a manner that can be easily compared to the ustekinumab clinical study database.

The company states that cervical cancers in situ and NMSCs are not included in the SEER database and, therefore, these malignancies were excluded from enumeration in this analysis.

These comparisons are similar to those provided in previous submissions for the psoriasis and PsA indications

<div style=\"page-break-after: always\"></div>

TSFMAL73C: Number of Subjects with 1 or More Malignancies Per Hundred Subject-Years of Follow-Up Through One Year\" of Follow Up for Inflammatory Bowel Disease(UlcerativeColitis and Crohn'sDisease)andPSAStudies and ThroughFiveYear's of FollowUpforPsOStudies (Comparingwith SEERData);TreatedSubjects inInflammatoryBowel Disease(Ulcerative Colitis and Crohn'sDisease)andPsoriaticDiseases (PsoriasisandPsoriatic Arthritis) Studiesb

|                                        | Ulcerative Colitis   | Ulcerative Colitis   | Crohn's Disease   | Crohn's Disease   | InflammatoryBowelDisease   | InflammatoryBowelDisease   | Psoriatic Diseases   | Psoriatic Diseases   | All Diseases Pooled   | All Diseases Pooled   |
|----------------------------------------|----------------------|----------------------|-------------------|-------------------|----------------------------|----------------------------|----------------------|----------------------|-----------------------|-----------------------|
|                                        | Placeboc             | Ustekinumabd         | Placeboc          | Ustekinumabd      | Placeboc                   | Ustekinumabd               | Placebo?             | Ustekinumab          | Placeboce             | Ustekinumabdf         |
| Subjects treated                       | 446                  | 825                  | 943               | 1749              | 1389                       | 2574                       | 1112                 | 4135                 | 2501                  | 6709                  |
| Ns                                     | 417                  | 757                  | 914               | 1689              | 1331                       | 2446                       | 1095                 | 4038                 | 2426                  | 6484                  |
| Total subject-years of follow-up       | 203                  | 577                  | 334               | 1048              | 537                        | 1625                       | 322                  | 9620                 | 860                   | 11245                 |
| Median subject-years of follow-up      | 0.4                  | 1.0                  | 0.2               | 0.6               | 0.2                        | 0.7                        | 0.2                  | 1.1                  | 0.2                   | 1.0                   |
| Observed number of subjectswithevent   |                      | 4                    | 0                 | 2                 |                            | 6                          |                      | 52                   | 2                     | 58                    |
| Expected number of subjects with event | 0.86                 | 2.34                 | 1.16              | 3.49              | 2.02                       | 5.83                       | 1.76                 | 56.48                | 3.78                  | 62.31                 |
| SIR'                                   | 1.17                 | 1.71                 | 0.00              | 0.57              | 0.50                       | 1.03                       | 0.57                 | 0.92                 | 0.53                  | 0.93                  |
| SIR 95% confidence interval            | (0.03, 6.51)         | (0.47, 4.38)         | (0.00, 2.58)      | (0.07, 2.07)      | (0.01, 2.76)               | (0.38, 2.24)               | (0.01, 3.17)         | (0.69, 1.21)         | (0.06, 1.91)          | (0.71, 1.20)          |

<div style=\"page-break-after: always\"></div>

## Post marketing experience

## Safety Surveillance

Post marketing information has been accruing since the first approval of ustekinumab on 12 December 2008. As of 31 December 2017, ustekinumab has received marketing authorization globally, including countries in North America, Europe, South America, and the Asia Pacific regions, for the treatment of adult and pediatric (age ≥12 to &lt;18 years) patients with chronic moderate to severe plaque psoriasis, adult patients with active PsA, and adult patients with moderately to severely active Crohn's disease.

The estimated cumulative global exposure to ustekinumab from launch through 31 December 2017 is 1,036,701 person-years. The evaluation of postmarketing data is part of the Sponsor's comprehensive safety surveillance program, which also includes review of data from ongoing clinical studies and registries. Periodic Safety Update Reports generated for ustekinumab reflect ongoing postmarketing safety surveillance as well as assessments of all important identified and potential risks.

The cut-off date for postmarketing data in this SCS is 31 December 2017, which coincides with the most recent Periodic Safety Update Report cutoff date, and through this time period, 15 Periodic Safety Update Reports have been completed. Based on the postmarketing safety surveillance, hypersensitivity reactions (including rash and urticaria), serious hypersensitivity reactions (including anaphylaxis and angioedema), lower respiratory tract infection, allergic alveolitis, eosinophilic pneumonia, erythrodermic psoriasis, and pustular psoriasis, were identified as ADRs.

Ustekinumab continues to have a favourable benefit-risk profile for the treatment of patients with moderate to severe plaque psoriasis, PsA, and/or moderately to severely active Crohn's disease.

The Sponsor will continue to monitor the safety profile of ustekinumab and report the safety findings as appropriate.

## Postmarketing Registries

A Crohn's disease postmarketing registry study (An observational postauthorization safety study to describe the safety of ustekinumab and other Crohn's disease treatments in a cohort of patients with Crohn's disease, RRA-20745), was initiated in the European Union in 2017. The objective of this study is to monitor the long-term safety profile of ustekinumab use in adult patients with moderately to severely active Crohn's disease. Currently, minimal data has been collected in this registry.

The most extensive post marketing registry data for ustekinumab are available from The Psoriasis Longitudinal Assessment and Registry (PSOLAR, C0168Z03), which is enrolling subjects with psoriasis treated with ustekinumab.

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 17: PSOLAR: Cumulative Incidence Rates of Adverse Events of Special Interest Per 1oo Patientyear's

| Ever Exposeda                                |                                   |                                    | Non-Sponsor                       |                           |                  |
|----------------------------------------------|-----------------------------------|------------------------------------|-----------------------------------|---------------------------|------------------|
| All-causemortality                           | 0.47 [110]                        | 0.50 [39]                          | 0.50 [116]                        | 0.65 [64]                 | 0.51 [329]       |
| Cardiovascular                               | 0.14 [32]                         | 0.13 [10]                          | 0.09 [21]                         | 0.18 [18]                 | 0.13 [81]        |
| Other                                        | 0.24 [56]                         | 0.26 [20]                          | 0.27 [63]                         | 0.32 [31]                 | 0.27 [170]       |
| Unexplained death                            | 0.09 [22]                         | 0.12 [9]                           | 0.14 [32]                         | 0.15 [15]                 | 0.12 [78]        |
| Major adverse                                |                                   |                                    |                                   |                           |                  |
| cardiovascularevents                         | 0.33 [77]                         | 0.34 [26]                          | 0.30 [70]                         | 0.41 [40]                 | 0.33 [213]       |
| Cardiovascular death                         | 0.14 [32]                         | 0.13 [10]                          | 0.09 [21]                         | 0.18 [18]                 | 0.13 [81]        |
| Nonfatalcerebrovascular accident             | 0.06 [15]                         | 0.06 [5]                           | 0.08 [18]                         | 0.10 [10]                 | 0.07 [48]        |
| Nonfatal myocardial infarction               | 0.13 [30]                         | 0.14 [11]                          | 0.13 [31]                         | 0.12 [12]                 | 0.13 [84]        |
| Malignancy excluding nonmelanomaskincancer's | 0.61 [141]                        | 0.88 [68]                          | 0.72 [166]                        | 0.78 [76]                 | 0.70 [451]       |
| Exposed within the 91-day window'            | Exposed within the 91-day window' |                                    |                                   |                           |                  |
| Events/100 patient-years [number of events]  | Ustekinumab (N=14151 PY)          | Other Sponsor biologic (N=4828 PY) | Non-Sponsor biologic (N=19030 PY) | Non-biologic (N=26004 PY) | All (N=64013 PY) |
| Seriousinfections and infestations           | 1.00 [142]                        | 2.71 [131]                         | 1.80 [342]                        | 1.30 [338]                | 1.49 [953]       |

Note: The \"Ustekinumab' cohort represents patients who received ustekinumab at any point, including pre-registry. ^Other Sponsor biologic' refers to the cohort of patients who received (infliximab or golimumab) and not ustekinumab at any point, including pre-registry. \"Non-Sponsor biologic' refers to the cohort of patients who received only non-Sponsor biologics predominately etanercept or adalimumab at any point, including pre-registry.

Two post marketing studies monitoring pregnancies in women exposed to ustekinumab are the Nordic Pregnancy Research Initiative [CNTO1275PSO4007] and the STELARA Pregnancy Exposure Registry-OTIS Autoimmune Diseases in Pregnancy Project [CNTO1275PSO4037]

## 2.5.1. Discussion on clinical safety

The safety database from the two Phase 3 Ulcerative Colitis clinical studies (UCO3001 induction and maintenance studies) comprises 825 ustekinumab-treated subjects. All 825 subjects received a single IV dose of ustekinumab. For the maintenance trial, the company uses the randomised population for primary analyses. This approach was also used for the analysis of safety data for the extension of indication in Crohn's Disease .

The most common adverse reactions (&gt; 5%) in controlled periods of the adult psoriasis, psoriatic arthritis and Crohn's disease clinical studies with ustekinumab were nasopharyngitis and headache. Based on the postmarketing safety surveillance, hypersensitivity reactions (including rash and urticaria), serious hypersensitivity reactions (including anaphylaxis and angioedema), lower respiratory tract infection, allergic alveolitis, eosinophilic pneumonia, erythrodermic psoriasis, and pustular psoriasis, were identified as ADRs.

Serious infections (including mycobacterial and salmonella infections) and malignancies represent important potential risks due to the mechanism of action. Current post-marketing registries for patients with moderate to severe psoriasis and Crohn's disease aim to further characterise long term safety for these indications.

Demographics of patients randomised with UC are broadly comparable to patients randomised with CD. Differences in terms of body weight (IBD patients had lower median body weight and a lower BMI than patients with psoriatic disease) as well as age (IBD patients were younger than patients with psoriatic disease) are consistent with the reported demographics of patients with UC and Crohn's. Overall, no trends

<div style=\"page-break-after: always\"></div>

were observed with regards to differences in the proportions of subjects reporting AEs, SAEs, or infections, when evaluated according to the subject's race or weight and the safety profile of ustekinumab was not affected by UC disease severity.

No major safety issues were identified as part of those trials.

Adverse events identified as related to exposure to Stelara (both intravenous and subcutaneous administrations) were consistent with known events described in the SmPC.

The number of adverse events (high level descriptions) in both induction and maintenance study appear similar across all treatment groups. Through Week 8 of the induction phase, 50.0%, 41.4%, and 48.0% of subjects had 1 or more AEs in the ~6 mg/kg, 130 mg, and placebo groups, respectively. Through the final safety visit of the induction phase, 42.4% of subjects in the combined ustekinumab IV group had 1 or more AEs compared with 48.0% of subjects in the placebo group. In the maintenance phase the proportions of subjects experiencing a treatment emergent AE was comparable amongst groups. Of the 523 subjects who were randomised at maintenance Week 0 and received at least 1 administration of study agent, 1 or more AEs were reported through Week 44 for 77.3%, 69.2%, and 78.9% of subjects in the ustekinumab q8w, ustekinumab q12w, and placebo groups, respectively.

The company has identified a new non-serious ADR of sinusitis (with a frequency of common [≥1/100 and &lt;1/10]) and this new ADR has been included in the SmPC.

For SAEs, through Week 8 of the induction phase, 3.1%, 3.7%, and 6.6% of subjects reported 1 or more SAEs in the ~6 mg/kg, 130 mg, and placebo groups, respectively. Through the final safety visit of the induction phase, 3.6% of subjects in the combined ustekinumab IV group and 6.9% of subjects in the placebo group reported SAEs. In randomised patients of the maintenance phase, serious AEs were reported in 8.5%, 7.6%, and 9.7% of subjects in the ustekinumab q8w, ustekinumab q12w, and placebo groups, respectively. Ulcerative colitis was the most commonly reported SAE across these randomized treatment groups, however in line with efficacy results, there was a decrease in the number of ustekinumab patients experiencing the SAE ulcerative colitis compared to placebo patients.

Overall, the levels of AEs and SAEs per 100 subject-years are lower for ustekinumab compared to placebo treated patients with UC. This data follows a similar trend observed as for CD and psoriatic diseases as evident in the pooled analysis of all diseases in the ustekinumab clinical development programme.

Two cases of DVTs occurred in the ~6 mg/kg group during the induction phase. Both cases were confounded, as was the PE which occurred in the maintenance study, though it is noted that a numerical increase in VTEs was also seen in the CD studies. The CHMP acknowledges that in the small number of VTE events reported in the CNTO1275UCO3001 clinical program, the occurrence appears to be sporadic with no clear relationship to the duration of ustekinumab exposure.  This important potential risk will be further monitored by means of a safety extension of trial CNTO1275UCO3001 (category 3 as described in the RMP) meant to generate further data on long-term safety (beyond 44 weeks with ustekinumab for maintenance treatment).

Whilst the CHMP agrees with inclusion of the long-term extension study of CNTO1275UCO3001 as a required additional pharmacovigilance to further characterise long-term safety in patients with ulcerative colitis the committee takes due account that no other agents with activity against IL-12 or IL-23 are available for ulcerative colitis, and therefore there is no experience in this population with other similar agents over the long-term. Certain safety concerns could potentially have longer latencies, for example malignancy and some infections, such that they would not have been detected in this trial which is not powered to evaluate safety concerns of interest. Therefore the MAH agreed to perform also two adequately powered prospective observational PASSs (on ustekinumab treated patients with ulcerative colitis and patients with ulcerative colitis treated with other treatments) to further characterise the long-term safety of ustekinumab in ulcerative colitis. Further detail on the sample size of these studies and the exploration of ways of pooling the data will be provided when the protocols are submitted in April 2020.

<div style=\"page-break-after: always\"></div>

One of the primary objectives for the proposed PASSs is venous thromboembolism. The secondary objectives of these studes will be to compare the long-term safety in adult patients with UC between patients treated with ustekinumab and patients treated with other UC disease therapies. The primary outcomes will be venous thromboembolism, malignancies and serious infections, as in the existing PASS in Crohn's disease.

Serious infections including TB and opportunistic infections have occurred following ustekinumab treatment. Through Week 8 of the induction phase, a total of 7 subjects had 1 or more serious infection as identified by the investigator (0.3% [1 subject], 0.6% [2 subjects], and 1.3% [4 subjects] in the ~6 mg/kg, 130 mg, and placebo groups, respectively). Among randomised subjects in the maintenance phase, serious AEs of infection were reported in 3 (1.7%), 6 (3.5%), and 4 (2.3%) subjects in the ustekinumab q8w, ustekinumab q12w, and placebo groups, respectively. No cases of active TB were reported in the induction or maintenance studies. A life threatening opportunistic infection of legionella pneumonia was reported for a subject in the placebo → ~6 mg/kg group of the induction phase. There were two cases of CMV colitis. Both events were of moderate intensity and resulted in hospitalization.

Overall the rate per 100 subject-years of infections and serious infections are lower for ustekinumab compared to placebo treated patients with UC. Again this follows a similar trend observed as for CD and psoriatic diseases as evident in the pooled analysis of all diseases.

There was 1 death reported through the final safety visit of the induction phase; a subject in the ~6 mg/kg group experienced sudden death on Study Day 42 attributed to an SAE of oesophageal varices hemorrhage. The event was considered not to be related to study agent by the investigator. The subject had no reported history of portal hypertension or cirrhosis. Two other deaths occurred in the study, one in the maintenance study attributed to acute respiratory failure that occurred during thyroid surgery for a multinodular goiter and the other which occurred during the ongoing LTE (after maintenance week 44) and attributed to failure to thrive. This latter death was complicated by CMV. The third case is considered possibly related to ustekinumab and confirms the need for the precautionary statement about treatment of elderly and patients with history of recurrent infections as per section 4.4 of the SPC.

Serious infections will be evaluated as a primary outcome of the proposed PASSs studies..

Seven subjects in the treatment group versus 1 in the placebo group developed malignancies. Most of these malignancies were diagnosed within 6 months of the first dose. The standardised incidence ratios (excluding in situ cervical cancer and non-melanoma skin cancer) using epidemiological data from the SEER database, adjusting for age and race, is presented to place these occurrences into context of what might be expected for the population. The SIR obtained is greater than 1 (1.7) for UC and almost three times the SIRs obtained for previous indications. The follow-up data to week 220 from the long-term extension study will help to give more information on the risk of malignancy in the trial population. In addition the category 3 PASS studies will monitor for the risk of malignancies in UC patients.

Although use of highly effective contraception was an inclusion criteria for ustekinumab patients in the UC trials, there were still a number of pregnancies during the trials, however the outcomes seen in the ustekinumab pregnancies are comparable with what is expected in the general population.

The observed safety profile in the induction phase appears less favourable in the elderly ( ≥ 65 years) in UC compared to placebo treatment. The numbers involved are low and so the ability to draw conclusions in this age group is limited. While proportions of those aged 65 years and older reporting AEs, SAEs and infections was greater than those &lt;65 years in the induction study, this pattern was not observed in the maintenance study. There was however, a significant difference in terms of the numbers of patients who discontinued because of an AE in the maintenance study (4% in those &lt;65 years versus 20% in those &gt;65 years) in the maintenance phase. The company provided safety summary statistics across the development programme for all indications for analysis for sub-populations &lt; 65 yrs and &gt; 65 yrs of age. There were no obvious trends

<div style=\"page-break-after: always\"></div>

in the data and it did not appear that there is a higher proportion of AEs or SAEs in those aged 65 yrs or above. It is noted that a warning exists in section 4.4 of the SmPC stating that 'the number of patients aged 65 and over is not sufficient to determine whether they response differently from younger patients. Because there is a higher incidence of infections in the elderly population in general, caution should be used in treating the elderly'.

Overall, following up to 1 year of ustekinumab treatment, there was no consistent evidence that ustekinumab increased cardiovascular risk, there were no cases of anaphylactic or delayed hypersensitivity reactions reported to ustekinumab treatment (there was 1 case of anaphylaxis in a placebo treated patient) and there was no increase in immunogenicity for ustekinumab patients compared to placebo patients.

## 2.5.2. Conclusions on clinical safety

Overall no new safety signals have arisen compared to CD and rates of AEs/SAEs are comparable across placebo and ustekinumab treatment groups. However the committee takes due account that no other agents with activity against IL-12 or IL-23 are available for ulcerative colitis and therefore there is no experience in this population with other similar agents over the long-term. Certain safety concerns could potentially have longer latencies, for example malignancy and some infections. Therefore long-term safety in patients with ulcerative colitis will be further characterised by means of a long term safety extension of the maintenance trial and two prospective observational category 3 PASSs as defined in the RMP..

## 2.5.3. PSUR cycle

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## 2.6. Risk management plan

The CHMP received the following PRAC Advice on the submitted Risk Management Plan:

The PRAC considered that the risk management plan version 15.4 is acceptable.

The MAH is reminded that, within 30 calendar days of the receipt of the Opinion, an updated version of Annex I of the RMP template, reflecting the final RMP agreed at the time of the Opinion should be submitted to h-eurmp-evinterface@emea.europa.eu.

The CHMP endorsed the Risk Management Plan version 15.4 with the following content:

<div style=\"page-break-after: always\"></div>

| Safety Concern                              | Risk Minimization Measures                                                                                                                                                                                                                                                                                                                                              | Pharmacovigilance Activities                                                                                                                                                                                                                 |
|---------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Serious systemic hypersensitivity reactions | Routine risk minimization measures: SmPC section 4.2 (Posology and Method of Administration) SmPC section 4.3 (Contraindications) SmPC section 4.4 (Special Warnings and Precautions for Use) and Package Leaflet section 2 SmPC section 4.8 (Undesirable Effects) and Package Leaflet section 4 Additional risk minimization measures: No additional risk minimization | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Adverse reaction follow-up questionnaire Additional pharmacovigilance activities: C0168Z03 PSOLAR CNTO1275PSO4005 (Nordic Database Initiative) |
| Facial palsy                                | Routine risk minimization measures: SmPC section 4.2 (Posology and Method of Administration) SmPC section 4.8 (Undesirable Effects) and Package Leaflet section 4 Additional risk minimization measures: No additional risk minimization measures.                                                                                                                      | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Adverse reaction follow-up questionnaire Additional pharmacovigilance activities: C0168Z03 PSOLAR CNTO1275PSO4005 (Nordic Database             |
| Pustular psoriasis                          | Routine risk minimization measures: SmPC section 4.2 (Posology and Method of Administration) SmPC section 4.8 (Undesirable Effects) and Package Leaflet section 4 Additional risk minimization measures: No additional risk minimization measures.                                                                                                                      | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Adverse reaction follow-up questionnaire Additional pharmacovigilance activities: C0168Z03 PSOLAR                                              |
| Erythrodermic psoriasis                     | Routine risk minimization measures: SmPC section 4.2 (Posology and Method of Administration) SmPC section 4.4 (Special Warnings and Precautions for Use) and Package Leaflet section 2 SmPC section 4.8 (Undesirable Effects) and Package Leaflet section 4 Additional risk minimization measures: No additional risk minimization                                      | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Adverse reaction follow-up questionnaire Additional pharmacovigilance activities: C0168Z03 PSOLAR                                              |

<div style=\"page-break-after: always\"></div>

| Safety Concern                                                         | Risk Minimization Measures                                                                                                                                                                                                                                                                                                                                                        | Pharmacovigilance Activities                                                                                                                                                                                                                                                                                                           |
|------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Serious infections (including mycobacterial and salmonella infections) | Routine risk minimization measures: SmPC section 4.2 (Posology and Method of Administration) SmPC section 4.3 (Contraindications) SmPC section 4.4 (Special Warnings and Precautions for Use) and Package Leaflet section 2 SmPC section 4.8 (Undesirable Effects) and Package Leaflet section 4 Additional risk minimization measures: No additional risk minimization measures. | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Adverse reaction follow-up questionnaire Additional pharmacovigilance activities: C0168Z03 PSOLAR CNTO1275PSO4005 (Nordic Database Initiative) STELARA UC postauthorization safety study (PASS) using SWIBREG STELARA UC PASS using SNDS |
| Malignancy                                                             | Routine risk minimization measures: SmPC section 4.2 (Posology and Method of Administration) SmPC section 4.4 (Special Warnings and Precautions for Use) and Package Leaflet section 2 SmPC section 4.8 (Undesirable Effects) Additional risk minimization measures: No additional risk minimization measures.                                                                    | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Adverse reaction follow-up questionnaire Additional pharmacovigilance activities: C0168Z03 PSOLAR CNTO1275PSO4005 (Nordic Database Initiative) STELARA UC PASS using SWIBREG STELARA UC PASS using SNDS                                  |
| Cardiovascular events                                                  | Routine risk minimization measures: SmPC section 4.2 (Posology and Method of Administration) Additional risk minimization measures: No additional risk minimization measures.                                                                                                                                                                                                     | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Adverse reaction follow-up questionnaire Additional pharmacovigilance activities: C0168Z03 PSOLAR CNTO1275PSO4005 (Nordic Database Initiative)                                                                                           |

<div style=\"page-break-after: always\"></div>

| Safety Concern                                    | Risk Minimization Measures                                                                                                                                                                                                                                         | Pharmacovigilance Activities                                                                                                                                                                                                                                                              |
|---------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Serious depression including suicidality          | Routine risk minimization measures: SmPC section 4.2 (Posology and Method of Administration) SmPC section 4.8 (Undesirable Effects) and Package Leaflet section 4 Additional risk minimization measures: No additional risk minimization measures.                 | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None. Additional pharmacovigilance activities: C0168Z03 PSOLAR CNTO1275PSO4005 (Nordic Database Initiative)                                                                                 |
| Reversible posterior leukoencephalopathy syndrome | Routine risk minimization measures: SmPC section 4.2 (Posology and Method of Administration) Additional risk minimization measures: No additional risk minimization measures.                                                                                      | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Adverse reaction follow-up questionnaire Additional pharmacovigilance activities: C0168Z03 PSOLAR CNTO1275PSO4005 (Nordic Database                                                          |
| Venous thromboembolism                            | Routine risk minimization measures: SmPC section 4.2 (Posology and Method of Administration) Additional risk minimization measures: No additional risk minimization measures.                                                                                      | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Adverse reaction follow-up questionnaire Additional pharmacovigilance activities: Long-term extension of CNTO1275CRD3003 RRA-20745 STELARA UC PASS using SWIBREG STELARA UC PASS using SNDS |
| Exposure during pregnancy                         | Routine risk minimization measures: SmPC section 4.2 (Posology and Method of Administration) SmPC section 4.6 (Fertility, Pregnancy, and Lactation) and Package Leaflet Section 2 Additional risk minimization measures: No additional risk minimization measures. | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Follow-up of pregnancy reports Additional pharmacovigilance activities: CNTO1275PSO4007 (Pregnancy Research Initiative)                                                                     |

<div style=\"page-break-after: always\"></div>

| Safety Concern                                                                                                                    | Risk Minimization Measures                                                                                                                                                                                                                                                                                                                                          | Pharmacovigilance Activities                                                                                                                                                                              |
|-----------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Use in patients with a history of latent TB or TB                                                                                 | Routine risk minimization measures: SmPC Section 4.2 (Posology and Method of Administration) SmPC Section 4.4 (Special Warnings and Precautions for Use) and Package Leaflet Section 2 Additional risk minimization measures: No additional risk minimization measures.                                                                                             | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None. Additional pharmacovigilance activities: C0168Z03 PSOLAR CNTO1275PSO4005 (Nordic Database Initiative) |
| Use in patients with concurrent malignancy or a history of malignancy                                                             | Routine risk minimization measures: SmPC Section 4.2 (Posology and Method of Administration) SmPC Section 4.4 (Special Warnings and Precautions for Use) and Package Leaflet Section 2 Additional risk minimization measures: No additional risk minimization measures.                                                                                             | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None. Additional pharmacovigilance activities: C0168Z03 PSOLAR CNTO1275PSO4005 (Nordic Database Initiative) |
| Use in patients with recent or concomitant use of immunosuppressive therapy other than MTX, 6-MP, AZA, 5 ASA, and corticosteroids | Routine risk minimization measures: SmPC Section 4.2 (Posology and Method of Administration) SmPC Section 4.4 (Special Warnings and Precautions for Use) and Package Leaflet Section 2 SmPC Section 4.5 (Interaction with Other Medicinal Products and Other Forms of Interaction) Additional risk minimization measures: No additional risk minimization measures. | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None. Additional pharmacovigilance activities: C0168Z03 PSOLAR                                              |
| Long-term safety in pediatric psoriasis patients 6 years and older                                                                | Routine risk minimization measures: SmPC section 4.2 (Posology and Method of Administration) Additional risk minimization measures: No additional risk minimization measures.                                                                                                                                                                                       | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None. Additional pharmacovigilance activities: CNTO1275PSO4056 ( Pediatric Psoriasis Registry)              |

<div style=\"page-break-after: always\"></div>

| Safety Concern                                                                               | Risk Minimization Measures                                                                                                                                                    | Pharmacovigilance Activities                                                                                                                                                                                                                 |
|----------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Long-term impact on growth and development in pediatric psoriasis patients 6 years and older | Routine risk minimization measures: SmPC section 4.2 (Posology and Method of Administration) Additional risk minimization measures: No additional risk minimization measures. | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None. Additional pharmacovigilance activities: CNTO1275PSO4056 (Pediatric Psoriasis Registry)                                                  |
| Long-term safety in adult patients with moderately to severely active Crohn's disease        | Routine risk minimization measures: SmPC section 4.2 (Posology and Method of Administration) Additional risk minimization measures: No additional risk minimization measures. | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None. Additional pharmacovigilance activities: Long-term extension of CNTO1275CRD3003 RRA-20745                                                |
| Long-term safety in adult patients with moderately to severely active UC                     | Routine risk minimization measures: SmPC section 4.2 (Posology and Method of Administration) Additional risk minimization measures: No additional risk minimization measures. | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None. Additional pharmacovigilance activities: Long-term extension of CNTO1275UCO3001 STELARA UC PASS using SWIBREG STELARA UC PASS using SNDS |

## 2.7. Update of the Product information

As a consequence of this new indication, sections 4.1, 4.2, 4.4, 4.5, 4.8 5.1 and 5.2 of the SmPC have been updated. The Package Leaflet has been updated accordingly. Furthermore the text 'No new safety concerns were identified in this study extension with up to 2 years of treatment in patients with Crohn's Disease' was moved from SmPC 4.8 to 5.1 as it relates to a specific study.

## 2.7.1. User consultation

No justification for not performing a full user consultation with target patient groups on the package leaflet has been submitted by the MAH. However, the changes to the package leaflet are minimal and do not require user consultation with target patient groups.

<div style=\"page-break-after: always\"></div>

## 3. Benefit-risk balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

The indication applied for is the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic or have medical contraindications to such therapies.

UC is a chronic, relapsing, inflammatory disease of the colon characterised by alternating episodes of remission and spontaneous relapse.

## 3.1.2. Available therapies and unmet medical need

No current pharmacological therapy is able to provide a cure for UC. The goal of UC medical treatment is the induction and maintenance of disease remission without the need for long-term corticosteroids. Approved systemic therapies for the treatment of UC include anti-tumor necrosis factor alpha (TNFα) agents such as golimumab, infliximab, and adalimumab, the α4β7 integrin antagonist vedolizumab, and most recently the Janus kinase inhibitor tofacitinib. These agents are currently available for the treatment of patients with UC who have had inadequate response or were intolerant to conventional therapy. Vedolizumab and tofacitinib are the only products of that group that do not target TNFα and the only products that have demonstrated efficacy in patients who have had an inadequate response to (ie, primary non-response or secondary loss of response) or are intolerant of anti-TNFs.

Despite the availability of these approved therapies, not all patients respond to induction therapy (ie, primary non-response). In addition, many patients who initially respond to the approved therapies may lose response over time (secondary loss of response).  While it appears to be decreasing, the long term cumulative colectomy rate after diagnosis is still considerable at 15-20%. An agent effective in both inducing and maintaining remission is desirable for clinicians and patients.

## 3.1.3. Main clinical studies

The evidence for the efficacy and safety of ustekinumab in the treatment of adult subjects with moderately to severely active UC is based on two pivotal Phase 3 studies, an IV induction study and an SC maintenance study, which were conducted under a single protocol (UCO3001) but were designed and analysed as two separate studies with separate endpoints and Type I error control. The induction study randomized adult subjects with moderately to severely active UC who had demonstrated an inadequate response to or failure to tolerate conventional or biologic therapy. The maintenance study was a randomized-withdrawal study targeting subjects with moderately to severely active UC who had demonstrated a clinical response to induction treatment with IV ustekinumab.

Subjects had moderate to severely active ulcerative colitis based on a Mayo score of 6 to 12, inclusive, including an endoscopy subscore ≥ 2 as assessed during central review of the video of the endoscopy. Subjects must also have had an inadequate response to or failed to tolerate biologic (TNF antagonists and/or the integrin antagonist, vedolizumab) or conventional therapy (corticosteroids and/or immunomodulators [6 mercaptopurine (6-MP)/azathioprine (AZA)]). To meet the criteria for biologic failure, subjects must have received treatment with one or more TNF antagonists or vedolizumab at a dose approved for the treatment of UC, and either did not respond initially, responded initially but then lost response, or were intolerant to the medication. Subjects who were not biologic failures may have been biologic naïve or may have been exposed to biologic therapy but not demonstrated an inadequate response to or intolerance to treatment with a biologic agent; these subjects had to have demonstrated an inadequate response to or failed to tolerate

<div style=\"page-break-after: always\"></div>

conventional, non-biologic UC therapies. Subjects who had demonstrated corticosteroid dependence were also eligible for entry into the study.

In induction study UCO3001, subjects were randomised in a 1:1:1 ratio to receive ustekinumab 130mg IV weight-range-based 6mg/kg IV or placebo. Subjects were evaluated at week 8 for the primary endpoint of clinical remission as well as clinical response. Enrolment into the SC maintenance study comprised of subjects who were randomized to receive IV ustekinumab at Week 0 of the induction study and were in clinical response at Week 8 and subjects who were randomized to receive IV placebo at Week 0 of the induction study and were not in clinical response at Week 8 but were in clinical response at Week 16 of the induction study after receiving an induction dose of IV ustekinumab (~6 mg/kg) at Week 8).

In maintenance study UCO3001 subjects who were in clinical remission or response were randomised in a 1:1;1 ratio to ustekinumab 90mg SC q8W, 90mg SC q12w or placebo. Subjects were stratified by clinical remission status (25% of maintenance subjects) and not prior biological therapy but the proportions were similar in each arm compared to the induction study. The study was conducted for 44 weeks.

## 3.2. Favourable effects

In the induction study UCO3001 the primary endpoint of clinical remission was achieved in 15.6 % (p&lt;0.001) and 15.5%(p&lt;0.001) in the 130mg IV and 6mg/kg groups. The placebo rate was 5.3%. The major secondary endpoint of endoscopic healing was achieved in 26.3%, 27% and 13.8% in the 130mg, 6mg/kg and placebo groups respectively(p&lt;0.001). The treatment effects (across primary and major secondary) were observed in subjects who were biological failures, non-biological failures and in subjects with failure to both anti-TNF and vedolizumab. Clinical remission in biological failures was achieved in 11.6%, 12.7% and 1.2% in 130mg, 6mg/kg and placebo (p&lt;0.001). Clinical remission in patients who were failures to anti-TNF and vedolizumab were achieved in 10.9%, 10.3% and 0% in 130mg, 6mg/kg and placebo(p&lt;0.05). With the exception of clinical response where there was a 10% treatment difference in favour of the 6mg/kg dose, the efficacy results were similar for both induction doses.

The primary endpoint in the maintenance study UCO3001 was clinical remission at week 44. The primary endpoint was achieved in 38.4%, 43.8% and 24% in the q12w, q8w and placebo groups (p&lt;0.01). The key secondary endpoint of steroid free clinical remission was achieved in 37.8%, 42% and 23.4% in the q12w, q8w and placebo respectively (P&lt;0.01). The absolute numbers in each group achieving both these endpoints were &gt;95% concordant. There were no large treatment effect differences between the two dosing regimens for the FAS. The primary and key secondary endpoint was achieved in subjects with biological failure with 22.9, 39.6 and 17% achieving clinical remission in the q12w, q8w and placebo groups (P&lt;0.5). In patient with biological failure, the treatment effect was larger (&gt;10%) in the q8w groups.

The endpoint of maintenance of remission in remitters at baseline was achieved in 65% (p&lt;0.05), 57.9% (P&gt;0.05) and 37.8% in the q12w, q8w and placebo. FAS

## 3.3. Uncertainties and limitations about favourable effects

The primary endpoint in the induction study was defined by Mayo score of 2 or less with no subscore exceeding 1. The CHMP/EWP/18463/2006 Guideline states that the primary endpoint should reflect both endoscopic and symptomatic remission and should include cessation of rectal bleeding i.e.  rectal bleeding sub-score of 0. It is noted that he applicant also applied the US definition of clinical remission which specified rectal score of 0 and this endpoint was also achieved. Furthermore, the ideal primary endpoint of remission at the end of maintenance should be steroid free remission. In this application a multiplicity controlled secondary endpoint meets that criteria of steroid free clinical remission rather than the primary but the proportions meeting both endpoints are almost the same.

<div style=\"page-break-after: always\"></div>

A plateau effect on the induction dose could not be clearly demonstrated however, as the totality of data supports the proposed induction, this is not further pursued.

There was no direct active comparator which limits conclusions on efficacy in comparison to other existing therapies. However, the clinical remission rates for the FAS are similar to historical phase 3 results for other non-conventional therapies. There is no efficacy data beyond one year.

Treatment of subjects with failure to biological therapy represent a key treatment goal relative to unmet need and this is part of the claimed indication wording. The maintenance of efficacy is demonstrated for subjects who have failed either anti-TNF or vedolizumab but there were limited patients enrolled in the pivotal  maintenance  trial  who  failed  both,  anti-TNF  and  vedolizumab  (70  subjects  randomized  into maintenance).

In patients with failure to anti-TNF and vedolizumab the primary endpoint was achieved in 22.7%, 33.3% and 14.8% in the q12w, q8w and placebo groups, but did not reach statistical significance. The study was not powered to detect a difference in this subgroup and the numbers were fewer than 10 in each group but the applicant has demonstrated point estimates of efficacy in different strata (including patients having been exposed to/failing non-TNFα biologics and patients failing both anti-TNF and vedolizumab) that indicate efficacy is present across strata.  Demonstration of clinically important efficacy of ustekinumab in the most refractory treatment group cannot be considered robust but it can be anticipated that ustekinumab will be used extensively in this patient population. Therefore existing data on this subgroup and are of particular interest to prescribers and were added to 5.1. of the SmPC.

## 3.4. Unfavourable effects

The most common adverse reactions (&gt; 5%) in controlled periods of the adult psoriasis, psoriatic arthritis and Crohn's disease clinical studies with ustekinumab were nasopharyngitis and headache. Based on the postmarketing safety surveillance, hypersensitivity reactions (including rash and urticaria), serious hypersensitivity reactions (including anaphylaxis and angioedema), lower respiratory tract infection, allergic alveolitis, eosinophilic pneumonia, erythrodermic psoriasis, and pustular psoriasis, were identified as ADRs.

Serious infections (including mycobacterial and salmonella infections) and malignancies represent important potential risks due to the mechanism of action. Current post-marketing registries for patients with moderate to severe psoriasis and Crohn's disease aim to further characterise long term safety for these indications.

One new ADR of sinusitis has been included in the SmPC of ustekinumab otherwise no new safety signals have  arisen  compared  to  CD  and  rates  of  AEs/SAEs  are  comparable  across  placebo  and  ustekinumab treatment groups. Cases of sinusitis were mainly non-serious. Other concerns are raised in relation to opportunistic infections, vascular thrombosis, and malignancies in patients with moderately to severely active ulcerative colitis treated with ustekinumab (please refer to 'uncertainties' below).

## 3.5. Uncertainties and limitations about unfavourable effects

The safety analysis of the current clinical development programme show a safety profile consistent with what is already known about Stelara. However, a higher standardised rate (SIR) of malignancies was identified in treated UC patients. The SIR obtained when compared to epidemiological data from the SEER database was greater than 1 (1.7) for UC and almost three times the SIRs obtained for previous indications. The follow-up data to week 220 from the long-term extension study will help to give more information on the risk of malignancy in the trial population.

Two cases of DVTs occurred in the ~6 mg/kg group during the induction phase versus none in the placebo group. A bilateral PE occurred in the maintenance study in the ustekinumab q12w group. While the numbers are low and it is acknowledged that these cases had risk factors, it is noted that a numerical increase in VTEs in ustekinumab treated patients was also seen in the CD studies.

<div style=\"page-break-after: always\"></div>

Taking into account that no other agents with activity against IL-12 or IL-23 are available for ulcerative colitis there is no experience in this population with other similar agents over the long-term in particular on opportunistic infections, vascular thrombosis and malignancies. Therefor the MAH will monitor and characterize the long-term safety of ustekinumab in patients with ulcerative colitis further post authorisation by means of a long term safety extension of the maintenance trial and two prospective observational PASSs as described as category 3 studies in the RMP.

## 3.6. Effects Table

Effects Table for Ustekinumab for Ulcerative colitis.

| Effect                                       | Short description                                  | Unit               | Treatment                                                                                           | Control            | Uncertainties / Strength of evidence                                                                                                                                                                      | References          |
|----------------------------------------------|----------------------------------------------------|--------------------|-----------------------------------------------------------------------------------------------------|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------|
| Favourable Effects                           | Favourable Effects                                 | Favourable Effects | Favourable Effects                                                                                  | Favourable Effects | Favourable Effects                                                                                                                                                                                        | Favourable Effects  |
| Primary efficacy endpoint clinical remission | Clinical remssion mayo score <2, no subscore >1    | %                  | Ustekinumab 130mg or 6mg/kg IV Treatment diff 10.2(P<0.001)6mg/kg Treatment diff 10.3(P<0.001)130mg | Placebo 5.3%       | Treatment effects (across primary and major secondary endpoints) observed in subjects who were biological failures, non-biological failures and in subjects with failure to both anti-TNF and vedolizumab | InductionUCO3001    |
| Key secondary endpoint                       | Endoscopic healing Mayo endoscopic subscore 0 or 1 | %                  | Ustekinumab 130mg or 6mg/kg IV 26.3% or 27% respectively                                            | Placebo 13.8%      | p<0.001                                                                                                                                                                                                   | InductionUCO3001    |
| Primary efficacy endpoint clinical remission | Clinical remssion mayo score <2, no subscore >1    | %                  | Ustekinumab 90mg SC q12w or q8w Treatment diff 14.5(P<0.001) q12w Treatment diff 19.7(P=0.002) q8w  | Placebo            |                                                                                                                                                                                                           | Maintenance UCO3001 |
| Key secondary efficacy endpoint Steroid free | Clinical remission mayo score <2, no subscore >1   | %                  | Ustekinumab 90mg SC q12w or q8w 37.8% or 42% respectively                                           | Placebo 23.4%      | (P<0.01)                                                                                                                                                                                                  | Maintenance UCO3001 |

<div style=\"page-break-after: always\"></div>

| Effect                                             | Short description                                | Unit                 | Treatment                                       | Control Uncertainties / Strength of evidence                                                     | References           |                      |
|----------------------------------------------------|--------------------------------------------------|----------------------|-------------------------------------------------|--------------------------------------------------------------------------------------------------|----------------------|----------------------|
| remission                                          | remission                                        | remission            | remission                                       | remission                                                                                        | remission            | remission            |
| Key secondary efficacy endpoint Endoscopic healing | Mayo endoscopy subscore of 0 or 1                | %                    | Ustekinumab 90mg SC q12w or q8w 43.6% or 51.1%) | Placebo 28.6% Ustekinumab 90 mg Q8W vs Placebo < 0.001 Ustekinumab 90 mg Q12W vs Placebo < 0.002 | Maintenance UCO3001  |                      |
| Unfavourable Effects                               | Unfavourable Effects                             | Unfavourable Effects | Unfavourable Effects                            | Unfavourable Effects                                                                             | Unfavourable Effects | Unfavourable Effects |
| Adverse events                                     | Subjects with 1 or more AEs through week 8 %     |                      | Ustekinumab IV 6mg/kg: 50.0 130mg: 41.4         | Placebo 48.0 Randomized placebo controlled trial                                                 | InductionUCO3001     |                      |
|                                                    | Subjects with 1 or more AEs through week 44 %    |                      | Ustekinumab s.c. Q8: 77.3 Q12: 69.2             | Placebo 78.9 No safety data beyond 1 year / Randomized withdrawal trial                          | Maintenance UCO3001  |                      |
| Serious AEs                                        | Subjects with 1 or more SAEs through week 8 %    |                      | Ustekinumab IV 6mg/kg: 3.1 130mg: 3.7           | Placebo 6.6 Randomized placebo controlled trial                                                  | InductionUCO3001     |                      |
|                                                    | Subjects with 1 or more SAEs through week 44 %   | Q8: 8.5 Q12: 7.6     | Ustekinumab s.c.                                | Placebo 9.7 No safety data beyond 1 year / Randomized withdrawal trial                           | Maintenance UCO3001  |                      |
| Serious infections                                 | Subjects with serious infections through week 8  | %(n)                 | Ustekinumab IV 6mg/kg: 0.3 (1) 130mg: 0.6 (3.5) | Placebo 1.3 (4) Randomized placebo controlled trial                                              | Induction UCO3001    |                      |
|                                                    | Subjects with serious infections through week 44 | %(n)                 | Ustekinumab s.c. Q8: 1.7 (3) Q12: 3.5 (6)       | Placebo 2.3 (4) No safety data beyond 1 year / Randomized withdrawal trial                       | Maintenance UCO3001  |                      |

<div style=\"page-break-after: always\"></div>

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

The pivotal studies were appropriately designed and representative of the intended treatment population. For the primary endpoint of clinical remission, induction therapy with ustekinumab was superior to placebo, even in heavily pre-treated patients. Statistically significant benefit was also demonstrated for the major secondary endpoints.

For the maintenance study the primary endpoint was clinical remission at 44 weeks and this was achieved. Steroid free remission was presented and controlled as a secondary endpoint but has been viewed with the primary endpoint to further align with the CHMP guidance. This was achieved and therefore a clinically meaningful benefit has been demonstrated for ustekinumab in patients with and without prior biological failure. It represents a new mechanism of action in the treatment of UC and the infrequent dosing (every 12 weeks or every 8 weeks if loss of response) may be considered as a patient advantage. For the same reason, compliance issues should be considered with regard to the infrequent dosing and the relapsing natural history of UC.

The safety profile appears to be consistent with what is known for ustekinumab. The newly identified adverse reaction of sinusitis does not alter the benefit-risk. Further long term safety data on ustekinumab Ulcerative Colitis will become available by means of two category 3 PASSs and a long term safety extension of the maintenance trial as defined in the RMP.

## 3.7.2. Balance of benefits and risks

The demonstrated clinical meaningful benefits of treatment with ustekinumab 130mg, 6mg/kg IV and 90mg SC outweigh the risks in patients with moderately to severely active UC who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic or have medical contraindications to such therapies. Based on the data presented to date, the AE profile in moderately to severely active UC appears to be consistent with the expected safety profile for ustekinumab. Whilst routine risk minimisation remains sufficient to minimise the risks of the product long term safety in adult patients with moderately to severely active ulcerative colitis has been included in the RMP as an area of missing information and will be addressed by the long-term safety extension of the maintenance trial and two category 3 PASSs as described in the RMP.

## 3.8. Conclusions

The overall B/R of Stelara for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic or have medical contraindications to such therapies (See Section 5.1)  is positive.

## 4. Recommendations

## Outcome

Based on the review of the submitted data, the CHMP considers the following variation acceptable and therefore recommends the variation to the terms of the Marketing Authorisation, concerning the following change:

<div style=\"page-break-after: always\"></div>

| Variation accepted   | Variation accepted                                                                                                             | Type    | Annexes affected   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a              | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIA         |

Extension of Indication for Stelara to include treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic or have medical contraindications to such therapies. As a consequence, the SmPC, Package Leaflet and RMP have been updated.

The variation leads to amendments to the Summary of Product Characteristics and Labelling and to the Risk Management Plan (RMP).

## 5. EPAR changes

The EPAR will be updated following Commission Decision for this variation. In particular the EPAR module 8 \" steps after the authorisation \" will be updated as follows:

## Scope

Extension of Indication for Stelara to include treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic or have medical contraindications to such therapies. As a consequence, the SmPC, Package Leaflet and RMP have been updated.

## Summary

Please refer to the scientific discussion Stelara EMEA/H/C/000958/II/0071 for further information.

## Attachments

1. SmPC, Annex II, Labelling and Package Leaflet (changes highlighted) as adopted by the CHMP on 25 July 2019.